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Antibodies have enormous diversity and form a crucial component of the humoral immune 
response. The relationship between antibody variable region sequences and specificity is still 
poorly understood, however recent advances in high-throughput sequencing technology has 
made the study of B cell repertoires possible. In this thesis we use, among other methods, 
high-throughput sequencing of B cell repertoires to examine variable region properties and 
specificity in a number of contexts. 
First, we attempted to identify common characteristics of autoreactive/polyreactive antibody 
variable regions by analysing a high-throughput sequencing dataset constructed from B cell 
variable region sequences isolated from pre- and post-tolerance B cell repertoires. We tested 
our predictions using immunocytochemistry and ELISA. We found that some antibodies which 
show a polyreactive phenotype in ELISA do not show polyreactivity in other settings, leading us 
to question the definition of these antibodies and their role in the immune response. 
Next, we investigated the physicochemical and structural properties of kappa and lambda light 
chains and the heavy chains with which they are paired. We found that the properties of the 
two light chain classes differ considerably, suggesting different roles in the immune response. 
However, we found no distinction between heavy chains paired with kappa and lambda light 
chains, providing no evidence of bias in heavy-light chain pairing. 
Finally, we used high-throughput sequencing and ribosome display to investigate the B cell 
repertoires of recent Ebola survivors to determine how this disease affects the repertoire and 
to attempt to identify new, cross-reactive, anti-Ebola glycoprotein antibodies. The most 
significant repertoire feature of the Ebola survivors was the high prevalence of clonal 
expansions incorporating multiple heavy chain classes. Several new anti-Ebola glycoprotein 
single chains were isolated using ribosome display and some of these showed evidence of 
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Chapter 1: Introduction 
1.1 Antibody Structure and Function 
Antibodies (also known as immunoglobulins) are Y-shaped glycoproteins produced by B cells as 
part of the adaptive immune response. Their main function is to bind to harmful agents such 
as pathogens, toxins or diseased cells and neutralise them or tag them for clearance by the 
immune system. Antibodies bind specifically to their targets (antigens) via variable regions at 
the apices of the two fragment antigen-binding (Fab) regions. They mediate effector functions 
via the highly conserved fragment crystallisable (Fc) region (see Figure 1-1 for structure). 
In humans, the Fab regions are composed of a heavy chain (IgH) and a light chain. The variable 
region is composed of a variable domain from the heavy chain (VH) and a variable domain 
from the light chain (VL). These are held in place by the first constant domain of the heavy 
chain (CH1) and the constant domain of the light chain (CL). The light chain can be one of two 
classes: kappa (IgK) or lambda (IgL). 
The Fc region is composed of the remaining constant domains of the heavy chain. Depending 
on the class of heavy chain (IgM, IgD, IgG, IgA, IgE) the Fc has either two (CH2, CH3) or three 
(CH2, CH3, CH4) domains. Each heavy chain class has a different Fc structure and so mediates 
different effector functions. Antibodies can either be secreted or bound to the B cell surface. 
The focus of this thesis is exclusively on human antibodies unless stated otherwise. 
 
Figure 1-1: Structure of IgG antibody. (A) Antibodies are Y-shaped proteins composed of heavy 
and light chains. Antigen is bound by the extremely diverse variable region and the conserved 
constant regions provide structure and mediate effector functions. (B) Protein surface 
representation of an IgG antibody (PDB ID: 1IGT). In both diagrams, the variable regions are 
coloured blue and the constant regions are coloured green. The light chain is a lighter shade of 
each colour than the heavy chain.  
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1.2 V(D)J Recombination 
The diversity of the antibody variable region is extremely high. This ensures a specific response 
can be mounted against any of the pathogens a host may encounter. It is estimated that the 
number of possible variable region sequences in the antigen-naïve B cell repertoire is greater 
than 1018, which is more than the number of B cells in the human body (Elhanati et al., 2015). 
Such variable region diversity cannot be encoded solely by the germline. Instead, multiple 
variable region gene segments are present in the germline and these are brought together at 
random in developing B cells to form functional variable region sequences (B cell development 
is described in detail in section 1.4 page 37). 
The variable region gene segments are split into three groups: Variable (V), Diversity (D) and 
Joining (J) (see Table 1-1 for the number of functional human VDJ genes in the germline). The 
process of rearranging the IgH, IgK and IgL loci to bring together VDJ genes to form functional 
variable region sequences is known as V(D)J recombination (see Figure 1-2). A functional heavy 
chain variable region is composed of a V gene, a D gene and a J gene and a functional light 
chain variable region is composed of a V gene and a J gene. 
Table 1-1: Number of functional VDJ and constant (C) germline gene segments at the IgH, IgK 
and IgL loci. The chromosomal localisation (Chr) of each set of genes is shown. Table from 
(Lefranc & Lefranc, 2001, Lefranc, 2016). 
Locus Chr V D J C 
IgH 14q32.33 38-46 23 6 9 
IgK 2p11.2 34-38 0 5 1 
IgL 22q11.2 29-33 0 4-5 4-5 
 
The IgH locus is rearranged first and begins with the recombination of a D gene segment and a 
J gene segment; the DNA between the recombined genes is removed. The D-J pair is then 
recombined with an upstream V gene segment to form a primary transcript (see Figure 1-2). 
The IgM constant region is spliced on to the variable region to form the mRNA transcript. 
The light chain loci are rearranged after the IgH locus. A single B cell may go through multiple 
light chain rearrangements due to the process of receptor editing (explained further in section 
1.4, page 37). IgK rearrangement usually precedes IgL rearrangement (Hieter et al., 1981) and 
a B cell will only successfully rearrange and express either kappa light chains or lambda light 
chains; only very rarely does a B cell express both. Light chain loci do not have D gene 
segments so recombination happens between a V gene segment and a J gene segment (see 
Figure 1-2). The J genes and constant region genes are arranged differently at the kappa and 
lambda loci. At the kappa locus, there is a single constant region gene downstream of multiple 
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J genes. In kappa transcripts the same constant region gene is always used. At the lambda 
locus, each J gene has its own constant region slightly downstream (see Figure 1-2); in lambda 
transcripts the constant region used depends on the J gene used. 
Kappa light chain usage is more common than lambda in the human peripheral blood; the 
proportion of antibodies using kappa light chains is reported to be between 3/5 and 2/3 (Mole 
et al., 1994, Brauninger et al., 2001, Montano & Morrison, 2002). However, this can differ 
depending on the class of antibody (Chui et al., 1990), for example, light chain usage in 
secreted IgA antibodies is predominantly lambda (Mole et al., 1994). 
Recombination can occur multiple times if the initial rearrangement produced a non-functional 
or autoreactive BCR (see section 1.4, page 37, for more details). However, as the DNA between 
recombined gene segments is lost, further recombination can only occur using upstream 
V genes and downstream J genes. 
 
Figure 1-2: V(D)J recombination at the IgH, IgK and IgL loci. In the germline, V, D and J gene 
segments are arranged linearly in a non-functional state. During V(D)J recombination gene 
segments are brought together in a stepwise fashion. At the IgH locus, D and J genes are 
rearranged first, then the D-J combination is rearranged with a V gene. At the light chain loci V 
and J genes are rearranged. The gene segments are rearranged in the correct order using 
complementary recombination signal sequences (RSS). This figure is published in Dunn-Walters 
et al. (2018).  
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V(D)J recombination is controlled in part by recombination signal sequences (RSS). Each 
V gene, D gene and J gene is flanked by either a 12RSS or a 23RSS (see Figure 1-2). 12RSS and 
23RSS are nucleotide sequences which consist of a highly conserved heptamer (5’ cacagtg 3’) 
and nonamer (5’ acaaaaacc 3’) separated by 12 nt and 23 nt spacer regions respectively. The 
heptamer end of each RSS is always adjacent to the gene. The 12-23 rule ensures that VDJ 
genes are brought together in the correct order; there is a strong preference for 
recombination between a 12RSS and a 23RSS as they are much more likely to result in open 
reading frames (ORFs) than recombination between two RSS of the same type (Tonegawa, 
1983). 
The process of recombination using RSS is mediated by the recombination-activating gene 
(RAG) enzyme complex; a lymphoid-specific enzyme complex composed primarily of RAG1, its 
cofactor RAG2 and high mobility group box 1 (HMGB1) proteins. The RAG complex binds the 
nonamer of one RSS and then binds a second RSS with a complementary spacer sequence 
(12-23 rule) (Figure 1-3A,B&C). At each RSS, the RAG complex makes a single-stranded DNA 
nick between the gene segment and the adjacent RSS heptamer. This results in a 3’ hydroxyl 
group which attacks the complementary DNA strand creating a double-stranded break and 
covalently-sealed “hairpins” are formed at the end of each strand of DNA (Figure 1-3D) (Schatz 
& Ji, 2011). These double-stranded DNA breaks are then repaired by non-homologous end 
joining. First, the Artemis complex cleaves the “hairpin” structure to create palindromic ssDNA 
overhangs (referred to as P-nucleotides). Terminal deoxynucleotidyl transferase (TdT) then 
adds nucleotides (referred to as N-nucleotides) to each P-nucleotide ssDNA overhang until the 
randomly added N-nucleotides form complementary sequences. The Artemis complex 
removes any additional unpaired nucleotides and the gaps are joined by DNA polymerase and 
DNA ligase (Motea & Berdis, 2010) (Figure 1-3E). The waste DNA is released as a DNA excision 
circle. 
The diversity created by V(D)J recombination is referred to combinatorial diversity, whereas 
the diversity introduced by P-nucleotides and N-nucleotides is known as junctional diversity. 
Further diversity can be introduced by the use of alternative IGHD reading frames and the use 
of two IGHD genes (Kalinina et al., 2011). Although extremely rare, there are reports of 
additional variation being introduced to immunoglobulin sequences by functional antibody 
variable regions incorporating additional pieces of DNA in a site of N nucleotide addition via 
interchromosomal DNA transposition from elsewhere in the genome (Tan et al., 2016). 
Polymorphisms in the highly conserved RSS heptamer/nonamer sequences (Akamatsu et al., 
1994) and mutations in the 12 bp or 23 bp spacer influences recombination frequency in 
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humans (Feeney et al., 2000, Nadel et al., 1998, Montalbano et al., 2003). This ultimately 
affects gene frequency in the human pre-B repertoire (Nadel et al., 1998). It is thought that 
greater kappa RSS similarity to a consensus sequence than lambda may explain the large kappa 
bias in the murine immunoglobulin repertoire (Ramsden & Wu, 1991). 
 
Figure 1-3: Recombination of genes by RAG recombinase. (A) In the genome, genes are 
encoded in a non-functional state. (B) RAG complex binds an RSS. (C) A complementary RSS is 
captured by the RAG complex. (D) Double-stranded breaks are created between the gene and 
the RSS and hairpin structures form at the ends of the nicked DNA. (E) Non-homologous end 
joining DNA repair factors join the DNA ends and TdT adds non-templated N nucleotides at the 
joint, increasing diversity. The wide end of each RSS arrow represents the heptamer end and 
the point represents the nonamer end. Figure adapted from Schatz &Ji (2011) and Motea 
&Berdis (2010).  
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1.2.1 Human Immunoglobulin Gene Nomenclature 
The nomenclature used to identify VDJ genes and constant regions classifies these genes into 
group, subgroup, gene and allele based on their level of similarity (Lefranc, 2014) (Figure 1-4A). 
Groups are genes which belong to the same multigene family within or between species. 
Higher vertebrates have 10 groups: IGHV, IGHD, IGHJ, IGHC, IGKV, IGKJ, IGKC, IGLV, IGLJ and 
IGLC. Subgroups are defined as genes in the same group which, within the species, share at 
least 75% identity at the nucleotide level. Groups are inter-species, whereas subgroups and 
genes are associated with individual species. Not all genes are functional, some are 
pseudogenes. Each V and D gene is identified by the subgroup to which it belongs and another 
number indicating which gene it is within that subgroup (e.g. IGHV3-15 and IGHV3-23 are 
different genes within the IGHV3 subgroup). Genes are further categorised into alleles, which 
are polymorphic variants of the genes. Each gene has a gene allele reference sequence 
(allele *01) and it is to this sequence that allelic variants are compared. Allelic variants of a 
gene are numbered *02, *03 etc. (Figure 1-4B). 
Heavy chain constant region genes are named according to their isotype (e.g. IGHA refers to 
IgA constant regions, IGHG refers to the IgG constant regions etc.). Light chain kappa and 
lambda constant regions are identified as IGKC and IGLC respectively. 
Despite the above nomenclature, in common usage (and in this thesis), constant region 
groups, genes and alleles are referred to as “class”, “subclass” and “allotype” respectively and 
VDJ subgroups are referred to as “families”. Unlike most genes, immunoglobulin genes do not 
need to be italicised when written (Lefranc, 2014). 
 
Figure 1-4: IMGT immunoglobulin gene and allele classification nomenclature. (A) IMGT 
classifies immunoglobulin genes by group, subgroup (family), gene and allele. (B) Example 
heavy chain nomenclature is shown. IGHJ and IGHC groups do not contain subgroups. Kappa 
and lambda light chain J and C groups also do not contain subgroups.  
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1.3 Complementarity-Determining Regions and Framework Regions 
The successfully rearranged, functional variable region of an antibody is composed of 
framework regions (FR) interspersed by complementarity-determining regions (CDR). FRs are 
highly conserved and primarily serve a structural purpose. The CDRs are much more diverse 
and form loops in the variable region which make the most contact with antigen. The CDR 
loops are therefore most important regions for antibody specificity. The heavy chain and the 
light chain each contribute three CDR loops to the antigen binding site. The heavy chain 
CDR-H1 and CDR-H2 are both encoded entirely by regions of the IGHV gene, whereas the 
CDR-H3 spans from the end of the IGHV gene to the beginning of the IGHJ gene. Similarly, the 
light chain CDR-L1 and CDR-L2 are both encoded in the IGKV/IGLV gene and the CDR-L3 spans 
the end of the IGKV/IGLV to the beginning of the IGKJ/IGLJ (see Figure 1-5). 
There is a fourth heavy chain loop positioned in the FR3 region which, although not classed as 
a hypervariable loop, can make contact with antigen and does undergo affinity maturation. 
This region is therefore sometimes referred to as the fourth CDR loop (CDR-H4) (Bond et al., 
2005), however this region is not as widely recognised as the six CDRs described above. 
 
Figure 1-5: Position of CDR loops within the framework regions (FR). The CDR loops are the 
most diverse regions of the antibody variable region and make most contact with the antigen. 
The CDR-H3 is the most diverse and is thought to be the most important for antibody 
specificity, the CDR-L3 loop is not as diverse as there is only one region of N-nucleotide 
addition. The FRs are much more conserved and are primarily structural. PDB ID: 1FVC. This 
figure has been published in Dunn-Walters et al. (2018). 
Due to the fact that the CDR-H3 loop is encoded by three separate gene segments and two 
regions of N-nucleotide addition (Figure 1-5A), this region is the most diverse part of the 
antigen-binding site and is often considered to be the most important region for antibody 
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specificity. Experiments in mice have shown that diversity in the CDR-H3 alone can be enough 
to produce an effective antibody repertoire with high levels of antibody specificity (Xu & Davis, 
2000). On average, approximately 31% of energetically important residues in the antigen 
binding site are contributed by the CDR-H3, followed by 23% from CDR-H2. CDR-H1, CDR-L2 
and CDR-L3 are approximately equally important, contributing 13% each. The contribution of 
CDR-L2 is usually negligible, contributing just 6% of energetically important residues (Kunik & 
Ofran, 2013). This means that while the majority of interactions with the antigen are formed 
with residues in the CDR-H3, approximately 70% of energetically important interactions are 
with residues on the other five loops. However, it is important to note that, as this work is 
based on structures in the Protein Data Bank (PDB) there is a bias towards antibodies with 
shorter CDR-H3. 
Although the majority of antigen binding is done by the three heavy chain CDR loops (Burkovitz 
& Ofran, 2016), the light chain is certainly important for antigen specificity. The CDR-L3 loop is 
the second most diverse as it incorporates two genes and a region of N-nucleotide addition 
(see Figure 1-5). The light chain is important for antibody specificity and diversity in the light 
chain can alter the specificity of the antibody (Persson et al., 2013). This is particularly 
important in receptor editing where switching the light chain alters the specificity of an 
antibody at the central tolerance checkpoint during B cell development with the aim of 
rescuing autoreactive antibodies (see section 1.4, page 37). 
The precise definitions of where the FRs and CDRs start and finish can vary somewhat and this 
can make a difference to e.g. physicochemical property calculations. Therefore, it is important 
to understand which numbering scheme has been used and where the FR and CDR boundaries 
lie. 
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1.3.1 Variable Region Numbering Schemes 
1.3.1.1 IMGT Numbering Scheme 
The IMGT numbering scheme is the most commonly used variable region numbering scheme 
and was first described in 1997 (Lefranc, 1997), with CDR3 and FR4 numbering added later 
(Lefranc et al., 2003). Importantly, the numbering scheme is the same for immunoglobulin 
heavy chains, light chains and also T cell receptors. In this thesis, the IMGT numbering scheme 
and CDR/FR definitions have been used in all cases unless stated otherwise. 
In the IMGT scheme, the variable region spanning the entire V(D)J region is referred to as the 
V-DOMAIN and amino acid positions are numbered 1-129. Conserved amino acids are always 
assigned the same numbers (residues highlighted in red in Figure 1-6). FR1 is defined as the 
region spanning amino acids 1-26, within FR1, there is a conserved cysteine (1st-CYS) at 
position 23. CDR1 can be between 5 and 12 amino acids long and spans positions 27-38. FR2 
contains a conserved tryptophan at position 41 (CONSERVED-TRP) and spans positions 39-55. 
CDR2 can be between 0 and 10 amino acids long and spans positions 56-65. FR3 spans 
positions 66-104, finishing with a conserved cysteine at position 104 (2nd-CYS). The CDR3 can 
vary a lot in length and is defined as starting at position 105 (just after 2nd-CYS) and finishing 
at position 117. The FR4 region begins with either a tryptophan (heavy chain) or a 
phenylalanine (light chain) at position 118 (J-TRP or J-PHE respectively) and ends at position 
129. The region beginning with 2nd-CYS and ending with J-TRP/J-PHE (i.e. two amino acids 
longer than the CDR3) is known as the JUNCTION. This is followed by a conserved glycine at 
position 119 (Glycine 119). Glycine 119 forms a hydrogen bond with 2nd-CYS (Lefranc et al., 
2003). 
 
Figure 1-6: IMGT V-DOMAIN numbering scheme. This scheme applies to both antibody heavy 
and light chains and T cell receptors. The conserved residues are shown in red.  
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To allow for the large range of CDR3 lengths, the IMGT scheme employs a flexible numbering 
system. If a V-DOMAIN has a CDR3 of less than 13 amino acids, gaps are created by removing 
numbered positions symmetrically in the following order: 111, 112, 110, 113, 109, 114 etc. 
(Figure 1-7A). If the V-DOMAIN has a CDR3 longer than 13 amino acids, positions are added 
symmetrically between positions 111 and 112 in the following order: 112.1, 111.1, 112.2, 
111.2 etc. (Figure 1-7B). By using this system, the CDR3 can be lengthened and shortened 
without affecting the numbering positions of structurally important conserved amino acids 
(Lefranc et al., 2003). 
 
Figure 1-7: IMGT CDR3 numbering scheme. The CDR-H3 shown in (A) is 10 amino acids long, so 
numbers 111, 112 and 110 have not been used. The CDR-H3 shown in (B) is 22 amino acids 
long, so 9 amino acids have been inserted in-between positons 111 and 112. 2nd-CYS and 
J-TRP are highlighted in red. Polar bonds are shown in orange. The CDR-H3 loops in A and B are 
from PDB structures 4KQ3 and 3GHE respectively. 
1.3.1.2 Kabat and Chothia Numbering Schemes 
The Kabat numbering scheme was the first standardised numbering scheme to be created 
(Kabat et al., 1983) and the improved Chothia numbering scheme followed soon after (Chothia 
& Lesk, 1987). The Kabat numbering scheme is more sequence-focussed, whereas the Chothia 
scheme is more structure-focussed (Abhinandan & Martin, 2008) and takes spatial positioning 
into account (corrected CDR-L1 and CDR-H1 (Honegger & Plückthun, 2001)). The Chothia 
CDR-H1 and CDR-L1 numbering schemes changed slightly in 1989 (Chothia et al., 1989), but 
reverted in 1997 (Al-Lazikani et al., 1997). 
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The Chothia numbering scheme is popular among structural modellers due to the 
straightforward way in which it deals with indels (Kovaltsuk et al., 2017). In this thesis, the 
Chothia scheme has only been used when modelling CDRs. 
Unlike the IMGT numbering scheme, the Chothia scheme has separate numbering for heavy 
chains and light chains (Figure 1-8). This scheme was devised using only the structure of the 
CDR loops, therefore any structurally important residues in the framework regions was not 
considered (Abhinandan & Martin, 2008). The CDR-H1 region occurs between residues 25 
(three residues upstream of the conserved cysteine) and 32, additional amino acids are 
inserted in-between residues 31 and 32 using 31A and 31B. The CDR-H2 region occurs 
between residues 51 and 56. Longer loops are accommodated by additional numbering 
between residues 52 and 53 using 52A, 52B and 52C. The CDR-H3 is located between residues 
94 (two residues upstream of the conserved cysteine) and finishes at position 102 (one residue 
downstream of the conserved tryptophan). Additional amino acids are added between 
residues 100 and 101 using lettering 100A-100K. The CDR-L1 region occurs between residue 23 
(conserved cysteine) and 32. Additional amino acids are added between residues 30 and 31 
with the lettering 30A-30F. The CDR-L2 region occurs between residues 49 and 56, there is no 
provision for additional amino acids The CDR-L3 region occurs between residue 88 (conserved 
cysteine) and 97. Additional amino acids are added between residues 95 and 96 using the 
lettering 95A-95F (Abhinandan & Martin, 2008). 
 
Figure 1-8: Chothia numbering scheme. There is a separate scheme for antibody heavy and 
light chain variable domains and it does not apply to T cell receptors.  
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1.3.1.3 Other Numbering Schemes 
A number of other numbering schemes have been developed. The AHo numbering scheme 
was described in 2001 and was the first scheme to use a numbering method which allowed 
CDR loops to extend symmetrically around key positions (Honegger & Plückthun, 2001). The 
Martin numbering scheme, an enhanced Chothia numbering scheme, was described in 2008. 
This was developed to address errors in the Chothia numbering scheme, particularly in the 
numbering of CDR-H2 and heavy chain FR3, and addressed the fact that the original Chothia 
scheme did not consider indels in the framework regions (Abhinandan & Martin, 2008). A 
paper published by North et al. (2011) did not propose a new numbering scheme, but after a 
comprehensive review of CDR canonical structures, did use CDR definitions which differed 
slightly from Kabat and Chothia. 
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1.4 B cell Development and Central Tolerance 
V(D)J recombination and receptor editing happens as B cells develop in the bone marrow. Due 
to the vast potential diversity created by V(D)J recombination, it is possible to get variable 
regions which bind self-antigen (autoreactive antibodies). If released from the bone marrow 
into the peripheral blood, these antibodies could cause autoimmune disease. Developing 
B cells in the bone marrow do not secrete antibody, instead they express their antibodies on 
the cell surface as B cell receptors (BCRs). At each stage of development, B cells are subject to 
positive and negative selection pressures to ensure that the B cell is developing correctly and is 
expressing functional BCRs which are not autoreactive. B cells which do express autoreactive 
BCRs are selected out of the repertoire during a process called central tolerance. 
Figure 1-9 shows the stages of B cell development in the bone marrow. VDJ recombination of 
the IgH locus happens in pro-B cells and the recombined heavy chain is then displayed on the 
surface of large pre-B cells in combination with a surrogate light chain. This structure is known 
as a pre-BCR and its purpose is to check that the heavy chain is functional and capable of 
pairing with light chains. If the heavy chain does not pair successfully with the surrogate light 
chain, a further heavy chain rearrangement is made using the second heavy chain allele. If the 
second heavy chain rearrangement also cannot pair, the B cell dies. However, if the heavy 
chain does pair successfully with the surrogate light chain, the B cell progresses to the small 
pre-B cell stage and the light chain loci undergo VJ recombination. The paired heavy and light 
chains are then displayed on the immature B cell surface as a BCR and it is at this point that 
central tolerance acts (Lydyard et al., 2011). 
During central tolerance, BCRs are tested for binding against antigens in the bone marrow. 
BCRs that do not bind any antigen in the bone marrow progress through the immature B cell 
stage and are released from the bone marrow into the peripheral blood. However, it is thought 
that if a BCR binds antigen in the bone marrow, the BCR is autoreactive and therefore should 
be removed from the repertoire. If a functional BCR on an immature B cell binds self-antigen in 




3. Receptor editing 
4. Ignorance 
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Clonal deletion and anergy both result in the removal of the functional B cell from the 
repertoire. Deletion uses B cell death to remove autoreactive B cells (Nemazee & Bürki, 1989). 
Anergy, on the other hand, is when the B cell enters a state of unresponsiveness in which the 
B cell is not stimulated by antigen binding (Goodnow et al., 1988). However, the primary 
mechanism of central tolerance is a process called receptor editing. In receptor editing, the 
specificity of the BCR is altered by further rearrangement of the light chain loci (and 
occasionally the heavy chain loci, although this is rare) (Nemazee, 2006). Kappa light chain 
rearrangement tends to precede lambda and lambda light chains seem to be better at rescuing 
autoreactive heavy chains than kappa (Wardemann et al., 2004). Light chains with low CDR 
isoelectric points (pI) or high aspartic acid usage are good at rescuing DNA-reactive 
autoantibodies (Li et al., 2001, Kalinina et al., 2014). If the autoreactive BCR does not 
encounter its cognate antigen in the bone marrow, the B cell will mature as if the BCR were 
not autoreactive; this is known as immunological ignorance. 
It is not well understood exactly under which circumstances a B cell will undergo receptor 
editing, or enter anergy or deletion. However, it is thought that B cells which bind in a strongly 
cross-linking manner to multivalent self-antigen are deleted from the repertoire (Fulcher et al., 
1996), whereas anergy is thought to be used when the B cell encounters weakly cross-linking 
antigen of low valence (Hartley et al., 1991). If receptor editing does not rescue an 
autoreactive BCR, the B cell is removed from the repertoire by deletion (Tiegs et al., 1993). 
It is thought that 55-75% of early immature B cells are autoreactive and the majority of these 
are removed from the repertoire by central tolerance (Wardemann et al., 2003). 
 
Figure 1-9: Central tolerance and receptor editing. Central tolerance acts on immature B cells 
to determine if the BCR binds self-antigen and is therefore autoreactive. If the BCR does not 
bind self-antigen, the immature B cell matures and is released into the peripheral blood. If the 
BCR does bind self-antigen, the BCR is pulled back inside the B cell and undergoes receptor 
editing. If receptor editing cannot rescue the B cell, it is removed from the repertoire by 
apoptosis. Diagram modified from Nemazee (2006) and Nemazee (2017).  
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1.5 B cell Activation and Peripheral Tolerance 
1.5.1 T-Independent B cell Activation 
T-independent B cell activation is triggered by certain types of antigen, known as thymus-
independent antigen (TI antigen). There are two types of TI antigen: TI-1 antigen and TI-2 
antigen. 
TI-1 antigen engages toll-like receptors (TLRs) on B cells in addition to BCRs in order to trigger 
B cell activation. Common TI-1 antigens include lipopolysaccharide (LPS), bacterial DNA and 
some viral particles (Fehr et al., 1998). B cells activated by TI-1 antigen only produce IgM 
antibodies and do not undergo somatic hypermutation or class switching. Although this limits 
the potency of the response, it is still a useful first line of defence. 
TI-2 antigens are large, highly repetitive carbohydrate or protein epitopes on the surface of 
pathogens. The large amount of TI-2 antigen on the pathogen surface cross-links multiple BCRs 
forming a cluster of cross-linked BCRs. This high level of cross linking triggers a Bruton’s 
tyrosine kinase (Btk)-dependent signalling cascade which overrides the requirement for a 
secondary activation signal and the B cell is activated in the absence of T cell help or TLRs (Vos 
et al., 2000). It was thought that TI-2 antigens only elicited primary antibody responses which 
did not lead to the generation of memory B cells. However, it has been shown that TI-2 
antigens can elicit a memory response against polysaccharides if aided by antigen-specific IgG 
antibodies (Obukhanych & Nussenzweig, 2006). Somatic hypermutation and class switching 
can also occur at low levels in response to TI-2 antigens (Toellner et al., 2002). 
1.5.2 T-Dependent B cell Activation 
Other antigens (primarily protein antigens) stimulate a T-dependent response, which means 
help from CD4+ T cells is required to activate the B cell against that antigen. When a B cell 
recognises a cognate T-dependent antigen in the lymphoid follicles, the B cell internalises the 
antigen and displays the processed peptide on its MHC class II molecules. In the T cell zone of 
the lymphoid follicle, CD4+ T cells bearing complementary TCRs bind the antigen-MHC class II 
complex on the B cell. The CD40L on the T cell also binds the CD40 receptor on the B cell and 
the CD28 co-receptor on the T cell binds CD80 and CD86 on the B cell (Owen et al., 2013, 
Hoffman et al., 2016). The T cell-activated B cells then either form primary foci, or germinal 
centres. 
The B cells which form primary foci do so at the interface between the T cell zone and B cell 
zone of the lymphoid follicle. These T cell-activated B cells differentiate into plasma cells and 
then migrate to the medullary cord regions of the lymph nodes or the red pulp region of the 
Chapter 1: Introduction 
40 
 
spleen where they secrete large amounts of antigen-specific IgM antibodies. Many of these 
cells die off after the primary response, but some migrate to the bone marrow where they 
remain as long-lived plasma cells. Antibodies produced by B cells in the primary foci provide a 
useful early antibody response as they appear in circulation approximately four days after their 
initial antigen stimulation (Owen et al., 2013). 
In contrast, the B cells which form the germinal centres in the lymph nodes and spleen take 
longer to mature (they appear in circulation approximately 6-10 days after their initial antigen 
stimulation) however, they produce a much more specific antibody response. Further 
differentiation of the germinal centre B cells is aided by follicular helper T cells (TFH) and 
follicular dendritic cells (FDC). Within the germinal centres, B cells undergo intense 
proliferation and affinity maturation. As B cells proliferate, further diversity is introduced into 
the BCR variable regions via somatic hypermutation (SHM) at a rate of approximately one 
mutation per 1000 bp per division. The B cells where SHM has resulted in increased affinity for 
cognate antigen will out-compete B cells bearing lower affinity BCRs and be preferentially 
selected. Alongside SHM, class switch recombination (CSR) occurs. CSR involves the 
recombination of the constant region genes, thus changing the functionality of the antibody. 
B cells stimulated in a T-dependent manner become plasma cells and memory cells (Owen et 
al., 2013). Both SHM and CSR are directed by activation-induced cytidine deaminase (AID) and 
are described in more detail in sections 1.6 and 1.7 respectively. 
1.5.3 Peripheral B cell Tolerance 
Autoreactive B cells are removed from the repertoire during central tolerance using apoptosis, 
anergy or receptor editing. However, central tolerance does not remove all autoreactive B cells 
and some escape into the periphery, perhaps due to immunological ignorance. Therefore a 
second tolerance checkpoint, which is believed to act primarily on the transitional B cells 
(Figure 1-9, page 38), removes autoreactive B cells in the peripheral blood (Wardemann et al., 
2003). This checkpoint is known as peripheral tolerance. 
Peripheral tolerance is thought to work as the inverse of T-independent and T-dependent 
B cell activation. If a BCR binds an antigen but the B cell does not receive the necessary 
secondary signals, the B cell is removed from the repertoire by apoptosis or anergy. Peripheral 
tolerance is necessary because autoreactive B cells may escape central tolerance or they may 
be created during somatic hypermutation. As autoreactive T cells are removed from the T cell 
repertoire during thymic maturation, the chances of a T cell being present which is also 
autoreactive to the same autoantigen is low (Parham, 2009).  
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1.6 Somatic Hypermutation 
Once a B cell has been successfully activated by its complementary antigen, the binding 
efficacy of the antibody is increased by somatic hypermutation (SHM). During SHM, point 
mutations are introduced to the heavy and light chain variable regions by activation-induced 
cytidine deaminase (AID). 
AID is expressed only in proliferating B cells and it converts cytosine to uracil in ssDNA, which is 
temporarily available during transcription. Uracil is a normal component of RNA, but not DNA. 
However, dU mimics dT during replication and therefore, although the cellular DNA repair 
pathways can convert the uracil into any of the four DNA bases, the dU tends to be converted 
into dT, resulting in a bias towards CT and GA mutations (Maul & Gearhart, 2010). The rate 
of mutation in SHM is one variable region mutation per cell division (this is over a million times 
greater than the mutation rate of a normal gene) (Parham, 2009). 
SHM occurs in the germinal centres and some mutations will result in increased affinity for the 
target antigen, others will result in decreased affinity. This leads to a Darwinian-like selection 
in which somatically mutated B cells must compete for a limited supply of antigen presented 
by follicular dendritic cells and helper T cells. The B cells bearing BCRs with the highest affinity 
for the antigen compete more effectively for antigen and are therefore preferentially selected 
to mature into plasma cells and memory cells (Victora & Nussenzweig, 2012). This process is 
known as affinity maturation. Mutations are concentrated in the CDRs rather than the FRs as 
CDRs have more contact with antigen (Parham, 2009). 
In addition to altering the protein composition of an antibody variable region, N-glycosylation 
sites can be introduced and removed in the antibody variable region during SHM and this also 
affects antibody specificity (Dunn-Walters et al., 2000). Despite there being only five germline 
genes which encode an N-linked glycosylation site (IGHV1-8, IGHV4-34, IGHV5-10-1, IGLV3-12 
and IGLV5-37), antibodies with N-glycans in their Fab regions are present at a frequency of 
about 15-25% of serum IgG antibodies, suggesting that these sites are commonly introduced 
during SHM (van de Bovenkamp et al., 2016). 
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1.7 Class Switch Recombination 
1.7.1 Mechanism of Class Switch Recombination 
Class switch recombination (CSR) is the process by which B cells switch from expressing 
antibodies using IgM/IgD constant regions to antibodies using IgA, IgE or IgG constant regions. 
CSR occurs almost exclusively as a result of T-dependent activation and it occurs alongside 
affinity maturation in the germinal centres (however some CSR can occur in a T-independent 
manner (Berkowska et al., 2011)). By swapping the constant region used by the antibody, the 
function of the antibody changes. Different antigens will elicit different constant region usage. 
CSR is difficult to study in vivo and so the precise triggers inducing the process is not fully 
understood, however, it is thought that it is triggered by BCR stimulation in combination with 
signals from CD40 and TLRs (Stavnezer & Schrader, 2014). 
Like SHM, CSR is mediated by AID. AID mediates the recombination between switch regions 
(guanine-rich regions with a high frequency of A/T-G-C-A/T motifs which sit just upstream of 
each constant region gene) by converting cytosines to uracils in an upstream donor switch 
region and a downstream acceptor switch region. Enzymes in the base excision repair pathway 
and the mismatch repair pathway then convert the uracils into double-stranded DNA breaks. 
The two DNA ends are then brought together by non-homologous end joining (Stavnezer & 
Schrader, 2014). The DNA between the donor and acceptor switch regions is released as a loop 
of DNA (Figure 1-10A). Successive CSR events can occur (Gearhart et al., 1980, Zhang et al., 
1994, Jackson et al., 2014), although only in the downstream direction as the intermediate 
DNA is looped out with each recombination. Antibodies using more downstream constant 
regions have higher levels of SHM. This is thought to be due to prolonged exposure to AID in 
the germinal centres (Jackson et al., 2014). Every CH gene can undergo alternative splicing to 
generate two carboxy termini: one anchors the immunoglobulin on the B cell as a BCR, the 
other allows the immunoglobulin to be secreted as an antibody (Schroeder & Cavacini, 2010). 
Certain recombination events are more common than others, for example, IgM/IgD B cells are 
most likely to switch to either IgG1 or IgA1 than other subclasses (Figure 1-10B). Subclasses are 
more likely to switch between members of the same class than switch to a different class 
(Kitaura et al., 2017). The data presented in Kitaura et al. (2017) suggests that the majority of 
expanded clones are of a single class, approximately 9% of expanded clones contain a mixture 
of subclasses within the same class, and only a very small proportion (approximately 1%) of 
expanded clones contain more than one class. However, this study used a very stringent 
definition of a clone (identical CDR-H3) and so the proportions may differ if a different 
definition was used. 




Figure 1-10: Class switch recombination direction and frequency. A) Order of heavy chain 
constant region (CH) genes in the genome. When class switch recombination occurs, the 
intermediate section of DNA gets looped out and discarded. Therefore further recombination 
can only occur in the downstream direction. Diamonds represent switch regions. Diagram 
adapted from Stavnezer et al. (2008). B) Recombination occurs at different frequencies. The 
most common switch for IgM/IgD expressing B cells is to IgG1 or IgA1. IgG1 then more 
commonly switches to other IgG subtypes and IgA1 most often switches to IgA2. Circle 
diameter reflects subtype abundance in the repertoire and arrow width is proportional to the 
frequency of each class switch as reported in Horns et al. (2016). Dotted lines represent class 
switches which are so uncommon they were not observed in the Horns et al. (2016) dataset. 
Diagram adapted from Horns et al. (2016). 
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1.7.2 Effector Functions of Heavy Chain Classes 
The five heavy chain classes of antibody are IgM, IgD, IgG, IgA and IgE. IgG and IgA are further 
subdivided into four and two subclasses respectively. The constant regions of IgG, IgA and IgD 
consist of three domains (CH1-CH2-CH3), whereas IgM and IgE have an additional domain 
(CH1-CH2-CH3-CH4). CH1 is located in the Fab region, whereas the remaining CH comprise the 
Fc region (Figure 1-11). The Fc fragments of the different heavy chain classes have different 
effector functions and CSR facilitates the selection of the most appropriate Fc for each immune 
response. 
The Fc regions mediate antibody effector functions by binding to Fc receptors on immune cells 
to activate responses such as ADCC and ADCP or by initiating complement. Different classes 
dominate in different reactions. For example, IgG is the most common class in the blood, 
whereas secreted IgA is most prevalent at mucosal surfaces. IgE is generally used in response 
to extracellular parasites and in allergic reactions (Schroeder & Cavacini, 2010). 
 
Figure 1-11: Antibody heavy chain classes form different conformations. The different Fc 
regions have differing numbers of CH domains, different glycosylation patterns and form 
different structures (monomers, dimers and pentamers). Each class is best suited to different 
roles in the immune response. The secretory component of IgA is only present on the secreted 
form of IgA.  




Monomeric IgM is displayed on the surface of all developing and antigen-naïve B cells in the 
form of B cell receptors (BCRs). Upon binding their specific antigen, BCR signalling triggers the 
maturation of the B cell. In addition to the membrane-bound IgM, there are two types of 
secreted IgM: natural IgM and adaptive IgM. 
Natural IgM arise spontaneously without antigenic stimulation. Natural antibodies provide an 
important innate-like first line of defence against invading pathogens and comprise a 
substantial part of peripheral blood lymphocytes in newborns. Natural antibodies often have 
near-germline V(D)J configurations and they bind antigen with a lower affinity than affinity-
matured antibodies. They are commonly polyreactive (Zhou et al., 2007). In addition to binding 
pathogens and activating complement, natural antibodies can also clear dead or dying host 
cells and exhibit anti-inflammatory effects (Grönwall & Silverman, 2014). 
Adaptive IgM is affinity matured and therefore has a high affinity. It was thought that IgM 
antibodies were not somatically mutated and could not form a memory response. However, it 
has been shown that they can be somatically mutated and IgM memory cells do exist (Díaz-
Zaragoza et al., 2015). 
IgM antibodies often have low affinities as they are often not somatically mutated. However, 
secreted IgM forms pentamer structures with ten antigen-binding sites resulting in high 
avidity. IgM pentamers are held together by disulphide bonds in the CH4 regions and 
incorporate a joining chain (J-chain) which facilitates secretion at mucosal surfaces (Schroeder 
& Cavacini, 2010). IgM pentamers are a very efficient activator of complement; a single IgM 
pentamer bound to an antigen is sufficient to bind the first complement component (C1) and 
start the complement cascade (two IgG in close proximity are alternatively required). 
Complement results in activation of mast cells, attraction of neutrophils, enhanced 
opsonisation by phagocytes and, if the pathogen is a microbe, lysis via the membrane attack 
complex (Lydyard et al., 2011). 
1.7.2.2 IgD 
IgD is co-expressed as a monomer alongside IgM on the surface of naïve B cells. However its 
role in the immune response is largely unknown. IgD is downregulated once the B cell has 
encountered antigen, however, B cells do occasionally class switch to IgD. These class-switched 
IgD antibodies are usually paired with lambda light chains (Arpin et al., 1998). IgD-secreting 
plasma cells are primarily found in the upper respiratory tract such as the nasal mucosa and 
Chapter 1: Introduction 
46 
 
the tonsils. B cells appear to undergo IgD CSR in situ and the resulting IgD antibodies recognise 
respiratory bacteria and bind circulating basophils (Chen et al., 2009). 
1.7.2.3 IgG 
IgG is the most abundant antibody class in human serum. This class is composed of four 
subclasses: IgG1, IgG2, IgG3 and IgG4 (named in order of decreasing abundance). These four 
subclasses of constant region genes share over 90% of their amino acid sequence identity, 
however there are significant structural differences in the hinge region (Liu & May, 2012) and 
upper CH2 domain, both of which are important for IgG binding to Fc-gamma receptors (FcγR) 
and complement component 1q (C1q) which elicit responses such as antibody-dependent 
cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and 
complement-dependent cytotoxicity (CDC) (Irani et al., 2015, Chan et al., 2015). The 
differences in Fc regions mean that each subclass predominantly targets certain types of 
antigen and is suited to certain effector functions. Each subclass also has a number of allotypes 
(constant region allelic variants) which affect the effector functions. 
IgG1 and IgG3 have very similar roles; both subtypes primarily react to soluble and membrane-
bound proteins. Anti-viral responses are mainly IgG1/IgG3, for example HIV (Raux et al., 2000) 
and Ebola (Leroy et al., 2001). The antibody response against Plasmodium falciparum malaria 
is also IgG1/IgG3 (Weaver et al., 2016). IgG1 and IgG3 Fc bind C1q, initiating complement and 
they also both bind all of the FcγR, indicating that they initiate cell-mediated responses such as 
ADCC (Vidarsson et al., 2014). Although IgG1 and IgG3 have similar effector functions, an IgG3-
dominant response is rare. Further, almost all therapeutic antibodies are of the IgG1 isotype 
and there are no approved IgG3 therapeutic antibodies. This may be due to the fact that IgG1 
is the most prevalent subtype in human serum, or it may be because IgG3 has a very extensive 
hinge region which makes it vulnerable to proteolysis. More practically, it may be because IgG3 
has a short half-life and it cannot be purified using protein A (Irani et al., 2015). 
IgG2 binds primarily to polysaccharides and is almost exclusively responsible for the IgG 
responses to bacterial capsular polysaccharide. People deficient for IgG2 antibodies experience 
recurrent bacterial infections, for example Streptococcus pneumoniae (Barrett & Ayoub, 1986). 
IgG2 is not a potent inducer of complement and only binds certain FcγRIIa allelic variants (e.g. 
H131). Therefore people with the H131 FcγRIIa allotype have better IgG2 opsonisation of 
bacteria such as Streptococcus pneumoniae and greater neutrophil phagocytosis (Jefferis, 
2012). 
Chapter 1: Introduction 
47 
 
IgG4 primarily binds protein antigen and is produced as the result of a Th2-dependent 
response. Like IgE, IgG4 is often raised in response to allergens and has been found to be 
important in the antibody response against Schistosoma mansoni (Boctor & Peter, 1990). IgG4 
does not induce complement and is not a potent binder of most FcγR. IgG4 responses are 
often formed following long-term or repeated exposure to an antigen, for example after a 
course of immunotherapy. It is thought that a major role of IgG4 is to regulate inflammatory 
IgE responses by blocking IgE antibodies from binding the antigen (Nouri-Aria et al., 2004, 
Francis et al., 2008, James et al., 2011, Boctor & Peter, 1990). 
IgG4 antibodies display a phenomenon known as IgG4 Fab arm exchange in which IgG4 half-
molecules randomly recombine with each other creating a bispecific antibody which is 
monovalent for each antigen; these antibodies cannot form immune complexes (Aalberse et 
al., 2009, Nirula et al., 2011). It is thought that the rate at which Fab arm exchange takes place 
is controlled by the redox environment and therefore may vary between tissues (Rispens et al., 
2011). 
1.7.2.4 IgA 
Secretory IgA is the predominant antibody at most mucosal surfaces, and serum IgA is the 
second most prevalent blood antibody after IgG. Serum IgA is made in the lymph nodes and 
bone marrow and tends to be monomeric, whereas secretory IgA is made in the lymphoid 
tissues at mucosal surfaces and tends to be dimeric. There are two IgA subclasses (IgA1 and 
IgA2), approximately 90% of serum IgA is IgA1, whereas secretory IgA is approximately 60% 
IgA2 and 40% IgA1, however this ratio varies between mucosal locations (Woof, 2013). 
The major structural difference between IgA1 and IgA2 is that IgA1 has a much longer hinge 
region than IgA2. This may give IgA1 a higher avidity by allowing bivalent reactions with more 
distant antigens, however the extended hinge region does make IgA1 vulnerable to cleavage 
by proteases expressed by certain pathogenic bacteria (Woof & Kerr, 2004). 
IgA can activate both the alternative and the lectin complement pathways (Roos et al., 2001). 
IgA interacts with the Fc-alpha receptor FcαRI which is expressed on cells such as neutrophils, 
eosinophils, monocytes, macrophages and Kupffer cells. Both monomeric and dimeric IgA is 
able to interact with FcαRI, however secreted IgA binding is hampered by steric hindrance 
caused by the secretory component. Therefore, while serum IgA is capable of triggering 
inflammatory responses such as phagocytosis and ADCC, secretory IgA is thought to be non-
inflammatory and primarily plays a role in preventing the adherence of microorganisms to 
mucosal surfaces (Bakema & van Egmond, 2011). Additionally, secretory IgA is present at very 
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high concentrations in breast milk and plays an important role in the passive protection against 
infection of infants (Hanson & Korotkova, 2002). 
Unlike the blood antibody repertoire, which have a bias towards kappa light chains, secreted 
antibodies have a bias towards lambda light chains (Mole et al., 1994). 
1.7.2.5 IgE 
IgE is the least prevalent class in the blood, with a half-life of just three days (compared to the 
IgG half-life of 20 days). However, most IgE is not in the serum, but is sequestered in relevant 
tissues (Gould et al., 2003). 
IgE is produced as part of a Th2 response against parasitic worm infections such as 
Schistosoma mansoni and Trichinella spiralis. IgE Fc interacts with two Fc-epsilon receptors: 
FcεRI and CD23 (FcεRII). FcεRI is a high-affinity IgE receptor and is expressed on mast cells, 
basophils, antigen-presenting cells, monocytes and eosinophils. The binding of FcεRI leads to 
degranulation of mast cells and a strong inflammatory response. IgE plays a role in allergy 
when these responses are raised against something harmless such as pollen (Gould & Sutton, 
2008). 
Certain IGHV families are associated with certain allergies. For example, there is a bias towards 
IGHV1 usage in the IgE antibodies of people with peanut allergies (Janezic et al., 1998). 
IGHV4-21 is prevalent in autoantibodies against red blood cells as a result of Epstein-Barr Virus 
infection (Chapman et al., 1993). IGHV5 has been associated with atopic dermatitis (Van der 
Stoep et al., 1993), asthma (Snow et al., 1995) and allergic rhinitis (Coker et al., 2005). 
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1.8 High Throughput Sequencing of Immunoglobulin Repertoires 
High-throughput sequencing technologies have become more accurate and more affordable in 
recent years. With this advance in technology, high-throughput sequencing has become a 
more popular method of investigating the B cell repertoires of healthy individuals and various 
patient groups. A summary of the main stages involved in building high-throughput B cell 
repertoire sequencing libraries is given below. 
1.8.1 Isolating Functional Antibody Variable Region Sequences 
The initial step of building a B cell repertoire library for high-throughput sequencing (HTS) is 
the isolation of functional immunoglobulin variable region sequences. These can be isolated 
from B cell gDNA or mRNA obtained from sorted B cell populations or total RNA from whole 
blood/tissue. If mRNA is used, this is reverse transcribed either using oligo-dT primers, random 
primers or specific primers. The immunoglobulin transcripts are amplified using PCR. 
There are two drawbacks of using PCR to generate enough sample material for HTS. Firstly, 
even if a very high-fidelity DNA polymerase is used, PCR does not have an error rate of zero. As 
immunoglobulin variable regions are extremely diverse (due to combinatorial diversity, 
junctional diversity and somatic hypermutation), it is often impossible to tell if a sequence 
contains errors. However, the number of errors can be minimised by using a high fidelity DNA 
polymerase and few rounds of PCR. The second drawback of using PCR to amplify variable 
regions is bias introduced by primers. It is common to use a set of V gene-specific and J gene-
specific primers based on the set described in Sblattero &Bradbury (1998). However, some 
primers may be present in the mix in higher quantities than others and some primers may bind 
better than others leading to biases in the frequency with which certain sequences are 
amplified and therefore represented in the resulting dataset. Furthermore, if there are 
mutations at the beginning of the V gene or the end of the J gene (due to either allelic 
variation or somatic hypermutation) these are erased by the primer sequence and this 
information is lost from the resulting dataset. A better method of variable region amplification 
is to introduce universal primer site for example using the 5’-template switch method 
described in Mamedov et al. (2013). In this method, a universal primer site is added at the 5’ 
end of the cDNA transcript during reverse transcription. A single forward primer which binds 
the universal primer site is then used for all amplifications. 
The template switch method has the added advantage that it allows the introduction of unique 
identifiers (UIDs) to the cDNA transcripts. Later, in the bioinformatic analysis, UIDs enable 
distinction between PCR amplification (identical UIDs) and clonal expansion (similar/identical 
variable regions with different UIDs). The mixture of UIDs needs to be diverse enough that the 
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chances of two variable regions being tagged with the same UID is low – this is known as the 
birthday paradox (Friedensohn et al., 2017). However, although UIDs allow the distinction 
between mRNA transcripts, this does not necessarily mean that the mRNAs came from 
different cells. Different cell types express different amounts of antibody, for example, plasma 
cells express large amounts of antibody and therefore have large amounts of immunoglobulin 
mRNA. One way to distinguish between mRNA originating from different cells is to sort the 
cells with barcoded beads using microfluidics. This method also addresses the problem of 
maintaining native heavy-light chain pairing information. 
Maintaining native heavy-light chain pairing is a significant problem in B cell repertoire 
analysis. IgH, IgK and IgL loci are located on separate chromosomes and are transcribed on 
separate mRNA. A B cell expressing functional immunoglobulins will express heavy chain 
mRNA and light chain mRNA on separate transcripts. Therefore, if all the mRNA from whole 
blood or a population of sorted B cells is used to amplify variable region sequences in a single 
reaction, it is impossible to determine which heavy and light chain sequences were paired in 
the individual B cells. One method sometimes employed is to assume that paired heavy and 
light chain sequences occur at similar frequencies in the repertoire and so heavy-light chain 
pairs can be inferred by matching frequencies. However, this is not a reliable method as primer 
biases can affect the extent to which sequences are amplified and repertoires tend to follow 
power-law distributions (Friedensohn et al., 2017). A “low-throughput” method of maintaining 
heavy-light chain pairing information is to sort single B cells into individual wells of 96-well 
plates and perform PCR reactions in the single wells (as used in Wardemann et al. (2003), for 
example). This method works as a way of maintaining heavy-light chain pairing information, 
however it is not possible to create very large datasets due to the large amount of time and 
reagents it would involve. So far, the most promising high-throughput method of maintaining 
heavy-light chain pairing information is encapsulating individual B cells in oil emulsion droplets 
containing oligo-dT-coated magnetic beads. The cell is lysed within the droplet and the mRNA 
is captured on the bead. The beads are then re-encapsulated in droplets containing reverse 
transcription and PCR reagents and overlap-extension PCR can take place, joining the heavy 
and light chain transcripts with a linker sequence. If the oligo-dT beads are also labelled with 
UIDs, and a single bead is encapsulated with a single cell, the transcripts are also labelled with 
a cell-identifying UID (as opposed to mRNA-identifying UIDs) and clonal expansions can be 
identified with even more certainty. A pioneer of this method was George Georgiou (DeKosky 
et al., 2015, McDaniel et al., 2016) and the technique is beginning to become more widespread 
(Rajan et al., 2018). However, encapsulating single cells in droplets and performing PCR within 
these droplets is technically challenging. 
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A further consideration is that the B cell repertoire (repertoire of functional rearranged 
immunoglobulin sequences encoded on mRNA in circulating B cells) may not be the same as 
the antibody repertoire (the physical antibody proteins present in the serum). Antibodies may 
be expressed from memory B cells in the bone marrow, and many B cells circulating in the 
blood will not be expressing soluble antibodies. It seems that only a small fraction of the 
antibodies encoded in circulating B cells express antibodies in the serum (Lavinder et al., 
2015). With the use of mass spectrometry, the antibody repertoire is something which can 
now be investigated. 
1.8.2 Clonality Analysis 
There are many definitions of clonal expansions with the very simplest being identical VDJ 
gene usage and identical CDR-H3 sequences. It is generally agreed that a clonal expansion 
should use the same V genes and J genes. Some papers also require identical CDR-H3 amino 
acid sequences. Although this may be suitable for the analysis of antigen-naïve repertoires, the 
stipulation for identical CDR-H3 is unnecessarily harsh when analysing antigen-experienced 
datasets as somatic hypermutation continues during clonal expansion and so clonally related 
B cells may not express antibodies with identical CDR-H3. 
Another issue with identifying clonal expansions is determining how the sequences should be 
compared. If the clone is identified at random and built around the first unique sequence 
identified, sequences at the “edges” of the clone may be placed differently in the clone than if, 
for example, the highest copy number sequence had been used as the starting point. 
Therefore, a better way of identifying clonal expansions is to take all potential members of a 
clone (e.g. all those with identical V gene and J gene usage) and to build a lineage tree. The 
branches of the tree are then “cut” and clones with a similar amount of mutation are 
considered part of the same clone (Hershberg & Luning Prak, 2015). The cut-off value chosen 
determines the level of similarity which defines a clonal expansion. 
A common method of measuring CDR-H3 similarity is the Hamming distance (Hamming, 1950). 
The primary drawback of this method is that the CDR-H3 must be of the same length to be a 
clonal expansion. However, during sequencing, homopolymers common in the IGHD genes can 
lead to sequencing errors which can lead to clonally related CDR-H3 with apparently different 
lengths. Furthermore, SHM can sometimes introduce indels which could alter the length of the 
CDR-H3 (Wilson et al., 1998, Goossens et al., 1998). Therefore, an alternative distance 
measure, which does allow for indels, is the Levenshtein distance (Levenshtein, 1966). 
Chapter 1: Introduction 
52 
 
It is the heavy chain (rather than the light chain) which is used for identifying clonal expansions 
as the diversity of the CDR-H3 means it would be very unlikely to find the same CDR-H3 twice 
by chance. The light chain is less diverse and public light chains can be found within multiple 
individuals (DeKosky et al., 2015). Therefore, although one would expect to find the same light 
chains within clonal expansions of paired heavy-light chain data, identifying clonally expanded 
light chains is not as reliable as with heavy chains. Also, because light chain rearrangement 
occurs in the bone marrow after some B cell proliferation, heavy chains from the same original 
B cell are found with different light chains (Wang et al., 2003). 
1.8.3 Tools for Repertoire Analysis 
IMGT High V-QUEST (Alamyar et al., 2012b, Alamyar et al., 2012a, Li et al., 2013, Giudicelli et 
al., 2015) has been available the longest and is the most popular. IMGT also maintains a 
number of immunoglobulin gene databases. There are a number of other tools available to 
identify VDJ genes. IgBLAST (Ye et al., 2013) is a modified version of the National Centre for 
Biotechnology Information (NCBI) BLAST tool (Altschul et al., 1997) which is aimed specifically 
at identifying immunoglobulin and T cell receptor genes, for example it is able to consider 
short (D gene) and long (V gene) matches simultaneously when analysing a rearranged variable 
region. IgDiscover (Corcoran et al., 2016) offers the capability to identify new V gene and 
alleles which are missing from current datasets, allowing the construction of personalised 
V gene datasets. JOINSOLVER (Souto-Carneiro et al., 2004) has a particular focus on analysing 
the CDR3. Other tools available include Ab-origin (Wang et al., 2008), VDJsolver (Ohm-Laursen 
et al., 2006), iHMMune-align (Gaëta et al., 2007), SoDA/SoDA2 (Volpe et al., 2006, Munshaw & 
Kepler, 2010) and VBASE2 (Retter et al., 2005). These methods use either sequence alignment 
or hidden Markov models to identify VDJ gene usage. IgSCUEAL (Frost et al., 2015) uses a 
phylogenetic approach to VDJ assignment. 
Aside from assigning VDJ genes and identifying CDR3 regions, further analysis such as clonality 
analysis, somatic hypermutation frequency and CDR3 property analysis is possible. There are a 
number of suites available to do this, some are R packages, for example bcRep (Bischof & 
Ibrahim, 2016) and Change-O (Gupta et al., 2015). Others have a more user-friendly web 
interface, for example ARGalaxy (IJspeert et al., 2017), VDJServer (Christley et al., 2018) and 
BRepertoire (Margreitter et al., 2018). 
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1.9 Autoimmune Disease 
Autoimmune disease occurs when the immune system attacks self-tissues, believing them to 
be pathogenic. Autoimmune diseases often involve autoreactive antibodies. Autoreactive 
antibodies can arise in a number of ways, primarily breakdown of tolerance, immunological 
ignorance (B cell did not encounter the autoantigen in the bone marrow) or as a result of an 
infection (molecular mimicry). The study of the B cell repertoire has allowed the identification 
of some common features of autoreactive antibodies such as frequent use of particular 
VDJ genes or a bias towards certain CDR3 properties (IGHV4-34 is very commonly associated 
with autoimmune disease). In some cases the B cell repertoire can be quite different in 
patients with an autoimmune disease compared to healthy controls (Dörner et al., 1999). 
One of the most well-known autoimmune diseases is systemic lupus erythematosus (SLE), a 
disease in which multiple organs are attacked by the immune system. Autoantibodies are an 
important feature of SLE (over 100 autoantibody targets have been associated with the 
disease) however the autoantibodies most strongly associated with SLE are anti-nuclear 
antibodies (ANAs), which are present in over 95% of SLE patients (Bashford-Rogers et al., 2018) 
and are often present before the onset of clinical symptoms (Arbuckle et al., 2003). The 
autoantibodies in SLE are predominantly somatically mutated IgG and it is thought that they 
originate from autoreactive naïve B cells which are present in the periphery at a high 
frequency due to defective tolerance checkpoints (Yurasov et al., 2005, Yurasov et al., 2006). 
IGHV4-34 usage is very strongly associated with SLE (Tipton et al., 2015) and this gene is 
associated with a multitude of autoimmune targets, for example dsDNA, rheumatoid factors 
and I/i self-antigen on red blood cells (Potter et al., 2002). There is also a higher frequency of 
charged amino acids (such as arginine) in the CDR3 of B cells isolated from SLE patients 
(Bashford-Rogers et al., 2018). DNA is an intracellular antigen and therefore usually resides in 
an immune-privileged site. However, intracellular antigens such as DNA can become accessible 
in times of stress, disease or trauma. 
Another example of autoimmune disease caused by antigen in an immune-privileged site is 
sympathetic ophthalmia. Sympathetic ophthalmia is an ocular autoimmune disease which 
occurs due to the release of immune-privileged antigens as a result of trauma to the eye 
(Margo & Harman, 2016). 
Multiple sclerosis (MS) is thought to be an autoimmune disease which may be caused by 
molecular mimicry. MS has also been linked to infection such as Epstein-Barr virus (EBV), 
human herpes virus-6 (HHV-6), varicella zoster virus (VZV) and Chlamydia pneumoniae (Weber 
et al., 2011). A characteristic feature of MS is the presence of antibodies in the cerebral spinal 
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fluid and symptoms are caused by the gradual demyelination of the myelin sheath of neurones 
in the brain and spinal cord. However, identifying specific self-antigens associated with MS has 
proved challenging. Nevertheless, it has been shown that there is an increased frequency of 
IGHV1 and IGHV4 families (particularly IGHV1-69, IGHV4-34 and IGHV4-39) and also IGHD2, 
IGHD3 and IGHJ4 families in the brain lesions of MS patients (Baranzini et al., 1999), indicating 
that autoantibodies may be involved in demyelination. 
Another well-known autoimmune disease is rheumatoid arthritis (RA). RA is the inflammation 
of the synovial membrane due to the activation of plasmablasts expressing autoantibodies 
against targets such as rheumatoid factor and citrullinated proteins (Tan et al., 2014). 
Dominant clones isolated from RA patient synovial fluid were enriched for IGHV4 usage 
(particularly IGHV4-34) and long CDR-H3 (Doorenspleet et al., 2014). 
In addition to immunological ignorance and molecular mimicry, a further cause of 
autoreactivity is thought to be polyspecificity. It is thought that polyreactive antibodies bind 
multiple epitopes and are therefore likely to be reactive with a self-antigen. Despite this 
apparent danger, polyreactive antibodies are a common feature of a healthy immune antibody 
repertoire. 
  




The traditional “lock and key” hypothesis of antibody binding suggested that antibodies have 
very rigid antigen-binding sites which would only bind a very particular complementary 
epitope. However, it was discovered that some antibodies were capable of binding multiple, 
structurally unrelated antigens. These antibodies are termed “polyreactive”. 
The mechanism of polyreactivity has been debated for some time and there is still no clear 
physicochemical or structural explanation or general rules for how polyreactive antibodies 
differ from monoreactive antibodies. One hypothesis is that a polyreactive antibody exists in 
multiple configurations/isomers before it even encounters antigen (Ma et al., 2002). 
Crystallographic studies have provided evidence of this (James et al., 2003). Another 
hypothesis is that the antigen-binding site is flexible and changes shape to fit various antigens 
(“induced fit” hypothesis) (Rini et al., 1992). This has been backed up by crystallographic 
studies which show, for example, that an anti-p24 (HIV1) monoclonal antibody binds a number 
of unrelated peptides, using different conformations and residues for binding (Keitel et al., 
1997, Kramer et al., 1997). There is a hypothesis that some polyreactive antibodies have a 
hydrophobic “sticky” variable region due to aromatic residues (Padlan, 1994, Droupadi, 1994), 
however others have disputed this, arguing that polyreactive antibodies bind to structurally 
different antigens using different specific hydrogen bonds (James & Tawfik, 2003). Polyreactive 
antibodies tend to bind antigen with a lower affinity than monoreactive antibodies, they are 
often of IgM isotype and their variable regions tend to be closer to the germline configuration 
(Notkins, 2004). Animal studies suggest that polyreactive antibodies have a shorter half-life 
than monoreactive antibodies as they are cleared from the circulation much faster (Sigounas 
et al., 1994). 
Polyreactivity is common in the natural antibody repertoire. Natural antibodies are antibodies 
that are secreted by B cells which have not been stimulated by cognate antigen. Natural 
antibodies are thought to be a first line of defence against an invading pathogen. The 
polyreactivity of natural antibodies allows them to bind new pathogens (albeit with a lower 
affinity than an antigen-matured antibody) and activate the complement pathway while a 
more specific humoral response is being mounted (Zhou et al., 2007). Furthermore, natural 
antibodies bind apoptotic cells to aid complement fixation and phagocytosis by macrophages 
(Gunti & Notkins, 2015). There is a high incidence of B cells expressing polyreactive antibodies 
in the thymus suggests that they may have a second role in tolerance, bringing self-antigen 
into the thymus from the periphery to help develop/maintain tolerance (Zhou & Notkins, 
2004). Polyreactive antibodies appear to be an important part of the normal adult repertoire 
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and are the predominant type in newborns’ repertoires (Chen et al., 1998). Polyreactive 
natural IgA antibodies may coat the microbiota in the gut (Bunker et al., 2017). 
Polyreactivity can be beneficial in that it increases the diversity of the antibody beyond that 
achieved by V(D)J recombination, N-nucleotide addition and heavy-light chain pairing. 
However, the drawback of increased diversity is that it can result in autoreactivity. Some 
studies have found that polyreactive antibodies are prevalent in the bone marrow, but are 
selected out of the repertoire at the tolerance checkpoints (Wardemann et al., 2003). 
Antibody polyreactivity has been linked to autoreactivity as polyreactive antibodies have been 
found to be more prevalent in people with rheumatoid arthritis (Samuels et al., 2005) and SLE 
(Yurasov et al., 2005). However, a different study found the converse, suggesting that 
polyreactive antibodies were equally or less common in the repertoire of those with Sjögren’s 
syndrome, rheumatoid arthritis and SLE (Chen et al., 1998). The studies used different 
methods to identify polyreactive antibodies; the former two used ELISA while the latter used 
FACS. This may have contributed to the differing results, however it does add to the 
conundrum of whether polyreactivity is advantageous or dangerous. There is plenty of 
evidence to suggest that polyreactivity is an important feature of natural antibodies, however 
they have also been found to be frequently autoreactive. Perhaps polyreactive antibodies are 
both advantageous and dangerous; a necessary evil to broaden the antibody repertoire and 
act as a first line of defence against infection, but with the risk of autoreactivity. 
Furthermore, our understanding of exactly what polyreactivity is and how to define it remains 
unclear. The most accepted definition of polyreactivity is that it is the specific binding by an 
antibody of multiple structurally unrelated antigens. However, this is difficult to measure 
without solving the crystal structure of an antibody in complex with multiple antigens. Some 
polyreactivity may be down to molecular mimicry (although it is argued that this is not true 
polyreactivity as the same epitope is being bound by the antibody), whereas other 
polyreactivity may be down to antibody “stickiness” where hydrophobic patches interact with 
multiple antigens. But is such “stickiness” truly polyreactivity? Many antibodies may show 
some interaction with multiple antigens at a high enough concentration or under particular 
circumstances, but the interaction may be weak. It is argued by some that antibodies should 
only be described as polyreactive if they bind structurally different antigens with 
physiologically relevant affinities (Dimitrov et al., 2013). Another issue is how to identify a 
monoreactive antibody. How many different antigens need to be tested before an antibody is 
classified as monoreactive? Nobody has yet been able to identify general physicochemical or 
structural properties which can reliably differentiate polyreactive and monoreactive 
antibodies.  
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1.11 Antibody Response against Ebola Virus 
1.11.1 Ebola Virus Disease 
Ebola virus disease (more commonly referred to as Ebola) is a viral haemorrhagic fever caused 
by members of the genus Ebolavirus, which contains five species: Zaire ebolavirus (Ebola virus, 
EBOV), Sudan ebolavirus (Sudan virus, SUDV), Taï Forest ebolavirus (Taï Forest virus, TAFV), 
Reston ebolavirus (Reston virus, RESTV) and Bundibugyo ebolavirus (Bundibugyo virus, BDBV). 
The genetic diversity between Ebolavirus species is 25-35% (Grard et al., 2011). The Ebolavirus 
genus is part of the Filoviridae family, which includes two other genera: Marburgvirus and 
Cuevavirus. Marburgvirus contains two viruses of the species Marburg marburgvirus: Marburg 
virus (MARV) and Ravn virus (RAVV), both of which cause a severe haemorrhagic fever in 
humans similar to Ebola. Cuevavirus contains one species: Lloviu cuevavirus (Lloviu virus, LLOV) 
which is not thought to be pathogenic to humans. The phylogenetic relationships of the 
Filoviridae species are shown in Figure 1-12. 
 
Figure 1-12: Filoviridae phylogenetic tree. The Filoviridae family contains three genera: 
Ebolavirus (red), Marburgvirus (blue) and Cuevavirus (green). Phylogenetic relationships were 
calculated by aligning complete viral genome sequences and displayed as an unrooted tree 
(Boc et al., 2012). 
Symptoms of Ebola can include fever, headache, vomiting, diarrhoea, impaired kidney and liver 
functions, internal and external bleeding and, in some cases, death. Ebola spreads by direct 
human-to-human contact with infected individuals. The case fatality rate ranges from 25% to 
90% depending on the outbreak and the Ebolavirus species responsible. The species most 
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frequently the cause of Ebola outbreaks, and also associated with the highest mortality, is 
Zaire ebolavirus (EBOV). EBOV was the cause of the 2014-2016 West African Ebola outbreak in 
which 28,610 people were infected and 11,308 people died in Sierra Leone, Liberia and Guinea 
(WHO, 2018a). 
EBOV is coated with membrane-bound glycoprotein (GP) which is used for host cell entry by 
binding to cell surface molecules such as lectin-type molecules. The virion enters the host cell 
by a combination of macropinocytosis and endocytosis. Within the endosome, cathepsins 
proteolytically cleave the GP and the virus fuses with the endosome membrane, releasing viral 
ribonucleoprotein into the host cell cytoplasm where the viral genome is transcribed and viral 
replication occurs. Viral GP is expressed on the surface of infected host cells and new viral 
genomes are transported to the surface where they bud off, releasing new virus (Baseler et al., 
2017). 
Membrane-bound GP is a major target for antibodies. Therefore, EBOV employs a number of 
immune evasion tactics to hide membrane-bound GP from the immune system. Membrane-
bound GP contains a very heavily glycosylated glycan cap and mucin-like domain (MLD) which 
shield the more conserved regions of the GP (Francica et al., 2010, Lennemann et al., 2014). 
Additionally, large amounts of secreted GP (sGP) (a truncated form of membrane-bound GP) is 
released extracellularly. It is thought that sGP acts as a decoy, binding GP-specific antibodies to 
prevent them from binding membrane-bound GP and neutralising the virus (Ito et al., 2001). 
The main cell types infected by EBOV are dendritic cells, monocytes and macrophages and 
infected cells travel to the lymph nodes, via the lymphatic system, where the virus replicates 
and is disseminated. The viral load in the blood increases exponentially in the first three days 
following the onset of symptoms, becoming widely disseminated. This indicates that the virus 
overcomes innate immune defences. EBOV is able to evade both the innate and the adaptive 
immune responses using a number of mechanisms. Viral protein (VP) 24 and VP35 both 
antagonise the interferon response and VP35 also inhibits the upregulation of MHC class I, 
MHC class II and various costimulatory molecules, impeding the CD8 and CD4 T cell response 
and thus the entire adaptive immune response (Baseler et al., 2017). 
Despite the immunosuppressive nature of Ebola, a strong antibody and T cell response is 
mounted during Ebola virus disease and antigen stimulation appears to continue for over a 
month after recovery as activated CD8 T cells persist for this length of time (McElroy et al., 
2015). Much of the pathology associated with Ebola is thought to be due to the host immune 
system’s response (e.g. release of cytokines). 
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It is unclear exactly when a patient has cleared the infection as viral RNA has been found to 
persist in other areas, such as urine and sweat, even after it no longer appears in the blood 
(Kreuels et al., 2014). 
1.11.2 Viral Glycoproteins 
Ebola viruses are enveloped, non-segmented negative-sense ssRNA viruses. The genome is 
approximately 19 kb and consists of seven genes (Figure 1-13A), all of which are monocistronic 
except the fourth gene in the genome (GP), which encodes three forms of glycoprotein (GP): 
envelope GP (GP), secreted GP (sGP), and small secreted GP (ssGP) (see Figure 1-13A). These 
three proteins are expressed from GP via transcriptional editing. The primary product is sGP 
and is translated from ORF 0. Approximately 71% of GP transcripts encode sGP. The secondary 
product is envelope GP. GP is expressed from ORF +1 after transcriptional editing where, 
during the transcription of seven uridines in the genomic RNA, an additional adenosine is 
added, causing a frameshift. Approximately 24% of GP transcripts encode GP. The tertiary 
product is ssGP. ssGP is the result of two adenosine insertions causing a frameshift to ORF +2. 
Approximately 5% of transcripts encode ssGP. sGP and ssGP are both secreted whereas 
envelope GP has a transmembrane domain and is therefore membrane-bound (Mehedi et al., 
2011). 
Envelope GP is first translated as a single peptide which is then cleaved with furin during post-
translational modifications into GP1 and GP2 subunits. These subunits come together to form 
heterodimers held together by disulphide bonds and three heterodimers join to form the 
membrane-bound GP trimer (Jeffers et al., 2002) (Figure 1-13B). The more conserved regions 
of GP required for host cell entry and interactions in the endosome sit near the base of the GP 
or within the structure and are protected by the heavily glycosylated glycan cap and mucin-like 
domain (MLD). The glycan cap contains four N-linked glycosylation sites and the mucin-like 
domain contains five N-linked and 12-17 O-linked glycosylation sites (Lee & Saphire, 2009). 
Marburg virus GP is only translated in a single reading frame and therefore expresses only 
membrane-bound GP. Like EBOV GP, Marburg GP is a trimer composed of three GP1-GP2 
dimers (Jeffers et al., 2002). 




Figure 1-13: EBOV genome and structure of EBOV GP. A) GP is the fourth gene in the EBOV 
genome and encodes GP, sGP and ssGP; their expression is controlled by transcriptional 
editing. B) GP is a membrane-bound trimer composed of GP1-GP2 heterodimers. GP1 is shown 
in green, with the glycan cap highlighted in teal. GP2 is shown in orange. The location of the 
mucin-like domains are shown by grey circles in the side view diagram. PDB ID: 3CSY. 
1.11.3 Antibody Response against Ebola Virus 
The immune response to Ebola virus disease is still not fully understood. However, it is known 
that patients who have high anti-Ebola antibody titres early in Ebola infection are more likely 
to survive, whereas low or absent antibody titres are associated with fatalities (Ksiazek et al., 
1999, Baize et al., 1999). This indicates that the antibody response is important in fighting 
Ebola virus disease. 
Ebola survivor serology shows that the IgG response to Ebola is stronger than the IgM 
response; the IgM response declines after early infection (by day 80), whereas the IgG 
response persists (MacNeil et al., 2011). However both isotypes are capable of neutralising the 
virus and IgA is also raised against GP (Khurana et al., 2016). By using cell sorting, it has been 
shown that even three months after primary infection, approximately 3% of the IgG+ B cells in 
a patient’s repertoire can still be EBOV GP-specific, which is similar to the frequency of 
antigen-specific antibodies seen in chronic HIV patients (Bornholdt et al., 2016b). Furthermore, 
circulating anti-EBOV GP antibodies are maintained for more than 10 years after infection 
(Misasi et al., 2016). 
When investigating the composition of the B cell repertoire in response to Ebola, it has been 
found that the anti-GP B cell repertoire is very diverse (unlike anti-HIV and anti-influenza 
repertoires which show lots of clonal expansion). The repertoire is slightly skewed towards IgK 
chain usage and longer CDR-H3, but with no bias in V(D)J gene usage (Bornholdt et al., 2016b). 
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The most promising anti-Ebola vaccine is VSV-ZEBOV, which has just passed clinical trials. The 
vaccine raises an antibody response against Ebola (Zaire) glycoprotein (GP). 
Vaccines are extremely important in the fight against Ebola, but so are post-exposure 
treatments as it can sometimes be difficult to get vaccines to everyone and sometimes 
vaccines do not confer complete, lifelong protection. Monoclonal antibody therapies are an 
important line of investigation for post-exposure treatments. 
1.11.4 Anti-Ebola Therapeutic Antibodies 
GP is the primary target of the antibody response against Ebola and membrane-bound GP 
trimers are the focus of efforts to find new antibody-based therapies. Antibodies have been 
discovered which bind a diverse range of antigenic sites on GP, for example the outward-facing 
glycan cap and mucin-like domain (MLD), the GP1-GP2 interface at the base of the structure 
and the ribosome-binding site (RBS) in a protected site within the GP (Figure 1-13B). 
When investigating the potential of antibodies as therapeutic candidates, three stages of 
testing are initially employed: 
1. Can the antibody bind to the GP in vitro? (e.g. ELISA, Biacore, Octet etc.) 
2. Can the antibody neutralise the virus in vitro? (neutralisation assay) 
3. Can the antibody protect animals in vivo from viral challenge? 
To be a useful anti-GP antibody, an antibody must fulfil the first criterion of binding the GP 
structure. However, the antibody does not necessarily have to fulfil both criteria 2 and 3 to 
have therapeutic value. Some antibodies show neutralisation in in vitro neutralisation assays, 
but are not efficacious in vivo. Conversely, some antibodies may not neutralise an antibody 
in vitro but are still somehow effective in vivo or may be useful as part of a cocktail of 
monoclonal antibodies which bind several antigenic sites (Duehr et al., 2017). 
Antibodies directed against different sites in the GP trimer have different in vitro neutralisation 
and in vivo protective efficacies. It is thought that antibodies which bind the GP1-GP2 interface 
at the base can neutralise the virus by preventing GP2 structural changes required for viral 
entry into host cells (Murin et al., 2014). Indeed, the human antibody KZ52 binds the GP1-GP2 
interface and neutralises EBOV in vitro (Maruyama et al., 1999) and is also protective in vivo in 
guinea pigs (Parren et al., 2002). However, KZ52 is not protective in vivo in non-human 
primates (Oswald et al., 2007) indicating that the efficacy of an antibody relies on multiple 
factors, not just whether it binds the right epitope. Nevertheless, the GP1-GP2 interface is a 
good therapeutic target and other antibodies which bind in this region are effective in non-
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human primates and humans. The best known examples of this are 2G4 and 4G7 which are 
part of the monoclonal antibody cocktails ZMab and ZMapp (Figure 1-14). Monoclonal 
antibody cocktails confer post-exposure protection and both ZMab and ZMapp were used to 
treat humans in the 2014 Ebola outbreak on compassionate grounds. 
 
Figure 1-14: Binding sites of anti-EBOV GP monoclonal antibodies and composition of three 
well known anti-EBOV monoclonal antibody cocktails. ZMapp is the most efficacious cocktail 
and uses the best antibodies from MB-003 and ZMab. Image modified from González-González 
et al. (2017). 
ZMab is composed of three mouse-derived anti-EBOV GP antibodies (1H3, 2G4 and 4G7). The 
cocktail provides 100% protection in macaques when administered within 24 hours of 
exposure and 50% protection when administered within 48 hours of exposure (Qiu et al., 
2012). ZMapp also contains 2G4 and 4G7, however they are mixed with another mouse-
derived antibody: 13C6 (Qiu et al., 2011, Wilson et al., 2000). ZMapp is more effective than 
ZMab as it shows 100% efficacy in non-human primates when administered up to five days 
post-infection (Qiu et al., 2014). The difference between the two cocktails is whether they use 
1H3 (ZMab) or 13C6 (ZMapp). Both antibodies bind the glycan cap, indicating that the slight 
difference in binding site substantially affects efficacy of the cocktail. 
Despite their clear value in monoclonal antibody cocktails, antibodies which bind in the glycan 
cap or MLC are rarely protective on their own or in the absence of complement (Murin et al., 
2014). However, there are exceptions to this and protective antibodies have been identified 
which bind the glycan cap. For example, two human monoclonal antibodies (mAB100 and 
mAB114) used in combination protect non-human primates from lethal challenge with EBOV 
(Misasi et al., 2016). mAB100 bound at the GP1-GP2 base and mAB114 bound at the glycan 
cap. Surprisingly, monotherapy with mAB114 alone was sufficient to provide protection to 
macaques against lethal EBOV challenge (Misasi et al., 2016). Furthermore, broadly-
neutralising antibodies have been isolated from the blood of human BDBV survivors which 
bind the glycan cap of multiple Ebolavirus species (Flyak et al., 2016). The identification of 
broadly-neutralising glycan cap-binders is particularly surprising because it is thought that the 
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main purpose of the heavily glycosylated glycan cap and MLD is to protect the more conserved 
GP epitopes (such as the RBS) from recognition by antibodies. 
Due to the difficulty in creating anti-Ebola antibody therapies and the substantial threat from 
lesser-studied Ebolavirus species such as BDBV or RAVV or newly emerging Filoviruses (LLOV 
was discovered in Spain as recently as 2002) (Burk et al., 2016), cross-neutralising antibodies 
are particularly important. However they are difficult to find, particularly amongst all species in 
the Filoviridae family due to low GP sequence identity: EBOV and SUDV (the most divergent 
Ebolavirus species) have 56% GP sequence identity, whereas EBOV and MARV GP have just 
30% sequence identity (Keck et al., 2016). 
The most conserved GP region within the Filoviridae is the RBS and GP2 and these are often 
the sites of broadly-neutralising antibody binding. MR72 is a human antibody isolated from a 
MARV survivor which can neutralise VSVs expressing cleaved GP from all known Filoviruses. It 
does this by binding the highly conserved RBS (Bornholdt et al., 2016a). However, MR72 is 
unable to bind uncleaved GP expressed on the vesicular stomatitis virus (VSV) surface. This is 
probably because the RBS is well protected on the viral surface by the heavily glycosylated 
glycan cap and MLD. Therefore, any therapeutic anti-RBS antibodies may have to be targeted 
to the endosome where the GP is cleaved by proteases and the RBS is revealed. However, an 
RBS-binding antibody (FVM04) has been discovered which, when 4G7 in ZMapp was replaced 
by FVM04, the anti-EBOV efficacy of the ZMapp was retained but the cocktail also protected 
guinea pigs against SUDV (Howell et al., 2016). This indicates that RBS-binding antibodies may 
have a role in antibody cocktails to increase the breadth of protection. 
EBOV-520 is a human IgG4 antibody which binds the base of GP. EBOV-520 shows in vitro 
neutralising capacity against EBOV, SUDV and BDBV and some in vivo protective capacity 
against these species in various animal models (Gilchuk et al., 2018). Furthermore, three 
antibodies isolated from BDBV human survivors (BDBV223, BDBV317 and BDBV340) bind to 
the bottom of the GP in the HR2 domain, close to the viral membrane and well below the 
GP1-GP2 interface. All three antibodies bind GP from EBOV, BDBV and SUDV. They also 
neutralise EBOV and BDBV in vitro and one of them neutralises RESTV (however they failed to 
neutralise SUDV). The antibodies also showed some protection against EBOV and BDBV in 
in vivo animal models (Flyak et al., 2018). 
Cross-reactive antibodies between EBOV and SUDV have also been found in Macaques which 
bind at conserved epitopes in the GP1 core, glycan cap and fusion domain of GP2 (Keck et al., 
2016). 
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As cross-protective antibodies are difficult to find, an alternative solution may be the use of bi-
specific antibodies. For example, a bispecific antibody has been created which protects mice 
from EBOV and SUDV (Frei et al., 2016). 
Post-exposure antibody therapies look to be a very promising treatment option against Ebola 
and we already have the efficacious monoclonal antibody cocktails ZMab and ZMapp. 
However, the greatest weakness of these treatments is that they are not cross-protective 
against multiple Filoviruses. Although many anti-GP antibodies have been characterised, the 
antibody, or mixture of antibodies, which will provide efficacious protection against multiple 
Filoviruses remains elusive. Antibodies isolated from human survivors are potentially very 
useful as they do not need to be humanised in order to be made safe for human use. However, 
the limited number of people who have been infected with Ebola makes this difficult. 
Furthermore, humans tend to be infected with just one strain, and so their antibodies are 
likely to be very strain-specific. Hybridoma and display technologies are therefore useful in the 
search for new cross-protective antibodies, which are essential in the development of 
monoclonal antibody therapies which could be used against any Filovirus outbreak. 
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1.12 Therapeutic Antibodies and their Discovery 
Monoclonal antibody therapies are particularly useful for treating chronic diseases such as 
cancers and autoimmune diseases and some of the most famous include adalimumab 
(Humira), bevacizumab (Avastin), trastuzumab (Herceptin) and rituximab (Rituxan) which treat 
rheumatoid arthritis, colorectal cancer, breast cancer and non-Hodgkin’s lymphoma 
respectively. Monoclonal antibody therapies for infectious diseases are less common as, to be 
most effective, they need to be administered as quickly as possible after infection. However, 
an anti-HIV antibody, ibalizumabuiyk (Trogarzo) has recently been approved and, as 
mentioned in the previous section, anti-Ebola monoclonal antibody cocktails have proved 
useful in the 2014 West Africa outbreak. 
Monoclonal antibodies (and other types of antigen-specific molecules) have huge therapeutic 
potential and their discovery is a large part of many pharmaceutical companies’ business. The 
two primary methods of isolating potentially therapeutic antibodies with the desired 
specificity is hybridoma and in vitro display technologies. 
1.12.1 Hybridoma 
Hybridoma is a method of generating antibodies using the immune response of an animal. The 
mouse (or other mammal) is challenged with the antigen of interest and it raises antibodies 
against the antigen. B cells are then harvested from the spleen of the animal and these are 
fused with an immortal B cell cancer cell line, creating the hybridoma cell line. The hybridoma 
cells are cultured from a starting point of one cell and each clonal population is screened for 
binding to the antigen of interest. 
The two primary issues with hybridoma are firstly, if the antibodies are to be used in humans, 
the animal antibodies must be humanised. In addition to expressing the antibody using a 
human Fc, the Fab region must also be humanised by, for example, expressing the mouse CDR 
sequences on a human FR framework. Humanisation can be problematic because the process 
can sometimes lead to loss of specificity. Although most therapeutic antibodies are either 
human in origin or have been humanised, there are a small number of licensed murine and 
chimeric antibodies (Irani et al., 2015). The second issue with hybridoma is that animals cannot 
be used to raise antibodies against certain antigens, for example if the antigen is toxic to the 
animal.  
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1.12.2 Display Technologies 
An alternative to hybridoma is display methods. These are in vitro methods of selecting for 
antibodies of interest in which a library is constructed of the immunoglobulin variable region 
sequences from the target species (often human). The variable regions are then displayed 
in vitro in a way that allows the phenotype (antibody variable region) to be linked to the 
genotype sequence which encoded it. The variable regions are screened for binding the target 
antigen in vitro (known as “panning selection”) and the nucleotide sequences of the binders 
are identified. The variable region sequences can then be expressed as complete antibodies for 
further investigation. 
The advantages of display methods over hybridoma are that animals are not used in the 
selection and the libraries can be used to find antibodies against almost any antigen. 
Furthermore, the synthetic libraries can be built from human repertoires, meaning that 
humanisation is not required. These synthetic libraries can be extremely large and can even be 
tailored to suit specific needs. 
However, a drawback of synthetic libraries is that, because they are designed by humans, they 
can be vulnerable to researchers’ preconceptions about what will make an effective antibody. 
For example, some libraries may rely on a limited range of V(D)J genes, or may introduce non-
random diversity only to very specific regions. It has been shown that synthetic antibodies rely 
more heavily on the CDR-H3 for interactions with antigen than any other loop, making the 
antigen binding sites less complex than naturally occurring antibodies (Burkovitz & Ofran, 
2016). Naturally occurring antibodies almost always use residues from at least three CDRs to 
make important contacts with antigen (Robin et al., 2014). 
A further drawback of synthetic libraries is that heavy and light chains are almost always linked 
at random and so heavy-light chain pairs are not native. This may make it more difficult to find 
antigen-specific variable regions. 
Variable regions are sometimes expressed as a whole Fab (scFab) but more commonly they are 
expressed as a single chain variable fragment (scFv). One reason for this is that Fab regions 
tend to be more toxic to E. coli and are expressed at a lower level. An scFv consists of the 
heavy and light chain variable regions of an antibody where, instead of being held together by 
the constant region, the variable regions are tethered together by a flexible linker peptide 
(Bird et al., 1988) (see Figure 1-15). 
Linker regions can be 10-25 amino acids long and tend to incorporate hydrophilic amino acids. 
The most common flexible linker is the serine-glycine linker (GGGGS)3, however other linkers, 
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such as ones incorporating part of the CH1/LH elbow regions (He et al., 1995, Tang et al., 
2012), are sometimes used. It has been found that linker sequences composed of elbow 
regions bind equally well as those with serine-glycine linkers, however scFv are expressed in 
greater quantities by E. coli if the VL region precedes the VH region rather than vice versa 
(Anand et al., 1991). 
There are multiple variations on the monomeric scFv. For example, by using shorter linker 
sequences, scFv can form diabodies or triabodies which allows for the possibility of bispecific 
or trispecific molecules. 
 
Figure 1-15: Single chain variable fragment (scFv) structure. Heavy and light chain antibody 
variable regions are joined by overlap extension PCR to form, when translated, an antigen 
binding site linked by a linker sequence instead of the CH1/CL region of a complete antibody. 
The VH sequence can precede the VL sequence or vice versa. 
Despite the flexibility of the scFv format, it is usually important for a variable region to be 
expressed in a full antibody if it is to be use for therapeutic purposes. Most licensed 
therapeutic antibodies are full-length antibodies (predominantly IgG1 due to its prevalence in 
the blood and potent effector functions) (Irani et al., 2015) and it has been shown that the Fc 
region can be important for the protective activity of the antibody (Abboud et al., 2010, 
Bournazos et al., 2014). Although scFv libraries are usually built from human repertoires, and 
so humanisation is not required, binding specificity is not always maintained due to slight 
conformational changes. 
The three most common display technologies for isolating antigen-specific scFv are phage 
display, ribosome display and yeast display. However, some less common techniques such as 
mRNA display and bacterial display are sometimes used. 
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1.12.2.1 Phage Display 
Phage display is the most commonly used in vitro display technology. It involves the use of 
phage (usually M13 phage). The library is built by inserting the DNA encoding the scFv 
upstream of the gene encoding the geneIII terminal protein in the phagemid vector. Three to 
five copies of the scFv are expressed at the terminal end of the phage, attached to the geneIII 
protein (Lee et al., 2007) (Figure 1-16A). 
To isolate antigen-specific scFv, the phage library is panned against the antigen of interest. The 
phage which do not bind are washed away and the phage which do bind are removed from the 
plate using trypsin protease which cleaves the c-Myc tag. The phage then infect TG1 E. coli via 
the F pili and helper phage induce the production and release of M13 phage from the E. coli. 
The rescued phage can then either be used in further panning selections or phage from 
individual E. coli colonies can be tested for antigen specificity using an ELISA (Lee et al., 2007) 
(Figure 1-16B). 
The benefits of phage display are that the libraries are relatively large with an estimated 
functional size of 1 X 106 to 1 X 1011 (Chao et al., 2006). However the drawbacks are that as the 
scFv are expressed in E. coli, they are not subject to post-translational modifications such as 
glycosylation and the screening procedure is slow as it is done in a 96-well format. 
Adalimumab (Humira), an anti-TNF mAb, was discovered using phage display (Lee et al., 2007). 
 
Figure 1-16: Phage display schematic. (A) The scFv library is inserted upstream of the geneIII 
expressing gene in M13 phage. (B) The M13 phage library is panned against the antigen. 
Antigen-binding M13 phage are used to infect TG1 E. coli. Helper phage cause the release of 
the M13 phage which can then be used either in another round of selection or in an ELISA. The 
diagram was based on the description of phage display set out in Lee et al. (2007).  
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1.12.2.2 Ribosome Display 
Unlike a phage display library, which is stored in phage, a ribosome display library is 
maintained as DNA (either linear or in plasmids). The library is created by PCR and it is 
important that upstream of each variable region sequence there is a promoter (e.g. T7) and a 
ribosome binding site and at the 3’ end it is very important that there is no stop codon. So that 
the library can be transformed into plasmids, restriction sites are also added at either end of 
the coding sequence. NcoI (5’-CCATGG-3’) is a good restriction site for the 5’ end as the ATG 
can also act as the start codon (Zahnd et al., 2007). 
Before the panning selection, the DNA library is transcribed and translated in vitro. When the 
ribosome gets to the 3’ end of the mRNA, as there is no stop codon, the ribosome cannot 
detach. The scFv and the mRNA are therefore linked by the ribosome (Figure 1-17A). A 
“spacer” nucleotide sequence is present downstream of the scFv-encoding region to sit in the 
ribosomal tunnel, allowing the scFv to protrude from the ribosome and fold correctly (Zahnd et 
al., 2007). A spacer is sometimes a non-functional sequence or could be part of the heavy or 
light chain constant region. 
 
Figure 1-17: Ribosome display schematic. (A) When the ribosome display library is transcribed 
and translated, the ribosome gets stuck at the 3’ end of the mRNA (no stop codon) and the 
scFv is joined to the coding mRNA. (B) The translated library is incubated on the antigen of 
interest. The non-binders are washed away and the mRNA from the binders is reverse 
transcribed and PCR amplified. The output library can either be used in a second round of 
panning selection or it can be inserted into expression plasmids and the scFv can be expressed 
in E. coli and characterised using ELISA. 
The scFv-mRNA-ribosome complexes are panned against the antigen of interest. The non-
binders are washed away and the binders are reverse-transcribed and amplified using PCR. The 
rescued library can then either be transcribed/translated and used again in further panning 
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selections or it can be inserted into an expression plasmid, transformed into E. coli and the 
specificity of scFv from individual E. coli colonies can be tested using ELISA. 
The benefits of ribosome display are that the libraries are extremely large with an estimated 
functional diversity of 1 X 1011 to 1 X 1013 (Chao et al., 2006). However, like phage display, as 
the scFv are expressed in E. coli they do not get post-translational modifications. Also, like 
phage display, the screening is slow as it is also done in a 96-well format. 
Also there is a large amount of PCR involved in building ribosome display libraries and in 
rescuing libraries after panning selections. Using such a large amount of PCR carries an 
increased risk of introducing mutations into the original immunoglobulin sequence. However, 
this can sometimes be turned into an advantage by using a low-fidelity DNA polymerase 
between rounds of panning selection to introduce random mutations and therefore create 
directed evolution where advantageous mutations are promoted with every round of 
selection. Higher-affinity scFv can therefore be created. 
1.12.2.3 Yeast Display 
The yeast display scFv library is displayed on the surface of each yeast cell at a frequency of 
1 X104 t 1 X105 copies per cell. Each scFv is c-Myc-tagged and the scFv are fused to the yeast 
agglutinin protein (Aga2p). The successful expression of scFv by yeast can be detected by 
binding fluorescent tags to the c-Myc tag expressed on the scFv. Unlike phage display and 
ribosome display, in yeast display the scFv are expressed on a eukaryotic cell. Therefore to 
perform a panning selection, the yeast library is mixed with biotinylated antigen, which can be 
detected with fluorescently-labelled avidin. The yeast library is then sorted in a cell sorter to 
isolate the antigen-binders (Chao et al., 2006). 
One of the benefits of yeast display is that the scFv are expressed in a eukaryotic system and 
they therefore undergo post-translational modifications (unlike phage and ribosome display 
libraries which are expressed in prokaryotes). The size of the libraries is much smaller than 
phage and ribosome display libraries with an estimated functional diversity of 1 X 107 to 
1 X 109 (Chao et al., 2006). However, the libraries can be screened for binders very efficiently 
using cell sorters and if multiple fluorescent colours are used, multi-specific binders can be 
screened. This means that millions of scFv could be screened in just a few hours, as opposed to 
screening lots of 96-well plates using ELISA. However, yeast have a slower doubling time than 
E. coli, meaning that the selection process takes longer.  
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1.13 Project Aims 
The overarching aim of this thesis is to better understand the relationship between antibody 
variable region properties and their specificity or potential role in the immune response. The 
primary method we used to investigate this was the high-throughput sequencing of various 
B cell repertoires. Further computational and wet lab experiments were then used to 
complement this work. The aims of the three results chapters are summarised below. 
Chapter 3: Tolerance, Autoreactivity and Polyreactivity 
A consequence of the huge diversity of the B cell repertoire is that autoreactive and/or 
polyreactive antibodies can arise. Such antibodies can cause autoimmune disease and are 
problematic in the pharmaceutical industry as it is imperative that biologics are highly specific 
and not autoreactive. The aims of this first chapter were to use the B cell Development dataset 
(the first high-throughput sequencing dataset created from human bone marrow and 
peripheral blood B cells) to identify heavy chain properties which may be selected against at 
the tolerance checkpoints and therefore may be associated with autoreactivity. We aimed 
then to test these predictions of autoreactivity/polyreactivity using immunocytochemistry and 
ELISA. It was our hope that using a high-throughput sequencing approach may allow us to 
identify common, predictive characteristics of autoreactive/polyreactive antibodies and that 
this information would be a useful timesaver in the search for potentially therapeutic 
antibodies. 
Chapter 4: Light Chain Selection and Isotype Properties 
In the literature (and also in Chapter 3) the focus of investigations into antibody specificity is 
often on the heavy chain as experiments have shown that the heavy chain usually makes more 
contacts with antigen than the light chain. However, light chains are important for antibody 
diversity and swapping light chains is the mechanism by which receptor editing rescues 
autoreactive heavy chains during central tolerance. Therefore the aim of this chapter was to 
investigate the properties of antibody light chains. We investigated two aspects of antibody 
light chains. Firstly, using the B cell Development dataset, we investigated which light chain 
properties appeared to be under selection as B cells matured through tolerance and therefore 
may be associated with autoreactivity/polyreactivity. Secondly, we compared the 
physicochemical and structural properties of kappa and lambda light chains to investigate 
whether the two classes of light chain had similar or different properties and therefore 
whether they may play different roles in the immune response. Further, we investigated the 
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properties of the heavy chains with which kappa and lambda light chains are paired to 
determine if we could identify any evidence of bias in heavy-light chain pairing. 
Chapter 5: The Antibody Response against Ebola 
The final aim of this thesis was, instead of considering antibody properties in the context of 
non-specific autoreactive and polyreactive responses, to investigate the B cell repertoire in 
response to a specific infection: Ebola virus disease. Ebola is a devastating disease which puts a 
huge toll on patients and has a very high mortality rate. Serology shows that a strong antibody 
response is linked to survival and studies looking at Ebola-specific antibodies and B cells have 
shown that the major target of the antibody response is the glycoprotein (GP) which coats the 
virus and it uses for host cell entry. Monoclonal antibody cocktails such as ZMapp are a 
promising post-exposure therapy, however a major drawback of those available so far is that 
they do not offer protection against multiple filoviruses. Therefore the aims of this chapter 
were to use high-throughput sequencing to attempt to investigate the properties of the B cell 
repertoires of recent Ebola survivors and how they differ from negative controls who have 
never suffered the disease. Additionally, we aimed to isolate new cross-reactive anti-Ebola GP 
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Chapter 2: Materials and Methods 
2.1 High-Throughput Sequencing: B cell Development Dataset1 
The B cell Development dataset is a human B cell repertoire high-throughput sequencing 
dataset constructed from immunoglobulin mRNA from sorted B cells at four different stages of 
development (pre-B, immature, transitional and naïve). The B cells were isolated from the 
bone marrow and peripheral blood of healthy adult human donors. Immunoglobulin mRNA 
was reverse-transcribed using random hexamers and the cDNA was amplified using V gene-
specific and constant region-specific primers. Multiplex identifier (MID) sequences were added 
using PCR to identify the donors in the data analysis. Heavy and light chain sequences were not 
paired. See Figure 2-1 for a schematic. 
The B cell Development dataset is used in Chapter 3 (Tolerance, Autoreactivity and 
Polyreactivity) and Chapter 4 (Light Chain Selection and Isotype Properties). 
 
Figure 2-1: PCR1 and PCR2 used to construct the B cell Development dataset. Random 
hexamers were used to reverse transcribe mRNA from isolated B cells. In PCR1, the forward 
primers (6X IgH, 6X IgK, 5X IgL) bind slightly downstream of the 5’ end of the V gene. The 
reverse primers bind close to the beginning of the IgM CH1 region or IgK/IgL constant regions. 
In PCR2, the primers bind in the same places but include a multiplex identifier (MID) which 
identifies the sample. Primers are represented in pink.  
                                                          
1 The B cell Development dataset was constructed in 2012. All work described in section 2.1 was conducted by 
Bryan Wu (KCL), David Kipling (Cardiff University), Joselli Silva-O’Hare (KCL), Victoria Martin (KCL) and Deborah 
Dunn-Walters (University of Surrey). This method has been published in Wu et al. (2015) and Townsend et al. 
(2016). 
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2.1.1 Sample Collection 
19 healthy adults undergoing hip replacement surgery at Guy’s Hospital, London, United 
Kingdom were recruited. The head of the femur was collected as the source of bone marrow 
and a sample of peripheral blood was also collected (Research Ethics Committee: 14/LO/1221). 
The patients ranged in age from 24 years to 86 years and had no known autoimmune disease 
or recent infections. 
2.1.2 Isolation of Lymphocytes from Bone Marrow 
The bone marrow matrix was scraped out of the femur head and residual cells were washed 
out of the cavity using BM isolation buffer (10 mM EDTA, 2% (v/v) HI-FCS, 1X PBS, pH 7.4) and 
transferred to a 50 ml graduated centrifuge tube. The volume was made up to 35 ml with BM 
isolation buffer. The cell suspension was then filtered through a 100 µm cell strainer. The cell 
suspension was layered onto 15 ml room temperature Ficoll (GE Healthcare) and the bone 
marrow mononuclear cells (BMMCs) were isolated by centrifugation at 400 g for 35 min (no 
break). The BMMC layer was removed, re-suspended in BM isolation buffer, and centrifuged at 
300 g for 10 min. The pelleted BMMCs were re-suspended in 1 ml RPMI suspension buffer 
(10% (v/v) HI-FCS, RPMI 1640) and centrifuged in a bench-top centrifuge at 2X 1000 for 5 min. 
The pelleted BMMCs were re-suspended in 1 ml RPMI suspension buffer and counted. The 
BMMCs were frozen in HI-FCS, 10% (v/v) DMSO at -80oC (Mr. Frosty Freezing Container, 
Thermo Scientific) and then transferred to liquid nitrogen for long-term storage. 
2.1.3 Isolation of Lymphocytes from Peripheral Blood 
10 ml of peripheral blood was mixed with 20 ml RPMI suspension buffer (section 2.1.2) and the 
30 ml blood solution was layered onto 15 ml Ficoll (GE Healthcare) in a Leucosep tube 
(Greiner). This was centrifuged at 448 g for 20 min (no break). The PBMC layer was transferred 
into a clean 50 ml graduated centrifuge tube, re-suspended in 10 ml RPMI suspension buffer 
and centrifuged at 275 g for 10 min. The pelleted PBMCs were re-suspended in 10 ml RPMI 
suspension buffer and centrifuged at 275 g for 10 min. The pelleted PBMCs were re-suspended 
in RPMI suspension buffer, counted, and frozen as described in section 2.1.2. 
2.1.4 B cell Isolation and Sorting 
Bone marrow CD19+ B cells were enriched to >98% using anti-human CD19 MicroBeads 
(Miltenyi Biotec) following the manufacturer’s instructions. The CD19+ enriched B cell 
suspension was blocked using blocking buffer (RPMI, 10% (v/v) normal mouse serum). The 
B cells were stained using the antibodies detailed in Table 2-2. 1000-10,000 large pre-B cells 
(IgK-IgL-IgM+CD38+) and 1000-10,000 immature B cells (IgK+/IgL+IgM+IgD-CD38+CD27-CD10+) 
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per donor were then sorted directly into PCR tubes containing 36 μl SLyRT buffer (Table 2-1) 
using the FACS Aria (BD Biosciences). Sorting strategy is shown in FACS plots in Figure 2-2A. 
Peripheral blood B cells were stained using the antibodies detailed in Table 2-3. 1000-10,000 
transitional B cells (IgD+CD27−CD10+) and 1000-10,000 naïve B cells (IgD+CD27−CD10−) per 
donor were sorted directly into PCR tubes containing 36 μl SLyRT buffer (Table 2-1) using the 
FACS Aria (BD Biosciences). Sorting strategy is shown in FACS plots in Figure 2-2B. 
Table 2-1: SLyRT buffer reagents. Scale up as necessary. The final reaction volume will be 40 μl 
after cDNA, SuperScript III Reverse Transcriptase and primers are added 
Reagent 1X Reaction Final Reaction Concentration 
First-Strand RT Buffer (5X)2 
Random hexamers pd(N)6 (50 ng/µl) 
5% (v/v) Triton X-100 in H2O 
RiboSafe RNase Inhibitor (40 U/µl)3 
DTT (0.1 M) 

















Table 2-2: Fluorescently-labelled antibodies used to sort BMMCs. 
Antibody Clone Manufacturer 
PE anti-human Ig light chain lambda 
APC anti-human Ig light chain kappa 
PE/Cy7 anti-human CD38 
PerCP/Cy5.5 anti-human IgD 
Pacific Blue anti-human IgM 

















Table 2-3: Fluorescently-labelled antibodies used to sort PBMCs. 
Antibody Clone Manufacturer 
APC anti-human CD19 
PerCP/Cy5.5 anti-human IgD 











                                                          
2 First-Strand RT Buffer (5X): 250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl2 
3 RiboSafe RNase Inhibitor (BIO-6502, Bioline) 
4 dNTP mix: 10 mM each of dATP, dTTP, dCTP and dGTP (Promega) 




Figure 2-2: FACS plot showing B cell sorting strategy of (A) BMMCs and (B) PBMCs to isolate 
pre-B, immature, transitional and naïve B cells. Image modified from Martin et al. (2016)5 
2.1.5 Reverse Transcription of Immunoglobulin mRNA 
The PCR tubes containing sorted B cells were mixed by vortexing and centrifuged at 3000 rpm 
for 2 min. 4 µl of 25 U/µl SuperScript III Reverse Transcriptase (18080093, Invitrogen) was 
added to each tube. Reverse transcription was performed using the conditions shown in Table 
2-4. 
Table 2-4: Reverse transcription thermal cycle. 














To remove cellular contaminants for future steps, the PCR tubes were centrifuged at 
13,000 rpm for 5 min and 35 µl of supernatant was transferred to new PCR tubes (leaving cell 
debris behind). 70 µl of H2O was added to the 35 µl supernatant (mixed by pipetting). This 
results in a 1:3 dilution of cDNA. 
2.1.6 Amplification of cDNA (PCR1) 
To amplify the immunoglobulin sequences from the cDNA, V gene-specific forward primers 
and constant region-specific reverse primers were used. Constant region-specific reverse 
primers (IgM, IgK and IgL) were used in separate reactions. Multiple V gene-specific forward 
                                                          
5 Figure 2-2 is a modified version of a figure created by Victoria Martin (KCL) and Deborah Dunn-Walters (University 
of Surrey) and published in Martin et al. (2016). 
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primers were used in combination with each constant region reverse primer in a multiplex 
PCR. See Table A-1 (page 261) for a list of the primers used to amplify IgM sequences, IgK 
sequences and IgL sequences. 
A PCR1 master mix (Table 2-5) was made for each class (IgH/IgK/IgL) using the appropriate 
primers (Table A-1). Each PCR1 master mix was aliquoted into eight PCR tubes (22 μl per tube) 
per donor. This means that if a donor had IgM, IgK and IgL sequences amplified, there would 
be 24 PCR reactions for that donor. 
3 µl of 1:3 diluted cDNA (section 2.1.5) from each donor was added to each of their respective 
PCR tubes. The conditions for PCR1 were as described in Table 2-5. 
Table 2-5: HTS PCR1 master mix reagents and thermal cycle. 
Reagent Quantity (X1 reaction) Quantity (X110 reactions) 
Phusion GC Buffer (5X)6 
1:40 Phusion Polymerase (0.125 U/µl)6 









































2.1.7 Addition of MIDs (PCR2) 
In order to identify the donor from which each sequence originated, 10 bp multiplex identifier 
(MID) sequences were added to PCR1 products (section 2.1.6) using a second PCR (PCR2). Due 
to the complexity of the MID-labelled primers, the PCR2 master mix was made up without 
primers (Table 2-6) and the relevant primer mix was then added to each tube. A separate 
primer mix was used per isotype (V gene-specific and constant region specific) and per donor 
(MID labels). See Table A-2 (page 262) and Table A-3 (page 262) for primer sequences. Each 
primer mix contained 835 nM each forward primer and 5 μM of the reverse primer. 
17 µl of PCR2 reaction mix (Table 2-6) was aliquoted into 16 PCR tubes per isotype/donor 
combination (i.e. 48 tubes per donor if IgM, IgK and IgL were being amplified). 1 μl of the 
                                                          
6 Phusion High-Fidelity DNA Polymerase (M0530, New England Biolabs) 
7 dNTP mix: 20 mM each of dATP, dTTP, dCTP and dGTP (Promega) 
8 Primer mix: 5’ end variable primers (835nM each) and 3’ end constant primer (5 µM). See Table A-1 for sequences. 
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appropriate MID-labelled isotype-specific primer mix was added into each tube. 2 μl of 
relevant PCR1 product (section 2.1.6) was added into each set of 16 PCR tubes (i.e. two PCR2 
reactions per PCR1 reaction). The conditions are shown in Table 2-6. 
The MIDs used to identify each donor in the B cell Development dataset are shown in Table 2-7 
(the same MID can be used more than once if the samples are sequenced on separate chips; 
12 MIDs can be used per chip). 
Table 2-6: HTS PCR2 master mix reagents and thermal cycle. 
Reagent Quantity (X1 reaction) Quantity (X110 reactions) 
Phusion GC Buffer (5X)9 
1:20 Phusion Polymerase (0.25 U/µl)9 








































Gender Chip ID MID to identify patient and cell repertoire 
Pre-B Immature Transitional Naïve 
122 24 Female BW062012a MID10 MID4 MID7 MID1 
159 28 Female BW062012a MID11 MID5 MID8 MID2 
138 41 Male BW062012a MID12 MID6 MID9 MID3 
107 43 Male HTS TD - - MID3 MID9 
120 44 Male HTS TD - - MID4 MID10 
118 48 Male BW062012c MID10 MID4 MID7 MID1 
146 50 Female BW062012c MID11 MID5 MID8 MID2 
103 52 Female BW062012c MID12 MID6 MID9 MID3 
128 52 Female N, T, Imm cells MID11 MID12 MID1 - 
126 53 Male N, T, Imm cells MID3 MID4 MID5 MID6 
141 65 Female BW062012d MID10 MID4 MID7 MID1 
105 67 Female N, T, Imm cells MID7 MID8 MID9 MID10 
119 68 Female BW062012d MID11 MID5 MID8 MID2 
160 70 Male BW062012d MID12 MID6 MID9 MID3 
111 71 Female BW062012b MID12 MID6 MID9 MID3 
149 72 Male BW062012b MID11 MID5 MID8 MID2 
132 76 Male HTS TD - - MID5 MID11 
162 78 Male HTS TD - - MID6 MID12 
140 86 Female BW062012b MID10 MID4 MID7 MID1 
                                                          
9 Phusion High-Fidelity DNA Polymerase (M0530, New England Biolabs) 
10 dNTP mix: 20 mM each of dATP, dTTP, dCTP and dGTP (Promega) 
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2.1.8 Isolation and Purification of Variable Region Amplicons 
Each set of 16 PCR2 products (i.e. each MID/Ig gene combination) was pooled (320 µl each). 
64 µl of 6X Orange G loading dye (0.25 g Orange G (Sigma Aldrich), 30 ml glycerol, 70 ml H2O) 
was added to each pooled PCR2 product. The mixtures were heated at 98oC for 5-10 min and 
then loaded onto a 1.5% agarose gel (TAE buffer) stained with GelStar Nucleic Acid Gel Stain 
(Lonza). The samples were run alongside Hyper Ladder IV ladder (Bioline) at 100 V for 60 min. 
Fragments of the correct size (Table 2-8) were excised from the gel and transferred to 15ml 
graduated centrifuge tubes. 
Table 2-8: Approximate HTS PCR2 fragment sizes. 








DNA was purified from the gel using the QIAquick Gel Extraction Kit (Qiagen) following the 
manufacturer’s quick start protocol with the following modifications: 
 Step 2: Incubate the gel slice in 5 ml Buffer QG until dissolved (expect about 6 ml total) 
 Step 5: Pass the entire 6 ml gel + QG Buffer mixture through a single QIAquick column 
750 µl at a time, saving the flow-through in a new 15 ml graduated centrifuge tube 
instead of discarding it. Repeat by passing the flow-through through the same 
QIAquick column a second time 
 Step 9: Elute the DNA in 55 µl H2O (incubate at room temperature for 3 min before 
centrifugation). Repeat this step by applying an additional 55 µl to the membrane, 
incubating for 3 min and eluting (final volume of eluted DNA is approximately 100 µl) 
The concentration and quality of the eluted DNA was measured using the Qubit dsDNA HS 
Assay Kit (Q32851, Invitrogen) on a Qubit 2.0 Fluorometer. 
2.1.9 Preparation of Library for Roche 454 Sequencing 
The purified PCR2 products were mixed into a single sequencing sample containing 900 µl per 
MID. If a donor’s heavy and light chains were sequenced, 300 µl of IgM, IgK and IgL were 
mixed. If just the donor’s light chains were sequenced, 450 µl of IgK and IgL were mixed. 
The library was concentrated using the Qiaquick PCR purification kit (Qiagen) according to 
manufacturer’s instructions and was eluted in 110 µl H2O (two lots of 55 µl as in section 2.1.8). 
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The concentrated library was quantified using Qubit dsDNA HS Assay Kit (Q32851, Invitrogen) 
on the Qubit 2.0 Fluorometer. For sequencing, the library needed to be a minimum of 5 µg 
DNA at a concentration of 100 ng/µl. 
The library was sequenced across three chips (Table 2-7, page 79) on the Roche 454 GS FLX 
Titanium platform (LGC Genomics, UK). 
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2.2 High-Throughput Sequencing: Ebola Response Datasets 
Unlike the B cell Development dataset (section 2.1), the Ebola Response datasets were built 
using mRNA from TRIzol-treated whole blood (the B cells could not be sorted for safety 
reasons) therefore B cell types could not be distinguished. The template switch method was 
used to add unique identifier (UID) sequences to each cDNA as it was reverse-transcribed, 
allowing better identification of clonal expansions. Forward primers bound the universal 
primer site (reducing primer bias) and reverse primers bound the constant region (allowing 
distinction between IgA, IgG and IgM classes and subclasses). PacBio identifier (PID) sequences 
were added using PCR to identify donors in the data analysis. Heavy and light chains were not 
paired. See Figure 2-3 for a schematic. 
When the Ebola Response Dataset was built, the Roche 454 sequencing platform was no 
longer supported and the sequencing reads we produced for this dataset were longer than for 
the B cell Development dataset. Therefore PacBio sequencing was used instead. One drawback 
of PacBio sequencing is its relatively high error rate (Rhoads & Au, 2015). However, this 
platform does support long sequencing reads, making it a suitable choice for this experiment. 
The Ebola Response Datasets were used in Chapter 5 (The Antibody Response against Ebola). 
 
Figure 2-3: HTS template switch method used to generate the Ebola Response datasets. 
Amplification of immunoglobulin variable region sequences from mRNA for high-throughput 
sequencing (HTS). Unique identifier sequences (UID) were added to each mRNA using 
SmartNNN primers. PIDs were added using primers in PCR2. Once PIDs have been added, all 
sequences can be pooled for HTS on a single PacBio sequencing chip. Primers are represented 
in pink.  
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2.2.1 Sample Collection 
2.2.1.1 Caucasian Aid Worker Survivor Dataset11 
TRIzol-treated whole blood12 from three Caucasian aid worker Ebola (EBOV) survivors from the 
2014 West Africa outbreak. Blood was collected after recovery, approximately one month after 
infection. No serology was available for these samples. RNA from these donors was used to 
build a high-throughput sequencing dataset and also a ribosome display library (see section 
2.14, page 118). (14/LO/1221, RES committee, Camberwell St Giles Substantial amendment #1, 
February 2015). 
No blood samples from before the aid workers were infected were available. Therefore PBMCs 
from the whole blood of three age- and gender-matched donors (see Table 2-9) who had never 
been exposed to Ebola were used as negative controls. Blood from the negative control donors 
had been collected before (day 0) and 28 days after (day 28) receiving a yellow fever vaccine 
(14/LO/1221, RES committee, Camberwell St Giles). 
Table 2-9: Caucasian Aid Worker Survivor Dataset donor information. 
Group Donor ID Age Gender Time of Sample 
Ebola Survivors 
215 29 Male In recovery 
216 34 Male In recovery 
217 39 Female In recovery 
Yellow Fever 
Vaccine Controls 
193 27 Male 
Day 0 
Day 28 
199 34 Male 
Day 0 
Day 28 




                                                          
11 The Caucasian Aid Worker Survivor Dataset was built in 2016 by Joselli Silva O’Hare (KCL), Audrey Page (KCL) and 
Catherine Townsend (author) 
12 TRIzol-treated whole blood from three Caucasian aid worker Ebola survivors was generously shared by Alain 
Townsend (University of Oxford) 
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2.2.1.2 African Survivor Dataset13 
mRNA from the whole blood of African survivors14 of the 2014 West Africa Ebola (EBOV) 
outbreak was used to build the African Survivor Dataset. Blood had been taken at several time 
points post-recovery from Ebola virus disease and serology information on the IgG and IgM 
response was also provided (Figure 2-4). RNA from two time points from five donors was used 
to build the African Survivor Dataset. The time points used are shown in Figure 2-4. 
(14/LO/1221, RES committee, Camberwell St Giles Substantial amendment #1, February 2015). 
 
Figure 2-4: IgG and IgM serology from the five African Ebola survivors15 used to make the 
African Survivor Dataset. The IgG serology of the five survivors showed different patterns over 
time. Note that time point zero is the first post-recovery time point on which blood was taken. 
(A) IgG started high and decreased over time. (B) IgG rose over time. (C) IgG was consistently 
high. The two time points used are shown by dotted lines. NOD = “normalised optical density”.  
                                                          
13 The African Survivor Dataset was built in 2017 by Audrey Page (KCL) and Alexander Stewart (University of Surrey) 
14 Purified total RNA from African Ebola survivors was generously shared by Callum Semple (University of Liverpool) 
15 The serology data graphed in Figure 2-4 was supplied by Callum Semple (University of Liverpool), the data was 
graphed by Audrey Page (KCL) 
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2.2.2 Isolation of Total RNA from Samples 
2.2.2.1 Caucasian Aid Worker Ebola Survivors16 
Blood samples were received as blood cone filters in TRIzol Reagent (15596, Invitrogen) (2.5 ml 
blood in 7.5 ml TRIzol Reagent). The samples were stored at -80oC until use. 
The samples (2.5 ml blood in 7.5 ml TRIzol Reagent) were thawed and pipetted up and down 
several times. The samples were incubated at room temperature for 5 min. 2 ml of chloroform 
was added per 10 ml sample. The tubes were shaken vigorously for 15 s, then allowed to stand 
for 10 min at room temperature. The samples were centrifuged at 12,000 g for 15 min at 
2-8oC. The colourless upper aqueous phase was transferred to a new tube. 
5 ml of 100% isopropyl alcohol was added to each sample. The samples were mixed and left to 
stand for 10 min at room temperature. The samples were centrifuged again at 12,000 g for 
15 min at 2-8oC. The RNA formed a pellet down the side of the tube. The supernatant was 
discarded and the RNA pellet washed with 10 ml 75% (v/v) ethanol. The sample was vortexed 
and centrifuged at 7,500 g for 5 min at 2-8oC (plus a further 5 min at 12,000 g if the RNA pellet 
was floating in the sample). The supernatant was discarded and the RNA pellet was left to dry 
for 5-10 min. 30 μl of H2O was added to elute the RNA. To facilitate dissolving of the RNA, the 
sample was mixed by pipetting and incubated at 55-60oC for 10-15 min. The RNA was 
quantified. 
2.2.2.2 Yellow Fever Vaccine Controls17 
50 ml of blood was taken from healthy donors before receiving the yellow fever vaccine 
(day 0) and 28 days after (day 28) receiving the live attenuated yellow fever vaccine. Donors 
received the vaccine at several clinics around London, United Kingdom. 
PBMCs were isolated by layering on Ficoll. Briefly, the blood sample was diluted in suspension 
media (RPMI-1640 (11875093, Gibco), 10% (v/v) FCS) in a 1:2 ratio. 35 ml of diluted blood was 
layered on top of 15 ml Ficoll-Paque Plus (17-1440-02, GE Healthcare). The samples were 
centrifuged at 400 g for 30 min (no break) at room temperature. PBMCs were collected using a 
Pasteur pipette and transferred into a clean 50 ml centrifuge tube. Suspension media was 
added and the PBMCs were centrifuged at 400 g for 10 min at 4oC. The supernatant was 
discarded and the PBMCs were re-suspend in 5 ml suspension media, then transferred to a 
clean 15 ml centrifuge tube. The PBMCs were counted using a haemocytometer. The PBMCs 
                                                          
16 All of the work described in section 2.2.2.1 was conducted by Joselli Silva O’Hare (KCL) 
17 In section 2.2.2.2, the PBMC isolation from whole blood was conducted by Joselli Silva-O’Hare (KCL) and Victoria 
Martin (KCL). The total RNA isolation from the frozen PBMCs was conducted by Audrey Page (KCL) and Catherine 
Townsend (author) 
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were centrifuged at 400 g for 10 min at 4oC. The PBMCs were re-suspend in ice-cold freezing 
media (90% (v/v) FCS, 10% (v/v) DMSO). 1 ml of 1.5 X 106 cells/ml PBMCs were aliquoted into 
cryovials. The PBMCs were frozen overnight at -80oC in Mr Frosty (Nalgene) isopropanol 
containers then transferred to liquid nitrogen for long-term storage. 
Two 1 ml PBMC aliquots were thawed per YF vaccine control sample in a 37oC waterbath until 
a small piece of ice remained. 2 ml pre-warmed media (RPMI, 10% (v/v) FCS) was added to 
15 ml centrifuge tubes. The PBMCs were carefully added to the media using a pipette. The 
mixture was topped up to 10 ml using the pre-warmed media (RPMI, 10% (v/v) FCS). The 
samples were incubated on ice until cold and then centrifuged at 300 g for 10 min at 4oC. The 
supernatant was decanted and the cells were re-suspended in 1 ml of media (RPMI, 10% (v/v) 
FCS). Cells were counted by taking a sample to mix in a 1:1 ratio with trypan blue and using a 
haemocytometer. The 1 ml cell suspension was topped up to 10 ml with media (RPMI, 
10% (v/v) FCS) and centrifuged at 300 g for 10 min at 4oC. The supernatant was discarded and 
the cells were re-suspended in 1 ml sterile PBS. Cells were stored on ice until RNA extraction. 
RNA was extracted from PBMCs using the Quick-RNA MicroPrep kit (R1050, Zymo Research) 
following the manufacturer’s protocol for cells in suspension with the following modifications 
and notes: 
1. Cells were pelleted at 300 g for 5 min at 4oC, all the PBS was removed from the cells 
and the cells were re-suspended in 300 μl lysis buffer 
2. The Sample Clearing step was performed 
3. The samples were eluted in 10 μl H2O (the H2O was incubated on the column for 1 min 
prior to elution to maximise the amount of RNA eluted) 
The RNA was stored at -70oC until use. 
2.2.2.3 African Ebola Survivors 
Samples were received as purified total RNA. Therefore samples could be reverse transcribed 
with no prior treatment. 
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2.2.3 Reverse Transcription of Immunoglobulin mRNA 
Oligo(dT) primers were used to reverse transcribe all mRNA. To denature the RNA and anneal 
the Oligo(dT) primers Mix 1 was set up as shown in Table 2-10. The amount of RNA per sample 
must be identical, so all samples are scaled to the sample with the lowest RNA concentration. 
To perform the reverse transcription using the SmartNNN template switch adapter primer, 
Mix 2 was set up as shown in Table 2-11. 
Table 2-10: Ebola HTS Mix 1 reagents and thermal cycle. 
Reagent Quantity 






To 4 µl 
4 µl 










Table 2-11: Ebola HTS Mix 2 reagents and thermal cycle. See Table A-4 for primer sequence.
Reagent Quantity 
5X First-Strand Buffer19 
DTT (20 mM)19 
SmartNNN primer (10 µM) 
dNTP Solution Mix (10 mM each)20 
SMARTScribe Reverse Transcriptase19 









Thermal Cycle Step Temperature Time Cycles 
Reverse Transcription 42oC 60 min X1 
 
The SmartNNN template switch adapter primer contains deoxyuridine. After cDNA synthesis, 
uracil-DNA glycosylase (UDG) was used to eliminate the SmartNNN primers to prevent the 
exchange of UIDs during PCR amplification. 
1 µl of UDG (M0280L, New England Biolabs) was added per reaction tube and was heated at 
37oC for 60 min. The UDG was deactivated by heating at 95oC for 10 min. 
  
                                                          
18 Oligo(dT)15 Primer (C1101, Promega) 
19 SMARTScribe™ Reverse Transcriptase (639537, Clontech) 
20 Deoxynucleotide (dNTP) Solution Mix (N0447L, New England Biolabs) 
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2.2.4 Amplification of Immunoglobulin Variable Regions 
Immunoglobulin variable region were amplified from cDNA in PCR1 as shown in Table 2-12. 
Eight PCR1 reactions were run per sample. 
Table 2-12: Ebola HTS PCR1 reagents and thermal cycle. See Table A-5 for primer sequences. 
Heavy Chain Reaction Light Chain Reaction 
Reagent Quantity Reagent Quantity 
 X1 X8  X1 X8 
5X Q5 reaction buffer21 
dNTP mix (10 mM each)22 
IGHA-1st primer (10 µM) 
IGHG-1st primer (10 µM) 
IGHM-1st primer (10 µM) 
Smart20 primer (10 µM) 
Q5 enzyme (NEB)21 
H2O 






















5X Q5 reaction buffer21 
dNTP mix (10 mM each)22 
IGLC-1st primer (10 µM) 
IGKC-1st primer (10 µM) 
 
Smart20 primer (10 µM) 
Q5 enzyme (NEB)21 
H2O 















































In the second PCR (PCR2), primers labelled with PIDs were used to amplify the PCR1 product. 
The addition of PIDs allowed the identification of the sample source in the bioinformatic 
analysis and allowed all samples to be pooled and sequenced on the same sequencing cells. 16 
PCR2 reactions were run per sample (two reactions per PCR1 reaction). The reagents and 
conditions for PCR2 are shown in Table 2-13. See Table 2-14 and Table 2-15 for the PIDs used 
in each dataset. 
                                                          
21 Q5 High-Fidelity DNA Polymerase, M0491L, New England Biolabs 
22 Deoxynucleotide (dNTP) Solution Mix, N0447L, New England Biolabs 
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Table 2-13: Ebola HTS PCR2 reagents and thermal cycle. See Table A-6 for primer sequences. 
Heavy Chain Reaction Light Chain Reaction 
Reagent Quantity Reagent Quantity 
 X1 X16  X1 X16 
5X Q5 reaction buffer23 
dNTP mix (10 mM each)24 
Step_1-Barcode primer 
(10  µM)  
IGHA/IGHG/IGHM-

























5X Q5 reaction buffer23 
dNTP mix (10 mM each)24 
Step_1-Barcode primer  
(10 µM)  
IGKC/IGLC-Barcode 


















































Table 2-14: PIDs used in Caucasian Aid Worker dataset. See Table A-7 for PID sequences. 
Donor ID Age (years) Gender Sample Type PID 
215 29 Male EBOV Survivor PID1 
216 34 Male EBOV Survivor PID2 
217 39 Female EBOV Survivor PID4 
193 27 Male Yellow Fever Control Day 0 PID17 
Yellow Fever Control Day 28 PID44 
199 34 Male Yellow Fever Control Day 0 PID9 
Yellow Fever Control Day 28 PID33 
207 36 Female Yellow Fever Control Day 0 PID22 
Yellow Fever Control Day 28 PID45 
 
Table 2-15: PIDS used in African Survivor Dataset. See Table A-7 for PID sequences. 
Group Donor ID Time point PID 
IgG starts high, 
decreases over time 
Donor 2 
Time 1 PID1 
Time 2 PID2 
Donor 50 
Time 1 PID4 
Time 2 PID9 
IgG rose over time 
Donor 14 
Time 1 PID17 
Time 2 PID33 
Donor 82 
Time 1 PID22 
Time 2 PID23 
IgG consistently high Donor 15 
Time 1 PID44 
Time 2 PID45 
                                                          
23 Q5 High-Fidelity DNA Polymerase, M0491L, New England Biolabs 
24 Deoxynucleotide (dNTP) Solution Mix, N0447L, New England Biolabs 
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PCR2 amplification was checked by running 5 µl PCR2 product mixed with 1 µl 6X gel loading 
dye (B7024S, New England Biolabs) on a 1.2% (w/v) agarose gel at 110 V for 1 h. The agarose 
gel was stained with GelStar Nucleic Acid Gel Stain, 50535, Lonza. The expected band sizes are 
shown in Table 2-16. 
Table 2-16: Ebola HTS expected PCR2 band sizes. Range of sizes is due to variation in CDR3 size. 












The PCR2 samples were pooled by combining each of the 16 PCR2 reactions per 
patient/isotype and purifying the PCR product using the Wizard SV Gel and PCR Clean-Up 
System (A9281, Promega) with the following alterations to the manufacturer’s protocol: 
 After the PCR product had been spun through the membrane once (Binding of DNA, 
step 3), the flow-through was collected, applied to the column again and the step was 
repeated to ensure maximum binding of PCR product. 
 After washing the column with 500 µl washing buffer (Washing, step 5), the column 
was transferred to a new collection tube and the column was re-centrifuged (Washing, 
step 6) for 5 min. 
 The DNA was eluted from the column in two elution steps (Elution, step 8), first in 
30 µl H2O, then a further 10 µl H2O was applied to the column and the column was 
spun again (i.e. 40 µl in total). 
Patient samples were processed one at a time to minimise the risk of cross-contamination. 
2.2.5 Isolating Amplicons of the Right Size 
The five bands (IgA, IgG, IgM, IgK, IgL) were isolated from each donor sample using the Pippin 
Prep (SAGE Science). 
The pooled PCR products from section 2.2.4 were topped up to 30 µl with H2O and each was 
mixed with 10 µl of loading solution with marker K (CDF1510, SAGE Science) and loaded into 
1.5% dye-free agarose gels (one gel per donor). The Pippin Prep was set to collect bands within 
the range 500-1060 bp for every isotype. 
The concentration of the DNA collected by the Pippin Prep was quantified using Qubit 3.0 
(Invitrogen) and the Qubit dsDNA HS Assay Kit (Q32851, Invitrogen). All samples had to contain 
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at least 100 ng of DNA. If a sample did not have enough DNA, more PCR2 product was 
amplified and purified (page 89 onwards) for that sample. 
2.2.6 Pooling Samples and Sequencing 
Equal quantities of DNA for each isotype and donor were pooled. The mixture was purified 
using the Agencourt AMPure XP PCR Purification kit (A63880, Beckman Coulter). The pooled 
PCR product was aliquoted into 100 µl volumes and the protocol for 96-well format was 
followed. For maximum PCR product binding to magnetic beads, the optional 5 min incubation 
(step 3) was performed. The DNA was eluted in 40 µl H2O per tube. The purified products were 
then pooled. 
The Qubit 3.0 was used as described above to quantify the eluted DNA. There needed to be at 
least 500 ng of DNA at a concentration of at least 13 ng/µl. 
A sample was the sent to the Earlham Institute (Norwich, United Kingdom) for high-throughput 
sequencing using single-molecule real-time (SMRT) sequencing on the PacBio RS II sequencing 
platform.  
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2.3 High-Throughput Sequencing: Ribosome Display Libraries 
To investigate the diversity of the ribosome display input libraries and the selection that took 
place, the ribosome display input and output libraries (described in section 2.14, page 118) 
used to select for EBOV GP-binding scFv were sequenced using high-throughput sequencing. 
2.3.1 Sample Collection 
The starting material was the PCR3 product input library (section 2.14.4, page 123) and the 
PCR4 product output library (section 2.15.1, page 126). Donor 216 did not have enough PCR 
product. Therefore only PCR product from donor 215 and donor 217 was used to build the HTS 
library. Kappa and lambda PCR products were amplified separately. 
2.3.2 Amplification of Input and Output scFv Sequences 
The PCR3 input libraries were at a higher concentration than the PCR4 output libraries. 
Therefore, the PCR3 input DNA was diluted with dH2O until the PCR3 and PCR4 products for 
each donor were at approximately equal concentrations. Four 8X PCR master mixes (Table 
2-17) were set up per donor (kappa and lambda PCR3 and PCR4). The master mixes were 
aliquoted into 8X 20 μl PCR reactions and run using the conditions shown in Table 2-17. The 
PIDs used for each sample are shown in Table 2-18. 
Table 2-17: Ribosome display HTS PCR reagents and thermal cycle conditions. Primer 
sequences are shown in Table A-8 (page 264). 
Reagent Quantity 
 X1 X8 
5X Q5 reaction buffer25 
dNTP mix (10 mM each) 
RDT7AB_PID primer (10 µM) 
NotK/NotL_PID primer (10 µM) 
Q5 enzyme (NEB)25  
H2O 
DMSO 












































                                                          
25 Q5 High-Fidelity DNA Polymerase, M0491L, New England Biolabs 
26 Donor 215: Kappa PCR3 input DNA = 15.3 ng/μl, kappa PCR4 output DNA = 13.7 ng/μl 
 Donor 217: Kappa PCR3 input DNA = 6.1 ng/μl, kappa PCR4 output DNA = 6.7 ng/μl 
27 Donor 215: Lambda PCR3 input DNA = 6.2 ng/μl, Lambda PCR4 output DNA = 6.9 ng/μl 
 Donor 217: Lambda PCR3 input DNA = 8.8 ng/μl, Lambda PCR4 output DNA = 8.2 ng/μl 
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Table 2-18: PID use for each ribosome display sample. PIDs attached to RDT7AB, NotK and 
NotL primers to label samples by donor and PCR3 input/PCR4 output. The same PIDs were 
used for kappa and lambda sequences. 
Donor ID Sample Age (years) Gender Sample Type PID 
215 PCR3 29 Male EBOV Survivor PID1 
215 PCR4 29 Male EBOV Survivor PID9 
217 PCR3 39 Female EBOV Survivor PID4 
217 PCR4 39 Female EBOV Survivor PID22 
 
2.3.3 Isolating Amplicons of the Right Size 
Each group of eight PCR reactions was pooled and the pooled PCR reactions were 
concentrated using the Wizard SV Gel and PCR Clean-Up System (A9281, Promega) as 
described in section 2.2.4 (page 88). PCR products of the correct size were then purified using 
the Pippin Prep (SAGE Science) using the protocol described in 2.2.5 (page 90). The Pippin Prep 
was set to collect bands within the range 800-1100 bp. The concentration of eluted DNA was 
confirmed using the Qubit 3.0 (Invitrogen) and the Qubit dsDNA HS Assay Kit (Q32851, 
Invitrogen). 
2.3.4 Pooling Samples and Sequencing 
All samples were pooled and purified using the Agencourt AMPure XP PCR Purification kit 
(A63880, Beckman Coulter) as described in section 2.2.6 (page 91) except the DNA was eluted 
in TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0). 
The sample was sequenced using PacBio Sequel sequencing at the Centre for Genomic 
Research (University of Liverpool).  
Chapter 2: Materials and Methods 
94 
 
2.4 High-Throughput Sequencing: Raw Data Clean-Up28 
2.4.1 Removal of Biologically Implausible Sequences 
Raw sequencing data is received in FASTA format. Firstly, biologically implausible sequences 
and sequences which contained PCR artefacts (e.g. sequences which were too short to be 
immunoglobulin sequences or the presence of internal or mismatched MIDs/PIDs) were 
removed. The MID/PID sequences were then removed from the nucleotide sequences and the 
sequences were renamed to contain the sample information which was associated with the 
MIDs/PIDs. 
2.4.2 V(D)J Gene Usage and CDR3 Amino Acid Sequence Properties 
The sequences were submitted to HighV-QUEST (Alamyar et al., 2012b) for biological 
annotation such as the identification of V(D)J genes and CDR3 amino acid sequences. 
Physicochemical properties of the CDR3 amino acid sequences were calculated using the R 
package Peptides (Osorio et al., 2015). The properties calculated were: GRAVY (Kyte & 
Doolittle, 1982), Boman (Boman, 2003), aliphatic index (Ikai, 1980), isoelectric point (pI) (Rice 
et al., 2000), instability (Guruprasad et al., 1990) and the ten Kidera factors (Kidera et al., 
1985a, Kidera et al., 1985b) (see Table 2-19 for Kidera factor definitions). The frequency of 
certain classes of amino acids (Rice et al., 2000) in the CDR3 regions was also calculated (Table 
2-20). 
The CDR regions were defined using the IMGT numbering scheme (see Figure 1-6, page 33), 
which is the same for heavy and light chains. The CDR1 comprised residues 27-38, the CDR2 
comprised residues 56-65, the CDR3 comprised residues 105-117. 
Table 2-19: Kidera factor definitions as listed in Rackovsky &Scheraga (2011). 













Extended structure preference 
Hydrophobicity 
Double-bend preference 
Partial specific volume 
Flat extended preference 




                                                          
28 All of the work described in section 2.4 was conducted by David Kipling (Cardiff University) and Deborah Dunn-
Walters (University of Surrey) 
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Table 2-20: Amino acid categories as defined in Rice et al. (2000).29 




















2.4.3 Clonotype Clustering 
Clonotype clustering was carried out by splitting the datasets into V family subsets. The CDR3 
nucleotide sequences were used to generate Levenshtein edit distance matrices of all possible 
pairwise comparisons. The matrices were then hierarchically clustered (complete linkage). The 
heavy chain dendrograms were cut at 0.18. The light chain dendrograms were cut at 0.05. The 
released branches constituted clones. The modal sequence of each clone was used as the 
representative of that clone. In most analyses, only the representative modal sequences were 
used to avoid large clones skewing the analysis. 
In the Ebola Response Datasets, UIDs were used to differentiate clonal expansions and PCR 
amplification, therefore PCR amplifications (identified by duplicate UIDs) were removed from 
clonal expansions. In the B cell Development Dataset UIDs were not used therefore it was not 
possible to differentiate clonal expansions and PCR amplifications. However, as the B cell 
Development dataset is an antigen-naïve dataset, it should not contain clonal expansions. As 
the Ribosome Display Library was amplified from DNA and was already the product of multiple 
rounds of PCR, UIDs were not used. However, clonal expansions were still calculated in order 
to estimate diversity and therefore the efficiency of experimental selection. 
  
                                                          
29 A = Alanine, B = Asparagine or Aspartic Acid, C = Cysteine, D = Aspartic acid, E = Glutamic acid, F = Phenylalanine, 
G = Glycine, H = Histidine, I = Isoleucine, K = Lysine, L = Leucine, M = Methionine, N = Asparagine, P = Proline, Q = 
Glutamine, R = Arginine, S = Serine, T = Threonine, V = Valine, W = Tryptophan, Y = Tyrosine, Z = Glutamine or 
Glutamic Acid 
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2.5 High-Throughput Sequencing: Data Analysis 
2.5.1 VDJ Gene Usage 
Pivot tables in Microsoft Excel 2010 were used to calculate the frequency with which heavy 
and light chain VDJ families and genes were used in each donor. Kappa and lambda sequences 
were analysed separately. Only a single, modal, sequence from each clonotype was used to 
calculate mean family/gene frequency (+/- 1 SD) to ensure the frequencies were not skewed 
by PCR amplification or clonal expansions. 
To ensure the VDJ family/gene frequencies being compared were based on meaningful data, 
the “5X rule” was used to exclude any samples that contained too few observations. The 5X 
rule stipulates that if the sequence count of a sample was less than five times the number of 
families/genes being investigated, that sample was excluded from the analysis because the 
sequence count was too low to give a meaningful representation of gene frequency. 
In the B cell development light chain dataset, a small number of light chain sequences were 
amplified from pre-B cells. During gene frequency analysis and CDR-L3 property analysis, pre-B 
sequences were grouped with the immature sequences and analysed collectively as immature 
B cells. These cells were likely to have been transitioning from pre-B to immature and so the 
cell surface markers were those of pre-B cells, but the light chain loci had begun rearranging. 
2.5.2 CDR3 Analysis 
Before analysing the properties of the heavy and light chain CDR3, entries which may skew the 
data are removed from the full dataset, resulting in a “clean” dataset. Entries were removed 
from the heavy chain datasets if the CDR-H3 length was reported to be greater than 35 amino 
acids and entries were removed from the light chain datasets if the CDR-L3 length was 
reported to be greater than 20 amino acids as this was deemed biologically implausible. 
Entries were removed from both the heavy and light datasets if IMGT had labelled them as 
unproductive because these sequences often contained frameshifts or stop codons which 
would interfere with the CDR3 amino acid sequence. 
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2.5.3 Principal Component Analysis 
Principal component analysis (PCA) was calculated for all 29,447 kappa and 8,876 lambda 
entries in the (“clean”) light chain B cell Development dataset using the “prcomp” function in 
R30. The 10 Kidera factors (Table 2-19, page 94) of each CDR-L3 amino acid sequence were 
used to calculate the PCA. Data were scaled. 
2.5.4 Calculating Diversity 
To calculate the clonal diversity in the Ribosome Display Libraries dataset, a new dataset was 
created from the full dataset (i.e. all members of each clonal expansion present, not just the 
single, modal, sequence) which contained the clone identifiers and a column containing the 
sample identifiers (i.e. the information by which the dataset should be split). The number of 
times a clone identifier appeared in the dataset indicated the size of the clone. The R package 
Alakazam (Gupta et al., 2015) was used to calculate and plot clonal diversity index curves using 
the default settings in the “rarefyDiversity” and “plotDiversityCurve” commands. 
  
                                                          
30 The R script used to calculate the principal component analysis (PCA) was written by Grace Lu (KCL) 
Chapter 2: Materials and Methods 
98 
 
2.6 Modelling Kappa/Lambda CDR Structural Differences31 
The Protein Data Bank (PDB) (Berman et al., 2000) was filtered for the antibody structures 
which had been solved by X-Ray diffraction to a resolution of less than 3 Å. The antibody 
structure had to have the heavy and the light chain. SAbDab (Dunbar et al., 2014) was used to 
build kappa and lambda datasets of the extracted structures. Redundancy in the PDB 
structures was eliminated by culling the structures using PISCES (Wang & Dunbrack, 2003) to a 
maximum mutual sequence identity of 99%. 
199 kappa and 106 lambda structures remained and were used for analysis. Due to incomplete 
CDR information in six PDB structures (4LSQ, 4OB5, 4Y5Y, 4HKX, 5D70, and 7FAB), kappa 
antibody CDR-H1, lambda antibody CDR-H2, and lambda antibody CDR-L2 analyses were 
performed using 197, 105, and 103 entries respectively. 
For this analysis the CDR regions were defined using the Chothia definition (Chothia & Lesk, 
1987, Al-Lazikani et al., 1997). Secondary structure probabilities were calculated for each of 
the heavy and light chain CDR regions using DSSP (Kabsch & Sander, 1983). The hydrogen bond 
definition energy cut-off was set to less than -0.5 kcal/mol. The secondary structure 
probabilities were normalised according to CDR length. The structural definitions were as set 
out in Table 2-21. 
Statistical significance was calculated in R using bootstrapping (boot function). 100 randomly 
resampled subsets were generated for each reference dataset. The mean frequency of each 
structure (Table 2-21) was plotted with error bars representing the 95% confidence intervals of 
the bootstrapped distributions. Datasets were considered significantly different if the 95% 
confidence intervals did not overlap. 
Table 2-21: Definitions of CDR loop structural groups used in the investigation of whether 






β-strands and β-bridges 
Random coil 
α-helices, 310-helices and π-helices 
3, 4 and 5 turns and non-hydrogen bonded bends 
  
                                                          
31 All of the modelling and statistical analysis described in section 2.6 was performed by Julie Laffy (KCL) 
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2.7 Antibody Cloning and Expression: Restriction Digest Method 
2.7.1 Cloning Immunoglobulin Variable Regions into PEU Vectors 
Antibody heavy and light chain variable region nucleotide sequences were ordered from 
Integrated DNA Technologies with restriction sites at either end to enable their insertion into 
expression vectors. The IgH variable region sequences had a BssHII site at the 5’ end and a 
BstEII site at the 3’ end. The IgL variable region sequences had an ApaLI site at the 5’ end and a 
PacI site at the 3’ end. The DNA was ordered in a lyophilised state and was reconstituted with 
DNase-free H2O to a concentration of 10 ng/μl. 
The IgH and IgL inserts underwent a restriction digest as detailed in Table 2-22. The restriction 
digest was incubated at 50oC for 1 h, then 60oC for 1 h. 
Table 2-22: Immunoglobulin variable region restriction digest. 
Heavy Chain Reaction Light Chain Reaction 
Reagent Quantity Reagent Quantity 

























The digested variable region inserts were purified using the NucleoSpin Gel and PCR Clean-up 
kit (Macherey-Nagel) following the manufacturer’s instructions. The fragments were eluted in 
30 μl dH2O. 
The expression vectors were linearized using a restriction digest as described in Table 2-23. 
PEU1.338 vector digestions were incubated at 50oC for 30 min, then increase to 60oC for 
30 min. PEU3.4 and PEU4.4 plasmid digestions were incubated for 37oC for 1 h. 
                                                          
32 BssHII, R0199S, New England Biolabs 
33 BstEII, R0162S, New England Biolabs 
34 NEBuffer 3.1, B7203S, New England Biolabs 
35 ApaLI, R0507S, New England Biolabs 
36 PacI, R0547S, New England Biolabs 
37 NEBuffer 1.1, B7201S, New England Biolabs 
38 The vectors PEU1.3, PEU3.4 and PEU4.4 are MedImmune property 
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Table 2-23: IgG expression plasmid restriction digest. 
Heavy Chain Reaction Light Chain Reaction 
Reagent Quantity Reagent Quantity 
 
 
PEU1.3 vector (9.3 kb) 
BssHII39 (4000 U/ml) 












PEU3.4 kappa vector (7.0 kb) 
or 
PEU4.4 lambda vector (6.8 kb) 
ApaLI42 (10,000 U/ml) 




13 μl (5 μg) 
 







The linearized vectors were run at 110 V for 30 min on a 1% (w/v) TAE agarose gel stained with 
SYBR SAFE (S33102, Invitrogen). The bands were excised (9.3kb, 7.0kb and 6.8kb for PEU1.3, 
PEU3.4 and PEU4.4 respectively) and purified using the NucleoSpin Gel and PCR Clean-up kit 
(740609, Macherey-Nagel) following the manufacturer’s instructions. The plasmid DNA was 
eluted in 30 μl dH2O and the concentration was measured using NanoDrop. 
The digested variable region inserts were ligated into the relevant linearized expression 
vectors using the ligation reaction described in Table 2-24. The ligation reaction was incubated 
at 25oC for 10 min. 
Heavy chain variable regions were cloned into the PEU1.3 vector upstream of an IgG1 heavy 
chain constant region. Kappa light chain variable regions were cloned into the PEU3.4 vector 
upstream of a kappa light chain constant region. Lambda light chain variable regions were 
cloned into the PEU4.4 vector upstream of a lambda light chain constant region. 
Table 2-24: Ligating variable region inserts into IgG expression plasmids. Plasmids and inserts 
were in a 1:3 molar ratio. 
Reagent Quantity 
PEU1.3/PEU3.4/PEU4.4 plasmid (Table 2-23) 
Variable region insert (Table 2-22) 
2X Quick Ligation Reaction Buffer45 




3-fold molar excess 
15 µl 
1.5 µl 
To 30 µl 
30 µl 
 
                                                          
39 BssHII, R0199S, New England Biolabs 
40 BstEII, R0162S, New England Biolabs 
41 NEBuffer 3.1, B7203S, New England Biolabs 
42 ApaLI, R0507S, New England Biolabs 
43 PacI, R0547S, New England Biolabs 
44 NEBuffer 1.1, B7201S, New England Biolabs 
45 Quick Ligation Kit, B2200S, New England Biolabs 
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Plasmids were transformed into E. coli by adding between 1 μl and 10 μl of the ligation 
reaction to 100 μl DH5α competent E. coli. The cells were incubated on ice for 5 min and then 
spread on 2X TY agar containing 100 μg/ml ampicillin, 2% (w/v) glucose. The plates were 
incubated overnight at 37oC. 
Colony PCR was used to check for the presence of inserts. 10 μl of PCR master mix (see Table 
2-25) was added to the required number of wells on a PCR plate. Individual colonies were 
picked and were transferred both to a PCR tube and 150 μl 2X TY broth containing 100 μg/ml 
ampicillin, 2% (w/v) glucose. The cultures were incubated at 37oC, 150 rpm until the results of 
the colony PCR indicated which contained variable region inserts. The colony PCR was run 
using the conditions detailed in Table 2-25. 
Table 2-25: IgG expression plasmid colony PCR reagents and thermal cycle. Quantities for 1 ml 
of master mix are given. Primer 3.4PCRrev was used for PEU3.4 vectors. Primer 4.4PCRrev was 
used for PEU4.4 vectors. All primers in this table are MedImmune property. 
Heavy Chain Reaction Light Chain Reaction 
Reagent Quantity Reagent Quantity 
2X ReddyMix PCR Master Mix46 
pEUPCRfor primer (100 μM) 
 
 










2X ReddyMix PCR Master Mix46 
pEUPCRfor primer (100 μM) 
3.4PCRrev primer (100 μM) 
or 



































The 10 μl PCR product was run on a 1% (w/v) agarose gel at 110 V for 10 min. The size of the 
bands indicated which ligations had worked. One successful ligation per insert was cultured in 
5 ml 2X TY broth containing 100 μg/ml ampicillin, 2% (w/v) glucose overnight at 37oC, 150 rpm. 
The colonies were sent for sequencing to confirm the presence of the correct insert. 
  
                                                          
46 2x ReddyMix PCR Master Mix, AB-0575/DC/LD, Thermo Scientific 
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2.7.2 Expression of IgG1 Antibodies from PEU Vectors47 
Plasmids containing the desired inserts (section 2.7.1) were transfected into CHO cells for 
expression as IgG1 antibodies. The antibodies were purified in PBS using a MabSelect SuRe 
affinity chromatography column (GE Healthcare) on an ÄKTA Pure protein purification system. 
SDS-PAGE was used to check the successful expression of complete heavy and light chains 
from each transfection. HP-SEC was used to measure the proportion of IgG1 monomers in the 
purified sample and any aggregation or fragmentation. 
  
                                                          
47 The work described in section 2.7.2 was performed by the IgG team at MedImmune (Cambridge, United Kingdom) 
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2.8 Antibody Cloning and Expression: PIPE Cloning Method 
Antibody variable region sequences were cloned into modified pVITRO1-hygro-mcs (Invivogen) 
expression vectors (see Figure A-1, page 270, for plasmid maps) using polymerase incomplete 
primer extension (PIPE) as described in Dodev et al. (2014). 
The principle of PIPE cloning is to amplify the two halves of the expression plasmid and the 
inserts using primers with complementary overhangs. The PCR used has a short extension time 
(55 s for plasmid halves, 5 s for inserts), ensuring that the extension is not always complete. 
This means that there is a single-stranded 5’ overhang at either end of some PCR products 
where the polymerase has not reached the end. As the primers for amplifying the vector 
halves and inserts were complementary, the 5’ overhangs are complementary. This means that 
the plasmid halves and inserts can simply be mixed, the complementary ends will ligate, and 
complete plasmids will assemble (see Figure 2-5 for schematic). Unlike the plasmids used in 
section 2.7, the heavy and light chain pair are inserted into the same pVITRO1 expression 
vector. 
 
Figure 2-5: PIPE cloning principle. Whole, circular, pVITRO1 plasmid is isolated from E. coli 
stocks. The plasmid is copied in two halves and the VH and VL inserts are amplified using 
primers with complementary overhangs. The short extension time ensures some incomplete 
PCR amplification, resulting in plasmid halves and inserts with complementary 5’ single-
stranded overhangs. The plasmid halves and inserts are mixed and they ligate to form 
complete plasmids. The original plasmid not containing insert is removed using a DpnI digest 
as only original plasmid will be Dam methylated. The lambda pVITRO1 plasmid has been used 
in this example; see Figure A-1 (page 270) for pVITRO1 plasmid maps. 
2.8.1 pVITRO1 Vector Linearization by PCR 
The pVITRO1-dV-IgG1_κ and pVITRO1-dV-IgG1_λ plasmids were copied into two linear halves 
(VFK1 + VFK2 and VFL1 + VFL2 respectively) by PCR. See Table 2-26 for vector linearization 
primers and Table 2-27 for PCR reagents and conditions. 
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Table 2-26: pVITRO1 vector linearization primers. See Table A-15 (page 268) for primer 
sequences. 
Vector template Forward primer Reverse primer Vector fragment 
pVITRO1-dV-IgG1_κ 
Linear_IgG1fwd Linear_Krev VFK1 
Linear_Kfwd Linear_Hrev VFK2 
pVITRO1-dV-IgG1_λ 
Linear_IgG1fwd Linear_Lrev VFL1 
Linear_Lfwd Linear_Hrev VFL2 
 
Table 2-27: pVITRO1 vector linearization PCR reagents and thermal cycle. The vector templates 
should be purified from E. coli culture. 
Reagent Quantity 
Vector template pVITRO1-dV-IgG1_κ/λ (10 ng/μl) 
Forward primer (10 µM) (see Table 2-26) 
Reverse primer (10 µM) (see Table 2-26) 
H2O 






























1 μl of amplified vector product was run on a 0.8% TAE agarose gel to confirm linearization. 
The bands should be approximately 4 kb in size. 
To minimise background colonies, a DpnI digest (Table 2-28) was performed on the linearized 
vector fragments to eliminate whole circular template plasmid. The DpnI digest was incubated 
at 37oC for 1 h. 
Table 2-28: pVITRO1 linearized vector DpnI digest. 
Reagent Quantity 
Linearized vector PCR product (Table 2-27) 










                                                          
48 Phusion Flash High-Fidelity PCR Master Mix (F548S, Thermo Scientific) 
49 CutSmart Buffer (B7204S, New England Biolabs) 
50 DpnI (R0176S, New England Biolabs) 
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2.8.2 PCR Amplification of Variable Region Sequences 
Antibody variable region sequences were amplified from starting material using the PCR 
described in Table 2-29. Forward and reverse primers were specific to the first and last five 
amino acids of the variable and joining regions. See Table A-17 (page 269) for the primer 
combinations used to amplify the heavy and light chain variable regions of each antibody 
expressed using this method. 
Table 2-29: Insert amplification PCR reagents and thermal cycle. Template DNA is the variable 
region sequence. See Table A-16 (page 268) for primer sequences. 
Reagent Quantity 
Template DNA 
Forward primer (10 μg/ml) 
Reverse primer (10 μg/ml) 
H2O 






























1 μl of each PCR product was run on a 1.3% TAE agarose gel to check for bands of the correct 
size (IgH ~400 bp, IgK/IgL ~350 bp). 
2.8.3 Vector Assembly and Transformation 
The DpnI-treated vector fragments (section 2.8.1) were mixed with the inserts (section 2.8.2) 
in the order and quantities shown in Table 2-30 and incubated at room temperature for 1 h. 
No heating or cooling was required. 
Table 2-30: pVITRO1 vector assembly reaction with inserts. 
Order Kappa Lambda Quantity 
1 H2O H2O 4 μl 
2 VFK1 plasmid half VFL1 plasmid half 1 μl 
3 VK variable region VL variable region 1 μl 
4 VFK2 plasmid half VFL2 plasmid half 1 μl 
5 VH variable region VH variable region 1 μl 
  
                                                          
51 Phusion Flash High-Fidelity PCR Master Mix (F548S, Thermo Scientific) 
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2 μl of vector assembly reaction mix (Table 2-30) was transformed into 25 μl NEB 10-beta 
Competent E. coli (C3019H, New England Biolabs). The transformation protocol was as per the 
manufacturer’s instructions with the single modification that the E. coli were re-suspended in 
475 μl SOC media and then incubated for 90 min at 37oC, 200 rpm. 200 μl of transformation 
reaction was spread on Fast-Media Hygro Agar (InvivoGen) or Fast-Media Base Agar 
(InvivoGen) supplemented with 100 μg/ml Hygromycin B Gold (InvivoGen) and incubated 
overnight at 37oC. 
Colonies were screened for the presence of a heavy chain variable region insert using colony 
PCR (Table 2-31). Each colony was saved on a patch plate (selective hygromycin-containing 
agar as described in previous paragraph). In every case, if a heavy chain variable region was 
present in the plasmid, the light chain variable region insert was also present in the plasmid. 
15 μl of colony PCR products were run on a 1.3% (w/v) TAE agarose gel to confirm the 
presence of insert. A band of approximately 1.7 kb indicates the presence of a heavy chain 
variable region. A band of approximately 1.4 kb indicates the absence of a heavy chain variable 
region. 




pVITRO1F primer (10 μg/ml) 
pVITRO1R primer (10 μg/ml) 
H2O 



























Colonies containing successfully assembled plasmids were cultured in 5 ml Fast-Media Hygro 
TB (InvivoGen) or Fast-Media Base LB (InvivoGen) supplemented with 100 μg/ml Hygromycin B 
Gold (InvivoGen). Plasmids were purified using the QIAprep Spin Miniprep Kit (27104, Qiagen) 
following the manufacturer’s instructions. Plasmids were eluted in 50 μl H2O and samples were 
sent for Sanger sequencing (Eurofins, Germany) to confirm the successful insertion of the 
antibody variable regions (see Table A-18, page 269, for sequencing primers).  
                                                          
52 OneTaq Quick-Load 2X Master Mix with Standard Buffer (M0486S, New England Biolabs) 
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2.8.4 Expression of IgG1 Antibodies from pVITRO1 Vectors 
Antibodies were either expressed in adherent HEK 293 cells or in FreeStyle 293-F cells in 
suspension. 
When antibodies were expressed in HEK 293 cells, cells were seeded in 12-well tissue culture 
plates at 1 X 105 cells/ml in 2 ml complete media (DMEM53, 10% (v/v) HI-FCS, 1% (v/v) 
penicillin-streptomycin). Cells were grown for 24 h before transfection. Cells were transfected 
using FuGENE HD transfection reagent (E2311, Promega) following manufacturer’s instructions 
in a 1:3 DNA:FuGENE ratio. 2 μg DNA was used per well. Cells were incubated at 37oC, 5% CO2 
for up to one week. Tissue culture supernatant was clarified by centrifugation in a benchtop 
centrifuge at maximum speed for 5 min. 
When antibodies were expressed in FreeStyle 293-F cells (Gibco), cells were seeded in 
suspension in a six-well tissue culture plate at a concentration of 1 X 106 cells/ml in 2 ml 
FreeStyle 293 Expression Medium (12338018, Gibco). Cells were immediately transfected with 
2 μg DNA as follows: DNA and PEI Max were separately diluted in Opti-MEM Reduced Serum 
Media as described in Table 2-32. The two solutions were then mixed together and incubated 
at room temperature for 20 minutes. The plasmid/PEI Max/Opti-MEM mixture (200 μl) was 
then gently added to the 2 ml of FreeStyle 293-F cells. The transfected cells were incubated at 
37oC, 7% CO2, 135 rpm for five days. Tissue culture supernatant was clarified by centrifugation 
at 1500 g for 10 min. 
In both methods, the concentration of IgG1 in the clarified tissue culture supernatant was 
measured using a quantitative ELISA (section 2.8.5). 
Table 2-32: DNA and PEI Max dilutions in OptiMEM. pVITRO1 DNA (μg) and PEI Max (μl) were 
used in a 1:3 ratio. The total of both solutions when mixed together was 200 μl, i.e. 10% of the 
FreeStyle 293-F cell culture volume. 
DNA solution PEI Max solution 
pVITRO1 plasmid DNA 
Opti-MEM54 
2 μg 
To 100 μl 





                                                          
53 DMEM, high glucose, GlutaMAX, pyruvate (31966, Thermo Fisher Scientific) 
54 Opti-MEM Reduced Serum Media, 31985062, Gibco 
55 Polyethylenimine Hydrochloride, Linear (MW 4,000) (24885, Polysciences Inc.) at 1 mg/ml in H2O 
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2.8.5 Quantitative ELISA 
A Nunc MaxiSorp 96-well ELISA plate was coated with 50 μl goat anti-human IgG-UNLB 
(204001, Oxford Biotech) at 2 μg/ml in PBS. The plate was incubated at 4oC overnight. The 
plate was washed three times with 0.05% (v/v) Tween-20 in PBS and blocked with 200 μl 
3% (w/v) skimmed milk powder in PBS for 1 h at room temperature. The plate was washed 
three times as before. To create the standard curve, rows A-C, columns 1-11, were coated with 
50 μl of two-fold serial dilutions of IgG from Human Serum (I4506, Sigma Aldrich) in PBS. The 
initial concentration in column one was 3 μg/ml. The concentration in column 11 was 
0.003 μg/ml. Column 12 contained PBS only. The rest of the plate was coated with 50 μl of 
clarified tissue culture supernatant (section 2.8.4) in various dilutions in PBS. The plate was 
incubated for 1 h at room temperature and then washed three times as before. The plate was 
then coated with 50 μl Anti-Human IgG (Fc specific)-Peroxidase antibody produced in goat 
(A0170, Sigma Aldrich) in a 1/10,000 dilution in blocking buffer. The plate was incubated for 
1 h at room temperature. The plate was washed three times as before. The plate was then 
coated with 50 μl OPD substrate56 and incubated for 30 min at room temperature in the dark. 
The reaction was stopped by the addition of 50 μl 3 M HCl. The plate was read at 492 nm. 
The concentration of antibodies in clarified supernatant was determined by finding the dilution 
at which the optical density of the antibody of interest intersects with the linear region of the 
standard curve. The concentration of the antibody can then be read off the graph as shown in 
Figure 2-6. 
 
Figure 2-6: Estimating IgG concentration from quantitative ELISA standard curve. Standard IgG 
is titrated in a series of 1-in-2 dilutions across the top 11 columns of a 96-well ELISA plate to 
create the standard curve. The concentration of expressed antibodies is then estimated by 
reading off the concentration of the standard IgG at the relevant optical density.  
                                                          
56 One 5 mg OPD tablet (Sigma, P6912-50 TAB) dissolved in 10 ml 1X peroxide substrate buffer (9 ml H2O, 1 ml 10X 
stable peroxide substrate buffer (Thermo Scientific, 34062)) 
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2.9 HEp-2 Immunocytochemistry 
2.9.1 HEp-2 Cell Culture on Glass Coverslips 
HEp-2 cells (CCL-23, ATCC) were seeded at 2 X 105 cells/ml in 500 μl of DMEM (41966-029, 
Gibco), 10% (v/v) HI-FCS, 1% (v/v) penicillin-streptomycin in 24-well tissue culture plates, each 
well contained a single sterile glass 13 mm coverslip (631-0150, VWR). The cells were 
incubated at 37oC, 5% CO2 until the cells reached 70% confluency on the coverslips. 
2.9.2 Immunofluorescence Staining of HEp-2 Cells 
The tissue culture supernatant was removed from each well and the coverslips were washed 
three times in PBS. The coverslips were incubated with 500 μl 4% (v/v) paraformaldehyde 
(PFA) in PBS at room temperature for 10 min. The coverslips were washed three times in PBS 
and incubated in 500 μl of 0.1% (v/v) Triton X-100, 3% (w/v) BSA in PBS at room temperature 
for 10 min. The coverslips were washed once in PBS and incubated in 300 μl 50 μg/ml primary 
antibody diluted in 3% (w/v) BSA in PBS at room temperature for 1 h. The coverslips were 
washed three times in PBS and incubated for 1 h at room temperature in 300 μl 1/500 goat 
anti-human IgG (H+L) Alexa Fluor 488 conjugate (polyclonal, A-11013, Thermo Fisher) and 
1/10,000 DAPI (D9542-10MG, Sigma Aldrich) diluted in 3% (w/v) BSA in PBS. The coverslips 
were washed three times in PBS, carefully removed from the 24-well plate and mounted on 
glass microscope slides using 5 μl Glycergel mounting medium (C0563, Dako). Slides were 
stored in the dark at 4oC until use. 
2.9.3 Fluorescent Imaging 
Slides were imaged using 3 μm Z-stacks on a Nikon Eclipse Ti widefield microscope. The 
exposure time for both the DAPI and Alexa Fluor 488 was 100 ms. The presence of DAPI-
stained nuclei was used to confirm that there were cells present in every picture. The ND2 
image files were analysed using ImageJ (Rasband, 1997-2016). 
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2.10 Solid-Phase ELISA 
96-well Nunc Maxisorp ELISA plates (M9410, Sigma Aldrich) were coated with 50 μl of antigen 
diluted in PBS to the optimal coating concentration (Table 2-34)57. The plates were incubated 
overnight at 4oC. Plates were washed three times with washing buffer (see Table 2-33) and 
then incubated with 200 μl-300 μl blocking buffer (Table 2-33) for 1 h at room temperature. 
The plate was then washed three times in washing buffer (Table 2-33). 50 μl of primary test 
antibody (IgG1) was added at a concentration of 1 μg/ml in PBS. 50 μl of primary positive 
control antibody in PBS (see Table 2-35 for working dilutions) was included on every plate. The 
primary antibodies were incubated under the conditions described in Table 2-33. The plates 
were washed three times with washing buffer (Table 2-33) and 50 μl of secondary, HRP-
conjugated, antibody diluted in blocking buffer (see Table 2-35 for working dilutions and Table 
2-33 for blocking buffers). The plates were then incubated as described in Table 2-33. The 
plates were washed three times with washing buffer (Table 2-33) and 50 μl OPD substrate58 or 
TMB substrate (T0440, Sigma Aldrich) was added per well. The plates were incubated on the 
bench until the positive controls changed colour. The reactions were stopped with 50 μl 3 M 
HCl (OPD substrate) or 0.5 M H2SO4 (TMB substrate). The plates were read at 492 nm (OPD 
substrate) or 450 nm (TMB substrate). 
Table 2-33: Blocking, washing and incubation conditions used in solid-phase ELISA. Blocking 
and washing condition combinations are shown together. 
Blocking conditions 
Blocking buffer Washing buffer 
3% (w/v) Marvell skimmed milk powder in 1X PBS 1X PBS 
3% (w/v) Bovine serum albumin (BSA) in 1X PBS 1X PBS 
0.05% (v/v) Tween-20, 2 mM EDTA in 1X PBS 0.05% (v/v) Tween-20, 2 mM EDTA 
in 1X PBS 
50 mM Tris, 1% (v/v) Tween-20, 0.3 M NaCl, pH 7.5 50 mM Tris, 1% (v/v) Tween-20, 
0.3 M NaCl, pH 7.5 
Incubation conditions 





2 h/1.5 h 
1 h/1 h 
  
                                                          
57 The optimal coating concentration for each antigen was determined by titration curves (Figure A-5, page 284) 
58 One 5 mg OPD tablet (Sigma, P6912-50 TAB) dissolved in 10 ml 1X peroxide substrate buffer (9 ml H2O, 1 ml 10X 
stable peroxide substrate buffer (Thermo Scientific, 34062)) 
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Table 2-34: Optimal coating concentrations for antigens used in solid-phase ELISA. Antigen 
coating concentrations were determined by titration curves (see Figure A-5, page 284). 
































Table 2-35: Working dilutions of commercial antibodies used in solid-phase ELISA. Positive 
control primary antibodies and HRP-conjugated secondary antibodies are shown. 
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2.11 Soluble ELISA 
Dynabeads M-280 Streptavidin (11205D, Thermo Fisher) were re-suspended and a total 
volume of 10 μl per reaction was transferred into two clean tubes (one for the experiment, 
one as a control). The beads were pelleted using a magnetic separator, the supernatant was 
discarded and the beads were re-suspended in the same volume of PBS. This wash step was 
repeated twice more. The beads were then re-suspended in the same volume of blocking 
buffer (3% (w/v) BSA in PBS) and incubated on a rotary mixer (20 rpm) for 1 h at room 
temperature. The beads were washed three times in PBS as described previously. The beads in 
one tube were re-suspended in 10X the original liquid volume of 0.1 μg/ml biotinylated 
insulin59 in blocking buffer. The beads in the control tube were re-suspended in the same 
volume of blocking buffer only. The tubes were incubated on a rotary mixer (20 rpm) for 1 h at 
room temperature. The beads were washed three times in PBS and, on the third wash, 10 µl 
was transferred into the required number of wells in a 96-well PCR plate. The plate was placed 
on a magnetic separator to pellet the beads and the 10 µl of PBS was carefully removed using a 
pipette. Without letting the beads dry out, the beads were re-suspended in 50 µl of 1 µg/ml 
primary antibody in PBS. As a positive control, 50 µl of anti-insulin antibody was used at the 
concentration stated in Table 2-35 (page 111). As a negative control, 50 µl PBS was used. The 
plate was incubated at 37oC, 200 rpm for 2 h. The beads were washed three times in 50 µl PBS 
as described previously. The beads were re-suspended in 50 µl secondary antibody in blocking 
buffer at the concentrations stated in Table 2-35. The plate was incubated at 37oC, 200 rpm for 
1.5 h. The beads were washed three times in PBS and, on the last wash, the beads were 
transferred to a clear, round-bottomed 96-well plate. The plate was placed on a magnetic 
separator and the PBS was removed. The beads were re-suspended in 50 µl TMB substrate 
(T0440, Sigma Aldrich) and the plate was incubated at room temperature until the positive 
controls had changed colour. The reaction was stopped by adding 50 µl 0.5 M H2SO4. The plate 
was read at 450 nm. 
This method is illustrated in a schematic in Figure 3-15 (page 168). 
  
                                                          
59 The biotinylated insulin was made in-house at MedImmune (Cambridge, United Kingdom); biotin was attached to 
the lysines on the insulin. A titration curve was used to determine that 0.1 μg/ml was sufficient to saturate the 
streptavidin-coated Dynabeads (see Figure A-6, page 284). 
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2.12 Thermal Shift Assay 
A thermal shift assay measures the temperature at which a protein denatures, exposing 
hydrophobic patches which are usually hidden when the protein is in its native state. 
20 μl of each purified antibody was added in triplicate to a white PCR plate. 5 μl 40X SYPRO 
Orange (S6650, Thermo Fisher Scientific) was added to each well (8X final concentration). An 
RT-PCR machine was used to perform a melting curve. The temperature started at 20oC and 
was increased by 1oC (holding at each temperature for 1 s) up to a final temperature of 90oC. 
The fluorescence was read at every 1oC increment. The melting temperature (Tm) could be 
determined from the point at which a fluorescent signal was detected. 
This method is illustrated in a schematic in Figure 3-22A (page 174). 
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2.13 Phage Display: Panning Selection against Multiple Antigens 
2.13.1 Panning Selections 
One well of a Nunc Maxisorp plate was coated with 100 μl antigen at an appropriate 
concentration (Table 2-34, page 111) and incubated overnight at 4oC. The plate was washed 
three times with PBS and incubated with 300 µl blocking buffer (3% (w/v) skimmed milk 
powder in PBS) for 1 h at room temperature and then washed once with PBS. 
A single 50 µl aliquot of BMVtrp phage library (1012 M13 phage)60 was blocked by adding 50 µl 
2X blocking buffer (6% (w/v) skimmed milk powder in 2X PBS) and incubating for 1 h at room 
temperature. 
The blocked phage library was first transferred to a blank ELISA well (coated with PBS only) 
which had been blocked with 3% (w/v) skimmed milk powder in PBS and incubated for 1 h at 
room temperature. The contents (i.e. phage that had not bound) was then transferred to the 
antigen-coated well and incubated for 1 h at room temperature. The well was washed five 
times with PBS to remove the unbound phage. To remove the antigen-bound phage, 100 μl 
trypsin solution (10 μg/ml trypsin in 0.1 M NaP buffer, pH 7.0) was added to the well and 
incubated at 37oC, 200 rpm for 30 min. 
The eluted phage were transferred to 0.8 ml mid-log phase TG1 E. coli and incubated at 37oC, 
200 rpm for 1 h. This allowed the eluted phage to infect the bacteria. 
2.13.2 Isolating Selected Phage and Calculating Output Titre 
To gauge the success of the selection, output titres were calculated. Output titres were 
created by serially diluting the M13 phage-infected TG1 E. coli from section 2.13.1, plating out 
the diluted E. coli and counting the resulting colonies. 
10 µl of the infected TG1 E. coli culture was diluted in 90 µl 2X TY broth and mixed thoroughly 
(10-1 dilution). 10 µl of infected TG1 E. coli was diluted in 990 µl 2X TY and mixed thoroughly 
(10-2 dilution). 100 µl of the 10-2 dilution was diluted in 900 µl 2X TY broth and mixed 
thoroughly (10-3 dilution). 100 µl of the 10-3 dilution was diluted in 900 µl 2X TY broth and 
mixed thoroughly (10-4 dilution). 100 µl of each dilution (10-1, 10-2, 10-3 and 10-4) was plated on 
a 2X TY agar plate supplemented with 100 µg/ml ampicillin and 2% (w/v) glucose. The cultures 
were grown at 30oC overnight. 
                                                          
60 The BMVtrp phage library was made in-house at MedImmune (Cambridge, United Kingdom). The original 
construction of this library was published in Vaughan et al. (1996). 
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The remaining E. coli was spread on a bioassay plate of the same media and grown at 30oC 
overnight. 
The colonies on the output titre plates were counted and the following equation was used to 
determine the number of colony-forming units per millilitre (cfu/ml): 
𝑁𝑜. 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝑉𝑜𝑙𝑢𝑚𝑒 𝑝𝑙𝑎𝑡𝑒𝑑 (𝑚𝑙)
= 𝑁𝑜. 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑦 𝑓𝑜𝑟𝑚𝑖𝑛𝑔 𝑢𝑛𝑖𝑡𝑠 𝑝𝑒𝑟 𝑚𝑙 (𝑐𝑓𝑢/𝑚𝑙) 
After calculating the output titre, individual output titre colonies could be picked for 
sequencing and testing the specificity of the scFv using ELISA (section 2.13.4). 
If the output titre was within a reasonable range, the bacterial lawn on the bioassay plate was 
scraped into 5 ml 2X TY broth supplemented with 50% (v/v) glycerol in a 2:1 ratio. The bacteria 
were re-suspended for 10 min on an end-over-end rotator. The phage from the bioassay plate 
E. coli were used in the next round of panning selection (section 2.13.3). 
2.13.3 Calculating Input Titre and Isolating Phage for Further Panning Selections 
The bioassay plate E. coli were grown in 25 ml 2X TY broth supplemented with 100 µg/ml 
ampicillin and 2% (w/v) glucose. The culture was grown at 37oC, 280 rpm, to an OD600 of 
0.5-1.0. The culture was then superinfected with 2.5 μl stock M13KO7trp helper phage 
(3 X 1013pfu/ml) and incubated at 37oC, 150 rpm for 1 h. 
The E. coli were pelleted at 2000 g for 10 min, re-suspended in 500 μl 2X TY broth 
supplemented with 100 µg/ml ampicillin and 50 µg/ml kanamycin. The re-suspended E. coli 
were then transferred to 25 ml of the same broth and were grown overnight at 25oC, 280 rpm. 
1 ml of E. coli culture was then pelleted in a benchtop centrifuge at maximum speed for 5 min. 
the input phage-containing clarified supernatant was transferred to a clean 1.5 ml 
polypropylene tube. 
Input titres were calculated by diluting 10 µl input phage in 990 µl 2X TY broth (10-2 dilution). 
The mixture was mixed thoroughly and 10 µl was diluted in 990 µl 2X TY broth (10-4 dilution). 
The mixture was mixed thoroughly and 10 µl was diluted in 990 µl exponentially growing TG1 
E. coli (10-6 dilution). The culture was incubated for 1 h at 37oC, 150 rpm. 100 µl of culture was 
then added to 900 µl 2X TY broth and mixed by pipetting (10-7 dilution). 100 µl was plated on 
2X TY agar supplemented with 100 µg/ml ampicillin and 2% (w/v) glucose. 100 µl of the 10-7 
dilution culture was diluted in 900 µl 2X TY (10-8 dilution) and 100 µl was plated out. This was 
repeated to create 10-9 and 10-10 dilutions. The 10-7, 10-8, 10-9 and 10-10 plates were incubated 
overnight at 30oC. 
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The colonies were counted and the input titre (cfu/ml) was determined using the same 
equation as the output titre. If the input titre was within a reasonable range (approximately 
1012 cfu/ml), the input phage could be used in a second round of selection (section 2.13.1). 
This process can be repeated several times (typically three to four times) to select for scFv 
which bind the selection antigens. 
2.13.4 Using Helper Phage to Release M13 Phage from Individual E. coli Colonies 
Individual colonies from the output titre plates (section 2.13.2) were picked into 500 μl 2X TY 
broth supplemented with 100 µg/ml ampicillin and 2% (w/v) glucose in a 96-well format. The 
cultures were grown for 5 h at 37oC, 280 rpm. 
Stock M13K07trp helper phage (3 X 1013 pfu/ml) were diluted by adding 5 μl stock helper 
phage per 10 ml 2X TY broth supplemented with 100 μg/ml ampicillin and 2% (w/v) glucose. 
100 μl diluted helper phage was then added to each well in the now visibly turbid 500 μl 
96-well liquid cultures. The cultures were incubated again for 1 h at 37oC, 150 rpm. 
The plates were centrifuged in a bench-top centrifuge at 3200 rpm for 10 min at room 
temperature. The supernatants were discarded and 500 μl 2X TY broth supplemented with 
100 μg/ml ampicillin and 50 μg/ml kanamycin was added to every well. The 96-well culture 
plates were incubated overnight at 25oC, 280 rpm to promote the expression of phage. 
The 500 μl cultures were blocked by adding 500 μl 2X blocking buffer (6% (w/v) milk powder in 
2X PBS) and incubating for 1 h at room temperature. The plates were centrifuged on a bench-
top centrifuge at 3200 rpm for 5 min at room temperature. The supernatants were then used 
in M13 phage ELISA (section 2.13.5). 
2.13.5 M13 Phage ELISA 
ELISA wells were coated with 50 μl of antigen at optimal concentration in PBS (see Table 2-34, 
page 111) and incubated overnight at 4oC. The plates were washed 3X with PBS and blocked 
with 300 μl 3% (w/v) skimmed milk powder in PBS. The plates were incubated for 1 h at room 
temperature. The blocked ELISA wells were washed 3X with PBS and 50 μl M13 phage-
containing supernatant (section 2.13.4) was added per well. The plate was incubated for 1 h at 
room temperature. The wells were then washed 3X with 0.1% (v/v) Tween-20 in PBS. 50 μl 
HRP/Anti-M13 Monoclonal Conjugate (27942101, GE Healthcare) diluted 1/5000 in 3% (w/v) 
skimmed milk powder in PBS was added to each well and incubated for 1 h at room 
temperature. 
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The wells were washed 3X with 0.1% (v/v) Tween-20 in PBS. 50 μl TMB substrate (T0440, 
Sigma Aldrich) was added per well and incubated until the positive controls changed colour. 
The reaction was stopped by adding 50 μl 0.5 M H2SO4 to each well. The plate was read on a 
fluorescent plate reader at a wavelength of 450 nm. 
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2.14 Ribosome Display: Building the DNA Libraries 
Ribosome display libraries were built for each donor in the Caucasian Aid Worker Ebola 
survivor dataset (section 2.2.1.1, page 83). Two libraries were built per donor: one using kappa 
light chains, the other using lambda light chains. A schematic of how the ribosome display 
libraries were built is shown in Figure 2-7. The linker sequences are shown in Table 2-36. 
 
Figure 2-7: Schematic of building the ribosome display libraries. In the first PCR (PCR1), 
V-specific and constant region specific primers were used to amplify variable regions from 
cDNA. IgA, IgG, IgM, IgK and IgL sequences were amplified. Linker sequences and restriction 
sites were added in a second round of PCR (PCR2). Heavy and light chains were linked at 
random in an overlap extension PCR (PCR3) and a T7 promoter site was added to the start of 
each amplicon. Each linker was composed of the first 24 nucleotides from the IgA, IgG or IgM 
CH1 region and the remaining 21 nucleotides is the complementary overhang region from the 
link primers in PCR2. When translated the linker is 15 amino acids long (see Table 2-36). See 
section A.1.4 (page 265) for all primer sequences. 
Table 2-36: Ribosome display linker sequences. In blue is the 5’ region of the CH1 region which 
can be used to identify the heavy chain class of the original antibody. In red is the overlap 
sequence used to join heavy and light variable regions. 
Isotype Linker nucleotide sequence (5’ to 3’) Linker amino acid sequence 
IgG gcctccaccaagggcccatcggtcttccccctggcgccctcctcc ASTKGPSVFPLAPSS 
IgM gcatccccgaccagccccaaggtcttccccctggcgccctcctcc ASPTSPKVFPLAPSS 
IgA gggagtgcatccgccccaacccttttccccctggcgccctcctcc GSASAPTLFPLAPSS 
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2.14.1 Reverse Transcription of mRNA from Total RNA 
Two reverse transcription reactions were set up per donor as shown in Table 2-37. One 
reaction used oligo-dT primers (thought to be optimal for light chain variable region sequences 
as they are shorter) and the other reaction used random hexamers (thought to be optimal for 
heavy chain variable region sequences as they are longer). 
Table 2-37: Ribosome display reverse transcription reagents for a single donor.
Tube 1 (optimal for light chains) Tube 2 (optimal for heavy chains) 
Reagent Quantity Reagent Quantity 






to 8 µl 
8 µl 






to 8 µl 
8 µl 
 
Both reactions (Table 2-37) were heated at 70oC for 5 min (denaturing) and then incubated on 
ice for 30 s. The contents of both tubes were pooled into a single PCR tube (16 µl) and a 
reverse transcription was set up as detailed in Table 2-38. 
Table 2-38: Ribosome display reverse transcription reagents and incubation. 
Reagent Quantity 
Pooled RNA from Table 2-37 
ProtoScript II Reaction Mix (2X)61 






















                                                          
61 ProtoScript II First Strand cDNA Synthesis Kit (E6560S, New England Biolabs) 
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2.14.2 Amplification of Variable Regions (PCR1) 
The cDNA from section 2.14.1 was used in a PCR reaction (PCR1) to amplify immunoglobulin 
sequences. A selection of V family-specific forward primers and constant region-specific 
reverse primers were used (see Table A-9, page 265, for the primer list). One PCR reaction was 
performed per primer pair (24X IgH reactions (i.e. 8X3), 4X IgK reaction, 9X IgL reactions). IgG, 
IgM, IgA, IgK and IgL sequences were amplified (see Figure 2-7 for a schematic). The PCR1 
reaction is shown in Table 2-39. 
Table 2-39: Ribosome display PCR1 reagents and thermal cycle. See Table A-9 for primers. See 
Figure 2-7 for schematic. 
Reagent Quantity 
Template cDNA (Table 2-38) 
Forward primer (10 µM) 
Reverse primer (10 µM) 
H2O 

































25 µl of each PCR1 product was mixed with 5 µl 6X gel loading dye (B7024S, New England 
Biolabs) and the whole 30 µl was run on a 1.3% (w/v) agarose gel (TAE buffer) stained with 
SYBR Safe (S33102, Invitrogen) at 90 V for 60 min. The bands were excised using a scalpel. 
Expected band sizes were as follows: IgH (~387-462 bp), IgK (~650 bp) and IgL (~650 bp). The 
DNA was purified using the QIAquick Gel Extraction Kit (28704, Qiagen) following the 
manufacturer’s instructions. DNA was eluted in 30 µl H2O and the concentration was measured 
using a NanoDrop (Thermo Scientific). 
  
                                                          
62 NEBNext Q5 Hot Start HiFi PCR Master Mix (M0543S, NEB) 
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2.14.3 Addition of Linker Regions (PCR2) 
To amplify and add linker sequences to the PCR1 products, PCR2 primers were used as 
described in Table 2-40. As the heavy chain sequences were amplified using a single reverse 
primer in PCR2, seven master mixes of heavy chain PCR1 products were made as described in 
Table 2-40 by adding equal volumes of each heavy chain PCR1 product. The heavy chain 
master mixes were used as the PCR starting material in PCR2. There was a 1:1 pairing of light 
chain PCR1 and PCR2 products so no master mixes were necessary. 
Table 2-40: Ribosome display library PCR1 and PCR2 primer pairs. PCR2 primer sequences are 
given in Table A-10 (page 266). 
PCR1 PCR Product 
Master Mix 
PCR2 
Chain Forward Reverse Forward Reverse 
VH1 GCH1link 









2 VH1257A GMACH1link VH1257 MCH1link 
VH1257 ACH1link 
VH2 GCH1link 
3 VH2A GMACH1link VH2 MCH1link 
VH2 ACH1link 
VH3A GCH1link 







5 VH4A GMACH1link VH4 MCH1link 
VH4 ACH1link 
VH4DP63 GCH1link 
6 VH4DP63A GMACH1link VH4DP63 MCH1link 
VH4DP63 ACH1link 
VH6 GCH1link 
7 VH6A GMACH1link VH6 MCH1link 
VH6 ACH1link 







VK2346 KC  VK2346link KCNotI 
VK36 KC  VK36link KCNotI 
VK5 KC  VK5link KCNotI 







VL1459 LC  VL1459link LCNotI 
VL15910 LC  VL15910link LCNotI 
VL2 LC  VL2link LCNotI 
VL3a LC  VL3alink LCNotI 
VL3b LC  VL3blink LCNotI 
VL3DLP16 LC  VL3DLP16link LCNotI 
VL6 LC  VL6link LCNotI 
VL78 LC  VL78link LCNotI 
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The PCR conditions are described in Table 2-41. The heavy chain reverse primer and the light 
chain forward primers had complementary overhangs, thus allowing them to join during the 
overlap extension step as described in section 2.14.4. 
Table 2-41: Ribosome display PCR2 reagents and thermal cycle. The quantities given are for 
each PCR reaction. In the heavy chain reaction, 3 µl of IgH PCR1 master mix is used, in the light 
chain reactions, 1 µl of light chain PCR1 product is used. See Table 2-40 for primer pairs and 
Table A-10 for primer sequences. See Figure 2-7 for schematic.
 
IgH reaction IgK/IgL reaction Reagent 
PCR1 product 
Forward primer (10 µM) 
Reverse primer (10 µM) 
H2O 







































The PCR2 products were run on a 1.3% agarose gel, the bands were excised and DNA was 
purified and quantified exactly as stated for PCR1 (section 2.14.2). 
  
                                                          
63 NEBNext Q5 Hot Start HiFi PCR Master Mix (M0543S, NEB) 
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2.14.4 Overlap Extension to Link Heavy and Light Chain Variable Regions (PCR3) 
3 µl of each PCR2 product was pooled to create three PCR2 master mixes: IgH, IgK and IgL. 
These master mixes were then used in an overlap extension PCR (PCR3) to randomly link heavy 
chains with kappa or lambda light chains. 
Heavy and light chains were joined using an assembly PCR as described in Table 2-42. 
Table 2-42: Ribosome display assembly PCR reagents and thermal cycle. Equal quantities of 
heavy and light chain master mixes were used to ensure an approximate 1:1 ratio of heavy and 
light chain sequences.
Reagent Quantity 
IgH PCR2 master mix 
IgK/IgL PCR2 master mix 
H2O 




to 25 μl 
12.5 μl 
25 µl 












The kappa and lambda assembly PCR products were then used in 24X kappa PCR3 reactions 
and 24X lambda PCR3 reactions per donor (48X PCR3 reactions per donor in total) as described 
in Table 2-43. 
Table 2-43: Ribosome display PCR3 reagents and thermal cycle. See Table A-11 for primers. See 
Figure 2-7 for schematic. 
Reagent Quantity  
 
Assembly PCR product 
RDT7AB primer (10 µM) 
ASKANG primer (10 µM) 
H2O 
DMSO 












































                                                          
64 NEBNext Q5 Hot Start HiFi PCR Master Mix (M0543S, NEB) 
65 NEBNext Q5 Hot Start HiFi PCR Master Mix (M0543S, NEB) 
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Each group of 24 PCR3 reaction products was pooled and purified using the Wizard SV Gel and 
PCR Clean-Up System (A9281, Promega) as detailed in section 2.2.4 (page 88) except the PCR3 
product was eluted in 60 µl H2O (40 µl + 20 µl). The entire elutedPCR3 product was mixed with 
the appropriate volume of 6X gel loading dye (B7024S, New England Biolabs) and was run on a 
0.8% (w/v) agarose gel (TAE buffer) stained with SYBR Safe (S33102, Invitrogen) at 90 V for 
30 min. 
Bands of the correct size (1.2 kb) were excised using a scalpel and the DNA was purified using 
the Wizard SV Gel and PCR Clean-Up System (A9281, Promega). 10 µl Membrane Binding 
Solution was added per 10 mg of gel. This was then heated at 56oC until the gel melted. The 
rest of the protocol was as detailed in section 2.2.4. The DNA was eluted in 30 µl H2O (20 µl + 
10 µl) and quantified using NanoDrop. 
This protocol resulted two libraries per donor: one using kappa light chains, the other using 
lambda light chains. 
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2.15 Ribosome Display: Panning Selection against EBOV GP 
Panning selection of the ribosome display libraries (section 2.14) against Zaire Ebola virus 
(EBOV) GP (section 2.17) was used to isolate EBOV GP-binding scFv from the repertoires of the 
three Caucasian Ebola survivors (section 2.2.1.1). A schematic of the ribosome display protocol 
is shown in Figure 2-8. 
 
Figure 2-8: Ribosome display method used to isolate Ebola GP-binders. A) The ribosome 
display libraries were built from functional immunoglobulin heavy and light chain variable 
region sequences which were reverse transcribed from mRNA, amplified by PCR and joined at 
random using overlap extension PCR (see section 2.14, page 118). The ribosome display 
libraries lack stop codons. B) The ribosome display libraries were transcribed and translated 
and the scFv mRNA and protein remained connected via the ribosome (due to the lack of a 
stop codon). C) The scFv-ribosome complexes were incubated with the EBOV GP antigen. The 
scFv which did not bind were washed away. D) The scFv-ribosome complexes which did bind 
the EBOV GP were recovered and the mRNA was reverse-transcribed. E) The cDNA was PCR-
amplified, inserted into the pESL expression vector and transformed into E. coli. F) The E. coli 
were plated out and cultured overnight. Individual colonies were picked and cultured in liquid 
media and scFv conjugated to NanoLuc (Nluc) luciferase were expressed. G) Specificity of scFv 
was confirmed using ELISA. Binding was detected using a luciferase assay.  
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2.15.1 Panning Selection against GP Antigen 
Nunc Maxisorp ELISA plates were coated with 60 µl of 20 µg/ml EBOV GP antigen (section 2.17, 
page 132) in molecular-grade PBS (10010023, Gibco) (one well per kappa library, one well per 
lambda library). The plate was incubated overnight at 4oC. The wells were washed once with 
300 µl molecular-grade PBS. The wells were blocked with 200 µl of 100 µg/ml purified BSA 
(B9001S, New England Biolabs) in molecular-grade PBS and incubated for 1 h at room 
temperature. 
To transcribe and translate the ribosome display libraries (section 2.14.4), the reaction shown 
in Table 2-44 was set up for each kappa and lambda library per donor. The reagents were 
mixed by pipetting and then centrifuged briefly. The reaction was incubated at 30oC for 
90 min. 
Table 2-44: Coupled transcription/translation reaction for scFv expression. 
Kappa Library Lambda Library 
Reagents Quantities Reagents Quantities 
TNT T7 Quick Master Mix66 
Methionine (1 mM)66 
T7 TnT PCR Enhancer66 







To 50 µl 
50 µl 
TNT T7 Quick Master Mix66 
Methionine (1 mM)66 
T7 TnT PCR Enhancer66 







To 50 µl 
50 µl 
 
4 µl RNaseOUT recombinant ribonuclease inhibitor (40 U/μl) (10777-019, Invitrogen) was 
added to each transcription/translation reaction (54 μl total per tube) and the tubes were 
incubated on ice until use. 
Blocking buffer was washed out of the antigen-coated wells by washing twice with 300 µl ice-
cold molecular grade PBS and the 54 µl transcription/translation reaction products were 
applied to the antigen-coated wells. The mixture was incubated on a rocker at 4oC for 1 h. The 
wells were washed three times with 300 µl ice-cold molecular-grade PBS to remove unbound 
scFv-mRNA-ribosome complexes. 
  
                                                          
66 T7 TnT Quick Coupled Transcription/Translation System (L1170, Promega) 
67 PCR3 product (section 2.14.4), ideally 1 µg DNA in ≤5 µl 
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The GP-bound scFv-mRNA-ribosome complexes were extracted from the wells using the 
RNeasy Micro Kit (74004, Qiagen) following the manufacturers quick start protocol with the 
following notes: 
 7 µl β-mercaptoethanol was added per 350 µl Buffer RLT, this was then pipetted up 
and down in the well to remove scFv-mRNA-ribosome complexes and then transferred 
to a clean 1.5 ml microcentrifuge tube 
 5 µl of 4 ng/μl carrier (poly-A) RNA was added to each tube 
 On-column DNaseI digestion was performed 
 The mRNA was eluted in 14 µl H2O 
Reverse transcription primers were annealed to the mRNA by mixing mRNA, primers and 
dNTPs as described in Table 2-45. The mixture was incubated at 70oC for 5 min, then put on 
ice. The reverse transcription reaction was performed as described in Table 2-46. The reverse-
transcribed sequences were amplified using PCR4 as described in Table 2-47. 
Table 2-45: Annealing reverse transcription primers to rescued mRNA. HuκF and HuλF primers 
are used for the kappa and lambda libraries respectively. See Table A-12 for primer sequences. 
Reagent Quantity 
mRNA from panning selection (section 2.15.1) 
HuκF or HuλF primer (10 µM) 







Table 2-46: Reverse transcription reaction reagents and thermal cycle. 
Reagent Quantity 
5X Reaction Buffer68 
RNaseOUT (40 U/μl)69 
DTT (0.1 M)68 
Nuclease-free H2O 
Reverse Transcriptase Enzyme68 
























                                                          
68 Protoscript II Reverse Transcriptase Kit (M0368, New England Biolabs) 
69 RNaseOUT recombinant ribonuclease inhibitor (40 units/ul) (10777-019, Invitrogen) 
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Reverse transcribed cDNA (Table 2-46) 
RDT7AB_short primer (10 µM) 
NotK or NotL primer (10 µM) 
Nuclease-free H2O 
Q5 Master Mix70 
Total 

























The PCR4 products were pooled and purified in 30 μl H2O using the Wizard SV Gel and PCR 
Clean-Up System (A9281, Promega) as detailed in section 2.2.4. 
The pooled PCR4 products were run on a 0.8% (w/v) agarose gel at 100 V for 20 min. The 
bands (760-800 bp) were excised using a scalpel and purified using the QIAquick Gel Extraction 
Kit (28704, Qiagen) in 30 μl H2O. The concentration was measured using NanoDrop. 
The PCR4 output sequences are shorter than the PCR3 input sequences because the reverse 
transcription primers bind further upstream in the light chain constant region. This is to 
increase yield of rescued PCR product because the 3’ end of the mRNA may have been 
damaged when the ribosome was removed. 
2.15.2 Insertion of scFv Sequences into pESL Plasmids 
The pESL plasmid (see Figure A-2, page 271, for plasmid map) and PCR4 product were digested 
using the reaction shown in Table 2-48. The reaction was incubated overnight at 37oC, then 
80oC for 20 min to inactivate the enzymes. 
                                                          
70 NEBNext Q5 Hot Start HiFi PCR Master Mix (M0543S, New England Biolabs) 
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Table 2-48: Restriction digest of PCR4 product and pESL plasmid. 
pESL plasmid digestion PCR4 insert digestion 
Reagent Quantity Reagent Quantity 
pESL plasmid 
CutSmart Buffer (10X)71 
NcoI-HF (20,000 U/ml)72 







To 50 µl 
50 µl 
PCR4 product 
CutSmart Buffer (10X)71 
NcoI-HF (20,000 U/ml)72 







To 25 µl 
25 µl 
 
The digested DNA was run on a 0.8% (w/v) agarose gel at 90 V. The bands were excised using a 
scalpel and the DNA was purified using QIAquick Gel Extraction Kit (28704, Qiagen). The pESL 
plasmid was eluted in 50 µl H2O and the PCR4 product was eluted in 30 µl H2O. The 
concentration of eluted DNA was measured using NanoDrop. 
The PCR4 insert library was ligated into pESL plasmids using a 1:3 plasmid to insert molar ratio 
as set out in Table 2-49. The reaction was incubated at room temperature for 1 h. 
Table 2-49: Ligation of PCR4 product into pESL plamid. The control ligation lacks insert DNA 
and gauges the background due to incomplete digestion. 
Reagent Quantity 
 
T4 DNA Ligase Buffer (10X)74 
Digested pESL (Table 2-48) 
Digested PCR4 product (Table 2-48) 







1 μl (400 U) 






1 μl (400 U) 
To 20 μl 
20 µl 
 
5 µl of ligation mix (Table 2-49) was transformed into NEB 5-alpha Competent E. coli (C2987R, 
New England Biolabs) following the manufacturer’s instructions. The transformed E. coli were 
plated on LB agar (Miller)75 supplemented with 50 µg/ml kanamycin (BP9065, Fisher Scientific) 
and incubated overnight at 37oC. 
94 colonies were picked per kappa and lambda library per donor and colony PCR was used to 
determine presence of PCR4 insert in each pESL vector. Colony PCR was performed as 
described in Table 2-50 and the product was run on 0.8% agarose gel. pESL containing insert 
                                                          
71 CutSmart Buffer (10X) (B7204S, New England Biolabs) 
72 NcoI-HF (20,000 units/ml) (R3193S, New England Biolabs) 
73 NotI-HF (20,000 units/ml) (R3189S, New England Biolabs) 
74 T4 DNA Ligase (M0202S, New England Biolabs) 
75 Tryptone 10 g/L, Yeast extract 5 g/L, Sodium Chloride 10 g/L (Fisher BioReagents Microbiology Media) 
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has a band of approximately 1600 bp. Empty pESL plasmid has a band of 980 bp. Only colonies 
with inserts of the correct size were tested in an ELISA against EBOV GP (section 2.16). 














T7F primer (10 µM) 
T7R primer (10 µM) 
OneTaq Quick-Load 2X Master Mix76 
Nuclease-free H2O 
Total 

























                                                          
76 OneTaq Quick-Load 2X Master Mix (M0486L, New England Biolabs) 
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2.16 Ribosome Display: Screening scFv for GP Binding (ELISA) 
Nunc FluoroF96 White MaxiSorp ELISA plates were coated with the desired concentration of 
glycoprotein (GP) (section 2.17, page 132) diluted in PBS and incubated at 4oC overnight. The 
wells were washed three times with 0.05% (v/v) Tween-20 in PBS, blocked with 200 µl blocking 
buffer (3% (w/v) skimmed milk powder in PBS) and incubated at room temperature for 1 h. 
The wells were washed three times with 0.05% (v/v) Tween-20 in PBS. 
Individual scFv-expressing E. coli colonies were picked and grown in 1 ml LB broth (Miller)77 
containing 50 µg/ml kanamycin (BP9065, Fisher Scientific) at 26oC, 200 rpm for 22 h. The 
bacteria were pelleted by centrifugation at 4500 rpm for 10 min. 50 µl of clarified supernatant 
was applied to each GP-coated ELISA well and incubated at room temperature for 2 h. The 
wells were washed three times with 0.05% (v/v) Tween-20 in PBS. 50 µl Nano-Glo solution 
(Table 2-51) was applied to each well and incubated at room temperature for 10 min. 
Luminescence was read on a Victor X Light plate reader (Perkin Elmer) (see Figure 2-9). 
Colonies expressing binders were sequenced using Sanger sequencing (Eurofins Genomics, 
Germany) using the T7F and pESL_SeqR primers (see Table A-14 for primer sequences). 
Table 2-51: Reagents to make up Nano-Glo substrate mixture. 
Reagent Quantity (X1 reaction) 
PBS 
Nano-Glo Luciferase Assay Buffer78 







Figure 2-9: Ribosome display scFv conjugated to NanoLuc luciferase. A) scFv are the 
immunoglobulin variable region held together by a linker instead of the antibody constant 
region. B) A secondary antibody was not required in the ELISA as the scFv were conjugated to 
NanoLuc luciferase, which breaks down Furimazine to create luminescence.  
                                                          
77 Tryptone 10 g/L, Yeast extract 5 g/L, Sodium Chloride 10 g/L (Fisher BioReagents Microbiology Media) 
78 Nano-Glo Luciferase Assay System (N1110, Promega) 
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2.17 Expression of Filoviridae Glycoprotein Ectodomains 
2.17.1 Glycoprotein Ectodomain Sequences79 
The nucleotide sequences encoding the glycoprotein (GP) ectodomains of Zaire Ebola virus 
(Mayinga strain)80 and Marburg virus (Ravn strain)80 (Table 2-52) were cloned into the pHL-sec 
expression plasmid (Aricescu et al., 2006) using restriction sites EcoRI and KpnI (see Figure A-3, 
page 271, for plasmid map). The ectodomain sequence was inserted upstream of a His-tag. 
The plasmids were cloned into NEB 10-beta E. coli (C3019H, New England Biolabs) and the 
bacteria were grown on LB agar/broth (Miller)81 supplemented with 100 μg/ml ampicillin. 
Plasmids were purified using NucleoBond Xtra Maxi prep kit (Macherey-Nagel) and eluted in 
H2O. 
Table 2-52: Filoviridae glycoprotein (GP) ectodomains expressed. GenBank accession number 
and the amino acid residues of expressed Ebola and Marburg virus GP ectodomain are shown. 
The cytoplasmic domain and transmembrane region of each GP was excluded. 
Filoviridae species Strain GenBank ID Residues Reference 
Zaire Ebola virus 
(Zaire ebolavirus) 
Mayinga U23187.1 1-632 Sanchez et al. (1996) 
Marburg virus 
(Marburg marburgvirus) 
Ravn ABE27071.1 1-642 Towner et al. (2006) 
 
2.17.2 Glycoprotein Expression82 
FreeStyle 293-F cells (Gibco) were seeded in FreeStyle 293 Expression Medium at a density of 
0.7 X 106 cells/ml. The cells were transfected the following day with plasmid DNA at a 
concentration of 2 μg/ml in a 1:6 ratio of DNA:PEI Max83. 
To transfect 1 L of FreeStyle 293-F cells, 2 mg of plasmid DNA was diluted in Opti-MEM 
Reduced Serum Media (31985062, Gibco) to a final volume of 50 ml and 12 ml PEI Max was 
diluted in Opti-MEM to a final volume of 50 ml. The two solutions were mixed together 
(100 ml total) and incubated for 30 min at room temperature before adding to the 1 l of cell 
culture. 
Cells were incubated at 37oC, 7% CO2, 135 rpm for 5 days.  
                                                          
79 The work detailed in section 2.17.1 was conducted by Audrey Page (KCL) 
80 Nucleotide sequences encoding the GP ectodomains were generously shared by Stuart Neil (KCL) 
81 Tryptone 10 g/L, Yeast extract 5 g/L, Sodium Chloride 10 g/L (Fisher BioReagents Microbiology Media) 
82 Zaire Ebola virus GP was expressed by Audrey Page (KCL) and Catherine Townsend (author), Marburg (Ravn) virus 
GP was expressed by Catherine Townsend (author) 
83 Polyethylenimine Hydrochloride, Linear (MW 4,000) (24885, Polysciences Inc.) at 1 mg/ml in H2O 
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2.17.3 Glycoprotein Purification84 
FreeStyle 293-F cell culture supernatant was clarified by centrifugation at 3000 rpm for 10 min 
at 4oC. The clarified supernatant was passed through a 0.22 μm filter. 2 M NaCl85 and 2 M 
Imidazole85 were added to the supernatant to a final concentration of 0.5 M NaCl, 30 mM 
imidazole, pH 7.4. The supernatant was kept on ice throughout the protocol. 
The His-tagged GP was purified by gravity flow separation using an Econo-Column 1.5 X 5 cm 
Chromatography Column (Bio-Rad) manually packed with 2 ml Ni Sepharose 6 Fast Flow slurry 
(17-5318-06, GE Healthcare). The slurry was not allowed to dry out at any point. The column 
was washed with five volumes of 0.22 μm filtered dH2O. The column was then equilibrated 
with 10 volumes of Binding Buffer85. The supernatant was loaded on to the column and filtered 
through the slurry by gravity. The column was then washed with 20 ml of Washing Buffer85. 
The His-tagged GP was eluted in 5 ml Elution Buffer (300 mM)85 then 5 ml Elution Buffer 
(500 mM)85. The eluent was collected in 1 ml fractions. 
A western blot was used to determine which eluent fractions contained protein. 10 μl of each 
1 ml fraction was mixed with 2 μl 6X Loading Buffer85 and run on a 0.75 mm 10% SDS-PAGE 
gel85 in SDS Running Buffer85 at 100 V for 1 h. The protein was transferred to a membrane in 
Transfer Buffer85 at 100 V for 1 h. The membrane was blocked for 1 h at room temperature in 
blocking buffer (5% (w/v) skim milk powder, 0.05% (v/v) Tween-20 in PBS). The membrane was 
incubated for 1 h at room temperature in 6X-His Tag Monoclonal Antibody (4A12E4) (37-2900, 
Invitrogen) diluted 1/5000 in blocking buffer. The membrane was washed four times in 
0.05% (v/v) Tween-20 in PBS and incubated for 30 min at room temperature in IRDye 680RD 
Goat (polyclonal) Anti-Mouse IgG (H+L) (926-68070, LI-COR) diluted 1/5000 in blocking buffer. 
The membrane was washed four times in 0.05% (v/v) Tween-20 in PBS and then kept in PBS 
until it was imaged. The membrane was imaged at a wavelength of 700 nm. 
The fractions containing protein were pooled, loaded into an Amicon Ultra-15 Centrifugal Filter 
Unit (UFC900308, Merck Millipore) and centrifuged at 3000 rpm for 30 min at 4oC. The flow-
through was discarded and 15 ml of PBS was loaded on to the column and centrifuged under 
the same conditions. This step was repeated once more. Approximately 200 µl of PBS 
containing protein was collected in the filter. The protein concentration was measured by 
NanoDrop and the purity was confirmed using an SDS-PAGE gelSDS-PAGE gel85 and 
Coomassie85 stain. 
                                                          
84 Zaire Ebola virus GP was purified by Audrey Page (KCL) and Catherine Townsend (author), Marburg (Ravn) virus 
GP was purified by Catherine Townsend (author) 
85 See pages 272 to 273 for buffer and gel recipes 
Chapter 2: Materials and Methods 
134 
 
2.17.4 Deglycosylation of Glycoproteins 
To deglycosylate EBOV GP, RAVV GP and HIV gp12086, 20 µg of glycoprotein was diluted to 
42 µl with PBS and incubated with 4 µl of Endo H (4.7 mg/ml)87 and 4 µl PNGase F (15 mg/ml)87 
(final glycoprotein concentration of 400 µg/ml in a volume of 50 µl). The reaction was 
incubated overnight at 37oC. As a control, 20 µg of glycoprotein was diluted to 50 µl in PBS 
only (no enzymes) and incubated at 37oC overnight. 
The success of the deglycosylation was checked by running a non-reducing 10% SDS-PAGE. The 
deglycosylated protein should run at a lower molecular weight than the complete protein. 
Additionally, an ELISA was used to check that PHA-L lectin bound less to the deglycosylated 
protein than the complete protein. 50 µl of complete and deglycosylated protein at 5 µg/ml in 
PBS was coated in triplicate onto a Nunc Maxisorp plate and incubated overnight. The plate 
was washed once with 0.05% (v/v) Tween-20 in PBS. The plate was incubated for 1 h at room 
temperature with 200 μl blocking buffer (3% (w/v) skim milk powder, 0.05% (v/v) Tween-20 in 
PBS). The plate was washed three times as above. 50 µl 5 µg/ml Biotinylated Phaseolus 
vulgaris leucoagglutinin (PHA-L) (B-1115, Vector Laboratories) in PBS was added to each well 
and incubated for 1 h at room temperature. The plate was washed three times as described 
above. 50 µl alkaline phosphatase-conjugated streptavidin (SA1008, Invitrogen) was added to 
each well at a 1/10,000 dilution in blocking buffer (as above) and incubated for 1 h at room 
temperature. The plate was washed three times as above and developed using SIGMAFAST 
p-Nitrophenyl phosphate Tablets (N1891, Sigma Aldrich) as described by the manufacturer. 
The plates were read at a wavelength of 405 nm. 
 
                                                          
86 HIV gp120 was expressed and purified by Luke Granger (KCL) 
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Chapter 3: Tolerance, Autoreactivity and Polyreactivity 
3.1 Introduction 
Autoreactive antibodies are highly undesirable in the peripheral repertoire as they pose the 
risk of inducing autoimmune disease. Polyreactivity is closely linked to autoreactivity as 
antibodies which bind multiple antigens are more likely to bind self-antigen. The ability to 
identify antibodies which are likely to be autoreactive and/or polyreactive based on their 
physicochemical or structural properties would be extremely valuable in the diagnosis of 
autoimmune disease and also in the pharmaceutical industry where it is imperative that 
therapeutic antibodies are highly specific to their target and not autoreactive. 
As autoreactive antibodies are potentially dangerous if released into the peripheral blood, it is 
thought that B cells bearing autoreactive antibodies are removed from the B cell repertoire at 
two tolerance checkpoints: central tolerance and peripheral tolerance. As has been described 
in detail in sections 1.4 and 1.5 (page 37 and 39 respectively), it is thought that central 
tolerance acts on the immature B cell repertoire in the bone marrow to remove the majority of 
autoreactive B cells before they enter the peripheral blood (Wardemann et al., 2003) and 
peripheral tolerance removes autoreactive B cells in the peripheral blood which escaped 
central tolerance. Relatively few characteristics associated with autoreactivity or polyreactivity 
have been identified; they tend to be long, hydrophobic and positively charged CDR-H3 loops. 
IGHV4-34 has also been associated with numerous autoimmune diseases (Tipton et al., 2015, 
Doorenspleet et al., 2014, Baranzini et al., 1999). 
With high-throughput sequencing of B cell repertoires now possible, we hypothesised that by 
sequencing B cell repertoires isolated from the bone marrow and peripheral blood, we could 
identify immunoglobulin variable region properties which may be associated with 
autoreactivity by looking for properties which are less prevalent in the peripheral blood 
repertoires compared to the bone marrow repertoires. Variable region properties associated 
with autoreactivity should have been selected against at the tolerance checkpoints. 
The dataset used for this analysis was the B cell Development dataset. The B cell Development 
dataset is a high-throughput sequencing dataset constructed from immunoglobulin mRNA 
isolated from bone marrow B cells (pre-B and immature) and peripheral blood B cells 
(transitional and naïve) isolated from healthy adult donors. The dataset contains information 
on VDJ gene usage and CDR3 physicochemical properties. For full materials and methods of 
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how the B cell Development dataset was constructed, see section 2.1 and (page 74) and 
section 2.4 (page 94). 
The results of the analysis of the B cell Development dataset were used to select some 
immunoglobulin heavy chain variable regions from the B cell Development dataset which 
possessed properties which may be associated with autoreactivity. These hypotheses were 
then tested by cloning antibodies containing the selected heavy chains and investigating their 
autoreactivity using HEp-2 immunocytochemistry. As polyreactivity is commonly associated 
with autoreactivity, the antibodies were also tested for polyreactivity using a solid-phase ELISA 
in which the antibodies were tested for binding to a range of autoantigens following the 
protocol set out in Tiller et al. (2008). This work led to the further investigation of the nature of 
binding of the antibodies which displayed a polyreactive phenotype in solid-phase ELISA. 
The main focus of this chapter is on the heavy chain properties because, firstly, the heavy 
chain is thought to be the most important region for antibody specificity (particularly the 
CDR-H3). Secondly, we found few differences in light chain variable region properties between 
the bone marrow and peripheral blood in the B cell Development dataset (this analysis is 
presented in section 4.2, page 192). 
When selecting heavy chain properties to investigate, emphasis was placed on the difference 
in frequency between the pre-B/immature repertoire and the naïve repertoire rather than the 
frequency in the transitional population. This was due to the controversy surrounding the 
linearity of B cell development from pre-B >> immature >> transitional >> naïve (Martin et al., 
2016). This issue is discussed in this chapter (section 3.7.1, page 178). 
In summary, the aim of this chapter is to further our understanding of the common 
characteristics of autoreactive/polyreactive antibodies using the following methods: 
1. Analysis of the heavy chain B cell Development dataset to identify variable region 
properties which increase or decrease in frequency as B cells mature and therefore 
may be related to autoreactivity 
2. Use this data analysis to identify potentially autoreactive heavy chain sequences, clone 
and express these as IgG1 antibodies and test for autoreactivity using 
immunocytochemistry against HEp-2 cells 
3. Investigate the nature of polyreactivity and the properties of antibodies which show a 
polyreactive phenotype in a solid-phase ELISA and try to isolate more polyreactive 
antibodies using phage display 
  
Chapter 3: Tolerance, Autoreactivity and Polyreactivity 
138 
 
3.2 Changes in Frequency of Heavy Chain Properties as B cells Mature 
3.2.1 VDJ Gene Usage in Bone Marrow and Peripheral Blood B cell Repertoires 
The frequency of usage of each IGHV, IGHD and IGHJ family and gene was calculated for the 
pre-B, immature, transitional and naïve cell repertoires in each of the 12 donors in the heavy 
chain B cell Development dataset. The mean frequency (+/- 1 SD) of each family/gene across 
the 12 donors was plotted in bar charts (Figure 3-1) and significant differences in family/gene 
frequency between cell repertoires was calculated using two-way unpaired ANOVA followed 
by Tukey’s multiple comparisons post-test. 
This analysis was performed on the full heavy chain dataset which contained 39,637 entries 
(Table A-19, page 274). However, data for donor 111 transitional cells was excluded from 
IGHV-D-J family analysis because there were only 19 sequences in this sample, which was too 
few to accurately calculate family frequency (see section 2.5.1, page 96, for details on the “5X 
rule”). Further donors were excluded from the IGHV and IGHD gene usage analysis for this 
reason and the details are shown in Table 3-1. 
Table 3-1: Donors excluded from IGHV and IGHD gene usage analysis. Donors excluded from 
IGHV gene usage analysis are shown in red (<305 entries). Donors excluded from IGHD gene 
usage are underlined (<130 entries). 
Donor ID Pre-B Immature Transitional Naïve 
103 87 364 65 1606 
111 620 74 19 1107 
118 2149 478 294 647 
119 2966 1704 908 367 
122 1290 285 343 259 
138 2629 76 195 497 
140 731 436 340 571 
141 722 1485 979 501 
146 3832 675 464 245 
149 1120 1135 178 146 
159 830 1880 502 349 
160 89 191 98 3109 
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The IGHV3 family was significantly less frequently used in the naïve repertoire compared to the 
pre-B, immature and transitional repertoires (Figure 3-1A). When looking at the individual 
genes, nine IGHV3 genes changed significantly in frequency between the cell types, with 
IGHV3-15, IGHV3-30, IGHV3-33 and IGHV3-7 decreasing in frequency as B cells matured (Figure 
3-1D). None of the other IGHV families showed significant differences in usage between the 
cell types. However, two IGHV1 genes (IGHV1-18 and IGHV1-69) did increase in frequency as 
the B cells matured (Figure 3-1D). IGHV4-34 and IGHV4-39 were significantly less frequent in 
the transitional repertoire compared to the pre-B and immature repertoires, however the 
frequency increased slightly in the naïve repertoire. Conversely, the frequency of IGHV3-30-3 
increased in the transitional repertoire and decreased again in the naïve repertoire (Figure 
3-1D). 
The frequency of the IGHD2 family is significantly lower in the transitional and naïve 
repertoires compared to the pre-B and immature repertoires (Figure 3-1B). This appears to be 
driven by a reduction in the frequency of IGHD2-15 and IGHD2-2 genes as B cells matured. 
IGHD3-3, IGHD4-17 and IGHD6-19 were slightly more frequent as the B cells matured (Figure 
3-1E) and the frequency of the IGHD3 family was significantly higher in the transitional 
repertoire, whereas there was no difference in frequency between the other three repertoires 
(Figure 3-1B). 
The IGHJ3 family is slightly more frequent in the naïve repertoire and the usage of IGHJ6 was 
significantly lower in the naïve repertoire compared to the pre-B and immature repertoires, 
however IGHJ6 was used significantly more frequently in the transitional repertoire. IGHJ4 and 
IGHJ5 were used significantly less frequently in the transitional repertoire (Figure 3-1C).  




Figure 3-1: BM dataset IGHV/D/J family and gene usage in four cell types. Mean (+/- 1 SD) of 
the frequency of usage of each (A) IGHV, (B) IGHD and (C) IGHJ family and (D) IGHV and (E) 
IGHD genes which showed a significant difference in frequency of usage between cell types 
across the 12 donors. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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3.2.2 CDR-H3 Properties in Bone Marrow and Peripheral Blood B cell Repertoires 
Before performing analysis of the CDR-H3 properties, sequences which may skew the analysis 
were removed from the heavy chain B cell Development dataset (see section 2.5.2, page 96) 
resulting in a dataset containing 29,016 variable region sequences (Table A-20, page 274). 
The following physicochemical properties were calculated (section 2.4.2, page 94) for each 
CDR-H3 amino acid sequence (IMGT definition): 
1. CDR-H3 length (amino acids) 
2. Aliphatic index 
3. Boman index 
4. Isoelectric point 
5. Hydrophobicity (GRAVY index) 
6. Instability index 
These properties were chosen because, although not orthogonal, they represent a wide range 
of peptide properties, some of which are known to be important in antibody specificity. 
Data for all 12 donors was pooled and the CDR-H3 physicochemical properties of each cell type 
(pre-B, immature, transitional and naïve) were plotted (Figure 3-2). The Kruskal-Wallis test 
followed by Dunn’s multiple comparisons post-test was used to identify significant differences 
in CDR-H3 properties between the cell types. 
The mean CDR-H3 length was significantly lower in the naïve repertoire compared to the other 
three repertoires (Figure 3-2A). The naïve repertoire also has a higher Boman index (Figure 
3-2C) and both the transitional and naïve repertoires have significantly lower GRAVY indexes 
than the pre-B and immature repertoires (Figure 3-2E). 
The aliphatic index is significantly lower in the transitional repertoire compared to the other 
three repertoires (Figure 3-2B) and the instability index is significantly lower in the immature 
repertoire compared to the other three repertoires (Figure 3-2F). 
Due to the shape of the isoelectric point (pI) histograms (Figure 3-2D), the differences in the 
means for each cell type do not reflect the complete picture. The histograms show that very 
few CDR-H3 have a pI between 5-6 or 7-8.5 in all four cell repertoires. The transitional 
repertoire has a significantly higher mean pI than the other three repertoires and the 
histograms show that this is predominantly due to a lower frequency of antibodies with a 
CDR-H3 pI between 3-5 and a higher frequency of antibodies with a CDR-H3 pI between 8-10.  




Figure 3-2: BM dataset CDR-H3 properties in four cell types. Histogram, cumulative frequency 
histogram and mean (+/- 1 SD) for the following six physicochemical properties of the CDR-H3 
amino acid sequences: (A) CDR-H3 length; (B) Aliphatic index; (C) Boman index; (D) Isoelectric 
point; (E) GRAVY index; (F) Instability index. Each set of three graphs shows the same data in 
different formats. The mean +/- 1 SD graphs are used to see significant differences between 
cell types, whereas the histograms and cumulative frequency plots show the shape of the data. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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The frequency of the following types of amino acids in the CDR-H3 was measured (see Table 










The mean frequency (+/- 1 SD) of each type of amino acid in the CDR-H3 regions was plotted 
(Figure 3-3) and the Kruskal-Wallis test followed by Dunn’s multiple comparisons post-tests 
was used to find significant differences between the four cell types. 
The frequency of charged and acidic amino acids was significantly higher in the naïve 
repertoire (Figure 3-3G&I) and the frequency of basic amino acids was significantly higher in 
transitional and naïve repertoires (Figure 3-3H). Small amino acids were significantly less 
frequent in the transitional and naïve repertoires (Figure 3-3B). The frequency of all amino 
acids except tiny and basic was significantly different in the transitional repertoire compared 
to the other three repertoires (Figure 3 5B, C, D, E, F, G, I). 
 
Figure 3-3: Frequency of each amino acid group in the CDR-H3. Mean frequency (+/- 1 SD) of 
(A) Tiny, (B) Small, (C) Aliphatic, (D) Aromatic, (E) Non-Polar, (F) Polar, (G) Charged, (H) Basic 
and (I) Acidic amino acids in pre-B, immature, transitional and naïve B cell repertoires. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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3.3 Identification of Potentially Autoreactive Heavy Chains 
Six rationales were used to identify potentially autoreactive/polyreactive heavy chains in the 
B cell Development dataset. These rationales are described in sections 3.3.1 to 3.3.6. The six 
rationales for heavy chain selection were derived from the data analysis in section 3.2 and also 
from information in the literature. 
As the B cell Development dataset does not contain heavy-light chain paring information, a 
rationale was required for selecting light chains with which to pair the heavy chains. The 12 
heavy chains described in section 3.3.1 were all paired with three public light chains (DeKosky 
et al., 2015) with very different properties (making 36 antibodies in total). All of the other 
heavy chains described in sections 3.3.2 to 3.3.6 were paired with the same light chain. 
Therefore 61 antibodies were expressed in total. 
All of the heavy and light chain sequences were identified in the B cell Development dataset 
and oligonucleotide sequences were ordered from Integrated DNA Technologies (Illinois, USA). 
The antibodies were expressed as IgG188 and purified in PBS. HP-SEC traces are shown in 
Appendix A.8 (page 280). Five of the antibodies could not be expressed. 
3.3.1 Selection of Forbidden Heavy Chains 
The analysis in section 3.2 showed that IGHV3, IGHD2 and IGHJ6 families were used less 
frequently either in the naïve repertoire, or in the transitional and naïve repertoires compared 
to the pre-B and immature repertoires (Figure 3-1A,B&C). Long CDR-H3, hydrophobic CDR-H3 
and CDR-H3 with a low Boman index were also used less frequently in the naïve or both the 
naïve and transitional repertoires (Figure 3-2A,E&C). We hypothesised that this meant that 
IGHV3, IGHD2, IGHJ6 families and long CDR-H3, hydrophobic CDR-H3 and CDR-H3 with low 
Boman indexes were selected against at tolerance, and therefore may be associated with 
autoreactivity/polyreactivity. To identify some heavy chains with these properties, the B cell 
Development dataset was filtered for sequences which possessed all of the following criteria: 
1. IGHV3 family usage 
2. IGHD2 family usage 
3. IGHJ6 family usage 
4. CDR-H3 ≥23 amino acids long 
5. CDR-H3 GRAVY index >0.163 
6. CDR-H3 Boman index <0.712 
                                                          
88 All antibodies described in sections 3.3.1 to 3.3.6 were cloned and expressed at MedImmune (Cambridge, United 
Kingdom) using the method described in section 2.7 (page 99). 
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The cut-offs for CDR-H3 properties were defined as being either one or two standard 
deviations from the mean of the naïve B cell repertoire in the six young (<65 years old) donors 
(122, 159, 138, 118, 146, 103) (Figure 3-4). 
 
Figure 3-4: CDR-H3 property range of Forbidden antibodies. Histograms showing the values 
from which sequences were chosen for the (A) long (2 SD higher than mean), (B) high GRAVY 
(1 SD higher than mean) and (C) low Boman (1 SD lower than mean) CDR-H3. Graphs show the 
entire repertoire for each of the four cell types for all donors. The cut-offs were calculated 
using the naïve B cell repertoire of only the young donors (<65 years old). 
When the B cell Development heavy chain dataset was filtered using these criteria, 62 heavy 
chain sequences remained (35 pre-B, 19 immature, four transitional and four naïve). 12 heavy 
chain sequences were selected (Table 3-2) from this group of 62 based on the fact that they 
used IGHV3 and IGHD2 genes that were less frequent in either the naïve or both the 
transitional and naïve repertoires compared to the pre-B and immature repertoires (IGHV3-15, 
IGHV3-30, IGHV3-33 and IGHD2-2) (Figure 3-1D&E). 
As the selection of these heavy chains was due to their use of “forbidden” properties, this 
groups of heavy chains was named the Forbidden heavy chains. 
Table 3-2: The 12 Forbidden IgH variable regions chosen for cloning. 






Family CDR-H3 amino acid sequence 
1 immh103_M_UN_29876 103 Immature IGHV3-15 IGHD2-2 IGHJ6 TTAPINIVVVVPAAIKDRDYYYYGMDV 
2 preh159_M_V3_60711 159 Pre-B IGHV3-15 IGHD2-2 IGHJ6 ILVHIVVVPAAINGYYDFWSGWDV 
3 naih111_M_V3_30355 111 Naïve IGHV3-30 IGHD2-2 IGHJ6 AKTLLDVVVVPAATPQNYYYYGMDV 
4 preh119_M_V3_110284 119 Pre-B IGHV3-15 IGHD2-2 IGHJ6 TTHIVVVPAAIPSHYYYYYGMDV 
5 preh149_M_UN_598450 149 Pre-B IGHV3-30 IGHD2-2 IGHJ6 AKGAPNIVVVPAAKSAHYYYGMDV 
6 preh118_M_V3_855230 118 Pre-B IGHV3-33 IGHD2-2 IGHJ6 ARDTGVGGLVVPAATGDLAGYYYGMDV 
7 immh103_M_V3_22024 103 Immature IGHV3-15 IGHD2-2 IGHJ6 TTVRDIVVVPAAIGLNYYYGMDV 
8 preh146_M_V3_253300 146 Pre-B IGHV3-30 IGHD2-2 IGHJ6 AKTASFVVVPAAISDGDGYYYYMDV 
9 immh149_M_V3_59726 149 Immature IGHV3-30 IGHD2-2 IGHJ6 AKDQFVAVVVPAAIHLGYYYGMDV 
10 preh149_M_UN_713160 149 Pre-B IGHV3-15 IGHD2-2 IGHJ6 TTDRWGIVVVPAAKLVSYYGMDV 
11 immh159_M_UN_59280 159 Immature IGHV3-15 IGHD2-2 IGHJ6 TTPPGHIVVVPAANSLIAAPYYYYGMDV 
12 preh138_M_V3_494120 138 Pre-B IGHV3-15 IGHD2-2 IGHJ6 TTDLFLRARVVPAAMAPYYYGMDV 
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Each of the heavy chains in Table 3-2 was paired with three light chains representing a broad 
range of physicochemical properties. All three light chains were public light chains, identified in 
DeKosky et al. (2015) and they all appeared in the B cell Development dataset. Public light 
chains occur in multiple individuals, paired with various heavy chains. Two kappa and one 
lambda light chain were chosen and the three light chains had a range of CDR-L3 
physicochemical properties, particularly the frequency of aromatic amino acids and aspartic 
acids in the CDR-L3 region as these features have been associated with rescuing autoreactive 
heavy chains (Li et al., 2001). The three light chains used are shown in Table 3-3. 
Once all of the 12 Forbidden heavy chains had been paired with each of the three public light 
chains, a total of 36 Forbidden antibodies were expressed (see Table 3-4 on the subsequent 
two pages for details). 
Table 3-3: Three public light chain variable region sequences. These light chains were chosen 
from the B cell Development dataset, however all their CDR-L3 nucleotide sequences also 
appear in a published list of public light chains (DeKosky et al., 2015). 







1 nail107_IGKV3_IGKC_111176 107 Naive  Kappa IGKV3-20 IGKJ2 QQYGSSPYT 
2 nail120_IGLC_UN_122004 120 Naive  Lambda IGLV1-44 IGLJ2 AAWDDSLNGVV 
3 imml103_IGKC_IGKV3_101790 103 Immature Kappa IGKV3-11 IGKJ4 QQRSNWPLT 
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Table 3-4: 36 Forbidden antibodies properties. Name of the antibody followed by the B cell 
Development dataset sequence ID of the heavy and light chains and sequence information for 
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3.3.2 Selection of Long Hydrophobic Heavy Chains 
The properties used to select the Forbidden heavy chains (section 3.3.1) were quite extreme 
and the resulting heavy chains were quite similar. Therefore, the heavy chains selected in this 
section had fewer constraints. The B cell Development dataset was filtered for entries which 
met both of these criteria: 
1. CDR-H3 >15.5 amino acids long 
2. CDR-H3 GRAVY index >-0.521 
The cut-offs for these properties were defined as being higher than the mean CDR-H3 length 
and mean GRAVY index in the young naïve population. The sequence with the highest GRAVY 
index and the sequence with the longest CDR-H3 were selected. The other three sequences 
were chosen semi-randomly (Table 3-5). 
All three Long Hydrophobic heavy chains were paired with the same light chain (see Table 3-5). 
Table 3-5: Properties of five Long Hydrophobic heavy chains and the light chain with which 
they were all paired. 
Antibody 





141 Immature IGHV4-39 IGHJ3 IGHD3-3 ARELGFGVVIILVLLIS 2.135 
CT0041 immh160_M_UN
_110852 
160 Immature IGHV4-61 IGHJ2 IGHD4-17 ASLYGDYVPTDWYFDL -0.150 
CT0050 preh111_M_V3_
567190 
111 Pre-B IGHV3-30 IGHJ3 IGHD2-15 AKVGGQDIVVVVAALDI 1.412 
CT0053 preh138_M_UN_
483280 





146 Pre-B IGHV3-15 IGHJ3 IGHD3-10 TTDPSNYGITMVQGVIITSS
NRDAFDI 
-0.056 
 Light chain ID Donor Cell Type IGKV gene IGKJ gene  CDR-L3 AA sequence  
 nail119_IGKV3_
UN_122382 
119 Naïve IGKV1-37 IGKJ5  QQYNNWPRT  
 
3.3.3 Selection of Preferred Heavy Chains 
The 12 Forbidden heavy chains were chosen because they had properties which decreased in 
frequency as B cells matured as it was hypothesised that they would be more likely to be 
autoreactive/polyreactive. Therefore, for comparison, five Preferred heavy chains were 
selected which had properties which increased in frequency as the B cells matured. It was 
hypothesised that these heavy chains should not show autoreactivity or polyreactivity as they 
possess properties which are not removed from the repertoire as B cells mature.  
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The B cell Development dataset was filtered for entries which met all of the following criteria: 
1. CDR-H3 <15.5 amino acids long 
2. CDR-H3 GRAVY index <-0.522 
3. CDR-H3 small amino acid frequency <0.559 
4. CDR-H3 Boman index >1.93 
5. CDR-H3 aromatic amino acid frequency >0.215 
6. CDR-H3 charged amino acid frequency >0.251 
7. CDR-H3 acidic amino acid >0.136 
The cut-off values chosen for each of these properties was the mean value in the young naïve 
population. Five sequences were chosen semi-randomly, ensuring that a variety of VDJ 
combinations were represented (see Table 3-6). 
Table 3-6: Properties of the five Preferred heavy chains selected and the light chain with which 
they were all paired. 
Antibody 
ID Heavy chain ID Donor Cell Type IGHV Gene 
IGHJ 









160 Immature IGHV5-51 IGHJ4 IGHD4-17 ARLSGDYRFDY -1.036 3.665 
CT0044 naih141_M_V4
_13619 
141 Naïve IGHV4-59 IGHJ4 IGHD7-27 ARDHQLGMFDY -0.873 2.700 
CT0052 preh119_M_V3
_526840 










141 Transitional IGHV3-23 IGHJ6 IGHD1-1 AKPREDYYYYYY
MDV 
-1.360 2.491 





sequence   
 nail119_IGKV3_
UN_122382 
119 Naïve IGKV1-37 IGKJ5 QQYNNWPRT   
 
3.3.4 Selection of Aromatic Heavy Chains 
There is some evidence from the literature (Droupadi, 1994) and work by other members of 
the Dunn-Walters lab that aromatic amino acid content of the CD-H3 region may be related to 
polyreactivity. Therefore, the B cell Development dataset was filtered for entries which met 
the following criteria: 
1. CDR-H3 aromatic amino acid frequency >0.315 
2. All other measured CDR-H3 physicochemical properties within 1 SD of the mean 
The cut-off was 1 SD greater than the mean aromatic amino acid frequency in the young naïve 
population. The five heavy chains selected had aromatic amino acids spread across the CDR-H3 
and it was ensured that a variety of VDJ genes were represented (Table 3-7). 
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Table 3-7: Properties of the five Aromatic heavy chains selected which have a high frequency 
of aromatic amino acids in the CDR-H3. Aromatic amino acids (F/H/W/Y) are underlined. Also 
the light chain with which they were all paired. 
Antibody 




Gene IGHD Gene CDR-H3 AA sequence 
CT0037 immh119_M_V3_21823 119 Immature IGHV3-30 IGHJ4 IGHD5-12 AGHDSGYDWPYFLY 
CT0045 naih140_M_V3_60340 140 Naïve IGHV3-48 IGHJ4 IGHD3-22 ARVGYYYDSSGYYFDY 
CT0047 naih160_M_V3_30414 160 Naïve IGHV3-23 IGHJ2 IGHD3-10 AKDAYGSGSYYNWYFDL 
CT0048 naih160_M_V4_11003 160 Naïve IGHV4-61 IGHJ2 IGHD6-19 ARDGSGWYGDWYFDL 
CT0060 trah146_UN_V3_28720 146 Transitional IGHV3-21 IGHJ6 IGHD6-6 ARDHAYSSSMDYWYYGMDV 




CDR-L3 AA sequence 
 nail119_IGKV3_UN_122382 119 Naïve IGKV1-37 IGKJ5 QQYNNWPRT 
 
3.3.5 Selection of pI 5.0-6.0 Heavy Chains 
It has been speculated that the frequency of charged amino acids and isoelectric points (pI) 
could be linked to polyreactivity (Zhang & Yeh, 1994). The histograms shown in Figure 3-2D 
(page 142) show that there is a very low frequency of CDR-H3 with a pI in the range 5.0-6.0 in 
all four cell types. We speculated that the reason for this may be that CDR-H3 with a pI in this 
region are more prone to autoreactivity/polyspecificity. The B cell Development dataset was 
filtered for entries which met the following criterion: 
1. CDR-H3 pI between 5.0 and 6.0 
Of the entries with met this criterion, the entry with highest pI (5.996) and the lowest pI 
(5.250) were selected. The other three were chosen semi-randomly, making sure that a variety 
of VDJ genes were represented (Table 3-8). 
Table 3-8: Properties of five pI 5.0-6.0 heavy chains selected which have a CDR-H3 with an 
isoelectric point within the range 5.0 to 6.0 and the light chain with which they were all paired. 
Antibody 
ID Heavy chain ID Donor Cell Type IGHV Gene 
IGHJ 
Gene IGHD Gene CDR-H3 AA sequence pI 
CT0039 immh141_M_V2_123166 141 Immature IGHV2-5 IGHJ4 IGHD3-16 AHSYYDYVWGSYRTYDP 5.408 
CT0043 naih119_M_V6_23731 119 Naïve IGHV6-1 IGHJ4 IGHD3-16 ARGVHDYVWGSPLGFDY 5.408 
CT0049 preh103_M_V3_555440 103 Pre-B IGHV3-23 IGHJ5 IGHD2-15 AKGCNCSGGSCYSGWFDP 5.996 
CT0057 preh149_M_V2_368690 149 Pre-B IGHV2-5 IGHJ5 IGHD3-9 AHLHILTGLDCGFDP 5.250 
CT0061 trah159_M_V3_33486 159 Transitional IGHV3-74 IGHJ6 IGHD2-15 ARDCTGAIGCHYGMDV 5.403 




CDR-L3 AA sequence  
 nail119_IGKV3_UN_122382 119 Naïve IGKV1-37 IGKJ5 QQYNNWPRT  
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3.3.6 Selection of pI 7.0-8.5 Heavy Chains 
The rationale for these heavy chains is the same as in section 3.3.5. There is a very low 
frequency of heavy chain sequences with a CDR-H3 pI of between 7.0-8.5 in all four cell types 
(Figure 3-2D). The B cell Development dataset was filtered for entries which met the following 
criterion: 
1. CDR-H3 pI between 7.0 and 8.5 
Of the entries which met this criterion, the entries with the highest pI (8.449) and the lowest pI 
(7.173) were chosen. The other three were chosen semi-randomly, making sure that a variety 
of VDJ genes were represented (Table 3-9). 
Table 3-9: Properties of five pI 7.0-8.5 heavy chains selected which have a CDR-H3 with an 
isoelectric point within the range 7.0 to 8.5 and the light chain with which they were all paired. 
Antibody 




Gene IGHD Gene CDR-H3 AA sequence pI 
CT0038 immh119_M_V3_64902 119 Immature IGHV3-11 IGHJ4 IGHD2-2 ARPYCSSTSCPANY 8.215 
CT0046 naih140_M_V3_70569 140 Naïve IGHV3-11 IGHJ6 IGHD2-2 AKCMGNCSSTSCYTFGHYYYGM
DV 
7.173 
CT0051 preh119_M_V3_279470 119 Pre-B IGHV3-30 IGHJ4 IGHD2-2 AKDYWLRGKPDCSSTSPRSSWF
DY 
8.499 
CT0055 preh146_M_V3_220600 146 Pre-B IGHV3-7 IGHJ6 IGHD5-24 ARVPPTHYYMDV 7.535 
CT0056 preh146_M_V3_592310 146 Pre-B IGHV3-23 IGHJ3 IGHD3-3 ARVHSSRDFWSGYYVGYGAFDI 7.528 






CDR-L3 AA sequence  
 nail119_IGKV3_UN_1223
82 
119 Naïve IGKV1-37 IGKJ5 QQYNNWPRT  
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3.4 Investigating Autoreactivity against HEp-2 Cells 
To determine if any of the antibodies selected in section 3.3 (Identification of Potentially 
Autoreactive Heavy Chains) are autoreactive, all of the antibodies which could be expressed 
were tested for binding to HEp-2 cells using immunocytochemistry. HEp-2 cells are commonly 
used in the clinical diagnosis of autoimmune disease (Sack et al., 2009, Buchner et al., 2014). 
Briefly, HEp-2 cells were cultured on glass coverslips, fixed with paraformaldehyde and blocked 
with BSA. The fixed cells were incubated with purified primary IgG1 antibody (section 3.3) and 
then fluorescently-labelled anti-human IgG secondary antibody. Slides were imaged using 
3 µm Z-stacks on a widefield fluorescence microscope. DAPI was used to confirm the presence 
of cells in every image. For full materials and methods see section 2.9 (page 109). 
3.4.1 Forbidden Antibodies 
Two of the Forbidden antibodies (CT0035 and CT0036) could not be expressed. IgH chain 12 
could only be expressed when in combination with one of the kappa light chains. 
Of the 34 Forbidden antibodies which could be expressed, 11 were strong HEp-2 binders, 13 
were weak HEp-2 binders and the remaining 10 did not bind HEp-2 cells. For results, see Figure 
3-5 on the following three pages and Table 3-10 on page 157. 
Of the HEp-2 binders, five bound both the nucleus and the cytoplasm, and the remaining 19 
bound the cytoplasm only (none bound the nucleus only). Six heavy chains (IgH chains 3, 4, 5, 
6, 9 and 11; Table 3-10, page 160) showed the same binding patterns with all three public light 
chains. IgH chains 1 and 7 both bound the HEp-2 cells when paired with the kappa light chains, 
but not when paired with the lambda light chain. The binding patterns of antibodies with IgH 
chains 2, 8 and 10 also differed depending on the light chain with which they were paired. 
  




Figure 3-5 continues on next page. See page 156 for caption. 




Figure 3-5 continues on next page. See page 156 for caption. 
 




Figure 3-5: HEp-2 immunocytochemistry for the 36 Forbidden antibodies. All images were 
taken using 0.3μm Z-stacks and the exposure was 100 ms. Images were analysed in ImageJ. 
DAPI was used to ensure cells were present in every image. Heavy and light chain numbers are 
as in Table 3-2 (page 145) and Table 3-3 (page 146). 
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Table 3-10: HEp-2 binding of 36 Forbidden antibodies. Refers to results from Figure 3-5. Dotted 
lines group the antibodies with the same heavy chain. Each heavy chain has been given a 
number in the IgH column. The class of light chain is shown in the IgL column. Details of each 
antibody are given in Table 3-4 (page 147). 
Antibody ID IgH IgL HEp-2 binding Cytoplasmic binding Nuclear binding 
CT0001 
1 
1 (κ) Weak  
CT0002 2 (λ) No binding  
CT0003 3 (κ) Weak  
CT0004 
2 
1 (κ) Strong  
CT0005 2 (λ) No binding  
CT0006 3 (κ) No binding  
CT0007 
3 
1 (κ) No binding  
CT0008 2 (λ) No binding  
CT0009 3 (κ) No binding  
CT0010 
4 
1 (κ) Strong  
CT0011 2 (λ) Weak  
CT0012 3 (κ) Strong  
CT0013 
5 
1 (κ) Weak  
CT0014 2 (λ) Weak  
CT0015 3 (κ) Weak  
CT0016 
6 
1 (κ) No binding  
CT0017 2 (λ) No binding  
CT0018 3 (κ) No binding  
CT0019 
7 
1 (κ) Strong  
CT0020 2 (λ) No binding  
CT0021 3 (κ) Weak  
CT0022 
8 
1 (κ) Weak  
CT0023 2 (λ) Weak  
CT0024 3 (κ) Weak  
CT0025 
9 
1 (κ) Strong  
CT0026 2 (λ) Strong  
CT0027 3 (κ) Strong  
CT0028 
10 
1 (κ) Strong  
CT0029 2 (λ) Weak  
CT0030 3 (κ) Strong  
CT0031 
11 
1 (κ) Weak  
CT0032 2 (λ) Weak  
CT0033 3 (κ) Strong  
CT0034 
12 
1 (κ) Strong  
CT0035 2 (λ) Not Expressed NA NA 
CT0036 3 (κ) Not Expressed NA NA 
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3.4.2 Long Hydrophobic Antibodies 
The Long Hydrophobic antibodies all had heavy chains with above-average CDR-H3 length and 
hydrophobicity. 
Of the five Long Hydrophobic antibodies, three bound HEp-2 cells. CT0050 showed weak 
nuclear binding and CT0053 and CT0054 showed strong cytoplasmic binding. CT0041 did not 
bind HEp-2 cells and CT0040 could not be expressed. See Figure 3-6 and Table 3-11 for results. 
 
Figure 3-6: HEp-2 immunocytochemistry for the five Long Hydrophobic antibodies. 
Table 3-11: HEp-2 binding of five Long Hydrophobic antibodies (antibodies with long, 
hydrophobic CDR-H3). Refers to results from Figure 3-6. All five antibodies have the same light 
chain. Details of each antibody are given in Table 3-5 (page 149). 
Antibody ID IgL HEp-2 binding Cytoplasmic binding Nuclear binding 
CT0040 κ Not Expressed NA NA 
CT0041 κ No binding  
CT0050 κ Weak  
CT0053 κ Strong  
CT0054 κ Strong  
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3.4.3 Preferred Antibodies 
The Preferred antibodies all had CDR-H3 properties which increased in prevalence as B cells 
matured, indicating that they may be less likely to be autoreactive. 
Of the five Preferred antibodies, CT0042, CT0044 and CT0052 showed no binding to HEp-2 
cells. CT0058 and CT0059 showed weak cytoplasmic and nuclear binding. All of the Preferred 
antibodies could be expressed. See Figure 3-7 and Table 3-12 for results. 
 
Figure 3-7: HEp-2 immunocytochemistry for the five Preferred antibodies. 
Table 3-12: HEp-2 binding of five Preferred antibodies. Refers to results from Figure 3-7. All five 
antibodies have the same light chain. Details of the antibodies are given in Table 3-6 
(page150). 
Antibody ID IgL HEp-2 binding Cytoplasmic binding Nuclear binding 
CT0042 κ No binding   
CT0044 κ No binding   
CT0052 κ No binding   
CT0058 κ Weak  
CT0059 κ Weak  
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3.4.4 Aromatic Antibodies 
The Aromatic antibodies all had very high frequencies (>1 SD above the mean) of aromatic 
amino acids in the CDR-H3. 
CT0037 showed very strong cytoplasmic binding, but no evidence of nuclear binding. CT0047 
and CT0060 showed weak cytoplasmic binding. CT0045 did not bind HEp-2 cells and CT0048 
could not be expressed. See Figure 3-8 and Table 3-13 for results. 
 
Figure 3-8: HEp-2 immunocytochemistry for the five Aromatic antibodies.  
Table 3-13: HEp-2 binding of five Aromatic antibodies (CDR-H3 contains high proportion of 
aromatic amino acids). Refers to results from Figure 3-8. All five antibodies have the same light 
chain. Details of the antibodies are given in Table 3-7 (page 151). 
Antibody ID IgL HEp-2 binding Cytoplasmic binding Nuclear binding 
CT0037 κ Strong  
CT0045 κ No binding  
CT0047 κ Weak  
CT0048 κ Not Expressed NA NA 
CT0060 κ Weak  
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3.4.5 pI 5.0-6.0 Antibodies 
The pI 5.0-6.0 antibodies all had CDR-H3 isoelectric points (pI) between 5.0 and 6.0. This pI 
range is very underused in all cell types measured. 
CT0039 and CT0043 bound only the nucleus and CT0049 bound both the nucleus and the 
cytoplasm. CT0057 did not bind HEp-2 cells and CT0061 could not be expressed. See Figure 3-9 
and Table 3-14 for results. 
 
Figure 3-9: HEp-2 immunocytochemistry for the five pI 5-6 antibodies. 
Table 3-14: HEp-2 binding of five pI 5.0-6.0 antibodies (CDR-H3 has a pI of between 5.0 and 
6.0). Refers to results from Figure 3-9. All five antibodies have the same light chain. Details of 
the antibodies are given in Table 3-8 (page 151). 
Antibody ID IgL HEp-2 binding Cytoplasmic binding Nuclear binding 
CT0039 κ Strong  
CT0043 κ Weak  
CT0049 κ Strong  
CT0057 κ No binding  
CT0061 κ Not Expressed NA NA 
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3.4.6 pI 7.0-8.5 Antibodies 
The pI 7.0-8.5 antibodies all had CDR-H3 isoelectric points (pI) between 7.0 and 8.5. This pI 
range is very underused in all cell types measured. 
CT0046, CT0051 and CT0056 strongly bind both the nucleus and the cytoplasm. CT0055 weakly 
binds the cytoplasm. CT0038 does not bind HEp-2 cells. All of the pI 7.0-8.5 antibodies could be 
expressed. See Figure 3-10 and Table 3-15 for results. 
 
Figure 3-10: HEp-2 immunocytochemistry for the five pI 7-8.5 antibodies. 
Table 3-15: HEp-2 binding of five pI 7.0-8.5 antibodies (CDR-H3 has a pI of between 7.0 and 
8.5). Refers to results from Figure 3-10. All five antibodies have the same light chain. Details of 
the antibodies are given in Table 3-9 (page 152). 
Antibody ID IgL HEp-2 binding Cytoplasmic binding Nuclear binding 
CT0038 κ No binding  
CT0046 κ Strong  
CT0051 κ Strong  
CT0055 κ Weak  
CT0056 κ Strong  
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3.5 Investigating Polyreactivity against a Panel of Unrelated Antigens 
It is thought that autoreactivity and polyreactivity are closely linked; if an antibody is 
polyreactive and binds multiple epitopes, it is likely that it will bind self-antigen. One method 
of investigating polyreactivity is to test the antibodies in an ELISA for binding against multiple 
antigens (Wardemann et al., 2003, Tiller et al., 2008). If an antibody binds to more than one 
antigen, it is considered polyreactive. 
3.5.1 Control Polyreactive Antibodies from the Literature 
The protocol to test antibodies for polyreactivity was set out in Wardemann et al. (2003) and 
Tiller et al. (2008). To confirm that the polyreactivity ELISA protocol worked in our lab, the 
following known polyreactive positive and negative controls were expressed89,90: 
1. ED38 - high polyreactive (Meffre et al., 2004) 
2. ei-JB40 - low polyreactive (Wardemann et al., 2003) 
3. m-GO53 - negative (Wardemann et al., 2003) 
The specificity of the three control antibodies was tested against dsDNA, insulin, LPS, HEp-2 
cell lysate and also blank negative control wells coated with PBS only. The ELISA protocol set 
out in Tiller et al. (2008) was followed. In this protocol, wells were blocked with 0.05% (v/v) 
Tween-20 2 mM EDTA in PBS only (no protein block). 
Binding patterns of ED38, ei-JB40 and m-GO53 reported in (Tiller et al., 2008) could be 
replicated for dsDNA, LPS, insulin and HEp-2 cell lysate. However, the same binding patterns 
were also observed for wells coated with no antigen (PBS only) (Figure 3-11). 
                                                          
89 Plasmids encoding ED38, ei-JB40 and m-GO53 were generously shared by Hedda Wardemann (German Cancer 
Research Center, Heidelberg, Germany) 
90 ED38, ei-JB40 and m-GO53 antibodies were expressed using the method described in section 2.8 (page 103) 




Figure 3-11: ELISA to test specificity of polyspecific control antibodies. All antibodies bind PBS-
coated negative control wells just as well as they bind antigen-coated wells. (A) The OD405 
when each antibody is at a concentration of 1μg/ml. (B) A replicate of the graphs used in the 
literature to show that the graphs follow the same curve in the absence of antibody as they do 
in the presence of antibody. Each graph shows the mean OD405 (+/- 1 SD) of each antibody 
tested in triplicate. 
In light of the PBS (blank) result in Figure 3-11, we investigated whether the phenotype 
displayed by ED38 and ei-JB40 may be due to the unusual blocking conditions used in the Tiller 
et al. (2008) protocol, four blocking conditions were investigated: 
1. 3% (w/v) milk powder in PBS (Figure 3-12A) 
2. 3% (w/v) BSA in PBS (Figure 3-12B) 
3. 0.05% (v/v) Tween-20 2 mM EDTA in PBS (Figure 3-12C) 
4. 1% (v/v) Tween-20 0.3 M NaCl in 50 mM Tris buffer (pH 7.5) (Figure 3-12D) 
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To save time and resources only dsDNA and insulin were used as antigens alongside the blank 
(PBS only) wells. Anti-dsDNA and anti-insulin commercial positive controls were included to 
confirm that antigen-specific antibodies could bind under all four blocking conditions. Antigens 
and positive controls are detailed in Table 2-34 and Table 2-35 respectively (page 111). 
 
Figure 3-12: Four blocking conditions to test specificity of control antibodies. Blocking 
conditions used were: 3% (w/v) skimmed milk powder in PBS, 3% (w/v) BSA in PBS, 0.05% (v/v) 
Tween-20, 2 mM EDTA, PBS and 50 mM Tris, pH 7.5, 1% (v/v) Tween-20, 0.3 M NaCl. Mean 
OD450 (+/- 1 SD) of antibodies tested in triplicate is shown. The grey line indicates the 
background on the plate. The control antibodies are described in Table 2-35 (page 111). 
The commercial anti-dsDNA and anti-insulin positive control antibodies bound their respective 
antigens under every blocking condition. However, ED38 and ei-JB40 only gave a positive result 
when the ELISA plate was blocked with 3% (w/v) BSA or 0.05% (v/v) Tween-20, 2 mM EDTA 
(Figure 3-12). This suggests that ED38 and ei-JB40 might not be polyreactive in the sense that 
they bind multiple unrelated antigens specifically. However they clearly show a distinct 
phenotype from the commercial positive controls and the negative control m-GO53. The cause 
of this phenotype is unclear and is therefore investigated in more detail in section 3.5.2 using 
antibodies discovered in the Dunn-Walters lab. In order to avoid confusion, this phenotype will 
henceforth be referred to as “promiscuous”.  
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3.5.2 Investigating the Promiscuous Antibody Phenotype 
Five antibodies displaying a promiscuous phenotype were discovered in the Dunn-Walters lab 
by Tihomir Dodev (see Table 3-16 for details). These antibodies were used to further 
investigate the properties of the promiscuous phenotype and will be referred to as the “GF 
antibodies”. 
The ELISA shown in Figure 3-13 was conducted exactly as stated in Tiller et al. (2008) and 
shows that GF1, GF5, GF7, GF9 and GF16 all showed a positive result in wells coated with 
dsDNA, insulin, LPS, HEp-2 cell lysate and PBS (blank). 
Table 3-16: Properties of the promiscuous GF antibodies. All chains are from the B cell 
Development dataset.91 
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Figure 3-13: Discovery of the promiscuous GF antibodies using ELISA. Unpurified antibodies 
GF1, GF5, GF7, GF9 and GF16 showed a promiscuous phenotype when following Tiller et al. 
(2008) protocol (Tween-20 block). Each graph represents a separate ELISA plate.91  
                                                          
91 Tihomir Dodev (KCL) discovered the GF antibodies in the B cell Development dataset and conducted the ELISA 
shown in Figure 3-13; this graph has been published in Laffy et al. (2016). The antibodies in Figure 3-13 were 
expressed by Tihomir Dodev using the method described in section 2.8 (page 103). 
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3.5.2.1 ELISA Conditions Affect the Promiscuous Phenotype 
Figure 3-12 (page 165) shows that blocking conditions affect the visibility of the promiscuous 
phenotype. Therefore, a number of blocking and incubation conditions were tested to 
determine which resulted in the strongest promiscuous signal in solid-phase ELISA. 
Three blocking conditions were tested: 
1. 3% (w/v) milk powder in PBS 
2. 3% (w/v) BSA in PBS 
3. 0.05% (v/v) Tween-20, 2 mM EDTA in PBS 
And two incubation conditions were tested: 
1. 37oC, 200 rpm 
2. Room temperature, static 
The promiscuous phenotype was strongest when the ELISA plate was blocked with BSA and 
incubated at 37oC, 200 rpm (Figure 3-14). In this ELISA, many of the GF antibodies did not show 
evidence of binding in any of the conditions. Of those that did, the OD450 in the Tween-20 block 
was much lower than in Figure 3-13and they appear to bind insulin, in particular on the BSA-
blocked wells; this was also a characteristic of ED38 (Figure 3-12, page 165). 
 
Figure 3-14: ELISA blocking conditions affect the promiscuous phenotype. Mean OD450 
(+/- 1 SD) of antibodies tested in triplicate under three blocking conditions: 3% (w/v) skimmed 
milk powder in PBS, 3% (w/v) BSA in PBS and 0.05% (v/v) Tween-20, 2 mM EDTA in PBS and 
two incubation conditions: 37oC, 200 rpm and room temperature, static. Each graph 
represents a separate ELISA plate and the grey lines indicate the background on each plate.92 
                                                          
92 The antibodies used in Figure 3-14 were expressed by the IgG team at MedImmune (Cambridge, United Kingdom) 
using the method described in section 2.7 (page 99). The control antibodies are given in Table 2-35 (page 111). 
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3.5.2.2 Promiscuous GF Antibodies do not bind Insulin in a Soluble ELISA 
Unlike commercial positive control antibodies, the ELISA results for the promiscuous GF 
antibodies could be changed by altering the blocking and incubation conditions (Figure 3-14). 
This suggests that the promiscuous antibodies may not be interacting with the antigens 
coating the ELISA wells. To test this, a soluble ELISA was performed using streptavidin-coupled 
magnetic beads coated with biotinylated insulin (see Figure 3-15 for schematic and section 
2.11 (page 112) for full materials and methods). As the magnetic beads are transferred to a 
new ELISA well before adding the HRP substrate, the colour will only develop if the antibodies 
are bound to the beads. The soluble ELISA was blocked with 3% (w/v) BSA and incubated at 
37oC, 200 rpm. 
The soluble ELISA showed no evidence that the promiscuous GF antibodies bind biotinylated 
insulin (Figure 3-16). 
 
Figure 3-15: Soluble ELISA method. Streptavidin-coupled magnetic beads coated with 
biotinylated insulin are incubated with primary and secondary antibodies. Magnets are used 
during the wash steps. The bead-antibody complexes are transferred to a new well before the 
addition of the HRP-substrate. 
 
Figure 3-16: Soluble ELISA to test binding of GF antibodies to biotinylated insulin. Mean OD450 
(+/- 1 SD) of antibodies tested in triplicate.93  
                                                          
93 The GF antibodies used in Figure 3-16 were expressed by the IgG team at MedImmune (Cambridge, United 
Kingdom) using the method described in section 2.7 (page 99) and the control antibodies are detailed in Table 
2-35 (page 111). 
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3.5.2.3 Promiscuous Antibodies are Autoreactive 
The promiscuous GF antibodies appear to bind dsDNA on an ELISA plate under certain 
conditions (Figure 3-13, Figure 3-14). Immunocytochemistry against HEp-2 cells was used (as in 
section 3.4, page 153) to determine whether the GF antibodies show any nuclear (i.e. dsDNA) 
binding, and whether the promiscuous antibodies are autoreactive. 
Only GF07 showed some evidence of nuclear binding; the other four antibodies did not bind 
the nucleus (see Figure 3-17 and Table 3-17). This suggests that positive result seen with 
dsDNA-coated ELISA wells (Figure 3-13 & Figure 3-14) was not dsDNA specificity. All five 
promiscuous GF antibodies showed cytoplasmic HEp-2 binding. 
 
Figure 3-17: Immunocytochemistry to test the binding of the GF antibodies to HEp-2 cells. 
Despite apparently binding dsDNA on the solid-phase ELISA, these antibodies did not bind 
dsDNA in the nuclei of HEp-2 cells. All five GF antibodies bound the cytoplasm. 
Table 3-17: HEp-2 binding specificities of GF antibodies. Refers to results shown in Figure 3-17. 
Antibody ID HEp-2 binding Cytoplasmic binding Nuclear binding 
GF01 Strong  
GF05 Strong  
GF07 Strong  
GF09 Strong  
GF16 Weak  
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3.5.3 Investigating the Predicted Autoreactive Antibodies for Promiscuity 
It was next investigated whether any of the antibodies cloned and tested for autoreactivity 
(sections 3.3 and 3.4 respectively) display a promiscuous phenotype. 
3.5.3.1 Three Antibodies showed a Strong Promiscuous Phenotype 
All of the antibodies which could be expressed out of the 61 cloned in section 3.3 were tested 
for the promiscuous phenotype using a solid-phase ELISA blocked with 3% (w/v) BSA in PBS 





4. Blank wells (PBS only) 
A number of antibodies showed a low-level promiscuous phenotype, however two antibodies 
(CT0053 and CT0054) showed a very strong promiscuous phenotype (Figure 3-18). 
A subset of the antibodies investigated in Figure 3-18 were tested in a second ELISA using the 
same blocking and incubation conditions, but against a larger panel of antigens. In this ELISA 
each antibody was tested in triplicate against the following antigens: 
1. dsDNA 
2. Insulin 
3. GIF (gastric intrinsic factor) 
4. LPS 
5. MPO (myeloperoxidase) 
6. Blank wells (PBS only) 
Again, CT0053 and CT0054 showed a very strong promiscuous phenotype, giving a positive 
signal in all the antigen-coated wells and the PBS-only wells (Figure 3-19). However, in this 
ELISA, CT0037 also showed a very strong promiscuous phenotype, whereas in Figure 3-18 it 
had appeared only weakly promiscuous. 




Figure 3-18: ELISA testing the Forbidden antibodies for the promiscuous phenotype. Mean 
OD450 (+/- 1 SD) of each antibody tested in triplicate. All the ELISA plates were blocked with 
3% (w/v) BSA in PBS and the primary antibodies were incubated at 37oC, 200 rpm. Asterisks 
indicate promiscuous antibodies. Each graph represents a separate ELISA plate. The grey line 
indicates the background on each plate. The control antibodies are described in Table 2-35 
(page 111).  




Figure 3-19: ELISA testing antibodies against further antigens. OD450 (+/- 1 SD) of each antibody 
tested in triplicate. All the ELISA plates were blocked with 3% (w/v) BSA in PBS and the primary 
antibodies were incubated at 37oC, 200 rpm (as in Figure 3-18). Each graph represents a 
separate ELISA plate. The grey line indicates the background on each plate. The control 
antibodies are described in Table 2-35 (page 111).  
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3.5.3.2 Three Promiscuous Antibodies do not bind Insulin in a Soluble ELISA 
The three antibodies which showed a promiscuous phenotype in Figure 3-19 (CT0037, CT0053 
and CT0054) were tested in a soluble ELISA against streptavidin-coupled magnetic beads 
coated with biotinylated insulin (as in section 3.5.2.2, page 168). None of the three antibodies 
showed evidence of binding to the biotinylated insulin in a soluble ELISA format (Figure 3-20). 
 
Figure 3-20: Three promiscuous antibodies do not bind insulin in soluble ELISA. Mean OD450 
(+/- 1 SD) of each antibody. CT0037, CT0053 and CT0054 were tested in triplicate over two 
ELISA plates, each containing a set of controls. In this figure, the controls from both plates 
have been pooled and therefore the mean (+/- 1 SD) is based on six data points. The control 
antibodies are detailed in Table 2-35 (page 111).Three Promiscuous Antibodies show 
Aggregation 
It was noticed that the three promiscuous antibodies (CT0037, CT0053 and CT0054) were also 
the three antibodies with the highest percentage aggregation in the HP-SEC traces provided by 
the MedImmune IgG team when the antibodies were purified in PBS (Figure 3-21). See 
Appendix Figure A-4 (page 283) for all antibody HP-SEC traces. 
 
Figure 3-21: HP-SEC trace for CT0037, CT0053 and CT0054. The purified CT0037, CT0053 and 
CT0054 comprised 51.72%, 71.34% and 43.23% monomers respectively. The large peak at 
9 min represents IgG1 monomers. The peaks to the left of 9 min (shorter time periods) are 
aggregated IgG. Any peaks to the right of 9 min (longer timer periods) are fragmented IgG1.  
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3.5.3.4 Three Promiscuous Antibodies show Unusual Thermal Stability Patterns 
A thermal shift assay was used to determine the melting temperature (Tm) of each antibody 
expressed. For full materials and methods, see section 2.12 (page 113). Briefly, each purified 
antibody is mixed in an aqueous solution with SYPRO Orange (a fluorophore which is quenched 
by water). The mixture is gradually heated in a real-time PCR machine and the fluorescence is 
measured regularly. Once the Tm is reached and the protein begins to unfold, hydrophobic 
pockets are revealed and the SYPRO Orange sequestered in these pockets fluoresces. 
Eventually the protein disintegrates and the fluorophore is quenched (see Figure 3-22A for a 
schematic). 
A thermal shift assay was performed for every antibody expressed. Most antibodies started 
fluorescing between 60oC and 70oC. However, CT0037, CT0053 and CT0054 all showed an 
unusual curve in which there was already fluorescence at 20oC (Figure 3-22B), particularly 
CT0037 and CT0054, which were the most aggregated in Figure 3-21. 
 
Figure 3-22: Thermal shift assay using SYPRO-Orange. (A) Principal of a thermal shift assay. (B) 
Thermal shift assay for all antibodies expressed. Each antibody was tested in triplicate and the 
line represents the mean of each reading. Antibodies CT0037, CT0053 and CT0054 are 
highlighted in blue, green and red respectively.  
Chapter 3: Tolerance, Autoreactivity and Polyreactivity 
175 
 
3.5.4 Promiscuous Antibody Phenotype may be linked to Autoreactivity 
22 of the 27 antibodies with a promiscuous phenotype (starred antibodies in Figure 3-18, page 
171) were autoreactive (as defined by HEp-2 binding), whereas only 17 of the 29 antibodies 
which did not have the promiscuous phenotype were autoreactive (Figure 3-23A). However, a 
two-sided Fisher’s exact test did not find this difference significant (p = 0.0843). 
When looking at where in the cell autoreactive antibodies bound (Figure 3-23B), there was no 
significant difference between the promiscuous antibodies and the not promiscuous 
antibodies (two-sided Fisher’s exact test p = 0.9298). 
However, it was observed that the three antibodies which showed a very strong promiscuous 
phenotype (CT0037, CT0053 and CT0054) (Figure 3-19, page 172) also showed very strong 
HEp-2 cytoplasmic binding (Figure 3-6, page 158, and Figure 3-8, page 160). 
 
Figure 3-23: Promiscuous antibodies are more likely to be autoreactive. The count of each 
group is displayed above the relevant bar.  
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3.6 Selecting for Polyreactive Antibodies using Phage Display 
In section 3.5, it was found that some antibodies displaying an apparent affinity for multiple 
antigens in certain solid-phase ELISA formats may not be binding the antigens with which the 
wells are coated. We named this phenotype “promiscuous”. This suggested that polyreactive 
antibodies which bind multiple unrelated antigens specifically may not be as common as 
previously thought (Wardemann et al., 2003). To investigate whether we could find 
polyreactive antibodies in the human repertoire, we used a phage display selection cascade. 
The principle of phage display is described in section 1.12.2.1 (page 68). Briefly, a phage 
display library is created by inserting scFv sequences into the bacteriophage genome, causing 
the scFv to be expressed on the phage surface. Panning selections are performed by incubating 
the phage library with the antigen of interest; those expressing antigen-specific scFv will bind 
the antigen and the non-binders will be washed away. The prevalence of antigen-specific scFv 
increases in the library with every round of selection. We hypothesised that, if polyreactive 
antibodies are common in the human B cell repertoire, it should be possible to isolate them by 
selecting against a different antigen at each round of selection as only the antibodies which 
bound all of the antigens (i.e. polyreactive) would remain. The phage display library used was 
the MedImmune in-house BMVtrp library. This library is an antigen-naïve human scFv library 
constructed from peripheral blood (15 donors) tonsil (4 donors) and bone marrow (24 donors) 
B cell mRNA (Vaughan et al., 1996). 
The BMVtrp library was selected against the following unrelated autoantigens (Figure 3-24): 
1. HEp-2 cell lysate 
2. dsDNA 
3. MPO (myeloperoxidase) 
4. ApoH (apolipoprotein H) 
To prevent the selection of promiscuous antibodies (as defined in section 3.5.1, page 163), the 
library and the wells were blocked with 3% (w/v) milk powder in PBS. This blocking buffer has 
been shown to inhibit the binding of promiscuous antibodies (Figure 3-12, page 165). 
Additionally, before being incubated with each antigen, the library was first incubated in a 
blank ELISA well which had been blocked with 3% (w/v) milk powder in PBS. The aim of this 
was to try to remove any scFv which were just binding the plastic well or protein block. To 
mitigate the risk of the selection failing at one of the antigens, the selection cascade was split 
into multiple arms using the antigens in different orders (Figure 3-24). The selection was 
monitored by measuring the input and output titres at each round of selection. The diversity 
was measured after each round of selection by sequencing 88 output colonies. Of each batch 
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of 88 output colonies, each unique scFv was tested in an anti-M13 phage ELISA, blocked with 
3% (w/v) milk powder in PBS, to determine if the antibodies bound multiple antigens (dsDNA, 
MPO and blank (PBS only) wells). The successful expression of M13 phage was confirmed for 
every ELISA well to ensure that a negative result was not due to lack of phage expression. 
Commercial anti-dsDNA and anti-MPO positive controls confirmed the presence of the 
antigens in the ELISA wells. For full materials and methods, see section 2.13 (page 114). 
The antigen ELISAs showed that none of the scFv isolated in any of the rounds of selection 
shown in Figure 3-24 bound specifically to both dsDNA and MPO, suggesting that the selection 
had not isolated polyreactive antibodies. 
 
Figure 3-24: Phage display selection cascade against multiple unrelated autoantigens. The 
BMVtrp library was selected against multiple unrelated autoantigens with the aim of isolating 
polyreactive scFv. The plates were blocked with milk and plastic-binders were de-selected at 
each round.  




3.7.1 Transitional Populations in the B cell Development Pathway 
The original hypothesis of this chapter was that autoreactive B cells are selected against at the 
central and peripheral tolerance checkpoints and therefore any variable region characteristics 
associated with autoreactivity would reduce in frequency as the B cells matured and any 
preferred characteristic would increase in frequency as B cells matured. One of our starting 
assumptions was that B cells progress linearly from pre-B >> immature >> transitional >> naïve. 
Therefore, we expected the frequency of each variable region property to show one of three 
patterns as the B cells matured through the four cell repertoires: 
1. No change in frequency, indicating no selection pressure 
2. Progressive increase in frequency, indicating that the property was positively selected 
3. Progressive decrease in frequency, indicating that the property was selected against 
However, a surprising finding in the B cell Development dataset analysis was that the 
transitional B cell variable region properties did not always fit the trajectory of gene loss/gain 
or CDR-H3 property increase/decrease expected if the whole B cell population progresses 
linearly from pre-B to naïve. For example, IGHD3 and IGHJ4 are used significantly more and 
less frequently respectively in the transitional repertoire when compared to the other three 
cell types (Figure 3-1, page 140). Furthermore, the frequency of IGHJ6 is significantly higher in 
the transitional repertoire compared to pre-B and immature, but the frequency in the naïve 
repertoire is significantly lower than in the immature repertoire. Some CDR-H3 properties also 
showed this trait; the mean CDR-H3 aliphatic index was significantly lower in the transitional 
repertoire and there was also a significantly higher frequency of CDR-H3 with a high isoelectric 
point in the transitional repertoire (Figure 3-2B&D respectively, page 142). 
The transitional repertoire can be split into three subsets: T1 (CD38+++CD24hiCD10++IgDlo/−), T2 
(CD38++CD24hiCD10+IgD+) and T3 (CD38+CD24+IgD+ABCB1−) (Martin et al., 2016) and flow 
cytometry data suggests that the transitional cells form a continuum between the immature 
and naïve repertoires (Palanichamy et al., 2009). However, if B cells do mature in a linear 
fashion from pre-B >> immature >> transitional >> naïve, it would waste resources to promote 
a property in one cell population and then select against it in the subsequent one (or vice 
versa). Therefore, our findings suggest that the progression from pre-B to naïve may not be 
linear and the whole of the transitional repertoire may not mature into naïve B cells. 
The role of the transitional repertoire is still not completely understood, however it has been 
found that both T1 and T2 subsets are present in the bone marrow and peripheral blood of 
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healthy adults, suggesting that both subsets can leave the bone marrow and both may have 
independent roles in the periphery (Agrawal et al., 2013). This raises questions about the 
linearity of the transition from immature >> T1 >> T2 >> T3 >> naïve. Our work supports the 
hypothesis that the transitional B cell repertoire contains a large population of cells which are 
not part of the linear development pathway from pre-B >> immature >> transitional >> naïve. 
We hypothesise that some of the B cells in the transitional repertoire are destined to form 
other B cell repertoires and are thus subject to different selection pressures (Martin et al., 
2016). 
Despite these surprising findings, there is evidence that central and peripheral tolerance do 
remove autoreactive B cells from the repertoire (Wardemann et al., 2003) and therefore we 
still analysed the B cell Development dataset to identify genes and CDR-H3 properties which 
may be associated with autoreactivity. However, when selecting heavy chain properties to 
investigate, emphasis was placed on the difference in frequency between the pre-B/immature 
repertoire and the naïve repertoire rather than the frequency in the transitional population as 
not all of the transitional population may be subject to the same tolerance pressures. 
3.7.2 Selection of Heavy Chain Variable Region Properties as B cells Mature 
To identify which heavy chain properties may be associated with autoreactivity, we 
hypothesised that properties which decreased in frequency as B cells matured may do so 
because they are selected out of the repertoire because they tend to be present in 
autoreactive antibodies. Conversely, we hypothesised that properties which increased in 
frequency as B cells matured may be beneficial. 
The only IGHV family which significantly changed in frequency of usage as B cells matured was 
IGHV3. IGHV3 was significantly less frequent in the naïve repertoire compared to all three prior 
repertoires (Figure 3-1A, page 140). This appeared to be driven by decreases in the frequency 
of IGHV3-30, IGHV3-33, IGHV3-15 and IGHV3-7 (Figure 3-1D). Although the IGHV1 family was 
more frequent on average in the naïve repertoire (Figure 3-1A), the difference was not 
statistically significant. However, IGHV1-18 and IGHV1-69 genes were significantly more 
common in the naïve repertoire. IGHV1-69 is an important antiviral gene due to the presence, 
in many alleles, of a phenylalanine at position 54 (Kabat scheme) which is at the apex of the 
CDR-H2 loop (Avnir et al., 2016). It has been noted previously that the IGHV3 family is less 
frequent and the IGHV1 family more frequent in switched memory populations compared to 
naïve populations (Wu et al., 2010), indicating that these families commonly highlight 
differences between cell repertoires. 
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IGHV4-34 is heavily associated with autoimmune disease such as SLE, RA and MS (Tipton et al., 
2015, Doorenspleet et al., 2014, Baranzini et al., 1999). We found that IGHV4-34 is significantly 
less common in the immature and transitional repertoires compared to the pre-B repertoire, 
suggesting that it may be selected against early in development. However, surprisingly, the 
frequency of IGHV4-34 significantly increases again in the naïve repertoire (Figure 3-1D), 
suggesting that this gene may, in some circumstances, be advantageous. 
The only IGHD family which significantly decreased in frequency as B cells matured was IGHD2. 
The IGHD2 family was significantly less common in the transitional and naïve repertoires 
compared to pre-B and immature (Figure 3-1B). This appeared to be driven by significant 
decreases in IGHD2-15 and IGHD2-2 usage (Figure 3-1E). 
IGHJ6 was significantly less common in the naïve repertoire compared to the immature 
repertoire, suggesting that it may be selected against (Figure 3-1C). IGHJ3 is significantly more 
frequent in the naïve repertoire, suggesting that it is preferred. 
The reason IGHD2-2, IGHD2-15 and IGHJ6 appear to be selected out of the repertoire as B cells 
mature may be due to the fact that they are very commonly found in antibodies with long 
CDR-H3. Long CDR-H3 are associated with autoreactivity (Wardemann et al., 2003). IGHD2-2 
and IGHD2-15 are among the longest IGHD genes and IGHJ6 is the longest IGHJ gene. IGHJ6 is 
present in over 75% of the longest CDR-H3 and IGHJ6 in combination with either IGHD2 or 
IGHD3 genes is seen in 58.8% of long CDR-H3 (Briney et al., 2012). However, IGHD3-3 is also 
very common in long CDR-H3 but this gene did not show evidence of being selected against, 
suggesting that the IGHD2-2 and IGHD2-15 genes may have additional properties which are 
selected against at tolerance. The IGHD2 family is more frequent in non-productive sequences 
than productive rearrangements (again indicating that the family is selected out of the 
repertoire), but has not been linked to autoreactive antibodies (Volpe & Kepler, 2009, Volpe & 
Kepler, 2008). 
The mean CDR-H3 length was shorter in the naïve repertoire compared to the other three 
repertoires (Figure 3-2A, page 142), suggesting that long CDR-H3 are selected against. Long 
CDR-H3 are often associated with autoreactivity, however the reason for this association is not 
well understood. It is speculated that it could be due to increased N-nucleotide addition and so 
the addition of non-germline-encoded amino acids which have not been subject to millennia of 
natural selection. There is a positive correlation between CDR-H3 length and N-nucleotide and 
P-nucleotide addition (Briney et al., 2012). Although potentially dangerous due to the risk of 
autoreactivity, long CDR-H3 loops are important for fighting off certain infections, particularly 
HIV, malaria and trypanosomes (Pancera et al., 2010, Henderson et al., 2007, Stijlemans et al., 
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2004). For example, two potent HIV broadly-neutralising antibodies (PG9 and PG16) both have 
CDR-H3 loops 28 amino acids long (Pancera et al., 2010). Long CDR-H3 can be useful because 
they can reach epitopes otherwise obscured in deep crevices or by heavy glycosylation. 
The mean hydrophobicity (GRAVY index) was significantly lower in the transitional and naïve 
repertoires compared to the pre-B and immature repertoires (Figure 3-2E), indicating that 
hydrophobic CDR-H3 are selected against. The mean Boman index of CDR-H3 was significantly 
higher in the naïve repertoire compared to the three preceding repertoires (Figure 3-2C). The 
Boman index is a measure of antibacterial (anti-membrane) activity (Boman, 2003) and was 
designed as an index to specifically measure propensity to bind bacterial membranes but not 
other proteins. Therefore, the promotion of antibodies with a high Boman index might reflect 
the positive selection of antibodies which bind bacterial membranes but not self-antigens. 
Almost no significant differences were seen between the pre-B and immature repertoires: only 
IGHV3-15 and IGHV4-34 were used at different frequencies and the isoelectric point and 
instability index of the CDR-H3 was significantly different. This lack of difference between the 
pre-B and immature repertoires supports the hypothesis that no selection takes place between 
these two repertoires and that pre-B proliferation is driven by its ability to recognise self-
antigen, indicating that it has functional BCRs (Köhler et al., 2008). 
3.7.3 Long, Hydrophobic and Aromatic CDR-H3 Linked to Cytoplasmic Binding 
The first set of heavy chains selected to test for autoreactivity possessed all of the properties 
mentioned above which had been identified as forbidden, and were therefore named the 
Forbidden antibodies. These heavy chains all used IGHV3-15/3-30/3-33, IGHD2-2 and IGHJ6 
genes and they all had exceptionally long, hydrophobic CDR-H3 with low CDR-H3 Boman 
indexes. In order to investigate the roles of the heavy and light chains independently, each 
heavy chain was paired with three public light chains. Of the 12 heavy chains investigated, six 
(IgH4, 5, 8, 9, 10 and 11) bound the HEp-2 cytoplasm when paired with all three light chains 
(Figure 3-5, page 156). Only two heavy chains (IgH3 and 6) did not bind the HEp-2 cytoplasm 
when paired with any of the light chains. IgH3 was the only heavy chain derived from a naïve 
B cell, suggesting that this cell had passed the tolerance checkpoints and, despite its risky 
properties, is not autoreactive. The fact that IGH1, 2 and 7 show variable autoreactivity 
depending on the light chain with which they are paired suggests that these heavy chains are 
prone to autoreactivity but can be rescued by receptor editing. All three of these antibodies 
bound HEp-2 cells when in combination with one or both of the kappa light chains. This 
supports the theory that lambda light chains are better at rescuing autoreactive heavy chains 
than kappa (Wardemann et al., 2004). IgH12 could not be expressed with two of the three light 
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chains. This suggests that some heavy-light chain combinations do not work either because 
they do not pair well or because the resulting antibody is toxic to the cell. Nine out of 12 
Forbidden heavy chains did show HEp-2 binding, indicating that these characteristics are 
associated with autoreactivity. However, a more robust experiment would have been to 
compare the Forbidden heavy chains with a set of randomly selected heavy chains and paired 
with the same three light chains to see if autoreactivity was more common in the Forbidden 
heavy chains. Furthermore, the 12 Forbidden heavy chains had such similar properties, there 
were no clear differences between those which did bind the HEp-2 cells and those that did not. 
This suggests that to get more accurate predictors of autoreactivity, one should probably look 
beyond the amino acid sequence and examine the structure. 
Further evidence that antibodies with long, hydrophobic CDR-H3 are associated with 
autoreactivity is that three out of the four Long Hydrophobic antibodies which could be 
expressed bound HEp-2 cells (CT0050, CT0053, CT0054). CT0053 and CT0054 showed strong 
cytoplasmic binding, whereas CT0050 showed weak nuclear binding (Figure 3-6, page 158). 
CT0050 has a string of valines in the CDR-H3. Valines are small, non-polar and aromatic (Table 
2-20 page 95). However, this string of valines is associated with the use of IGHD2 genes and all 
of the Forbidden antibodies used IGHD2-2 but they did not all show signs of nuclear binding. 
This suggests that it may be the long, hydrophobic CDR-H3 which is mainly responsible for the 
autoreactivity shown by these antibodies, rather than the VDJ genes as the VDJ gene usage 
was not considered when selecting the Long Hydrophobic heavy chains. 
In the literature (Droupadi, 1994) and from experiments in the Dunn-Walters lab, aromatic 
antibodies show some association with autoreactivity/polyreactivity. Therefore, heavy chains 
with a CDR-H3 with a very high aromatic amino acid content were investigated for 
autoreactivity. Like the antibodies with long, hydrophobic CDR-H3 loops, the Aromatic 
antibodies showed a propensity to cytoplasmic binding. Three of the four Aromatic antibodies 
that could be expressed showed cytoplasmic binding (CT0037, CT0047, CT0060). CT0037 in 
particular showed very strong cytoplasmic binding (Figure 3-8, page 160). 
3.7.4 Unusual CDR-H3 Isoelectric Points are Associated with Nuclear Binding 
The analysis of the heavy chain B cell Development dataset showed that the frequency of 
antibodies in all four cell repertoires with CDR-H3 loops with an isoelectric point (pI) between 
5.0-6.0 (net negative charge at neutral pH) or 7.0-8.5 (net neutral to positive charge at neutral 
pH) was very low (Figure 3-2D, page 142). This suggests that these properties may be 
disadvantageous and so very rarely occur in the repertoire, potentially because they are 
heavily associated with autoreactivity. Two groups of five antibodies with CDR-H3 loops with pI 
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values within these boundaries (pI 5.0-6.0 and pI 7.0-8.5) were cloned and tested for 
autoreactivity. 
Surprisingly, both groups of antibodies showed a tendency towards strong nuclear binding. 
Three of the pI 5.0-6.0 antibodies showed nuclear binding (CT0039, CT0043, CT0049), two of 
which showed exclusively nuclear binding (CT0039 and CT0043) (Figure 3-9, page 161). Four of 
the five pI 7.0-8.5 antibodies showed cytoplasmic binding (CT0046, CT0051, CT0055, CT0056), 
and three of these also showed nuclear binding (CT0046, CT0051, CT0056) (Figure 3-10, page 
162). This suggests that these isoelectric points may be underused in the repertoire because 
they are prone to nuclear binding. Anti-nuclear antibodies are associated with various 
autoimmune disease, particularly SLE (Arbuckle et al., 2003), and alternating CDR-H3 charge 
patterns are associated with anti-nuclear antibodies in lupus mice (Liang et al., 2004). 
3.7.5 Preferred Characteristics did not Guarantee Lack of Autoreactivity 
Our hypothesis was that antibodies with properties which are selected against at tolerance 
would have a high probability of being autoreactive, but conversely, antibodies with properties 
which are promoted at the tolerance checkpoints would have a low chance of being 
autoreactive. We selected five Preferred heavy chains which possessed all the characteristics 
which significantly increased as B cells matured. 
Surprisingly, of the Preferred antibodies, two showed both nuclear and cytoplasmic binding 
(CT0058, CT0059), however the binding was weak (Figure 3-7, page 159). This suggests that 
either just possessing preferred characteristics is not enough to guarantee no autoreactivity or 
certain anti-nuclear antibodies are not harmful. Both nuclear-binding heavy chains were from 
transitional cells indicating that they had passed central tolerance. 
It is known that autoreactive antibodies do escape central tolerance and are found in the 
peripheral blood (Wardemann et al., 2003), and unless a complementary autoreactive T cell is 
also present, the B cell should not be activated (Parham, 2009). However, it was surprising that 
two autoreactive Preferred antibodies showed nuclear binding as this phenotype is heavily 
associated with SLE (Arbuckle et al., 2003). 
However, it is important to remember that these heavy chains are all paired with the same 
light chain which is almost certainly not their native pair. It is possible that these heavy chains 
would not have shown autoreactivity if paired with their native light chains. 
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3.7.6 Antibody Polyreactivity may be Promiscuity 
The work in this chapter was initially based on work in the landmark Wardemann et al. (2003) 
Science paper where it was shown that autoreactivity and polyreactivity are closely linked and, 
like autoreactive antibodies, polyreactive antibodies are removed from the repertoire at the 
tolerance checkpoints. They showed that polyreactive antibodies are very prevalent in the 
early immature B cell repertoire (55.2%) but approximately 90% are removed at the central 
tolerance checkpoint leaving 6.9% and 7.4% polyreactive antibodies in the immature and new 
emigrant B cell populations respectively. Peripheral tolerance then removes a further 42% of 
polyreactive B cells, leaving a frequency of approximately 4.3% in the naïve mature repertoire. 
This indicates that most polyreactive antibodies are not advantageous in the mature naïve 
B cell population, potentially because they may lead to autoimmune disease. Many papers 
have followed on from this 2003 study, each defining a polyreactive antibody as an antibody 
which binds multiple unrelated antigens (usually dsDNA, ssDNA, insulin and LPS) in the solid-
phase ELISA protocol set out in detail in Tiller et al. (2008). In almost all of these papers ED38, 
ei-JB40 and m-GO53 are used as high-polyreactive, low-polyreactive and negative controls 
respectively. Studies using this definition of polyreactivity have found that the frequency of 
polyreactive antibodies differs dramatically in different B cell repertoires, for example, the 
frequency of polyreactive antibodies is significantly higher in IgA+ and IgG+ intestinal 
plasmablasts (Benckert et al., 2011, Berkowska et al., 2015) indicating that the polyreactive 
phenotype may play a role in maintaining mucosal immunity. Polyreactivity is less frequent in 
the IgM+ memory B cell compartment than the mature naïve repertoire (Tsuiji et al., 2006), 
but it is more common in the IgG+ memory B cell compartment due to somatic hypermutation 
(Tiller et al., 2007). This indicates that there may be an additional tolerance checkpoint 
between the mature naïve repertoire and the IgM+ memory B cell repertoire and there could 
be an additional tolerance checkpoint between the IgG+ memory repertoire and the antibody-
secreting plasma cell repertoire. Polyreactivity is also more common among an unusual group 
of peripheral blood B cells which co-express normal light chains and surrogate light chains 
(V-preB+L+) (Meffre et al., 2004). 
Polyreactivity (as defined in Tiller et al. (2008)) is also more common in patients with 
autoimmune diseases such as rheumatoid arthritis (Samuels et al., 2005) and both active 
systemic lupus erythematosus (SLE) and SLE in remission (Yurasov et al., 2005, Yurasov et al., 
2006). Polyreactivity is more common in patients with various defects in B cell development 
such as those with X-linked agammaglobulinemia (defective Bruton’s tyrosine kinase) (Ng et 
al., 2004), people with chronic lymphocytic leukaemia (particularly the non-mutated clones) 
(Hervé et al., 2005), CD40L-deficient patients (Hervé et al., 2007) and AID-deficient patients 
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(Meyers et al., 2011, Cantaert et al., 2015). Interestingly, antibodies which bind HIV gp140 and 
also antibodies which bind the influenza hemagglutinin (HA) stalk frequently show 
polyreactivity (Mouquet et al., 2010, Andrews et al., 2015) indicating that polyreactivity may 
be advantageous in protection against viral infections such as HIV and influenza. 
The polyreactive phenotype described in all of the papers mentioned above is clearly 
biologically very important and can be advantageous in certain circumstances, but must be 
tightly controlled by various checkpoints due to the risk of autoimmune disease. We therefore 
wanted to test our panel of cloned antibodies (section 3.3, page 144) for polyreactivity using 
the same protocol. However, when we tried to replicate the ELISA described in these papers 
using ED38, ei-JB40 and m-GO53, we found that, when the plate was blocked with the protein-
free blocking buffer described in Tiller et al. (2008), ED38, ei-JB40 and m-GO53 gave the same 
signal regardless of whether the ELISA wells were coated with antigen (Figure 3-11, page 164). 
Additionally, the binding pattern of these antibodies can be altered by changing the blocking 
conditions, whereas the binding of commercial antigen-specific antibodies remains unchanged 
(Figure 3-12, page 165). These results suggested that the polyreactive phenotype displayed by 
ED38 and ei-JB40 may not be specific binding to multiple antigens. This assertion needed to be 
investigated further and to avoid confusing terminology we referred to this non-specific 
phenotype as “promiscuous”. 
The promiscuous phenotype was studied further with the “GF antibodies” which showed a 
strong promiscuous phenotype when they were initially discovered (Figure 3-13, page 166), 
but for some of them the phenotype proved temperamental as they did not all show it again in 
further ELISAs (Figure 3-14, page 167). The GF antibodies showed no evidence of binding 
biotinylated insulin in a soluble ELISA format (Figure 3-16, page 168), indicating that despite 
the signal in the solid phase ELISA, these antibodies do not bind insulin (although it is possible 
that the binding site was blocked by the biotinylation). All but GF07 did not bind the HEp-2 
nuclei in immunocytochemistry (Figure 3-17, page 169), indicating that the antibodies do not 
bind dsDNA either. However, all five GF antibodies showed strong cytoplasmic binding, 
indicating that they may be autoreactive. 
These results were mirrored by the three antibodies selected from the B cell Development 
dataset which showed a strong promiscuous phenotype: CT0037, CT0053 and CT0054 (Figure 
3-19, page 172). These three antibodies did not bind biotinylated insulin in the soluble ELISA 
(Figure 3-20, page 173) or HEp-2 nuclei in the immunocytochemistry (Figure 3-6 and Figure 
3-8, pages 158 and 160 respectively). However, like the GF antibodies, all three promiscuous 
antibodies showed very strong HEp-2 cytoplasmic binding. 
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CT0037 had a CDR-H3 with a high aromatic amino acid content (section 3.3.4, page 150) and 
CT0053 and CT0054 had long, hydrophobic CDR-H3 (section 3.3.2, page 149). All of these 
properties have been linked with polyreactivity in the literature (Meffre et al., 2004, Ng et al., 
2004, Berkowska et al., 2015). A very striking feature of these three highly promiscuous 
antibodies was their propensity to aggregate as shown by the HP-SEC trace generated during 
their purification (Figure 3-21, page 173). This suggests that, alongside cytoplasmic binding, the 
promiscuous phenotype may be closely linked to antibody aggregation. All three antibodies 
also had unusual thermal shift assay traces (Figure 3-22, page 174); this may have been due to 
the disintegration of aggregates. 
The promiscuous phenotype described in this chapter has been observed in human serum. 
Some sera being tested for diagnostic purposes do display background interactions in wells 
lacking test antigen (Fujii et al., 1989, Jørgensen et al., 2005, Terato et al., 2014, Güven et al., 
2014) and sometimes appear to bind multiple autoantigens when coated on an ELISA plate, 
but not in other formats (Güven et al., 2014). Further, changing the blocking conditions can 
alter this background binding. For example, certain protein blocks (Terato et al., 2014) or a 
high-salt blocking buffer (Jørgensen et al., 2005) can remove this phenotype from serum as it 
did with ED38 and ei-JB40 in Figure 3-12 (page 165). The promiscuous phenotype in serum 
correlates with inflammatory mediators and immune complexes and could be induced by 
heating the serum to 40oC (Güven et al., 2014). However, we observed this phenotype in 
purified antibodies, suggesting that other serum components are not required, but we did 
notice an association with aggregation propensity (Figure 3-21). Although the visibility of the 
promiscuous phenotype on the solid-phase ELISA is dependent on the blocking buffer used, 
the fact that not every antibody shows this phenotype (for example m-GO53) indicates that 
the phenotype is not simply caused by antibody protein sticking to a poorly blocked ELISA well. 
In an attempt to isolate polyreactive antibodies from the human repertoire which do bind 
specifically to multiple unrelated antigens, we used phage display. The BMVtrp human scFv 
library was used in a panning selection against four unrelated autoantigens (HEp-2 cell lysate, 
dsDNA, MPO and ApoH). To prevent the isolation of promiscuous scFv, the selections were 
blocked using 3% (w/v) milk powder in PBS. Multiple selection cascades were used to mitigate 
the risk of one failing due to the order of the antigens (Figure 3-24, page 177). Unfortunately, 
no polyreactive antibodies were isolated from any of the selection cascades. We do not think 
that there was a problem with the phage display protocol as we did manage to isolate one 
anti-dsDNA antibody from the selection, however, we do acknowledge that the selection may 
not have been optimal; we may have found some polyreactive scFv if more colonies had been 
picked per round, different antigens had been used or a different phage display library had 
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been used. However, it is worth noting that the BMVtrp library contained sequences from the 
human bone marrow (Vaughan et al., 1996). If 55.2% of immature B cells are polyreactive 
(Wardemann et al., 2003), one would expect some polyreactive scFv to be isolated from the 
BMVtrp library using this selection cascade. 
Despite these findings, we are not advocating that polyreactive antibodies do not exist. 
Polyreactivity can be caused by molecular mimicry (Oldstone, 1998) and it has been shown 
with X-ray crystallography that some antibodies can bind to multiple unrelated antigens by 
making different specific contacts (James et al., 2003, Kramer et al., 1997, Fields et al., 1995). 
However, these antibodies do not bind every antigen against which they are tested and it is 
unknown how common they are in the human repertoire (although it is possible that all 
antibodies are polyreactive and the limiting factor for identifying them is the size of the panel 
of antigens against which they are tested). 
From the results of this chapter, we are suggesting that polyreactive antibodies which can 
specifically bind to antigens as diverse as DNA, LPS and insulin are much rarer than was 
suggested in Wardemann et al. (2003). Instead, we propose that the phenotype observed in 
papers using the protocol set out in Tiller et al. (2008) or similar may in fact be promiscuity. We 
do not believe promiscuity to be specificity to multiple antigens or “stickiness” as we do not 
see evidence of antigen-binding outside of the solid-phase ELISA format. 
The cause of the promiscuous phenotype needs to be investigated further to determine why it 
is physiologically important and what role it plays in the immune response. It appears that the 
promiscuous phenotype is heavily selected at multiple tolerance checkpoints and is associated 
with various autoimmune diseases. It also appears to be linked to autoreactivity as the 
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Chapter 4: Light Chain Selection and Isotype Properties 
4.1 Introduction 
The antigen binding site of an antibody is composed of a heavy chain and a light chain. When 
investigating antibody specificity, the focus is often centred on the heavy chain, in particular 
the CDR-H3. However, the light chain is certainly important for antibody specificity and should 
not be overlooked. On average, the CDR-L1, CDR-L2 and CDR-L3 together contribute 
approximately 32% of the energetically important residues during antigen binding (Kunik & 
Ofran, 2013). Furthermore, light chains are swapped during receptor editing for the purpose of 
altering BCR specificity to rescue autoreactive B cells (Yachimovich et al., 2002, Halverson et 
al., 2004). We showed in Figure 3-5 (page 156) that antibodies with the same heavy chain but 
different light chains can alter the binding specificity of the antibody. 
Like heavy chains, light chains are implicated in some autoimmune diseases (Dörner et al., 
1998, Steinsbø et al., 2014) and therefore it follows that they may be subject to similar 
selection pressures during B cell development as heavy chain variable region sequences. 
Although a previous study has not found evidence of selection pressures on light chain 
properties during B cell development (Wardemann et al., 2003), this was based on a relatively 
small “low throughput” dataset. 
Following on from the heavy chain data analysis presented in the previous chapter (section 
3.2), we hypothesised that examining bone marrow and peripheral blood light chain variable 
region properties using a large high-throughput sequencing dataset may highlight properties 
under selective pressures not visible when examining smaller datasets. Therefore, we used the 
light chain B cell Development dataset to determine whether any light chain properties 
significantly increased or decreased in prevalence as B cells matured, indicating that they may 
be under selection from tolerance mechanisms. We also investigated whether the light chain 
properties of transitional B cells show the same non-linear pattern of B cell progression as was 
observed in the heavy chain B cell Development dataset. 
Furthermore, human light chains can be one of two classes: kappa or lambda. Unlike heavy 
chain classes (IgA, IgD, IgE, IgG, IgM) which are swapped onto the same variable region during 
class switch recombination (section 1.7, page 42), kappa and lambda light chains are encoded 
by separate sets of variable and constant region genes encoded on separate chromosomes. 
Kappa light chains are encoded on chromosome 2 (Malcolm et al., 1982) and lambda light 
chains are encoded on chromosome 22 (Erikson et al., 1981). These two classes are not used 
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equally in the B cell repertoire. As kappa and lambda variable regions are encoded by separate 
sets of genes, this suggests that they may have different properties which may lead to 
different roles in the antibody response. Light chains are more rarely the focus of publications 
than heavy chains, however there is some evidence that kappa and lambda light chains have 
differing roles. During B cell development, the kappa locus is usually rearranged before the 
lambda locus (Hieter et al., 1981) and it is thought that lambda light chains are better at 
rescuing autoreactive heavy chains than kappa light chains (Wardemann et al., 2004). In the 
peripheral blood, there is a bias towards kappa light chains with approximately 3/5 to 2/3 of 
the B cell repertoire using kappa light chains as opposed to lambda (Mole et al., 1994, 
Brauninger et al., 2001, Montano & Morrison, 2002). However, in antigen-selected populations 
this ratio can differ (Chui et al., 1990) for example, lambda light chains are more prevalent 
than kappa in secreted (predominantly IgA) antibodies (Mole et al., 1994). Additionally, HIV 
Env-specific antibodies isolated from chronic HIV patients have a very strong bias towards 
lambda light chains (Sajadi et al., 2016) and hairy cell leukaemia patients also have a bias 
towards lambda light chains (Forconi et al., 2008). Phenotypic differences such as 
conformational flexibility (Stanfield et al., 2006) and half-life (Montano & Morrison, 2002) have 
also been found between antibodies bearing kappa and lambda light chains. 
These differences in kappa and lambda frequency and functionality and the fact that they are 
encoded by completely separate sets of variable and constant region genes suggests that 
kappa and lambda light chains may have different roles in the immune system. We 
hypothesised that if kappa and lambda light chains do have different roles in the immune 
response (e.g. binding different types of antigen), this may be reflected in their 
physicochemical and/or structural properties. Therefore, we analysed the CDRs of kappa and 
lambda light chains to determine whether there were physicochemical and/or structural 
differences in the variable regions of the two classes. 
Furthermore, there is much debate around whether immunoglobulin heavy-light chain pairing 
is entirely random or whether there are biases in which heavy and light chains pair together. 
We hypothesised that if we saw differences in the physicochemical/structural properties of 
kappa and lambda light chains, this may be reflected by physicochemical/structural differences 
in the heavy chains with which kappa and lambda light chains are paired. If this were the case 
it would suggest that heavy-light chain pairing is not random. 
Finally, we investigated whether the mean amount of random N-nucleotide addition in the 
CDR3 regions differed between individuals, and whether there was any correlation between 
the amount of N-nucleotide addition in the heavy and light chain CDR3 regions. 
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In summary, the aim of this chapter is to further our understanding of the properties of 
immunoglobulin light chains and heavy-light chain pairing using the following methods: 
1. Analysis of the light chain B cell Development dataset to identify variable region 
properties which increase or decrease in frequency as B cells mature as these 
properties may be associated with autoreactivity 
2. Compare the physicochemical properties of kappa and lambda CDR-L3 in the light 
chain B cell Development dataset to determine if they are significantly different, 
suggesting that kappa and lambda light chains may bind better to different types of 
antigen 
3. Use a published, paired heavy-light chain high-throughput sequencing dataset to 
compare the physicochemical properties of CDR-H3 of heavy chains paired with kappa 
and lambda light chains to determine if there is evidence of non-random heavy-light 
chain pairing 
4. Investigate the structural properties of all the CDRs of kappa and lambda antibodies in 
the Protein Data Bank (PDB) to determine if there are structural differences between 
kappa and lambda CDRs or the CDRs of the heavy chains with which they are paired 
5. Investigate the mean N-nucleotide addition at the kappa, lambda and heavy chain 
CDR3 regions in each donor in the B cell Development dataset to determine if there is 
any correlation in the mean number of N-nucleotides added 
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4.2 Light Chain Properties under Selection as B cells Mature 
4.2.1 VJ Gene Usage in Bone Marrow and Peripheral Blood B cell Repertoires 
The mean frequency of usage of each light chain family/gene (+/- 1 SD) in the immature, 
transitional and naïve B cell repertoires was calculated for each of the 19 donors in the light 
chain B cell Development dataset. Significant differences in family/gene frequency between 
the B cell repertoires were calculated using two-way unpaired ANOVA followed by Tukey’s 
multiple comparisons post-test. 
The analysis was performed on the entire light chain dataset which contained 30,161 kappa 
and 14,183 lambda entries (Table A-21, page 275), however a small number of samples were 
excluded due to there being too few sequences to accurately calculate family/gene usage (see 
section 2.5.1, page 96, for details of the “5X rule”). The samples excluded from analysis are 
shown in Table 4-1. 
Table 4-1: Samples excluded from VJ family usage analysis due to “5X rule”. Samples excluded 
from V family usage analysis are shown in red (<35 kappa entries/ <50 lambda entries). Donors 
excluded from J family usage are underlined (<25 kappa entries/ <35 lambda entries). A red 
dash indicates samples for which no data was available. 
Donor ID 
Kappa  Lambda 
Immature Transitional Naïve Immature Transitional Naïve 
122 1380 349 470  308 52 87 
159 1292 419 532  349 140 135 
138 255 130 961  22 125 - 
107 - 1476 163  - 686 152 
120 - 841 378  - 568 212 
118 464 249 281  348 88 58 
146 948 485 131  516 109 37 
103 371 15 554  164 3 307 
128 567 360 -  400 234 - 
126 259 664 1651  83 242 897 
141 2021 475 478  1414 233 73 
105 288 183 417  170 83 303 
119 2175 666 334  1609 27 162 
160 304 130 757  207 71 37 
111 188 151 708  79 67 644 
149 848 - 246  689 - 171 
132 - 896 515  - 381 267 
162 - 1139 1  - 1 249 
140 553 279 764  368 174 382 
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Very little difference was seen in kappa or lambda VJ family/gene usage between the 
immature, transitional and naïve B cell repertoires. Like the heavy chain analysis, there were 
several examples of a gene being used significantly more or less frequently in the transitional 
repertoire compared to the other repertoires, supporting the hypothesis that B cells do not 
progress entirely linearly and that transitional B cells may become a variety of different cell 
types, subject to different selection pressures. 
The only IGKV family which significantly differed in frequency between the cell repertoires was 
IGKV4 which was slightly less frequent in the naïve repertoire compared to the immature 
repertoire (Figure 4-1A). This may have been driven by the IGKV4-1 gene, which became 
significantly less frequent as B cells matured. IGKV1-39 and IGKV3-11 became significantly 
more frequent as B cells matured and IGKV3-20 was significantly less frequent in the 
transitional and naïve repertoires compared to the immature repertoire. IGKV1-33 was 
significantly less frequent in the transitional repertoire compared to the immature and naïve 
repertoires. 
Lambda light chains had slightly more significant differences between cell repertoires than 
kappa. IGLV1 became significantly less frequent and IGLV2 became significantly more frequent 
as B cells matured (Figure 4-1B). IGLV2-23 was significantly more common in the transitional 
and naïve repertoires compared to the immature repertoire and IGLV2-14 was significantly 
more common in the naïve repertoire compared to the immature repertoire, but the usage in 
the transitional repertoire was significantly lower than either the immature or naïve 
repertoires. IGLJ1 was significantly more common and IGLJ3 was significantly less common in 
the naïve repertoire compared to the immature repertoire. 
  




Figure 4-1: Light chain VJ family and gene frequencies in each cell repertoire. Mean frequency 
(+/- 1 SD) of (A) kappa and (B) lambda families/genes in immature, transitional and naïve B cell 
repertoires. Only V genes which differed significantly between cell types are shown. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001.  
Chapter 4: Light Chain Selection and Isotype Properties 
195 
 
4.2.2 CDR-L3 Properties in Bone Marrow and Peripheral Blood B cell Repertoires 
Before performing analysis of the CDR-L3 regions, sequence were removed from the light 
chain B cell Development dataset which may skew the analysis (section 2.5.2, page 96). The 
resulting dataset contained 20,571 kappa and 8,876 lambda entries (Table A-22, page 275). 
The following physicochemical properties were calculated (section 2.4.2, page 94) for each 
CDR-L3 amino acid sequence: 
1. CDR-L3 length (amino acids) 
2. Aliphatic index 
3. Boman index 
4. Isoelectric point 
5. Hydrophobicity (GRAVY index) 
6. Instability index 
Data for the 19 donors was pooled and frequency distributions and the mean (+/- 1 SD) were 
calculated for each cell type (immature, transitional and naïve). The Kruskal-Wallis test 
followed by Dunn’s multiple comparisons post-test was used to identify significant differences 
between the cell types. 
There were very few significant differences in the kappa CDR-L3 properties between the three 
cell types. The only significant difference was in the mean isoelectric point (pI). Like the heavy 
chain repertoire (Figure 3-2D, page 142), the mean pI of the transitional repertoire was 
significantly higher than the mean pI of the immature and naïve repertoires (Figure 4-2D). 
There were more significant differences in the CDR-L3 properties of the lambda repertoire 
than the kappa repertoire. The aliphatic index was significantly lower in the naïve repertoire 
compared to the immature and transitional repertoires (Figure 4-3B). The naïve repertoire also 
had more hydrophobic (higher GRAVY index) CDR-L3 regions on average than the immature 
and transitional repertoires (Figure 4-3E). The Boman index was significantly higher in the 
transitional repertoire than the immature repertoire, but was not different to the naïve 
repertoire (Figure 4-3C). The mean CDR-L3 length of the transitional repertoire was 
significantly shorter than the immature repertoire, bit not different to the naïve repertoire 
(Figure 4-3A). The mean pI was significantly higher in the naïve repertoire than the immature 
repertoire (Figure 4-3D). The CDR-L3 instability index was significantly higher in the transitional 
and naïve repertoires compared to the immature repertoire (Figure 4-3F).  




Figure 4-2: Kappa CDR-L3 physicochemical properties in each cell type. Histogram, cumulative 
frequency histogram and mean (+/- 1 SD) for six physicochemical properties of the kappa 
CDR-L3 regions of B cells isolated from the immature, transitional and naïve repertoires. (A) 
CDR-L3 length; (B) Aliphatic index; (C) Boman index; (D) Isoelectric point; (E) GRAVY index; (F) 
Instability index. Each set of three graphs shows the same data in different formats. The mean 
+/- 1 SD graphs were used to see significant differences between cell types, whereas the 
histograms and cumulative frequency plots show the shape of the data. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.  




Figure 4-3: Lambda CDR-L3 physicochemical properties in each cell type. Histogram, 
cumulative frequency histogram and mean (+/- 1 SD) for six physicochemical properties of the 
lambda CDR-L3 regions of B cells isolated from the immature, transitional and naïve 
repertoires. (A) CDR-L3 length; (B) Aliphatic index; (C) Boman index; (D) Isoelectric point; (E) 
GRAVY index; (F) Instability index. Each set of three graphs shows the same data in different 
formats. The mean +/- 1 SD graphs were used to see significant differences between cell types, 
whereas the histograms and cumulative frequency plots show the shape of the data. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001.  
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4.3 Kappa and Lambda CDRs Have Different Physicochemical Properties 
In section 4.2.2 (page 195), the light chain CDR-L3 physicochemical properties were compared 
between the immature, transitional and naïve cell repertoires to determine which properties 
may be under selection as B cells matured. In this section, the kappa and lambda CDR 
physicochemical properties were compared with each other to investigate whether these two 
light chain classes have significantly different CDR properties. 
Firstly, the physicochemical properties of kappa and lambda CDR-L3 regions in each cell 
repertoire (immature, transitional and naïve) were compared. The same light chain dataset 
was used as in section 4.2.2 (page 195) and the kappa and lambda CDR-L3 physicochemical 
properties were plotted as cumulative frequency histograms. The Kolmogorov-Smirnov (KS) 
test was used to test for significant differences between each kappa and lambda repertoire. 
In all three cell repertoires the kappa and lambda CDR-L3 had very different physicochemical 
properties (Figure 4-4A). The lambda CDR-L3 were significantly longer, more hydrophobic and 
had a higher aliphatic index than the kappa CDR-L3. The kappa CDR-L3 had higher Boman 
indexes and higher isoelectric points (pI). Interestingly, like the heavy chain pI cumulative 
frequency graphs (Figure 3-2D, page 142), both kappa and lambda repertoires had very few 
CDR-L3 with a pI in the range either side of approximately 6.0. However, the lambda repertoire 
had a higher frequency CDR-L3 with a low pI and the kappa repertoire had a higher frequency 
of CDR-L3 with a high pI. 
The frequency of each type of amino acid (Table 2-20, page 95) in kappa and lambda CDR-L3 
was investigated. The mean frequency (+/- 1 SD) of each type of amino acid was plotted and 
significant differences between the kappa and lambda repertoires were found using multiple 
t-tests followed by the FDR correction for multiple comparisons. The kappa and lambda 
repertoires had very different CDR-L3 amino acid usage (Figure 4-4B). The lambda repertoire 
had a significantly higher frequency of small, tiny, non-polar, aliphatic, charged and acidic 
amino acids, whereas the kappa repertoire has a significantly higher frequency of polar, 
aromatic and basic amino acids. 
The 10 Kidera factors (Table 2-19, page 94) were calculated for each CDR-L3 and these 10 
orthogonal measures of physicochemical and structural properties were used in a principle 
component analysis (PCA) (Figure 4-4C). The PCA separated the kappa and lambda repertoires 
into distinct groups. Kidera 10, Kidera 2, Kidera 5 and Kidera 6 were the factors which 
separated the kappa and lambda classes most.  




Figure 4-4: Physicochemical properties of kappa and lambda CDR-L3. All graphs show the 
CDR-L3 properties of kappa (red) and lambda (blue) CDR-L3 of B cells isolated from the 
immature, transitional and naïve repertoires of 19 healthy donors. (A) The physicochemical 
properties of kappa and lambda CDR-L3 plotted as cumulative frequency graphs. (B) Mean 
frequency (+/- 1 SD) of each group of amino acids (see Table 2-20, page 95) in kappa and 
lambda CDR-L3 (asterisk indicates significance). (C) PCA using the ten Kidera factors (Table 
2-19, page Table 2-1994) calculated for kappa and lambda CDR-L3.94  
                                                          
94 The graphs shown in Figure 4-4 have been published in Townsend et al. (2016). The R script used to perform the 
PCR shown in Figure 4-4C was written by Grace Lu (KCL). 
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CDR-L3 are encoded by germline V and J genes and also random N-nucleotide addition. This 
raises the question of whether the physicochemical differences seen in the complete CDR-L3 
(Figure 4-4) are due to differences encoded by the V and J gene segments, or by the 
N-nucleotide addition. 
To investigate this, a dataset of “germline” CDR-L3 which lacked N-nucleotide 
addition/deletion was created by combining germline light chain V and J gene amino acid 
sequences in the same frequency with which each V-J pair was seen in the B cell Development 
dataset. To do this, IMGT Protein Displays (Scaviner et al., 1999) were used to obtain the 
amino acid sequences of the CDR-L3 regions of germline V genes and J genes (i.e. V gene 
position 105 onwards and the first two amino acids of the J gene). Only *01 alleles were used. 
The frequency of recombination of each V gene and J gene in the real datasets (20,571 kappa 
and 8,876 lambda entries) was determined. The CDR-L3 sections of the V gene and J gene 
germline sequences were combined at the equivalent frequency. 428 entries were removed 
due to the resulting CDR-L3 regions being unproductive. The final dataset contained 20,379 
kappa and 8,648 lambda entries. 
The physicochemical properties of each “germline” CDR-L3 was calculated using the R package 
Peptides as described in section 2.4.2 (page 94). The kappa and lambda CDR-L3 properties 
were then compared as described for Figure 4-4A. 
The same differences in physicochemical properties were seen between the kappa and lambda 
“germline” CDR-L3 as were seen in the real-life dataset (Figure 4-5). This indicates that the 
differences in CDR-L3 physicochemical properties seen between kappa and lambda are 
encoded in the germline and are not the result of differences in N-nucleotide addition. 
However, the physicochemical properties of the “germline” CDR-L3 were significantly different 
from their real life counterparts indicating that N-nucleotide addition does significantly 
influence the physicochemical properties of CDR-L3, however the lack of directionality in this 
difference indicates that it does so randomly. 




Figure 4-5: Physicochemical properties of kappa and lambda “germline” CDR-L3. CDR-L3 
physicochemical properties of real (solid line) and germline (dotted line) kappa (red) and 
lambda (blue) CDR-L3 plotted as cumulative frequency graphs. Real CDR-L3 data from the 
immature, transitional and naïve repertoires of 19 healthy donors was pooled for this figure.95  
                                                          
95 The graphs shown in Figure 4-5 have been published in Townsend et al. (2016). 
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Cumulative frequency graphs and the KS test were used to determine if there were any 
significant differences in the physicochemical properties of CDR-L1 or CDR-L2 (IMGT definition) 
between the kappa and lambda repertoires. Significant differences were observed (Figure 4-6), 
however the differences are smaller than those seen in the CDR-L3 regions and, due to lower 
diversity in the CDR-L1 and CDR-L2 regions, the graphs are not as smooth. 
 
Figure 4-6: Physicochemical properties of kappa and lambda CDR-L1 and CDR-L2. The 
physicochemical properties of kappa (red) and lambda (blue) (A) CDR-L1 and (B) CDR-L2 
regions isolated from immature, transitional and naïve B cells of 19 healthy donors plotted as 
cumulative frequency graphs.96  
                                                          
96 The graphs shown in Figure 4-6 have been published in the supplemental material of Townsend et al. (2016). 
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4.4 CDR-H3 of Kappa and Lambda Antibodies are not Different 
In order to compare the CDR-H3 physicochemical properties of heavy chains paired with kappa 
and lambda light chains, heavy-light chain pairing information was needed. The B cell 
Development dataset does not contain heavy-light chain pairing information, so a published 
dataset was used (DeKosky et al., 2016). This dataset was generated by the George Georgiou 
lab using their technique of paired heavy-light chain sequencing (DeKosky et al., 2015, 
McDaniel et al., 2016) and comprises paired heavy and light chain sequences from the antigen-
naïve repertoires of three healthy donors. Donor 1 had 13,771 sequences, Donor 2 had 26,343 
sequences and Donor 3 had 15,193 sequences. We split the heavy chain dataset based on 
whether the heavy chains were paired with kappa or lambda light chains. 
Physicochemical properties for each CDR-H3 were calculated as described in section 2.4.2 
(page 94) and the CDR-H3 physicochemical properties of heavy chains paired with kappa and 
lambda light chains were compared using cumulative frequency graphs and the KS test. 
VDJ family usage in the kappa- and lambda-paired heavy chains was investigated by plotting 
the mean frequency (+/- 1 SD) of each family across the three donors. Significant differences 
between kappa- and lambda-paired heavy chain repertoires were tested using multiple t-tests 
followed by FDR correction for multiple testing. 
A significant difference was seen in the CDR-H3 isoelectric points (pI) of Donor 1 and Donor 2, 
and in the CDR-H3 length of Donor 2. No other significant differences in CDR-H3 
physicochemical properties were observed (Figure 4-7A). No significant differences in the 
mean VDJ family usage was observed between kappa and lambda repertoires (Figure 4-7B). 




Figure 4-7: CDR-H3 properties of heavy chains paired with kappa or lambda light chains. All 
graphs show the CDR-H3 properties of heavy chains paired with kappa (red) and lambda (blue) 
light chains. Data was taken from the antigen-naïve dataset published in DeKosky et al. (2016). 
(A) The physicochemical properties of kappa and lambda CDR-H3 of each donor plotted as 
cumulative frequency graphs. (B) Mean frequency (+/- 1 SD) of IGHV, IGHD and IGHJ family 
usage in the three donors in heavy chains paired with kappa and lambda light chains.97  
                                                          
97 The graphs shown in Figure 4-7 have been published in Townsend et al. (2016). 
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4.5 Kappa and Lambda CDR Loops are Structurally Different 
In Figure 4-4C (page 199), the kappa and lambda repertoires could be separated by PCA based 
on their CDR-L3 Kidera factors, which are linked to structural properties. This suggests that in 
addition to physicochemical differences, there are structural differences in the CDR loops. 
Antibody structures from the Protein Data Bank (PDB) were used to determine if there are 
structural differences between kappa and lambda classes in the CDR-L1, CDR-L2 and CDR-L3. 
For full materials and methods, see section 2.6, page 98. Briefly, all of the high-quality paired 
heavy-light chain crystal structures in the PDB were downloaded and redundancy was 
eliminated. 199 kappa and 106 lambda structures remained. Due to some incomplete CDR 
information, kappa antibody CDR-H1, lambda antibody CDR-H2, and lambda antibody CDR-L2 
analyses were performed using 197, 105, and 103 entries respectively. The secondary 
structure occupancies of each heavy and light chain CDR (Chothia definition) were calculated 
for each of the PDB structures included in the analysis. The mean secondary structure 
occupancies (+/- 95% CI) were calculated for each CDR. Differences in the mean probability of 
secondary structures between kappa and lambda antibodies were considered significant if the 
95% confidence intervals did not overlap. 
The secondary structures investigated were Beta, Coil, Helix and Turn (see Table 2-21, page 98, 
for definitions). Example CDR-L3 loops with high Beta, Coil and Helix content are shown in 
Figure 4-8. Turn structure was not considered meaningful as this structure serves to link more 
regular secondary structure types. 
 
Figure 4-8: Example CDR-L3 loops with high Beta, Coli and Helix structures. See Table 2-21 
(page 98) for definitions of Beta, Coil and Helix. CDR-L3 loops are from the following PDB 
structures: 4UT7 (Beta), 4ZD3 (Coil) and 5DT1 (Helix).  
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The Beta content of kappa CDR-L1 and CDR-L2 was significantly higher than lambda, but the 
Beta content of kappa CDR-L3 was significantly lower than lambda. In the CDR-L2 and CDR-L3, 
these differences in Beta content were compensated for by differences in Coil content, 
whereas in the CDR-L1, the differences in Beta content were compensated for by differences in 
Helix content (Figure 4-9A). 
The only significant structural difference observed in the heavy chains paired with kappa or 
lambda light chains was a significantly lower probability of Helix content in the CDR-H2 of 
heavy chains paired with lambda light chains (Figure 4-9B). No other significant structural 
differences were found in CDR-H1, CDR-H2 or CDR-H3. 
 
Figure 4-9: Structural differences between kappa and lambda CDR loops. The mean probability 
of Beta, Coil, Helix and Turn secondary structures (+/- 95% CI) occurring in the six CDR loops 
was plotted for kappa and lambda antibody structures extracted from the Protein Data Bank.98  
                                                          
98 The data plotted in Figure 4-9 was generated by Julie Laffy (KCL). The graphs shown in this figure have been 
published in Townsend et al. (2016). 
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4.6 CDR3 N-Nucleotide Addition is Positively Correlated within Individuals 
This chapter has demonstrated that there are significant physicochemical and structural 
differences between kappa and lambda CDR-L3. Figure 4-5 showed that these differences are 
primarily encoded in the germline rather than by random N-nucleotide addition. The number 
of N-nucleotides in light chain CDR-L3 regions is too low to investigate the physicochemical 
properties of the amino acids they encode. However, we could investigate whether there was 
any difference in the number of N-nucleotides added at the kappa and lambda CDR-L3. 
We found that the amount of N-nucleotide addition was on average slightly higher in lambda 
CDR-L3 compared to kappa, however the Wilcoxon matched-pairs signed rank test showed 
that the difference was not significant (p > 0.999). 
However, when the mean N-nucleotide addition at the kappa and lambda CDR-L3 for each 
donor was plotted on an X-Y graph, there was a very clear and highly significant positive 
correlation (Figure 4-10A). Furthermore, when the mean N-nucleotide addition at the kappa 
and lambda CDR-L3 regions was plotted against the mean N-nucleotide addition at the CDR-H3 
within the same donors, there was also a significant positive correlation (Figure 4-10B&C 
respectively). Spearman’s rank correlation coefficient was used to investigate the correlation. 
 
Figure 4-10: Positive correlation of mean number of N-nucleotides within individuals. Mean 
number of N-nucleotides in the kappa, lambda and heavy chain CDR3 regions of each donor 
are plotted. Number of donors indicated by “N”. Spearman’s rank correlation coefficient 
indicated by “r”. Two-tailed p values indicated by “p”.99 
There was a very large range of mean N-nucleotide addition at each CDR3. The difference 
between the donors with the lowest and highest mean N-nucleotide addition at the kappa, 
lambda and heavy CDR3 regions was 2.5 nt, 4.3 nt and 3.0 nt respectively. There was no 
correlation between the amount of N-nucleotide addition and the age of the donor.  
                                                          
99 The graphs shown in Figure 4-10 have been published in Townsend et al. (2016). 




4.7.1 Light Chain Variable Regions show little Evidence of Selection 
As with the heavy chain analysis, we hypothesised that light chain variable region properties 
which decreased in frequency in the B cell Development dataset as the B cells matured may do 
so because they are selected out at tolerance checkpoints due to autoreactivity. We 
hypothesised the converse for properties which increased in frequency. 
In Chapter 3, it was found that the heavy chain properties of the transitional B cell repertoire 
do not always fit the pattern that would be expected if B cells matured linearly from pre-B >> 
immature >> transitional >> naïve (discussed in section 3.7.1, page 178). In this chapter, we 
found that this trend was also present in the light chain B cell Development dataset. IGKV1-33 
and IGLV2-14 occurred significantly less frequently in the transitional repertoire compared to 
the immature and naïve repertoires whereas IGKV1-39 occurred significantly more frequently 
in the transitional repertoire compared to the immature and naïve repertoires (Figure 4-1, 
page 194). The isoelectric point of the kappa transitional CDR-L3 repertoire was significantly 
higher than the immature and naïve repertoires (Figure 4-2D, page 196). 
Unlike the heavy chain variable region properties investigated in Chapter 3 (section 3.2, page 
138), there was very little evidence of positive or negative selection of light chain variable 
region properties as B cells matured from immature to naïve. 
In the kappa repertoire, the only IGKV family which was significantly less frequent in the naïve 
repertoire compared to the immature repertoire was IGKV4. As IGKV4 only contains one gene 
(IGKV4-1), this was due to the decrease in frequency of IGKV4-1 in both the transitional and 
naïve repertoires compared to immature (Figure 4-1A, page 194). This suggests that IGKV4-1 
may be selected against by tolerance mechanisms. IGKV4-1 is known to be over-represented in 
the repertoire of people with SLE (Dörner et al., 1998) and is associated with coeliac disease 
(Steinsbø et al., 2014). Based on the frequency of IGKV4-1 in DNA vs. cDNA it has been 
previously speculated that the gene may be selected against at tolerance (Hehle et al., 2015), 
but only now have the frequencies in the bone marrow and peripheral blood B cells been 
compared, allowing us to conclude this with more certainty. Alongside IGKV4-1, IGKV3-20 also 
decreased in frequency as B cells matured, whereas IGKV3-11 increased in frequency. It was 
surprising that long kappa CDR-L3 regions did not decrease in frequency as B cells matured 
(Figure 4-2A, page 196) as it has been shown that kappa CDR-L3 regions longer than 11 amino 
acids are associated with rheumatoid arthritis (Samuels et al., 2005), however the mean kappa 
CDR-L3 length in the B cell Development dataset in all three cell types was approximately nine 
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amino acids with a standard deviation of approximately one, so a kappa CDR-L3 region of 11 
amino acids or longer would be very unusual. 
There was slightly more evidence of selection in the lambda repertoire than the kappa. The 
IGLV1 family significantly decreased in frequency as the B cells matured whereas the IGLV2 
family increased. This appeared to be in part driven by an increase in frequency of the 
IGLV2-23 gene as B cells matured. Differences were also seen in the IGLJ genes with IGLJ1 
increasing in frequency and IGLJ3 decreasing in frequency as the B cells matured (Figure 4-1B, 
page 194). There was also slightly more evidence of selection of the lambda CDR-L3. Lambda 
CDR-L3 with a high aliphatic index decreased in frequency as the B cells matured (Figure 4-3B, 
page 197), whereas lambda CDR-L3 with high isoelectric points (pI) and high instability index 
increased in frequency as the B cell matured, indicating that they may be promoted at 
tolerance (Figure 4-3D&F respectively). 
It was interesting that there was more evidence of selection in the lambda repertoire 
compared to the kappa repertoire. It is known that the kappa locus tends to be rearranged 
before the lambda locus during receptor editing and lambda light chains have been associated 
with rescuing autoreactive heavy chains. One possibility may be that lambda light chains are 
more often paired with autoreactive heavy chains than kappa and these antibodies are more 
commonly selected out of the repertoire. 
4.7.2 Kappa and Lambda Light Chains have Different CDR Properties 
In agreement with previous findings (DeKosky et al., 2016), we found that lambda CDR-L3 are 
significantly longer and more hydrophobic than kappa CDR-L3 (Figure 4-4A, page 199). Given 
that long, hydrophobic CDR-H3 have been associated with autoreactivity (Wardemann et al., 
2003) and are removed from the repertoire at tolerance checkpoints (Raaphorst et al., 1997, 
Volpe & Kepler, 2009, Larimore et al., 2012), it was surprising to find that lambda light chains 
have longer, more hydrophobic CDR-L3 than kappa as lambda light chains are rearranged after 
kappa during receptor editing (Brauninger et al., 2001) and are thought to be more able to 
rescue autoreactive heavy chains (Wardemann et al., 2004). This might suggest that the 
CDR-H3 and CDR-L3 have different roles in the antigen-binding site and that although long, 
hydrophobic CDR-H3 appear to be associated with autoreactivity, this may not be the case for 
long, hydrophobic CDR-L3. 
Both kappa and lambda light chains had a high frequency of CDR-L3 with an isoelectric point 
(pI) of between 6.08 and 6.10. This suggests that a slightly acidic CDR-L3 pI (net negative 
charge at neutral pH) is advantageous for both kappa and lambda light chains. Conversely, very 
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few light chains of either class had CDR-L3 with a pI of 7.0, indicating that a net neutral charge 
at neutral pH is not desirable. It has been suggested that, in the heavy chain repertoire, 
CDR-H3 with basic pI (net positive charge at neutral pH) may be associated with polyreactivity 
(Zhang & Yeh, 1994). As lambda CDR-L3 have a lower mean pI and a higher frequency of acidic 
amino acids than kappa CDR-L3, it might be that the aforementioned ability of lambda light 
chains to rescue autoreactive heavy chains (Wardemann et al., 2004) is in some part due to an 
acidic CDR-L3 pI counteracting a basic CDR-H3 pI. Light chains with acidic CDR pI and high 
aspartic acid usage have been shown to be good at rescuing anti-DNA antibodies (Li et al., 
2001, Kalinina et al., 2014). This may be due to the fact that DNA is negatively charged. 
However, despite the speculations above that kappa and lambda light chains may complement 
certain heavy chains, the CDR-H3 physicochemical properties of heavy chains paired with 
kappa or lambda light chains showed no significant differences across all three donors, 
although there were some small donor-specific significant differences for some CDR-H3 
properties (Figure 4-7A, page 204). We also found no significant difference in VDJ family usage 
between heavy chains paired with kappa or lambda light chains (Figure 4-7B). This analysis 
does not suggest that heavy chains with particular properties are predisposed to pair with 
either kappa or lambda light chains. This is in agreement with most of the literature on the 
topic which concludes that heavy-light chain pairing is random (DeKosky et al., 2016, Glanville 
et al., 2009, Brezinschek et al., 1998), however small biases in heavy-light chain pairing have 
been reported in some individuals (Jayaram et al., 2012). Despite these findings, it is possible 
that we are looking in the wrong place for heavy-light chain pairing bias. Biases may exist 
outside of the CDR loops, for example at the heavy-light chain interface. 
Alternatively, the reason for the difference between kappa and lambda light chains may be 
independent of their heavy chain partners. Light chains are expressed by B cells in excess of 
heavy chains and therefore free light chains (also known as Bence Jones proteins) are 
expressed by plasma cells and can be found in the blood. There is some evidence that free light 
chains may have a role of their own in the immune response as it has been shown that they 
can bind antigen and activate mast cells in the absence of heavy chains (Thio et al., 2012). If 
free light chains do have a significant role in the immune system, it may be in this role that the 
difference between kappa and lambda is most significant. 
Another hypothesis for the difference between kappa and lambda light chains is not that they 
have evolved to bind different types of antigen in the immune response, but that kappa and 
lambda light chains have evolved to respond to antigen in different ways. Due to the codons 
used in kappa and lambda variable regions, the two classes have quite different affinity 
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maturation patterns. Kappa CDRs are more prone to non-conservative mutations than lambda 
CDRs, however this means that they are more prone to the introduction of stop codons 
(Hershberg & Shlomchik, 2006). This means that the properties of kappa CDRs can change 
more dramatically more quickly than lambda CDRs, which change more gradually. The pattern 
of somatic hypermutation has been shown to be different between lambda light chains and 
heavy chains, suggesting that different chains use SHM in different ways (Boursier et al., 2003). 
The physicochemical differences between kappa and lambda CDR-L3 were encoded in the 
germline (Figure 4-5, page 201) and are therefore the result of more than 450 million years of 
evolution since the divergence of the two classes (Greenberg et al., 1993). Mammals have two 
light chain classes (kappa and lambda), however, two light chain classes are not universal. 
Amphibians and bony fish have three classes (kappa, lambda and sigma), whereas birds have 
only the one (lambda) (Das et al., 2008, Das et al., 2012). Camelids have antibodies which lack 
light chains completely (Hamerscasterman et al., 1993). This indicates that a light chain is not 
essential for a functioning antibody. However, camelid antibodies lacking a light chain have 
alternative mechanisms of diversity, indicating that the additional diversity brought by light 
chains is advantageous (Nguyen et al., 2000). 
In addition to physicochemical differences in the kappa and lambda CDRs, we also found 
differences in the structural composition of the CDR loops between the two classes. We found 
significant differences in the structural composition of kappa and lambda CDR-L3. In particular, 
we found that the likelihood of Beta structures was significantly higher in kappa CDR-L1 and 
CDR-L2, but significantly lower in CDR-L3 in comparison to lambda CDRs. The differences in 
CDR-L1 and CDR-L2 beta content was compensated for in lambda light chains by Helix and Coil 
propensities respectively (Figure 4-9A, page 206). There were significant differences between 
kappa and lambda CDR-L3 for Beta, Coil and Turn content. It has previously been reported that 
approximately 80% of kappa CDR-L3 have the same canonical structure, whereas lambda 
CDR-L3 have much more variety (Chailyan et al., 2011). As with the physicochemical 
properties, we found almost no structural differences in the CDR loops of heavy chains paired 
with kappa or lambda light chains (Figure 4-9B). 
4.7.3 Random N-Nucleotide Addition is Positively Correlated within Individuals 
One of the most striking findings of this chapter was the strong positive correlation in mean 
N-nucleotide addition at the kappa, lambda and heavy chain CDR3 regions within individuals 
(Figure 4-10, page 207). This suggests that there may be differences between individuals in the 
efficiency of the TdT enzyme or in the expression of the three TdT splice variants (hTdTS, 
hTdTL1 and hTdTL2). The three splice variants are expressed at various times during B cell and 
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T cell development and have differing exonuclease and transferase activity (Thai & Kearney, 
2004). 
Long CDR-H3 have been associated with autoreactivity (Wardemann et al., 2003) and it has 
been speculated that autoreactivity may be more likely when the CDR-H3 contains more non-
germline encoded amino acids as they have not been subject to natural selection. Our analysis 
shows that some individuals can have on average three more N-nucleotides per CDR-H3 than 
others. This means that some people may have on average one more non-germline encoded 
amino acid per CDR-H3 than others. It would be interesting to investigate whether people with 
a higher mean N-nucleotide addition are more prone to autoimmune disease than those with 
less N-nucleotide addition or whether people with differing mean N-nucleotide addition 
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Chapter 5: The Antibody Response against Ebola 
5.1 Introduction 
Ebola is a devastating disease with a very high mortality rate; the outbreak in West Africa in 
2014, caused by the Zaire strain of Ebola virus (EBOV), resulted in 28,616 cases and 11,310 
deaths (WHO, 2016). On the 1st August 2018, the World Health Organisation (WHO) declared 
an outbreak of Ebola virus disease in the Democratic Republic of the Congo. At the time of 
writing, 78 cases had been identified, 44 of which were fatal (WHO, 2018b). 
The virology of, and immune response to, Ebola are not fully understood. The early replication 
sites of Ebola are thought to be dendritic cells, monocytes and macrophages and the virus later 
disseminates to hepatocytes, fibroblasts and epithelial cells (Falasca et al., 2015). It is thought 
that Ebola invokes a very strong immune response which damages host tissues, resulting in a 
high mortality rate. However, some people do not suffer this outcome. The differences 
between people who survive and people who do not are not well understood. However it has 
been observed that a strong antibody response is a good indicator of survival (Ksiazek et al., 
1999, Baize et al., 1999). 
The primary target for anti-Ebola antibodies is the glycoprotein (GP) which coats the viral 
membrane and is used for viral entry into host cells. The membrane-bound GP is a trimer 
composed of three GP1-GP2 heterodimers and the structure is heavily glycosylated to shield 
the most conserved parts of the protein from the immune response (Figure 1-13, page 60). 
Some of the promising anti-Ebola drugs currently in development are monoclonal antibody 
cocktails targeting GP, for example ZMapp (see Figure 1-14, page 62, for the binding sites of 
well-known monoclonal antibody cocktails). A significant drawback of the antibody cocktails 
which have been used so far in Ebola outbreaks is that they are only specific to the Zaire strain 
of Ebola virus (EBOV). Although EBOV was responsible for the 2014 outbreak and is thought to 
be the strain with the highest mortality rate, the threat posed by other, lesser-studied, 
Filoviridae species to cause lethal outbreaks is not to be underestimated (Burk et al., 2016). 
However, cross-specific or cross-neutralising antibodies which bind GP from multiple 
Filoviridae species (particularly from more than one viral genus) are rare. It is important to 
keep searching for such antibodies as they may be valuable therapeutically either alone or as 
part of an antibody cocktail. 
By examining the anti-GP B cell repertoire specifically, it has previously been reported that the 
anti-Ebola response may be very polyclonal and anti-GP antibodies show no clear bias in their 
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V(D)J usage or CDR3 properties (Bornholdt et al., 2016b). However, the whole B cell repertoire 
of recent Ebola survivors has not yet been studied. Therefore, in an effort to further our 
understanding of the features of a successful anti-Ebola antibody response, we used high-
throughput sequencing of the B cell repertoires of recent Ebola survivors to investigate how 
they differ from negative, uninfected controls in terms of variable region properties, clonal 
expansions and heavy chain class usage. 
Two high-throughput sequencing (HTS) datasets, known as the Ebola Response datasets 
(section 2.2, page 82) were built from survivors of the 2014 West Africa EBOV outbreak and 
also uninfected negative controls. The first HTS dataset, known as the Caucasian Aid Worker 
Survivor dataset, was built from total RNA isolated from the blood of three Caucasian aid 
workers and three uninfected negative controls. The second HTS dataset, known as the African 
Survivor dataset was built from total RNA isolated from the blood of five African EBOV 
survivors at two time points post-recovery. This dataset was useful for comparison with the 
Caucasian Aid Worker Survivor dataset to determine whether differences seen between the 
aid worker survivors and the negative controls were supported by trends seen in the African 
survivors. 
The second aim of this chapter was to attempt to find new cross-reactive anti-GP antibodies 
using ribosome display. It has been shown previously that cross-reactive antibodies can be 
isolated from the repertoires of people who were infected with a single species of Ebolavirus 
(BDBV) (Flyak et al., 2016). Therefore, we hypothesised that we may be able to isolate new 
cross-reactive anti-GP antibodies using ribosome display libraries built from the B cell 
repertoires of recent EBOV survivors (see section 1.12.2.2, page 69, for the principle of 
ribosome display). The libraries were built using RNA from the same three Ebola survivors that 
were used for the Caucasian Aid Worker Survivor HTS dataset. The ribosome display libraries 
underwent one round of panning selection against EBOV GP and the specificity of the isolated 
scFv was then tested against GP from EBOV and other viruses. 
In summary, the aims of this chapter were as follows: 
1. Compare the B cell repertoire of recent EBOV survivors to negative controls to identify 
potential EBOV-specific features of the B cell repertoire 
2. Find new anti-EBOV GP-specific antibodies using ribosome display and determine if 
they are cross-reactive to GP from multiple Filoviridae species 
3. Investigate the selection pressures of the ribosome display and the properties of the 
GP-specific scFv that are isolated  
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5.2 B cell Repertoire Analysis of Caucasian Aid Worker Ebola Survivors 
The template switch method of high-throughput sequencing was used to create the Caucasian 
Aid Worker Survivor dataset (see section 2.2, page 82, for method). This method of library 
construction added a UID to each cDNA transcript which allowed more reliable identification of 
clonal expansions than the method used to construct the B cell Development dataset (section 
2.1, page 74). 
The Caucasian Aid Worker Survivor dataset was built from mRNA isolated from whole blood 
samples taken from three Caucasian aid worker EBOV survivors and three healthy Caucasian 
age- and gender-matched negative controls who had never been infected with EBOV but did 
receive a yellow fever (YF) vaccine. Blood was taken from the negative controls at a baseline 
before receiving the vaccine (day 0) and again 28 days after receiving a yellow fever vaccine 
(day 28). This resulted in three sample groups: 
1. Ebola survivors      Donor IDs: 215, 216, 217 
2. YF vaccine controls (day 0)   Donor IDs: 193, 199, 207 
3. YF vaccine controls (day 28)  Donor IDs: 193, 199, 207 
The use of blood taken pre- and 28 days post- vaccination with the live, attenuated yellow 
fever vaccine allowed the distinction between B cell repertoire differences caused by viral 
infection in general and differences caused specifically by Ebola virus disease. 28 days is 
approximately the same as the time between Ebola infection and blood-taking in the Ebola 
survivors (although it was not possible to get the exact timings of this). 
V(D)J gene usage and CDR3 physicochemical properties were calculated as described in section 
2.4.2 (page 94). Clonotype clustering was performed as described in section 2.4.3 (page 95). 
Unless otherwise stated, only a single, modal, sequence from each clonal expansion was 
included in the data analysis so as not to skew the dataset with large clonal expansions. 
V(D)J family/gene usage, CDR3 physicochemical properties and the size and class-composition 
of clonal expansions were investigated to determine whether there were any significant 
differences in the B cell repertoire of the Ebola survivors compared to the YF vaccine controls 
at day 0 and day 28.  
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5.2.1 V(D)J Gene Usage 
The mean frequency (+/- 1 SD) of each heavy and light chain V(D)J family and gene was 
calculated for the IgA, IgG, IgM, IgK and IgL repertoires of each donor. The heavy chain dataset 
contained 24,415 entries in total and the light chain dataset contained 25,918 entries in total 
(see Table A-23 and Table A-25, pages 276-277, for the number of sequences per donor). 
Significant differences in V(D)J family usage between sample groups were identified using two-
way ANOVA followed by Tukey’s multiple comparisons post-test. Data were paired by donor 
(age-/gender-matched) and heavy chain (IgA, IgG, IgM) or light chain (IgK, IgL) class. 
When investigating heavy chain IGHV gene and IGHD gene usage, some donor-class 
combinations had too few sequences for reliable frequency analysis and so were excluded 
from the heavy chain gene analysis (see section 2.5.1, page 96, for the “5X rule”). The samples 
excluded from IGHV gene and IGHJ gene analysis are shown in Table 5-1. Paired analysis for 
IGHV gene and IGHJ gene usage was not possible and so ANOVA followed by Tukey’s multiple 
comparisons post-test was used on unpaired data. There were enough light chain samples to 
perform paired two-way ANOVA followed by Tukey’s multiple comparisons post-test for light 
chain family and gene analysis (Table 5-1). 
Table 5-1: Number of sequences in the Aid Worker Ebola Survivor V(D)J analysis. Samples 
excluded from IGHV gene analysis due to the “5X rule” are shown in red. Samples excluded 
from IGHD analysis are underlined in red. No sequences were excluded from the light chain 
analysis. 
  Heavy Chain Classes Light Chain Classes 
Group Donor IgA IgG IgM IgK IgL 
Ebola 
Survivors 
215 2910 3821 1745 3992 1420 
216 2009 2257 1427 3606 1195 




193 369 388 435 2133 347 
199 597 322 324 1964 339 




193 291 778 1106 1543 756 
199 310 273 118 1223 325 
207 308 126 599 443 472 
 
Figure 5-1 shows the mean frequency (+/- 1 SD) of each heavy chain IGHV, IGHD and IGHJ 
family in the three sample groups. IGHV1 and IGHV3 families were significantly less common in 
the Ebola survivors than the YF vaccine day 0 and day 28 controls, whereas IGHV4 was 
significantly more common. IGHD3 family usage was significantly more common in the Ebola 
survivors than the YF vaccine control day 0 samples, but not the day 28 samples. There was no 
significant difference in the frequency of any of the IGHJ genes. Nine IGHV genes showed a 
significant difference in frequency between donor cohorts. IGHV1-2, IGHV1-69, IGHV1-8, 
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IGHV3-23, IGHV3-30, IGHV3-9 and IGHV4-38-2 were all significantly less frequent in the Ebola 
survivors than the YF vaccine controls. IGHV1-3 and IGHV4-39 were significantly more common 
in the Ebola survivors than the YF vaccine controls. IGHV4-39 in particular was a lot more 
frequently used in the Ebola survivors with a mean frequency in the B cell repertoire of 0.136 
compared to 0.027 and 0.039 in the YF vaccine day 0 and day 28 controls respectively. 
 
Figure 5-1: Heavy chain VDJ usage in the Caucasian Aid Worker Survivor dataset. The mean 
frequency of usage (+/- 1 SD) of all heavy chain VDJ families and also IGHV genes with a 
significant difference in frequency between donor groups are shown. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
Figure 5-2 shows the mean frequency (+/- 1 SD) of VJ family and V gene usage in the kappa and 
lambda light chain repertoires. Figure 5-2A shows that none of the IGKV families differed 
significantly in frequency between the Ebola survivors and the YF vaccine controls. However, 
the IGKV genes IGKV1-39 and IGKV4-1 were significantly more frequent in the Ebola survivors 
than the YF vaccine controls. IGKJ1 was significantly more frequent in the Ebola survivors than 
the YF vaccine controls at day 28, but there was no significant difference in frequency with 
day 0. Figure 5-2B shows that there were no significant differences in IGLV family usage 
between the sample groups. However, the IGLV gene IGLV1-40 was significantly less frequent 
in the Ebola survivors than the YF vaccine controls and IGLV2-23 was significantly more 
frequent. IGLJ1 was significantly more frequent in the Ebola survivors than the YF vaccine 
controls and IGLJ3 was significantly less frequent. 




Figure 5-2: Light chain VJ usage in the Caucasian Aid Worker Survivor dataset. The mean 
frequency of usage (+/- 1 SD) of all (A) kappa and (B) lambda light chain V and J families and 
also V genes with a significant difference in frequency between donor groups are shown. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
5.2.2 CDR3 Physicochemical Properties 
Before analysing the physicochemical properties of the heavy and light chain CDR3 regions, 
sequences which may skew the analysis were removed from the full dataset (section 2.5.2, 
page 96). The resulting heavy chain dataset contained 19,168 entries (Table A-24, page 276) 
and the resulting kappa and lambda datasets contained 15,582 and 4,505 entries respectively 
(Table A-26, page 277). 
For each CDR3 amino acid sequence, the following physicochemical properties were calculated 
(section 2.4.2, page 94): 
1. CDR3 length (amino acids) 
2. Aliphatic index 
3. Boman index 
4. Isoelectric point 
5. Hydrophobicity (GRAVY index) 
6. Instability index 
Data for each sample group (Ebola survivors, YF vaccine controls day 0 and YF vaccine controls 
day 28) were pooled and histograms were drawn for each heavy and light chain class (IgA, IgG, 
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IgM, IgK and IgL). Significant differences between the sample groups were identified using the 
Kruskal-Wallis test followed by Dunn’s multiple comparisons post-test. 
We found no significant differences in the heavy and light chain CDR3 physicochemical 
properties between the Ebola survivors and both YF vaccine control day 0 and day 28 time 
points. However, in both the kappa and lambda light chain repertoires, the mean CDR-L3 
isoelectric point was significantly lower in the Ebola survivors than in the day 28 YF vaccine 
controls (7.11 vs. 7.21 in the kappa repertoire and 5.61 vs. 5.77 in the lambda repertoire). 
5.2.3 Clonal Expansions 
The heavy chain clone size distribution in each sample is shown in Figure 5-3 and the 
frequency of each class is also indicated. Only clonal expansions up to size 10 were plotted as 
clones larger than 10 were rare, however the largest clone size observed in each sample is 
indicated at the end of each x axis. Only heavy chain clonal expansions were investigated as 
public light chains make the identification of clonal expansions using light chains less reliable. 
The most frequent clone size observed in all donors was a clone size of one. A clone size of one 
meant that no other related heavy chain was identified in the dataset. Approximately 80% of 
clones were of clone size one in all but one of the samples (YF vaccine control 199 day 0) which 
had a clone size one frequency of 62.6%. The remaining sequences were part of expanded 
clones (clone size two or bigger). 
In the Ebola survivors, the majority of clone size one heavy chains were IgG (48.5%), IgA was 
the second most common (28.4%) and IgM was least common (23.2%). In Ebola survivor 
expanded clones the frequency of IgM classes occurred at a frequency of 3.5%, whereas IgA 
and IgG occurred at a frequency of 46.4% and 50.1% respectively. 
Much greater variation was seen in the frequency of heavy chain classes of the YF vaccine 
controls. In donor 207 day 0 and day 28 and donor 193 day 28 the majority of clone size one 
sequences were IgM. However this was not seen in the other three YF vaccine control samples. 
The variation seen in the frequency and class composition of clonal expansions in the YF 
vaccine controls may be due to the fact that fewer sequences were isolated from these 
samples. 




Figure 5-3: Clonal expansion frequency in Caucasian Aid Worker Survivor dataset. Only clone 
sizes up to 10 have been plotted as clones larger than this are rare. The largest clone size per 
donor has been indicated by an arrow on the x axis of each graph. The isotype frequency is 
also indicated. The number of clones of each size is indicated above the relevant bars. 
5.2.4 Cross-Class Clones 
It is often assumed that a clonal expansion consists of antibodies all of the same class (an IgA 
response, IgG response, IgM response etc.). Figure 5-3 was created using the isotype of the 
modal sequence of each clonal expansion and therefore each clonal expansion was displayed 
as a single class. 
However, when examining all of the constituent sequences of each clonal expansion, we found 
that not every member of a clone did have the same heavy chain class. Some clonal expansions 
contained multiple heavy chain classes; we named such clonal expansions “cross-class clones”. 
We refer to clonal expansions containing a single heavy chain class as “single-class clones”. 
Table 5-2 shows the number of expanded clones identified in the Ebola Survivors and YF 
vaccine controls. 
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Table 5-2: Number of expanded clones in the Caucasian Aid Worker Survivor dataset. 
Expanded clones are those with a clone size of two or greater. 
Sample 
 Single-Class Clones Cross-Class 
Clones 
Total Number of 
Clonal Expansions Donor IgA IgG IgM 
Ebola Survivors 
215 575 579 63 297 1514 
216 377 277 36 77 767 
217 63 179 42 51 335 
YF Vaccine Controls 
Day 0 
193 128 127 12 7 274 
199 280 147 38 15 480 
207 29 73 9 1 112 
YF Vaccine Controls 
Day 28 
193 55 359 58 18 490 
199 78 120 1 10 209 
207 81 32 40 1 154 
 
The frequency of cross-class clones as a proportion of all expanded clones (clone size of two or 
greater) was calculated for each donor/time point. The frequency of cross-class clones was 
significantly higher (Fisher’s exact test) in every Ebola survivor repertoire compared to every 
age- and gender-matched YF vaccine control at both time points (Figure 5-4A). The frequency 
of cross-class clones was between 10-20% in the Ebola survivors and between 1-3% and 1-5% 
in the day 0 and day 28 YF vaccine controls respectively. 
Figure 5-4B shows the frequency of each heavy chain class combination in cross-class clones. 
The most frequent cross-class clone composition was IgA and IgG. The least frequent was IgA, 
IgG and IgM. The combination of IgA and IgM was slightly more common than IgM and IgG. 
Due to the small number of cross-class clones in the YF vaccine control samples, it was not 
possible to meaningfully compare the class composition of cross-class clones between the 
Ebola survivors and the YF vaccine controls. 




Figure 5-4: Frequency of cross-class clones in the Caucasian Aid Worker dataset. (A) The 
proportion of expanded clones which are single-class and cross-class. (B) The class 
combinations of each cross-class clone. The number of clones is displayed above each bar. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Multiple heavy chain classes within clonal expansions indicate that cross-class clones may have 
undergone multiple class-switch recombination events and therefore may have undergone 
significant clonal expansion and somatic hypermutation. We hypothesised that cross-class 
clones may therefore be on average larger than single-class clones and their variable regions 
may have more somatic hypermutation than those of single-class clones. 
To investigate the size of cross-class clonal expansions compared to single-class clonal 
expansions, the mean sizes (+/- 1 SD) of all expanded clones were compared between the 
cross-class clones and single-class clones (separated by class) using the Kruskal Wallis test 
followed by Dunn’s multiple comparisons post-test. Figure 5-5 shows that in the Ebola 
survivors, the mean cross-class clone size was significantly higher than IgM, IgG and IgA single-
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class clones (4.927 compared to 2.487, 2.908 and 4.032 respectively). By contrast, the mean 
size of cross-class clones in the YF vaccine controls at day 0 was only significantly higher than 
the IgM single-class clones and in the YF vaccine control day 28 samples there was no 
significant difference in mean clone size between the cross-class clones and any of the classes 
of single-class clone. 
The mean size of IgM single-class clones was approximately the same across all three sample 
groups. However, the mean size of the IgG and IgA single-class clones was very different 
between the Ebola survivors and the YF vaccine controls. In the Ebola survivors, the mean size 
of IgA single-class clones was significantly higher than IgG single-class clones. However, in both 
the YF vaccine control time points, the mean size of IgG single-class clones was significantly 
higher than IgG single-class clones. 
 
Figure 5-5: Mean size of single-class and cross-class clonal expansions. The size of every clonal 
expansion (clone size of two or greater) is plotted and grouped by whether the clones are 
cross-class or single-class (IgM, IgG and IgA). The mean clone size (+/- 1 SD) in each group is 
plotted over the top and the mean clonal expansion size is written above each group. 
The fact that, in the Ebola survivors, the mean clone size of cross-class clones was significantly 
higher than all three single-class clones, whereas this was not always the case in the YF vaccine 
controls presents the possibility that, as there were more sequences available from the Ebola 
survivors, more large clones could be identified and large clones have a higher probability of 
containing more than one heavy chain class than small clones. Therefore, to confirm that the 
Ebola survivors have a higher frequency of cross-class clones, independent of clone size, we 
measured the frequency of single-class clones and cross-class clones in the two most common 
expanded clone sizes: clone size two and clone size three (make up 52.8% and 19.4% of the 
expanded clones dataset respectively). In clone sizes two and three, the frequency of cross-
class clones was still significantly higher (Fisher’s exact test) in the Ebola survivors than the YF 
vaccine controls in most cases, indicating that it is not just an effect of clone size (Figure 5-6). 




Figure 5-6: Frequency of cross-class clones in clone sizes two and three in the Caucasian Aid 
Worker Survivor dataset. The proportion of expanded clones that are cross-class and single-
class are indicated and the number of clones in each group is displayed above each bar. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
The level of somatic hypermutation (SHM) of the modal sequence of each clonal expansion 
was measured using the IMGT HighV-QUEST V-REGION percentage identity; the lower the 
V-REGION percentage identity, the more SHM had taken place. Significant differences in 
V-REGION percentage identity were measured using the Kruskal Wallis test followed by Dunn’s 
multiple comparisons post-test. Figure 5-7 shows that in the Ebola survivors, cross-class clones 
had the same level of V-REGION identity as IgG single-class clones (94.09% and 93.56% 
respectively) and significantly higher V-REGION identity than IgA single-class clones (92.10%). 
As expected, IgM single-class clones had significantly higher V-REGION identity than all other 
groups (96.28%). At both YF vaccine control time points, the V-REGION identity was highest in 
the IgM single-class clones and lowest in the IgA single-class clones. The V-REGION identity of 
the cross-class clones was not significantly different to the IgG or IgA single-class clones in 
either YF vaccine control time point (Figure 5-7). 
 
Figure 5-7: V-REGION identity of clonal expansions. The V-REGION percentage identity to 
germline of the single, modal, sequence of each single-class (IgM, IgG and IgA) and cross-class 
clonal expansion. The mean V-REGION percentage identity (+/- 1 SD) is plotted over the top. 
The mean V-REGION percentage identity is written above each group. 
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To determine whether the properties of cross-class clone variable regions differed from single-
class clone variable regions, the heavy chain VDJ family frequencies and CDR-H3 properties 
were compared. Due to the small number of expanded clones, there were too few sequences 
to reliably investigate the frequency of IGHV and IGHD genes (see section 2.5.1, page 96, for 
information on the “5X rule”). Only the Ebola survivors were investigated as there were too 
few cross-class clones in the YF vaccine controls to reliably investigate them. 
Figure 5-8 shows the mean frequency (+/- 1 SD) of each heavy chain VDJ family in the single-
class and cross-class clones. The data were paired by donor and two-way ANOVA followed by 
Tukey’s multiple comparisons post-test was used to identify significant differences between 
the types of clonal expansion. There were no significant differences in IGHV, IGHD or IGHJ 
family usage between the cross-class clones and any of the single-class clones. 
 
Figure 5-8: Heavy chain VDJ family usage in cross-class and single-class clones. The mean 
frequency (+/- 1 SD) of each IGHV, IGHD and IGHJ family in the cross-class and single-class 
clones of the three Ebola survivors. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
The CDR-H3 physicochemical properties (as listed on page 219) of the cross-class and single-
class clones in the Ebola survivors were compared using the Kruskal-Wallis test followed by 
Dunn’s multiple comparisons post-test. No significant differences in CDR-H3 physicochemical 
properties were found. 
  
Chapter 5: The Antibody Response against Ebola 
227 
 
5.3 African Ebola Survivors also have high Prevalence of Cross-Class Clones 
It was shown in section 5.2.4 that the Caucasian aid worker Ebola survivors had a significantly 
higher frequency of cross-class clones in their clonally-expanded B cell repertoire than the YF 
vaccine controls (Figure 5-4A). To determine whether this high frequency of cross-class clones 
is donor-specific or if it may be related to Ebola virus infection, we measured the frequency of 
cross-class clones in a second B cell repertoire dataset; the African Survivor dataset. The 
African Survivor dataset was built from total RNA isolated from the whole blood of five African 
survivors of the 2014 EBOV West Africa outbreak at two time points after their recovery (see 
section 2.2, page 82, for full materials and methods). Serology was available for the five donors 
(donor 14, 15, 2, 50 and 82) and showed varying IgM and IgG response to EBOV GP in the 
months following infection (Figure 2-4, page 84). 
We found that the frequency of cross-class clones in the African EBOV survivors was very 
similar to that of the Caucasian aid worker EBOV survivors (Figure 5-9A). Furthermore, the 
frequency of cross-class clones was not significantly different (Fisher’s exact test) at the two 
time points for four out of the five African survivors despite there being a gap of up to eight 
months between them. 
The class composition of the cross-class clones varied a little between time points, but there 
was no clear pattern (Figure 5-9B) and there was no clear relationship with the serology 
patterns shown in Figure 2-4 (page 84). Like in the Caucasian aid worker data, the 
overwhelming majority of cross-class clones in the African survivors were composed of a 
combination of IgA and IgG antibodies. 
  




Figure 5-9: Frequency of cross-class clones in the African Ebola survivors. (A) The proportion of 
expanded clones which are single-class and cross-class. (B) The class combinations of each 
cross-class clone. The number of clones is displayed above each bar. The numbers on the x-axis 
are donor IDs. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
The cross-class clones in the Caucasian aid worker EBOV survivors were shown to have a 
slightly higher mean clone size than the single-class clones (Figure 5-5, page 224). In the 
African survivors, at both time points, the mean size of the cross-class clones was significantly 
higher than the single-class clones (Figure 5-10). 
Like in the Caucasian aid worker survivors (Figure 5-7, page 225), the cross-class clones of the 
African survivors did not have very different V-REGION identities to the single-class clones 
(Figure 5-11). 
In both cases, significance was measured using the Kruskal Wallis test followed by Dunn’s 
multiple comparisons post-test. 




Figure 5-10: Cross-class and single-class clone sizes in African Ebola survivors. Each point 
represents a clonal expansion. The mean clone size (+/- 1 SD) is plotted over the top. 
 
Figure 5-11: Cross- and single-class clone V-REGION identity in African Ebola survivors. Each 
point represents the single, modal, sequence in a clonal expansion. The mean V-REGION 
identity (+/- 1 SD) is plotted over the top. 
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5.4 Anti-EBOV GP scFv were Isolated using Ribosome Display 
Ribosome display libraries were constructed using total RNA from the same three EBOV 
survivors used for the Caucasian Aid Worker Survivor HTS dataset (section 5.2). The principle 
of ribosome display is described in section 1.12.2.2 (page 69) and the complete materials and 
methods are set out in sections 2.14 and 2.15 (page 118 and 125 respectively). Briefly, a kappa 
and lambda PCR3 input library was constructed for each donor (six libraries in total). Each 
library was panned against EBOV GP (expressed in-house using the method described in 
section 2.17, page 132). The mRNA of binders was reverse-transcribed and the cDNA was PCR 
amplified (PCR4), creating PCR4 output libraries. The PCR4 output libraries were inserted into 
pESL expression vectors upstream of a NanoLuc luciferase gene (Figure A-2, page 271). The 
plasmids were transformed into E. coli and grown on selective agar. scFv binding to GP was 
tested by growing individual E. coli colonies in selective LB broth and using the scFv-containing 
clarified supernatant in a solid-phase ELISA. scFv binding was detected using a luciferase assay 
(see section 2.16, page 131, for full materials and methods). 
Quality control experiments were required to confirm that the ribosome display method was a 
reliable way of isolating EBOV GP-specific scFv from the donor repertoires. The quality control 
experiments were: 
1. Confirming that the diversity of the PCR3 input library was high 
2. Confirming that scFv created using this protocol can bind antigen specifically 
The results of the quality control experiments are described below in sections 5.4.1 and 5.4.2. 
The results of the panning selection are then described in sections 5.4.3 and 5.4.4. 
5.4.1 Diversity of the Ribosome Display PCR3 Input Libraries 
Unlike the high-throughput sequencing libraries (sections 5.2 and 5.3), the ribosome display 
libraries were built using many rounds of PCR and multiple V gene-specific primers. This 
introduced the risk of considerable over-/under-representation of certain sequences due to 
primer bias. Large biases may have led to libraries with a low diversity, which would risk 
potential binders being missing from the library. 
It was therefore important to check the diversity of the PCR3 input libraries to confirm that 
they were representative of the donor repertoires. To do this, the PCR3 input libraries of donor 
215 and 217 (there was not enough sample to sequence the donor 216 libraries) were 
sequenced using high-throughput sequencing (see section 2.3, page 92, for method). The 
clonal diversity, V(D)J frequency and CDR3 properties of the PCR3 input libraries were 
compared to the donor 215 and 217 HTS libraries (section 5.2). The HTS libraries were built 
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using the template-switch method with a universal primer site and had PCR duplicates 
removed from the library. The HTS libraries should therefore be highly representative of the 
donors’ repertoires. 
To compare the clonal diversity of the PCR3 input libraries and the HTS libraries, a diversity 
curve was drawn for the heavy and light chain sequences of each library (section 2.5.4, page 
97). The diversity curves (Figure 5-12) show that the diversity of the PCR3 input libraries was 
similar to that of the HTS libraries, although the diversity of the PCR3 input libraries was 
slightly lower. However, this indicates that the PCR3 input libraries had good diversity and 
were representative of the donors’ repertoires. 
 
Figure 5-12: Diversity of HTS library and ribosome display PCR3 input library of donors 215 and 
217. General diversity index (qD) with 95% CI versus the clonal frequency (q). As q tends 
towards zero, rarer clones are weighted more heavily, as q tends towards infinity common 
clones are weighted more heavily. Lower qD values indicate lower diversity. 
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Next, the range of V(D)J families and CDR3 length distribution in the PCR3 input libraries was 
compared to the HTS datasets to confirm that they were representative of the donors’ 
repertoires. 
The mean heavy and light chain V(D)J family usage (+/- 1 SD) in donor 215 and 217 PCR3 input 
libraries and HTS libraries was plotted. Due to the small number of donors, statistical analyses 
were not meaningful in comparing V(D)J frequencies. Histograms were also plotted of the 
heavy and light chain CDR3 lengths in the donor 215 and 217 PCR3 input libraries and HTS 
libraries. CDR3 lengths of the PCR3 input library and HTS library were compared for each donor 
using the Kruskal-Wallis test followed by Dunn’s multiple comparisons post-test. 
The mean frequency of each heavy chain VDJ family was quite similar between the PCR3 input 
and HTS libraries, except IGHV3 was less frequent in the PCR3 input library than the HTS 
library. There was no significant difference in the distribution of CDR-H3 lengths between the 
PCR3 input libraries and the HTS libraries (Figure 5-13A). 
The IGKV and IGKJ family usage was similar between the PCR3 input and HTS libraries. 
However, there were some differences in the IGLV and IGLJ libraries; IGLV2 and IGLJ2 were less 
common in the PCR3 input library and IGLV3 and IGLJ1 were more common. There was no 
significant difference in the kappa or lambda CDR-L3 length distribution between the PCR3 
input libraries and the HTS libraries (Figure 5-13B). 
Overall, this suggests that, despite the use of V gene-specific forward primers and multiple 
rounds of PCR, the diversity and representativeness of the PCR3 input library is quite similar to 
that of the HTS library. This suggests that the PCR3 input library has the diversity required for 
effective use in a panning selection. 




Figure 5-13: Diversity of PCR3 input library compared to HTS dataset. The mean frequency 
(+/- 1 SD) of each V(D)J family and a histogram of the CDR3 length distribution for the (A) 
heavy chain repertoire and (B) light chain repertoires in the ribosome display PCR3 input 
library and the HTS dataset.  
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5.4.2 Antigen-Specificity of scFv 
scFv are composed of a heavy and a light chain variable region linked by a linker peptide 
(instead of the constant region) and are expressed by E. coli instead of mammalian cells. The 
scFv were expressed with a NanoLuc luciferase enzyme at the C-terminus (Figure 2-9, page 
131). As the scFv are structurally different to antibodies and are expressed from E. coli, there 
was a risk that the scFv may not show specificity in the same way that the same variable 
regions would in antibody form. Therefore, to confirm that antibody binding specificity is 
maintained in scFv form, we expressed KZ52 (Maruyama et al., 1999) as an scFv and tested its 
specificity. 
KZ52 is a well-known human antibody which binds EBOV GP at a conformational epitope which 
spans the GP1 and GP2 subunits (Lee et al., 2008) (Figure 1-14, page 62). The specificity of the 
KZ52 scFv was tested in a solid-phase ELISA against three viral glycoproteins: 100 
1. EBOV GP 
2. Marburg virus Ravn strain (RAVV) GP 
3. HIV gp120 dimers 
As the KZ52 antibody is highly specific to EBOV GP, KZ52 scFv should only show binding to 
EBOV GP. As predicted, KZ52 scFv showed specific binding to EBOV GP and did not show 
binding to either RAVV GP or HIV gp120 (Figure 5-14). To confirm that only EBOV GP-specific 
scFv will bind EBOV GP, a negative control scFv (discovered during an early practice selection) 
was tested in solid-phase ELISA against the same glycoproteins. The negative control scFv 
showed no binding against any of the glycoproteins, confirming that only specific scFv will bind 
EBOV GP (Figure 5-14). 
 
Figure 5-14: Positive and negative controls confirm scFv specificity. KZ52 binds specifically to 
in-house and commercial EBOV. The negative control scFv does not bind any of the 
glycoproteins. 50 µl neat E. coli supernatant was applied to every well. Supernatant was tested 
in duplicate and binding was detected by measuring luminescence (mean +/- 1 SD shown).  
                                                          
100 EBOV GP, RAVV GP and HIV gp120 were all made in-house, however the scFv were also tested against a 
commercial EBOV GP (Zaire Ebolavirus envelope glycoprotein, P-300-100, Icosagen) to confirm that the scFv 
would also bind that 
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5.4.3 EBOV GP-Specific scFv Isolated from Panning Selection 
After a single round of panning selection against in-house EBOV GP, 94 E. coli colonies from the 
kappa and lambda output libraries were picked per donor (188 colonies per donor in total) and 
screened for scFv inserts using colony PCR. Colonies containing scFv inserts were grown in 1 ml 
liquid culture and the scFv-containing clarified supernatants were used in solid-phase ELISA to 
test for binding to EBOV GP. Binding specificity was confirmed by testing 50 μl neat scFv-
containing supernatants in triplicate against GP titrated in two-fold serial dilutions from 
10 µg/ml to 0.156 µg/ml and against wells coated with blocking buffer only (3% (w/v) skimmed 
milk powder in PBS). 
Of the 564 scFv isolated from the kappa and lambda libraries of the three Caucasian aid worker 
EBOV survivors, 22 EBOV GP-binding scFv were isolated. Seven were isolated from donor 215, 
six were isolated from donor 216 and nine were isolated from donor 217. However one was a 
duplicate of 217_A01 and was therefore excluded from the reported results. 
Due to differing levels of scFv expression, the peak luminescence values varied between 
samples. However, because the luminescence from the NanoLuc-conjugated scFv decreased as 
the concentration of EBOV GP on the ELISA well decreased, this indicates that the scFv were 
binding specifically to EBOV GP (Figure 5-15). 
Every scFv in Figure 5-15 was sequenced using Sanger sequencing. The heavy and light chain 
nucleotide sequences were analysed using IMGT V-QUEST to determine V(D)J gene usage, 
CDR3 amino acid sequence and V-REGION identity. The heavy chain class (IgA, IgG, IgM) of the 
original antibody was deduced from the linker sequence (Table 2-36, page 118). The 
sequencing information is shown in Table 5-3 (page 237). Four of the 21 sequences shown in 
Table 5-3 are non-functional either because they are out of frame or incomplete. 
Seven of scFv heavy chain sequences in Table 5-3 appeared in the repertoire of their respective 
donors in the heavy chain Caucasian Aid Worker Survivor HTS dataset (215_E06, 215_F09, 
215_G07, 216_B01, 216_D01, 217_A07, 217_A09). All but one of these sequences (215_G07) 
were part of expanded clones in the HTS dataset. Moreover, all of the sequences were either 
part of a cross-class clone in the HTS dataset (215_E06) or the scFv isolated with ribosome 
display was of a different IgH class to the clone identified in the HTS dataset, indicating that 
the clone is cross-class. 
Only the seven scFv which appeared in the HTS dataset were taken forward for further 
investigation of their binding specificity in sections 5.5 and 5.6.  




Figure 5-15: EBOV GP binding curves of scFv isolated using ribosome display. Mean 
luminescence (+/- 1 SD) of scFv tested in triplicate against EBOV GP in solid-phase ELISA. Neat 
scFv-containing E. coli supernatant was applied to each ELISA well. EBOV GP was titrated using 
six 1 in 2 dilutions in PBS from a starting concentration of 10 µg/ml.  
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Table 5-3: IgH and IgL details of EBOV GP-binding scFv. V(D)J and CDR3 as defined by IMGT 
V-QUEST. IgH class is determined by the scFv linker sequence. % V ID refers to the percentage 
V-REGION identity (i.e. identity to germline). HTS Dataset indicates whether an identical 
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5.4.4 How Panning Selection Altered the Ribosome Display Libraries 
To determine whether selection took place, the diversity of the PCR4 output libraries was 
compared to the diversity of the PCR3 input libraries. Figure 5-16 shows that the PCR4 output 
libraries are much less diverse than the PCR3 input libraries. This suggests that the PCR4 
libraries were built from fewer starting sequences than the PCR3 library and therefore 
suggests that the panning selection reduced the diversity of the library by removing some of 
the sequences which did not bind EBOV GP. 
 
Figure 5-16: Diversity curves of PCR3 input and PCR4 output libraries. General diversity index 
(qD) with 95% CI versus the clonal frequency (q). As q tends towards zero, rarer clones are 
weighted more heavily, as q tends towards infinity common clones are weighted more heavily. 
Lower qD values indicate lower diversity. In every case, the PCR4 output libraries are much less 
diverse than the PCR3 input libraries.  
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Although Figure 5-16 shows that the heavy and light chain diversity decreased in the PCR4 
output library, there was little evidence of directional selection in the heavy and light chain 
V(D)J family usage (Figure 5-17); only the frequency of some IGLV and IGLJ families was slightly 
different after panning selection. Furthermore, there were no significant differences in any of 
the CDR-H3 or CDR-L3 region properties between the PCR3 input and PCR4 output libraries. 
 
Figure 5-17: V(D)J family frequency in PCR3 input and PCR4 output libraries. The mean 
frequency (+/- 1 SD) of each (A) heavy chain and (B) light chain V(D)J family in donor 215 and 
217 PCR3 input and PCR4 output libraries. 
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When looking at the V gene and D gene usage in the selected scFv (Table 5-3, page 237) some 
occur frequently (e.g. IGHV2-26, IGHV4-34, IGHV3-74, IGHD6-19, IGHD3-3, IGHD3-22, IGKV5-2 
and IGLV1-19). Therefore, the frequency of these genes in the PCR3 input and PCR4 output 
libraries was plotted to investigate if they increased in frequency after panning selection, 
implying that they had been selected for. Figure 5-18 shows the mean frequency (+/- 1 SD) of 
each gene used in the selected scFv. There was little evidence of strong positive selection of 
any of the V genes or D genes, and the frequency of several genes decreased after panning 
selection (e.g. IGHV3-11, IGHD3-22, IGHD3-9, IGHD5-12 and IGKV3-20). However, IGHV1-69, 
IGHV4-34 and IGLV3-25 increased in frequency after the panning selection (Figure 5-18). 
 
Figure 5-18: Frequency of scFv genes in PCR3 input and PCR4 output libraries. The mean 
frequency (+/- 1 SD) in the donor 215 and 217 PCR3 input and PCR4 output libraries of each (A) 
heavy chain and (B) light chain gene used by the scFv isolated by panning selection and listed 
in Table 5-3 (page 237).  
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5.5 scFv Cross-React with EBOV GP, RAVV GP and HIV gp120 
Antibodies which bind GP from more than one Filoviridae species could be very useful 
therapeutically, but such antibodies are rare. The seven EBOV GP-binding scFv which occurred 
in the HTS dataset (Table 5-3, page 237) were tested for binding GP isolated from Marburg 
(Ravn) virus (RAVV GP) to determine whether they could cross-react with GP from other 
Filoviridae. As a negative control, the scFv were also tested for binding to HIV gp120 dimers. 
It was hypothesised that if the scFv were specific to EBOV GP only, they would not bind RAVV 
GP or HIV gp120. If the scFv were cross-reactive with GP from multiple Filoviridae, they would 
bind EBOV GP and RAVV GP but not HIV gp120. Binding was assessed using solid-phase ELISA. 
Surprisingly, the scFv bound all three glycoproteins (Figure 5-19). Even more surprisingly, they 
showed strongest binding to HIV gp120. This suggested that the scFv may be binding to 
something all the glycoproteins had in common. All the glycoproteins were glycosylated, and 
all of them were His-tagged. 
 
Figure 5-19: Specificity of scFv against three viral glycoproteins. Mean luminescence (+/- 1 SD) 
of scFv tested in duplicate against EBOV GP (both in-house and commercial), RAVV GP and HIV 
gp120 in solid-phase ELISA. Each glycoprotein was titrated using six 1 in 2 dilutions in PBS from 
a starting concentration of 10 µg/ml. 50 µl neat scFv-containing E. coli supernatant was applied 
to each ELISA well.  
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5.6 Glycoprotein-Binding scFv Bind Less to the Deglycosylated Form 
All three glycoproteins investigated are heavily glycosylated. EBOV GP and RAVV GP have both 
N-linked and O-linked glycans, whereas gp120 has almost exclusively N-linked glycans. All 
three glycoproteins have a His-tag. 
To investigate whether the seven scFv which showed binding to EBOV GP, RAVV GP and HIV 
gp120 (Figure 5-19) may be binding N-linked glycans, the glycoproteins were deglycosylated 
and tested again for scFv binding using solid-phase ELISA. 
The glycoproteins were deglycosylated by incubating with the enzymes Endo H and PNGase F 
overnight at 37oC (see section 2.17.4, page 134 for method). Endo H is a recombinant 
glycosidase which cleaves the chitobiose core of high-mannose glycans but it does not cleave 
complex glycans. PNGase F is an amidase which cleaves the innermost N-acetylglucosamine 
and asparagine residues in both high-mannose and complex glycans. Both enzymes only cleave 
N-linked glycans (see Figure 5-20). 
 
Figure 5-20: Endo H and PNGase F glycan cleavage sites. Endo H only cleaves the chitobiose 
core of high-mannose glycans. PNGase F cleaves just above the asparagine (Asn) residue of 
both high-mannose and complex glycans, therefore removing the whole glycan. It can 
sometimes improve the efficiency of PNGase F to “clear” some of the high-mannose glycans 
using Endo H, providing better access for PNGase F, hence why both enzymes were used. 
The successful cleavage of EBOV GP, RAVV GP and HIV gp120 by Endo H and PNGase F was 
confirmed by SDS-PAGE (Figure 5-21A) and ELISA using biotinylated lectin PHA-L (Figure 
5-21B). PHA-L binds mannose, galactose and N-acetylglucosamine on complex N-linked glycans 
and therefore the loss of PHA-L binding indicates deglycosylation. The integrity of the protein 
was confirmed by checking that KZ52 scFv binds both complete and deglycosylated EBOV GP 
(Figure 5-21C). 




Figure 5-21: Confirmation of glycoprotein deglycosylation. (A) 10% SDS-PAGE stained with 
Coomassie Blue. Arrows indicate the position of the complete (C) and deglycosylated (D) 
glycoproteins. (B) Mean OD405 (+/- 1 SD) of biotinylated PHA-L lectin tested in triplicate against 
complete and deglycosylated glycoproteins in a solid-phase ELISA. Binding was detected using 
alkaline phosphatase-conjugated streptavidin. (C) Mean luminescence (+/- 1 SD) of scFv tested 
in duplicate against complete and deglycosylated EBOV GP, RAVV GP and HIV gp120 in solid-
phase ELISA. Neat scFv-containing E. coli supernatant was applied to each ELISA well. Each 
glycoprotein was titrated using six 1 in 2 dilutions in PBS from a starting concentration of 
10 µg/ml. 
After confirming that EBOV GP, RAVV GP and HIV gp120 had been successfully deglycosylated, 
the seven scFv shown in Figure 5-19 (page 241) were tested for binding to the complete and 
deglycosylated forms of these three glycoproteins (Figure 5-22). 215_F09 and 216_B01 
showed much greater binding to the complete glycoproteins than the deglycosylated 
glycoproteins, suggesting that these two scFv might be specific to the N-linked glycans. The 
expression of the other five scFv was not as good, however 215_E06, 215_G07 and 217_A09 
showed somewhat more binding to the complete GP than to the deglycosylated GP, suggesting 
that they could be binding the N-linked glycans. 216_D01 and 217_A07 did not show a large 
difference in binding between the complete GP and deglycosylated GP, suggesting that they 
probably are not binding the N-linked glycans. However, this result is inconclusive as these two 
scFv had very low expression. 




Figure 5-22: Specificity of scFv to complete and deglycosylated glycoproteins. Mean 
luminescence (+/- 1 SD) of scFv tested in duplicate against complete and deglycosylated EBOV 
GP, RAVV GP and HIV gp120 in solid-phase ELISA. Neat scFv-containing E. coli supernatant was 
applied to each ELISA well. Each glycoprotein was titrated using six 1 in 2 dilutions in PBS from 
a starting concentration of 10 µg/ml. 
Unfortunately, when the scFv were expressed as IgG1101, none bound complete EBOV GP in 
solid-phase ELISA (Figure 5-23). As a positive control, KZ52 was expressed as IgG1 alongside 
the test antibodies using the same expression protocol. KZ52 IgG1 bound EBOV GP, suggesting 
that the IgG1 expression protocol and the ELISA were working correctly. 
Some antibodies were expressed in higher quantities than others (see table in Figure 5-23) and 
217_A07 could not be expressed at all. 
                                                          
101 IgG1 antibodies were expressed using the method described in section 2.8 (page 103). 




Figure 5-23: Specificity of EBOV GP-binding scFv expressed as IgG1. Specificity of IgG1 to 
complete (glycosylated) EBOV GP tested in solid-phase ELISA. Mean OD492 (+/- 1 SD) of each 
antibody tested in duplicate in neat tissue culture supernatant. The concentration of each IgG1 
in neat tissue culture supernatant is shown in the table.  




5.7.1 B cell Repertoires of Recent Ebola Survivors 
The first aim of this chapter was to identify characteristics of the B cell repertoire which might 
be linked to a successful immune response to Ebola virus disease. This was done by using high-
throughput sequencing to compare the properties of the B cell repertoires of three aid 
workers who had recently recovered from Ebola virus disease with three age- and gender-
matched negative controls (Caucasian Aid Worker Survivor dataset). We hoped that the 
information gleaned from this investigation would help us to understand the characteristics of 
a successful anti-Ebola antibody response because, although the immune response against 
Ebola is not fully understood, it is known that a strong antibody response is linked to recovery 
from Ebola virus disease (Ksiazek et al., 1999, Baize et al., 1999). 
We found a few small but significant differences in V(D)J usage and the CDR3 physicochemical 
properties between the Ebola survivors and their matched controls at both day 0 and day 28. 
IGHV1 and IGHV3 were significantly less frequent in the Ebola survivors’ repertoires than those 
of the negative controls and these differences were reflected by the frequency of IGHV1-2, 
IGHV1-69 and IGHV3-23. IGHV4 was significantly more common in the Ebola survivors’ 
repertoires, and this appeared to be driven by the very large difference in IGHV4-39 usage. 
IGHV4-39 was approximately three times more common in the B cell repertoires of the Ebola 
survivors than the negative controls (Figure 5-1, page 218). 
There were fewer differences in the light chain repertoire between the sample groups. IGKJ1 
was significantly more common in the Ebola survivors than the YF vaccine day 28 controls and 
IGLJ1 was significantly more common in the Ebola survivors compared to both YF vaccine 
control time points, whereas IGLJ3 was less common (Figure 5-2, page 219). In the V gene 
repertoires, IGKV1-39, IGKV4-1 and IGLV2-23 were significantly more frequent in the Ebola 
survivors’ repertoires than the negative controls. As discussed in the previous chapter in 
section 4.7.1 (page 208), IGKV4-1 is over-represented in autoimmune diseases such as SLE 
(Dörner et al., 1998) and coeliac disease (Steinsbø et al., 2014). 
It was slightly surprising that there were not larger differences between the Ebola survivors 
and YF vaccine controls (we found no significant differences in heavy and light chain CDR3 
properties between the sample groups). However, it has been found previously that Ebola 
virus disease does not lead to very large clonal expansions and it is thought that the virus may 
elicit a more polyclonal response than other viral infections such as HIV and influenza 
(Bornholdt et al., 2016b). Consistent with this theory, we found no clear difference in the 
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distribution of clonal expansions in the Ebola survivors compared to the YF vaccine controls 
(Figure 5-3, page 221). 
An experimental reason which may partially explain why we found few differences between 
the Ebola survivors and the negative controls was that, for safety reasons, blood was taken 
after the donors had cleared the infection. This meant that the libraries were built from donors 
no longer fighting infection and so the B cell repertoires may have been returning to baseline 
by the time blood was taken. However, the immune response against Ebola is still detectable 
several months after the infection has cleared (McElroy et al., 2015, Bornholdt et al., 2016b, 
Misasi et al., 2016) and in some patients, even three months after primary infection, 3% of 
circulating IgG+ B cells are still GP-specific (Bornholdt et al., 2016b), therefore we believe that 
the differences we observed could have been a result of the recent Ebola infection, although 
differences may have been clearer had we been able to sort the B cells into relevant 
populations before building the libraries (whole blood was stored in TRIzol which meant that 
cell sorting was not possible). 
Although the differences in V(D)J usage may have been a result of Ebola virus disease, we may 
just have been measuring inter-individual variation (Galson et al., 2015). When constructing 
the Caucasian Aid Worker Survivor HTS dataset, it was impossible to obtain blood samples 
from the Ebola survivors from before they contracted the disease. Therefore, the best negative 
controls which could be achieved were age- and gender-matched healthy individuals. In order 
to be more certain of the differences we saw, much larger age- and gender-matched studies 
would need to take place. 
5.7.2 Cross-Class Clones in Ebola Survivors 
Despite the experimental limitations discussed above, we did find a very significant difference 
in the frequency of clonal expansions comprising more than one heavy chain antibody class. 
We called these clones “cross-class clones” (as opposed to “single-class clones”). 
Figure 5-4A (page 223) showed that in the Caucasian Aid Worker Survivor dataset, the 
frequency of cross-class clones as a proportion of all expanded clones was significantly higher 
(approximately 10-20%) in all of the Ebola survivors compared to the YF vaccine controls both 
at day 0 and day 28 (approximately 1-5%). There was no difference in the frequency of cross-
class clones between day 0 and day 28 of the YF vaccine controls, indicating that the YF vaccine 
(our negative control viral challenge) does not induce an increase in the frequency of cross-
class clones in the B cell repertoire. 
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As discussed in the previous section, it must be borne in mind that any differences we see 
between donors could be inter-individual variation rather than a specific response to Ebola 
virus disease. However, almost exactly the same frequency of cross-class clones was also 
observed in a second HTS dataset we built: the African Survivors dataset. Figure 5-9A (page 
228) shows that approximately 8-18% of expanded clones in the five African Ebola survivors 
were cross-class clones. The fact that similarly high frequencies of cross-class clones were 
observed in two groups of Ebola survivors from different backgrounds strengthens the case 
that this could be a feature of Ebola virus disease and not merely inter-individual variation. 
Interestingly, the high frequency of cross-class clones was maintained in the African survivors 
across the two time points at which blood was collected (Figure 5-9A) even though the time 
interval was between three and eight months (Figure 2-4, page 84). It is known that Ebola can 
hide in immune privileged sites and viral RNA can be present in bodily fluids such as sweat, 
urine, breast milk and conjunctival fluid (Chughtai et al., 2016) and has been detected in 
semen up to 15 months after patients leave hospital (Deen et al., 2017). Therefore it is 
conceivable that, if a high frequency of cross-class clones is indicative of Ebola virus disease, 
maintenance of a high frequency of cross-class clones might be indicative of the infection 
having not completely cleared. However, it is unknown whether any of the donors in this study 
did maintain EBOV in immune privileged sites or if they suffered any viral re-activation. To 
investigate further it would be interesting to follow survivors over many years. 
We have only found one instance in the literature of the quantification of the frequency of 
cross-class clones using high-throughput sequencing (Kitaura et al., 2017). In this publication, 
the frequency of clonal expansions comprising more than one heavy chain class were reported 
to be approximately 1% of expanded clones. This approximately agrees with the frequency we 
observed in the YF vaccine controls (1-5%), indicating that this is an accurate estimate of the 
frequency of cross-class clones in healthy individuals. 
In both the Aid worker Ebola survivors and the African Ebola survivors, the mean size of cross-
class clones was higher than single-class clones (Figure 5-5 & Figure 5-10, pages 224 & 229), 
however they do not have greater levels of somatic hypermutation (SHM) than IgG single-class 
clones (Figure 5-7 & Figure 5-11, pages 225 & 229). Sequential class switching to more 
downstream heavy chain classes can be associated with higher levels of SHM due to increased 
exposure to AID (Jackson et al., 2014). 
One potential clue for the role of cross-class clones comes from the study of the IgE response. 
In order to create very high affinity IgE, sequential class switching is required via IgG1 (Xiong et 
al., 2012). Furthermore, IgG1 memory B cells can produce IgE-expressing B cells in the 
Chapter 5: The Antibody Response against Ebola 
249 
 
secondary antibody response (He et al., 2017). We are not aware that this phenomenon has 
yet been reported for other antibody classes, however it is possible that the use of multiple 
antibody classes to produce a strong memory response is not just used in the IgE response, but 
is common to lots of antibody responses. Perhaps our cross-class clones are evidence of this. 
Much more experimentation is required to determine if a high frequency of cross-class clones 
is caused by Ebola virus disease and, if it is, whether a high frequency of cross-class clones is an 
advantageous response. For stronger evidence that cross-class clones increase in frequency as 
a result of Ebola infection, the B cell repertoire or more survivors needs to be sequenced. To 
investigate whether cross-class clones are associated with survival, the B cell repertoires of 
non-survivors could be sequenced to determine whether a high frequency of cross-class clones 
is also seen in this patient cohort. 
Aside from sequencing more donors, a further experiment to investigate the nature of cross-
class clones may be to clone some of the antibodies from cross-class clones and test their 
specificity to determine if they are Ebola-specific. 
5.7.3 Ribosome Display Panning Selection against EBOV GP 
The second aim of this chapter was to use ribosome display to identify new antibodies (scFv) 
which cross-react with glycoprotein (GP) from multiple Filoviridae species. Cross-reactive anti-
Ebola antibodies are rare and their discovery is important because they could be useful in 
future therapeutic monoclonal antibody cocktails. 
Membrane-bound GP coats the Ebola virus and is used for viral entry into host cells (Baseler et 
al., 2017); it is also the most common target for therapeutic antibodies. It has been shown 
previously that cross-reactive anti-GP antibodies can be isolated from human donors who have 
only been infected with a single species of Ebola virus (Flyak et al., 2016). Therefore, we aimed 
to isolate new cross-reactive anti-GP antibodies using ribosome display. The ribosome display 
libraries were built from total RNA isolated from the three Ebola survivors from the Caucasian 
Aid Worker Survivor dataset. 
After a single round of panning selection against EBOV GP, 21 unique EBOV GP-binding scFv 
were isolated (Figure 5-15, page 236). Of these, seven appeared in the HTS dataset (Table 5-3, 
page 237). Supporting the hypothesis discussed in the previous section that cross-class clones 
may be important in the anti-Ebola response, all seven of these scFv were either part of a 
cross-class clone in the HTS dataset or were of a different class to the one that appeared in the 
HTS dataset. 
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The V(D)J gene usage in the selected scFv were relatively limited. Notably, two of the scFv used 
IGHV4-34. IGHV4-34 is heavily associated with autoimmune diseases such as SLE (Tipton et al., 
2015), MS (Baranzini et al., 1999) and RA (Doorenspleet et al., 2014) this may be significant as 
Ebola virus disease has been linked to autoreactive antibodies, specifically antibodies against 
dsDNA and heat shock protein 60 (HSP60) (Fausther-Bovendo et al., 2017). It has also been 
reported that, like autoreactive antibodies, anti-GP antibodies tend to have longer CDR-H3. 
However, the mean CDR-H3 length of the 17 GP binders we isolated was 14.94 amino acids, 
which is slightly lower than the mean for these Ebola survivors in the HTS dataset as a whole 
(15.03 amino acids). Despite this apparent link between IGHV4-34 and EBOV GP specificity, 
IGHV4-34 was not more frequent in the HTS dataset of the Ebola survivors compared to the YF 
vaccine controls (Figure 5-1, page 218). But IGHV4-34 did appear to be slightly positively 
selected in the ribosome display library after the panning selection (Figure 5-18A, page 240). 
IGKV5-2 was used in six of the 21 scFv (Table 5-3), however it is rare in the HTS dataset (Figure 
5-2, page 219). This suggests that IGKV5-2 may be linked to EBOV GP specificity. However, 
IGKV5-2 is more common in the PCR3 input library than the HTS library, indicating that primer 
bias may have led to its over-representation and thus its prevalence in the selected scFv. 
IGKV5-2 was not more common in the PCR4 output library compared to the PCR3 input library 
(Figure 5-18B, page 240), indicating that this gene was not positively selected. 
None of the genes used in the scFv in Table 5-3 were a lot more common in the PCR4 output 
dataset (Figure 5-18) and there was no clear directionality observed in the selection (Figure 
5-17, page 239) although diversity was reduced in the PCR4 output (Figure 5-16, page 238). 
However, one round of panning selection may not have been enough to see large trends in 
selection. Additionally, the anti-GP repertoire has previously been reported to be very diverse 
(Bornholdt et al., 2016b), therefore large biases and may not be present. 
The majority of scFv isolated from the ribosome display were IgA or IgM. It has been reported 
that IgA and IgM may be important in the response against Ebola (Khurana et al., 2016), 
however, the frequency of IgA and IgM antibodies was higher in the PCR3 input ribosome 
display library than the HTS library. This was probably due to primer bias. This may therefore 
be the reason for the high frequency of IgA and IgM scFv rather than an increased IgA and IgM 
response in the survivors. 
It was concerning that four of the 21 scFv isolated because they bind EBOV GP had sequences 
which were non-functional either because they are out of frame or incomplete (Table 5-3). 
216_A01, 216_A07, 217_A06 and 217_A12 should not have shown binding to EBOV GP and 
they should not have shown luminescence because stop codons separated the scFv sequence 
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from the NanoLuc luciferase gene in the pESL plasmid. The quality control checks done to 
confirm that scFv show specific binding and not every scFv will bind EBOV GP (Figure 5-14, 
page 234) gave us confidence that the ribosome display system was robust. However we could 
not find an explanation for why these scFv apparently showed binding and luminescence in the 
titration ELISAs (Figure 5-15, page 236). However, their luminescence was lower than most of 
the other scFv. 
5.7.4 EBOV GP-Binding scFv may Bind N-linked Glycans 
A selection of the EBOV GP-binding scFv were tested against GP from Marburg virus Ravn 
strain (RAVV) to determine if they are cross-reactive. Marburg virus was chosen as there is less 
sequence similarity with EBOV than another Ebola virus (Keck et al., 2016) and cross-reactive 
antibodies which bind Ebola viruses and Marburg viruses are particularly rare. In addition, as a 
negative control, the scFv were tested against gp120 from HIV. It was expected that if the scFv 
were monoreactive, they would bind EBOV GP only, if they were cross-reactive they may bind 
EBOV GP and RAVV GP. It was not expected that they would bind gp120 from HIV. 
Very surprisingly, all of the seven scFv bound EBOV GP, RAVV GP and HIV gp120 in the solid-
phase ELISA (Figure 5-19, page 241). This suggested that the scFv may have been binding 
something that all three glycoproteins have in common. EBOV GP and RAVV GP contain both 
N-linked and O-linked glycans (Lee & Saphire, 2009, Feldmann et al., 1994), however HIV 
gp120 contains almost exclusively N-linked glycans (Stansell et al., 2015). Furthermore, all 
three proteins were His-tagged. Therefore, we suspected that the scFv were binding either the 
N-linked glycans or the His-tags. 
To investigate whether the scFv were binding the N-linked glycans, the glycoproteins were 
deglycosylated using Endo H and PNGase F (Figure 5-21, page 243). Of the seven scFv tested, 
215_F09 and 216_B01 showed substantially less binding to the deglycosylated glycoproteins 
(Figure 5-22, page 244). The other five scFv showed little or no clear difference in binding 
between the complete and deglycosylated glycoproteins. This may indicate that these scFv are 
not glycan-specific and may be binding another epitope shared by all three glycoproteins (e.g. 
the His-tag). However, the luminescence signal from these scFv was low and it may be that the 
level of scFv expression was too low for a clear result. 
Unfortunately, none of these scFv showed binding to complete EBOV GP when expressed by 
mammalian cells as IgG1 (Figure 5-23, page 245). It is known that variable regions which show 
binding as scFv do not always maintain their specificity when expressed as IgG (Steinwand et 
al., 2014). This may be because of differences in structure; the heavy and light chain variable 
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regions of scFv are joined with a flexible linker peptide instead of the constant region of an 
antibody. It may also be because of the difference in expression system; scFv are expressed by 
E. coli and are not subject to post-translational modifications, whereas IgG1 expressed by 
mammalian cells are. Furthermore, the original antibodies of these scFv were IgA and IgM, 
whereas when they were tested in ELISA they were expressed as IgG1. The constant region can 
affect the binding affinity of the variable region (Janda et al., 2016) so they may bind if they 
were expressed as IgA or IgM. The majority (58%) of known anti-glycan antibodies are IgM 
(Sterner et al., 2016). 
Further experiments are needed to determine for certain whether 215_F09 and 216_B01 do 
bind N-linked glycans, whether they bind them with an affinity that is biologically meaningful, 
and whether they could be therapeutically useful. However, even if not useful for neutralising 
filoviruses or HIV, if the antibodies are specific for N-linked glycans, they still may be useful for 
other purposes as the range of anti-carbohydrate antibodies is very limited, particularly anti-
N-linked glycan antibodies. This may be because N-linked glycans are common in mammals 
and so have low immunogenicity. Furthermore, many N-linked glycans have similar structure, 
making antibody specificity a problem; many antibodies recognise groups of N-linked glycans 
rather than individual ones (Sterner et al., 2016). 
Due to time constraints, no further experiments were possible. However, we think the 
following experiments are necessary to clarify the binding specificity of the scFv, whether they 
can bind as antibodies and whether they may be therapeutically useful: 
1. Competition ELISA in the presence of sugars to test if they block scFv binding to the 
glycoproteins 
2. Competition ELISA in the presence of another His-tagged protein to determine 
whether the scFv bind His-tags 
3. Test binding to glycoproteins deglycosylated individually with Endo H or PNGase F to 
test whether the scFv bind complex glycans (only PNGase F cleaves complex glycans) 
4. Use a glycan array to determine the type of glycan the scFv are binding 
5. Purify and quantify the scFv in order to compare binding efficacies 
6. Determine whether the strength of binding is biologically meaningful (e.g. Biacore) 
7. Express the scFv as the original antibody class (IgA or IgM) to determine whether they 
bind the glycoproteins in this format 
8. Perform neutralisation assays using purified scFv or antibody to investigate whether 
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Chapter 6: Final Discussion and Future Work 
This thesis comprises three chapters all linked by the common theme of antibodies, but each 
addressing different issues. 
6.1.1 Tolerance, Autoreactivity and Polyreactivity 
The first aim of this chapter was to identify antibody heavy chain variable region 
characteristics which are associated with autoreactivity and polyreactivity and could 
potentially be used as predictors of these phenotypes. A high-throughput sequencing 
approach was used to identify variable region properties which may be associated with 
autoreactivity/polyreactivity because they decreased in prevalence as B cells matured from 
pre-B to naïve. This hypothesis was based on the finding that autoreactive/polyreactive 
antibodies are selected out of the repertoire at central and peripheral tolerance checkpoints, 
which are thought to act on the immature and transitional B cell repertoires respectively 
(Wardemann et al., 2003). 
However, the hypothesis that B cells mature linearly from pre B >> immature >> transitional >> 
naïve and therefore autoreactive/polyreactive characteristics would become sequentially less 
common in each repertoire was found not necessarily to be the case. We discovered that the 
B cell variable region properties did not always fit the trajectory of gene usage loss/gain 
(Figure 3-1, page 140) or CDR-H3 property increase/decrease (Figure 3-2, page 142) which 
would be expected if the whole B cell population progresses linearly from pre-B to naïve. Our 
findings suggested that transitional cells may mature into several distinct B cell populations, 
each with different mean variable region properties and differing roles in the immune system 
(Martin et al., 2016). 
Our data analysis showed that the frequency of IGHV3, IGHD2 and IGHJ6 family usage (Figure 
3-1) and also long CDR-H3, hydrophobic CDR-H3 and CDR-H3 with a low Boman index (Figure 
3-2A,E&C) decreased as B cells matured, suggesting that heavy chains with these properties 
may be more likely than average to be autoreactive. Furthermore, CDR-H3 with isoelectric 
points (pI) between 5.0-6.0 and 7.0-8.5 were very rarely found in any of the B cell repertoires 
(Figure 3-2D), suggesting that there could be something disadvantageous about these 
properties; potentially autoreactivity. These hypotheses were tested using 
immunocytochemistry against HEp-2 cells and it was found that long, hydrophobic CDR-H3, 
and also aromatic CDR-H3, tended to be associated with cytoplasmic binding (section 3.4, page 
153). Furthermore, the underrepresented CDR-H3 pI were associated with nuclear binding 
(section 3.4.5 & 3.4.6, pages 161 & 162). Anti-nuclear antibodies are heavily associated with 
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systemic lupus erythematosus (SLE) and it has been shown that CDR-H3 pI is linked to DNA 
binding in mice (Liang et al., 2004). It would therefore be interesting to see if these antibodies 
are associated with SLE in humans. 
A further surprise finding in this chapter was that, when we came to investigate antibody 
polyreactivity using solid-phase ELISA, the two polyreactive positive controls we used from the 
literature (Meffre et al., 2004, Wardemann et al., 2003) showed the same binding pattern in 
solid-phase ELISA even in the absence of antigen on the plate (Figure 3-11, page 164). 
Furthermore, this apparent polyreactive phenotype disappeared when using certain protein or 
high-salt blocking buffers (Figure 3-12, page 165). We followed this up with experiments using 
our own antibodies (GF antibodies) and found that antibodies displaying this unusual 
polyreactive phenotype in solid-phase ELISA did not appear to bind these antigens in other 
formats such as soluble ELISA (Figure 3-16, page 168) or immunocytochemistry (Figure 3-17, 
page 169). In the literature, this blocking buffer-dependent phenotype has been described in 
various human sera (Fujii et al., 1989, Jørgensen et al., 2005, Terato et al., 2014, Güven et al., 
2014) and it is associated with inflammatory mediators (Güven et al., 2014). We decided to 
refer to antibodies displaying this phenotype as “promiscuous” to distinguish them from 
antibodies which bind multiple unrelated antigens specifically. 
We believe that antibodies which show a polyreactive phenotype when using the protein-free 
blocking solid-phase ELISA protocol described in Tiller et al. (2008) might in fact be 
promiscuous. These antibodies are selected against at tolerance checkpoints (Wardemann et 
al., 2003) and are associated with autoimmune diseases such as RA (Samuels et al., 2005) and 
SLE (Yurasov et al., 2005, Yurasov et al., 2006). They are also more common in people with 
conditions such as a deficiency in AID (Meyers et al., 2011, Cantaert et al., 2015) or CD40L 
(Hervé et al., 2007). If these antibodies are promiscuous, this would suggest that the 
promiscuous phenotype is very physiologically relevant. However, the nature of their 
interactions with antigen remains to be fully understood. 
From modelling the GF antibodies, promiscuous antibodies seem to have highly structured 
CDR-H3 (Laffy et al., 2016). Experiments with CT0037, CT0053 and CT0054 showed that the 
promiscuous phenotype might be linked to aggregation (Figure 3-21, page 173) and all of the 
promiscuous antibodies we found bound to the cytoplasm of HEp-2 cells, indicating that they 
may be autoreactive. Further investigation is needed to fully characterise promiscuous 
antibodies and determine their role in the immune response. 
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6.1.2 Light Chain Selection and Isotype Properties 
The antibody variable region is composed of a heavy and a light chain. However, the 
contribution of the light chain is sometimes overlooked as the heavy chain (particularly the 
highly diverse CDR-H3) often makes most of the contacts with antigen. However, light chains 
do contribute important contacts (Kunik & Ofran, 2013) and are central to receptor editing 
(Nemazee, 2006). Furthermore, some light chain properties are associated with autoimmune 
disease (Dörner et al., 1998, Steinsbø et al., 2014, Samuels et al., 2005). 
The first aim of this chapter was to investigate how the properties of light chain variable 
regions change as B cells mature to determine whether light chains may be subject to the 
same tolerance selection pressures as heavy chains. We found very little evidence of positive 
or negative selection of light chain variable region properties as B cells matured (section 4.2, 
page 192), suggesting that the selection pressures may be different on light chains than on 
heavy chains. There was slightly more evidence of selection in the lambda repertoire than the 
kappa repertoire. This made sense as lambda light chains tend to be rearrange after kappa 
light chains during receptor editing and lambda light chains are better than kappa light chains 
at rescuing autoreactive heavy chains (Wardemann et al., 2004). 
The fact that there are two classes of light chain (kappa and lambda) is often overlooked in the 
literature. The different roles of the heavy chain classes have been studied extensively, but 
light chains are sometimes considered as one group with no distinction made between the 
classes. However, there is evidence to suggest that kappa and lambda light chains may play 
different roles in the immune system. For example, kappa light chains are more common than 
lambda in the peripheral blood (Mole et al., 1994, Brauninger et al., 2001, Montano & 
Morrison, 2002), however lambda light chains are more frequently found in secreted 
antibodies (Mole et al., 1994). There are also biases observed in certain antigen-selected 
populations, such as anti-HIV Env antibodies (Sajadi et al., 2016). 
The second aim of this chapter was to compare the physicochemical properties of kappa and 
lambda CDR-L3 and we found that kappa and lambda light chains have very different CDR-L3 
physicochemical properties. For example, lambda CDR-L3 are significantly longer and more 
hydrophobic than kappa CDR-L3 (Figure 4-4, page 199). Kappa and lambda CDRs also have 
different structural compositions (Figure 4-9A, page 206). This difference suggests that kappa 
and lambda light chains might have different roles in the immune system and that they might 
have different heavy chain pairing preferences, perhaps to complement the contrasting 
physicochemical properties of the kappa and lambda light chains. 
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Whether heavy-light chain pairing is random is debated in the literature (DeKosky et al., 2016, 
Glanville et al., 2009, Brezinschek et al., 1998, Jayaram et al., 2012), however patterns in 
heavy-light chain pairing have not yet been identified. Therefore we compared the VDJ usage 
and CDR-H3 properties of heavy chains paired with kappa and lambda light chains to 
determine if there were any biases which might suggest that certain heavy chains paired well 
with kappa or lambda light chains. However, we found no difference in the properties of the 
heavy chains (Figure 4-7, page 204) and this was supported by structural data (Figure 4-9B, 
page 206). This supports the hypothesis that heavy-light chain pairing is random. However, 
much more work is needed to confirm whether heavy-light chain pairing truly is random, for 
example other properties or parts of the variable regions may drive heavy-light chain pairing. 
The final finding of this chapter was that there is a strong positive correlation between the 
number of N-nucleotides in kappa, lambda and heavy chain CDR3 regions within individuals 
(Figure 4-10, page 207). Furthermore, the difference in mean N-nucleotide addition between 
some of the donors was as much as 2.5 nt, 4.3 nt and 3.0 nt at the kappa, lambda and heavy 
chain CDR3 regions respectively; enough to encode an additional amino acid. As long CDR-H3 
with lots of N-nucleotide addition is associated with autoreactivity, it would be very interesting 
to examine the mean N-nucleotide addition in various patient groups with different 
autoimmune diseases to determine whether people with a higher mean N-nucleotide addition 
are more prone to autoimmune disease. It would also be interesting to investigate if differing 
amounts of N-nucleotide addition led to differing responses to infection, for example the 
likelihood of developing broadly neutralising antibodies to HIV (Pancera et al., 2010). 
6.1.3 The Antibody Response against Ebola 
The immune response to Ebola virus disease is not completely understood, however serology 
has shown that a strong antibody response is associated with survival (Ksiazek et al., 1999, 
Baize et al., 1999). Therefore the first aim of this chapter was to learn more about the B cell 
response to the most deadly strain of Ebola virus, Zaire (abbreviated to EBOV), by studying the 
properties of the B cell repertoire in recent EBOV survivors and age- and gender-matched 
negative controls who had received a yellow fever (YF) vaccine. 
Only small differences were found in the V(D)J usage between the recent Ebola survivors and 
YF controls (section 5.2.1, page 217) and no significant differences were found in CDR3 
properties (section 5.2.2, page 219). This may have been because the anti-Ebola response is 
quite polyclonal (Bornholdt et al., 2016b). Alternatively, it may have been a consequence of 
only being able to use blood samples taken after the donors had recovered or, because it was 
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not possible to obtain negative control blood samples from the Ebola survivors, inter-individual 
variation was a factor (Galson et al., 2015). 
However, one significant finding of this data analysis was that the frequency of clonal 
expansions comprising multiple heavy chain classes (“cross-class clones”) was significantly 
higher in the Ebola survivors than the YF negative controls (Figure 5-4, page 223) or figures 
stated in the literature (Kitaura et al., 2017). Furthermore, a similarly high frequency of cross-
class clones was observed in the African Ebola survivors (Figure 5-9, page 228). The fact that 
very similar levels of cross-class clones were found in completely separate patient groups 
suggests that this is not simply inter-individual variation and it could be that cross-class clones 
are associated with Ebola virus disease. More samples and further experiments are required to 
confirm this link, and to determine whether a high frequency of cross-class clones is 
advantageous in the immune response against Ebola virus disease. 
The second aim of this chapter was to use ribosome display to identify new anti-Ebola GP scFv 
and also cross-reactive scFv. We identified 21 unique EBOV GP-binding scFv (Figure 5-15, page 
236). There was little evidence of positive selection of the V(D)J genes used in the scFv (Figure 
5-18, page 240), however seven of the scFv did occur in the HTS dataset. Most were part of 
expanded clones and all appeared to be part of cross-class clones (Table 5-3, page 237). 
Surprisingly, not only did these seven scFv bind EBOV GP, they also showed binding to RAVV 
GP and HIV gp120 (Figure 5-19, page 241). Furthermore, two of these scFv lost binding to the 
deglycosylated forms of these glycoproteins (Figure 5-22, page 244) indicating that they may 
be binding the N-linked glycans. However, unfortunately none of these variable regions bound 
complete EBOV GP when expressed as IgG1 (Figure 5-23, page 245). 
If these scFv genuinely are cross-reactive, it would certainly be worth investigating them 
further with a view to any therapeutic potential they may have. This is because a large 
drawback of the anti-Ebola monoclonal antibody cocktails currently in use is that they are only 
specific to EBOV. EBOV is the most lethal Ebola virus, however other, lesser studied species 
also pose a substantial threat (Burk et al., 2016) and it is important to develop treatments 
which could be used in any Ebolavirus, or ideally Filoviridae, outbreak. Furthermore, if the 
antibodies are specific to an N-linked glycan this would also be very useful as antibodies which 
bind N-linked glycans are rare. 
This was the final chapter of work and, due to time constraints, we were unable to conduct the 
experiments required to determine whether the scFv are truly cross-reactive, whether they 
bind N-linked glycans, whether they bind when expressed as IgA or IgM and whether they may 
be therapeutically useful (the list of immediate experiments required is given on page 252).  
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6.1.4 Concluding Remarks 
The work in this thesis has examined the properties of both antigen-naïve and antigen-
experienced B cell repertoires in a number of different contexts: the antigen-naïve repertoires 
of B cell development, the light chain repertoires separated by kappa and lambda class and the 
antigen-experienced repertoires of recent Ebola survivors. In doing so, we have identified 
some antibody characteristics which may be associated with autoreactivity, investigated 
promiscuous antibodies, highlighted the very different properties of kappa and lambda light 
chains, investigated heavy-light chain pairing, identified a high frequency of cross-class clones 
in Ebola survivors and have identified some potentially cross-reactive or N-linked glycan-
specific scFv. 
As a whole, perhaps the most striking inference that can be drawn from this work is that 
antibody variable regions are so diverse and complex that it is currently not possible to state 
any hard and fast rules governing antibody specificity. Only a few general associations 
between variable region properties and certain binding specificities can be identified. 
Hopefully, as computing power and molecular modelling techniques continue to improve, 
spatial and environmental factors can be more easily taken into account when considering 
antibody specificity and we will understand ever more about the subject. Something which will 
help immensely with the future investigation of antibody specificity is the ability to conduct 
paired heavy-light chain sequencing. As high-throughput sequencing techniques become 
capable of longer and more precise sequencing reads and with the development of 
technologies such as single-cell microfluidics, paired sequencing will hopefully become the 
norm in the near future. This type of sequencing will also be extremely helpful in settling 
whether heavy-light chain pairing is truly random and for understanding more about the role 
of light chains in the antibody response. 
A lot of questions have been raised in this thesis regarding, among other things, the nature of 
polyreactivity, the role of kappa and lambda light chains in the antibody repertoire and the 
purpose of cross-class clones in the repertoires of Ebola survivors. We hope that this work 
paves the way for further investigation into these topics, improving our understanding of both 
antigen-naïve and antigen-experienced human B cell repertoires and hopefully enhancing our 










A.1 Primer List 
A.1.1 High-Throughput Sequencing Primers: B cell Development Dataset 
Table A-1: Primers used for B cell Development dataset HTS PCR1. 
Primer name Sequence (5' to 3') Direction  





IGHV2 TCCTGCGCTGGTGAAACCCACACA Forward 
IGHV3 GGTCCCTGAGACTCTCCTGTGCA Forward 
IGHV4 TCGGAGACCCTGTCCCTCACCTGC Forward 
IGHV5 CAGTCTGGAGCAGAGGTGAAA Forward 
IGHV6 CCTGTGCCATCTCCGGGGACAGTG Forward 
IGHM GGGGAATTCTCACAGGAGAC Reverse 






IGKV2 GATATTGTGATGACCCAGWCT Forward 
IGKV3 GACRCAGTCTCCAGCCACCCTG Forward 
IGKV4 GACATCGTGATGACCCAGTCT Forward 
IGKV5 GAAACGACACTCACGCAGTCT Forward 
IGKV6 GAAATTGTGCTGACTCAGTCT Forward 
IGKC CCTTCCACTGTACTTTGGCCTC Reverse 





IGLV2 CAGTCTGCCCTGACTCAGCC Forward 
IGLV3 CCTATGAGCTGACWCAGCCAC Forward 
IGLV4/5 CAGCCTGTGCTGACTCARYC Forward 
IGLV6 CCAGNCTGTGSTGACTCAG Forward 





Table A-2: Primers used for B cell Development dataset HTS PCR2. MID1 is used as an example. 
MID sequences are shown in blue lowercase and the full list of 12 MIDs is shown in Table A-3. 
Primer name Sequence (5' to 3') Direction 
MID1_IGHV1 acgagtgcgtCCTCAGTGAAGGTCTCCTGCAAGG Forward 
MID1_IGHV2 acgagtgcgtTCCTGCGCTGGTGAAACCCACACA Forward 
MID1_IGHV3 acgagtgcgtGGTCCCTGAGACTCTCCTGTGCA Forward 
MID1_IGHV4 acgagtgcgtTCGGAGACCCTGTCCCTCACCTGC Forward 
MID1_IGHV5 acgagtgcgtCAGTCTGGAGCAGAGGTGAAA Forward 
MID1_IGHV6 acgagtgcgtCCTGTGCCATCTCCGGGGACAGTG Forward 
MID1_IGHM acgagtgcgtCAGGAGACGAGGGGGAAAAGG Reverse 
MID1_IGKV1 acgagtgcgtCATCCAGWTGACCCAGTCTCC Forward 
MID1_IGKV2 acgagtgcgtGATATTGTGATGACCCAGWCT Forward 
MID1_IGKV3 acgagtgcgtGACRCAGTCTCCAGCCACCCTG Forward 
MID1_IGKV4 acgagtgcgtGACATCGTGATGACCCAGTCT Forward 
MID1_IGKV5 acgagtgcgtGAAACGACACTCACGCAGTCT Forward 
MID1_IGKV6 acgagtgcgtGAAATTGTGCTGACTCAGTCT Forward 
MID1_IGKC acgagtgcgtCCTTCCACTGTACTTTGGCCTC Reverse 
MID1_IGLV1 acgagtgcgtCAGTCTGTGCTGACKCAGCC Forward 
MID1_IGLV2 acgagtgcgtCAGTCTGCCCTGACTCAGCC Forward 
MID1_IGLV3 acgagtgcgtCCTATGAGCTGACWCAGCCAC Forward 
MID1_IGLV4/5 acgagtgcgtCAGCCTGTGCTGACTCARYC Forward 
MID1_IGLV6 acgagtgcgtCCAGNCTGTGSTGACTCAG Forward 
MID1_IGLC acgagtgcgtGCCACTGTCACRGCTCCCGGG Reverse 
 
Table A-3: MID sequences used on PCR2 primers for B cell Development dataset HTS. PCR2 
primers using MID1 are shown in Table A-2. 

















A.1.2 High-Throughput Sequencing Primers: Ebola Response Dataset 
Table A-4: SmartNNN primer used for reverse transcription in Ebola HTS. N represents any 
nucleotide 
Primer Name Sequence (5' to 3') Direction 
SmartNNN AAGCAGUGGTAUCAACGCAGAGUNNNNUNNNNUNNNNUCTTGGGGG Forward 
 
Table A-5: Primers used in PCR1 for Ebola HTS. 
Primer Name Sequence (5' to 3') Direction 
Smart20 CACTCTATCCGACAAGCAGTGGTATCAACGCAG Forward 
IGHA-1st CTTCACGTGGCATGTCACGGAC Reverse 
IGHG-1st TCCTGAGGACTGTAGGACAGC Reverse 
IGHM-1st TGACGTCCTTGGAAGGCAGCAG Reverse 
IGKC-1st GTAGTCTGCTTTGCTCAGCGTCAG Reverse 
IGLC-1st ACGGTGCTCCCTTCATGCGTG Reverse 
 
Table A-6: PID-labelled primers used in PCR2 for Ebola HTS. PID1 is used as an example and is 
shown in blue lowercase. All PIDs used are listed in Table A-7. 
Primer Name Sequence (5' to 3') Direction 
PID1_Step_1 ggtagtcatgagtcgacactaCACTCTATCCGACAAGCAGT Forward 
PID1_IGHA-2nd ccatcgcgatctatgcacacgTACAGGTCCCCGGAGGCATC Reverse 
PID1_IGHG-2nd ccatcgcgatctatgcacacgGACAGCYGGGAAGGTGTGCAC Reverse 
PID1_IGHM-2nd ccatcgcgatctatgcacacgCGGGTACTGCTGATGTCAGAG Reverse 
PID1_IGKC-2nd ccatcgcgatctatgcacacgTGAGGCTGTAGGTGCTGTCCTTG Reverse 
PID1_IGLC-D-2nd ccatcgcgatctatgcacacgTTCATGCGTGACCCGGCAGC Reverse 
 
Table A-7: PIDs used on PCR2 primers to label Ebola HTS dataset samples. PID1-labelled PCR2 
primers are shown in Table A-6. 
PID Forward (5' to 3') Reverse (5' to 3') 
PID1 ggtagtcatgagtcgacacta ccatcgcgatctatgcacacg 
PID2 ggtagtatctatcgtatacgc ccatctgcagtcgagatacat 
PID4 ggtagacgtacgctcgtcata ccatctacagcgacgtcatcg 
PID9 ggtagtcatgcacgtctcgct ccatcagtatcacagtcgctg 
PID17 ggtagcacgtcactagagcga ccatccagacgtgactgatat 
PID22 ggtaggtgctgagcatcagac ccatctgagacatactgagtg 
PID23 ggtagcactgatcgatatgca ccatcatgtgcactagtgtac 
PID33 ggtagatacagcacagatgtg ccatcgagtcgtatcgctcat 
PID44 ggtagctcgatacgtgtagct ccatctgtcagtagatgactc 





A.1.3 High-Throughput Sequencing Primers: Ribosome Display Libraries 
Table A-8: PID-labelled primers used to amplify ribosome display inputs and outputs. PIDs are 
shown in blue and lowercase and are the same as the ones shown in Table A-7. 

















A.1.4 Ribosome Display Primers 
Table A-9: Primers used for ribosome display PCR1. Degenerate nucleotides102 are in bold and 
underlined. Gene-specific sequences are in black, overhang sequences are in red. 
Name Primer sequence (5’ to 3’) Ta (oC) Direction 
VH1 CAGGTCCAGCTKGTRCAGTCTGG 70 Forward 
VH1257 CAGGTGCAGCTGGTGSARTCTGG 72 Forward 
VH2 CAGRTCACCTTGAAGGAGTCTG 66 Forward 
VH3A GAGGTGCAGCTGKTGGAGWCC 70 Forward 
VH3B GAGGTGCAGCTGKTGGAGWCT 70 Forward 
VH4 CAGGTGCAGCTGCAGGAGTCSG 72 Forward 
VH4DP63 CAGGTGCAGCTACAGCAGTGGG 72 Forward 
VH6 CAGGTACAGCTGCAGCAGTCA 71 Forward 
GCH1link GGAGGAGGGCGCCAGGGGGAAGACCGATGGGCCC Reverse 
MCH1link GGAGGAGGGCGCCAGGGGGAAAAGGGTTGGGGCGGATGCACTCCC Reverse 
ACH1link GGAGGAGGGCGCCAGGGGGAAGACCTTGGGGCTGGTCGGGGATGC  Reverse 
VK1  GACATCCRGDTGACCCAGTCTCC 67 Forward 
VK2346 GATATTGTGMTGACBCAGWCTCC 60 Forward 
VK36 GAAATTGTRWTGACRCAGTCTCC 59 Forward 
VK5 GAAACGACACTCACGCAGTCTC 66 Forward 
KC AGACTCTCCCCTGTTGAAGCTCTTTGTGACGGGCGAGCTCAG  Reverse 
VL1 CAGTCTGTSBTGACGCAGCCGCC 72 Forward 
VL1459 CAGCCTGTGCTGACTCARYC 64 Forward 
VL15910 CAGCCWGKGCTGACTCAGCCMCC 72 Forward 
VL2 CAGTCTGYYCTGAYTCAGCCT 62 Forward 
VL3a TCCTATGWGCTGACWCAGCCAC 67 Forward 
VL3b TCCTATGAGCTGAYRCAGCYACC 63 Forward 
VL3DLP16 TCCTCTGAGCTGASTCAGGASCC 70 Forward 
VL6 AATTTTATGCTGACTCAGCCCC 63 Forward 
VL78 CAGDCTGTGGTGACYCAGGAGCC 70 Forward 
LC AGAAGATTCTGTAGGGGCCACTGTCTTCTCCACGG Reverse 
  
                                                          




Table A-10: Primers used for ribosome display PCR2. Degenerate nucleotides103 are in bold and 
underlined. Gene-specific sequences are in black, overhang sequences are in red. 
Name Primer sequence (5’ to 3’) Ta (oC) Direction 
VH1A AGTCGCCGCCATGGCCCAGGTCCAGCTKGTRCAGTCTGG 70 Forward 
VH1257A AGTCGCCGCCATGGCCCAGGTGCAGCTGGTGSARTCTGG 72 Forward 
VH2A AGTCGCCGCCATGGCCCAGRTCACCTTGAAGGAGTCTG 66 Forward 
VH3AA AGTCGCCGCCATGGCCGAGGTGCAGCTGKTGGAGWC 70 Forward 
VH4A AGTCGCCGCCATGGCCCAGGTGCAGCTGCAGGAGTCSG 72 Forward 
VH4DP63A AGTCGCCGCCATGGCCCAGGTGCAGCTACAGCAGTGGG 72 Forward 
VH6A AGTCGCCGCCATGGCCCAGGTACAGCTGCAGCAGTCA 71 Forward 
GMACH1link GGAGGAGGGCGCCAGGGGGAA   Reverse 
VK1link CCCCCTGGCGCCCTCCTCCGACATCCRGDTGACCCAGTCTCC 67 Forward 
VK2346link CCCCCTGGCGCCCTCCTCCGATATTGTGMTGACBCAGWCTCC 60 Forward 
VK36link CCCCCTGGCGCCCTCCTCCGAAATTGTRWTGACRCAGTCTCC 59 Forward 
VK5link CCCCCTGGCGCCCTCCTCCGAAACGACACTCACGCAGTCTCC 66 Forward 
KCNotI CCCGTTGGCCTTGCTTGCGGCCGCAGACTCTCCCCTGTTGAAG
CTCTTTGTGACGGG 
  Reverse 
VL1link CCCCCTGGCGCCCTCCTCCCAGTCTGTSBTGACGCAGCCGCC 72 Forward 
VL1459link CCCCCTGGCGCCCTCCTCCCAGCCTGTGCTGACTCARYC 64 Forward 
VL15910link CCCCCTGGCGCCCTCCTCCCAGCCWGKGCTGACTCAGCCMCC 72 Forward 
VL2link CCCCCTGGCGCCCTCCTCCCAGTCTGYYCTGAYTCAGCCT 62 Forward 
VL3alink CCCCCTGGCGCCCTCCTCCTCCTATGWGCTGACWCAGCCAC 67 Forward 
VL3blink CCCCCTGGCGCCCTCCTCCTCCTATGAGCTGAYRCAGCYACC 63 Forward 
VL3DLP16link CCCCCTGGCGCCCTCCTCCTCCTCTGAGCTGASTCAGGASCC 70 Forward 
VL6link CCCCCTGGCGCCCTCCTCCAATTTTATGCTGACTCAGCCCC 63 Forward 
VL78link CCCCCTGGCGCCCTCCTCCCAGDCTGTGGTGACYCAGGAGCC 70 Forward 
LCNotI CCCGTTGGCCTTGCTTGCGGCCGCAGAAGATTCTGTAGGGGCC
AC 
  Reverse 
  
                                                          




Table A-11: Primers used for ribosome display PCR3. Gene-specific sequences are in black, 
overhand sequences are in red. 
Name Primer sequence (5’ to 3’) Direction 
RDT7AB GCTAATACGACTCACTATAGGGAGTCGCCGCCATGGCCC Forward 
ASKANG CCCGTTGGCCTTGCTTG Reverse 
 
Table A-12: Primers used for ribosome display reverse transcription. Degenerate nucleotides104 
are in bold and underlined. 
Name Primer sequence (5’ to 3’) Direction 
HuκF TCCAGATTTCAACTGCTCATCAGATGGCGG Reverse 
HuλF GGCTTGGAGCTCCTCAGAGGAGGGYGGGAA Reverse 
 
Table A-13: Primers used for ribosome display PCR4. Gene-specific sequences are in black, 
overhand sequences are in red. 
Name Primer sequence (5’ to 3’) Direction 
RDT7AB_short GCTAATACGACTCACTATAGGGAGTCG Forward 
NotK TATAGCGGCCGCAGATTTCAACTGCTCATCAGATGG Reverse 
NotL ATATGCGGCCGCTTGGAGCTCCTCAGAGGAG Reverse 
 
Table A-14: Primers used for ribosome display colony PCR and sequencing. T7F and T7R are 
used for colony PCR. T7F and pESL-seqR are used for sequencing. 
Name Primer sequence (5’ to 3’) Direction 
T7F TAATACGACTCACTATAGGG Forward 
T7R GCTAGTTATTGCTCAGCGG Reverse 
pESL_seqR CATGAATATCAATTTTCAGGC Reverse 
  
                                                          




A.1.5 Polymerase Incomplete Primer Extension (PIPE) Cloning Primers 
Table A-15: pVITRO1-dV-IgG1 plasmid PIPE linearization primers. 
Primer name Sequence (5' to 3') Direction 
Linear_Hrev GGAGTGCGCGCCTGTGGCGGCCGCCACCAAGAAGAGGATC Reverse 
Linear_IgG1fwd GCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCT Forward 
Linear_Lrev AGAGTCGACTCCGGATCCATAAGCAAGGAGTCCGAGGAGA Reverse 
Linear_Lfwd CTAGGTCAGCCCAAGGCGGCGCCCTCGGTCACTCTGTTCC Forward 
Linear_Krev ACCGCGGCTAGCTGGAACCCAGAGCAGCAGAAACCCAATG Reverse 
Linear_Kfwd CGTACGGTGGCGGCGCCATCTGTCTTCATCTTCCCGCCAT Forward 
 
Table A-16: PIPE cloning primers for variable region amplification. The variable region-
complementary regions are in capital letters and the amino acid sequences they encode are 
indicated in the primer names. The pVITRO1 plasmid-complementary regions are in lowercase. 
Primer name Primer sequence (5' to 3') Chain Direction 
QVQLV_VH_FW cacaggcgcgcactccCAGGTGCAGCTGGTG IgH Forward 
EVQLL_VH_FW cacaggcgcgcactccGAGGTGCAGCTGTTG IgH Forward 
QVTLK_VH_FW cacaggcgcgcactccCAGGTCACCTTGAAG IgH Forward 
QVQLQ_VH_FW cacaggcgcgcactccCAGGTGCAGCTGCAG IgH Forward 
EVQLV_VH_FW cacaggcgcgcactccGAGGTCCAGCTGGTA IgH Forward 
VTVSS_IgG1_RV ggcccttggtgctagcTGAGGAGACGGTGAC IgH Reverse 
DIQLT_VK_FW tccagctagccgcggtGACATCCAGTTGACC IgK Forward 
DIQMT_VK_FW tccagctagccgcggtGACATCCAGATGACC IgK Forward 
ETTLT_VK_FW tccagctagccgcggtGAAACGACACTCACG IgK Forward 
DIVLT_VK_FW tccagctagccgcggtGACATCGTGTTGACG IgK Forward 
EIVLT_VK_FW tccagctagccgcggtGAAATTGTGTTGACG IgK Forward 
DIRMT_VK_FW tccagctagccgcggtGACATCCGGATGACC IgK Forward 
DIRLT_VK_FW tccagctagccgcggtGACATCCGGTTGACC IgK Forward 
ELVMT_VK_FW tccagctagccgcggtGAGCTCGTGATGACC IgK Forward 
RLEIK_IgK_RV gcgccgccaccgtacgTTTAATCTCCAGTCG IgK Reverse 
KVDIK_IgK_RV gcgccgccaccgtacgTTTGATATCCACTTT IgK Reverse 
KLEIK_IgK_RV gcgccgccaccgtacgTTTGATCTCCAGCTT IgK Reverse 
KVEIK_IgK_RV gcgccgccaccgtacgTTTGATTTCCACCTT IgK Reverse 
SSELS_VL_FW atccggagtcgactctTCCTCTGAGCTGAGT IgL Forward 
SYELM_VL_FW atccggagtcgactctTCCTATGAGCTGATG IgL Forward 
SSELT_VL_FW atccggagtcgactctTCTTCTGAGCTGACT IgL Forward 
QSVLT_VL_FW atccggagtcgactctCAGTCTGTGCTGACT IgL Forward 
TKLTV_IgL_RV ccttgggctgacctagGACGGTCAGCTTGGT IgL Reverse 





Table A-17: PIPE cloning primer combinations for each antibody expressed as IgG1. 
Antibody 
Heavy chain amplification Light chain amplification 
Forward primer Reverse primer Forward primer Reverse primer 
215_B12 QVTLK_VH_FW VTVSS_IgG1_RV ETTLT_VK_FW KVEIK_IgK_RV 
215_E06 QVQLQ_VH_FW VTVSS_IgG1_RV ETTLT_VK_FW KLEIK_IgK_RV 
215_F09 QVTLK_VH_FW VTVSS_IgG1_RV ETTLT_VK_FW KLEIK_IgK_RV 
215_F11 QVQLV_VH_FW VTVSS_IgG1_RV SSELS_VL_FW TKLTV_IgL_RV 
215_G01 QVQLQ_VH_FW VTVSS_IgG1_RV SSELS_VL_FW TKLTV_IgL_RV 
215_G07 QVQLQ_VH_FW VTVSS_IgG1_RV SYELM_VL_FW TKVTV_IgL_RV 
215_G10 QVQLV_VH_FW VTVSS_IgG1_RV SSELT_VL_FW TKLTV_IgL_RV 
216_A02 QVQLQ_VH_FW VTVSS_IgG1_RV DIVLT_VK_FW KLEIK_IgK_RV 
216_A05 EVQLV_VH_FW VTVSS_IgG1_RV ETTLT_VK_FW KVEIK_IgK_RV 
216_B01 QVQLQ_VH_FW VTVSS_IgG1_RV EIVLT_VK_FW RLEIK_IgK_RV 
216_D01 QVQLV_VH_FW VTVSS_IgG1_RV SSELS_VL_FW TKLTV_IgL_RV 
217_A01 EVQLV_VH_FW VTVSS_IgG1_RV ETTLT_VK_FW KLEIK_IgK_RV 
217_A07 EVQLV_VH_FW VTVSS_IgG1_RV DIRMT_VK_FW KVEIK_IgK_RV 
217_A09 QVQLQ_VH_FW VTVSS_IgG1_RV ETTLT_VK_FW KLEIK_IgK_RV 
217_A10 QVQLV_VH_FW VTVSS_IgG1_RV DIRLT_VK_FW KVEIK_IgK_RV 
217_B05 EVQLL_VH_FW VTVSS_IgG1_RV QSVLT_VL_FW TKLTV_IgL_RV 
GF01 QVQLV_VH_FW VTVSS_IgG1_RV DIQLT_VK_FW RLEIK_IgK_RV 
GF05 EVQLL_VH_FW VTVSS_IgG1_RV DIQMT_VK_FW KVDIK_IgK_RV 
GF07 QVQLV_VH_FW VTVSS_IgG1_RV DIQMT_VK_FW KLEIK_IgK_RV 
GF09 QVQLV_VH_FW VTVSS_IgG1_RV DIQMT_VK_FW RLEIK_IgK_RV 
GF16 QVQLV_VH_FW VTVSS_IgG1_RV DIQMT_VK_FW KLEIK_IgK_RV 
KZ52 EVQLL_VH_FW VTVSS_IgG1_RV ELVMT_VK_FW KVEIK_IgK_RV 
 
Table A-18: pVITRO1 colony PCR and sequencing primers. 
Primer name Sequence (5' to 3') Direction 
pVITRO1F TTTTGAGCGGAGCTAATTCTCGGG Forward 
pVITRO1R AAAAAACCTCCCACACCTCC Reverse 
pVITRO2F GAGGCTAATTCTCAAGCCTC Forward 





A.2 Vector Maps 
A.2.1 pVITRO1 IgG1 Expression Plasmids 
 
 
Figure A-1: pVITRO1 IgG kappa and lambda expression plasmids. For pVITRO1_kappa, primer 
pair Linear_Kfwd and Linear_Hrev amplify one half of the plasmid and primer pair Linear_Krev 
and Linear_IgG1fwd amplify the other half. For pVITRO1_lambda, primer pair Linear_Lfwd and 
Linear_Hrev amplify one half of the plasmid and primer pair Linear_Lrev and Linear_IgG1fwd 
amplify the other half. Heavy and light chain variable regions are inserted upstream of their 
respective constant regions using PIPE cloning. The plasmid contains a hygromycin resistance 
gene (HygR). Orange arrows indicate ORFs in direct orientation, green arrows indicate ORFs in 




A.2.2 pESL scFv Expression Plasmid 
 
Figure A-2: pESL scFv expression plasmid. scFv are inserted using the NcoI and NotI restriction 
sites upstream of a NanoLuc luciferase gene and His-tag. Gene expression is under the control 
of a T7 promoter. The plasmid contains a kanamycin resistance gene (KanR) Orange arrows 
indicate ORFs in direct orientation, green arrows indicate ORFs in reverse orientation. pESL has 
a pET41 backbone and is a low copy number plasmid. 
A.2.3 pHL-sec GP Ectodomain Expression Plasmid 
 
Figure A-3: pHL-sec glycoprotein (GP) expression vector.Filoviridae glycoprotein (GP) 
ectodomain sequences were inserted using restriction enzymes EcoRI and KpnI. The resulting 
protein is His-tagged. The plasmid contains an ampicillin resistance gene (AmpR). Orange 
arrows indicate ORFs in direct orientation, green arrows indicate ORFs in reverse orientation. 




A.3 Buffer Recipes 
Binding Buffer (GP purification) 
Sodium Phosphate Buffer  50 ml 
2 M NaCl        62.5 ml 
dH2O         to 250 ml 
pH          7.4 
Filter (0.22 μm) 
Coomassie Blue (western blot) 
Methanol       125 ml 
Acetic acid       25 ml 
Coomassie Blue G-250   0.5 g 
dH2O         100 ml 
Coomassie Destain (western blot) 
Methanol       50 ml 
Glacial acetic acid     75 ml 
dH2O         to 1 L 
Note: add 800 ml dH2O to bottle before 
adding the methanol and acetic acid 
Elution Buffer (300 mM) 
(GP purification) 
Binding Buffer (filtered)   17 ml 
2 M Imidazole (filtered)   3 ml 
Final imidazole concentration: 300 mM 
Prepare immediately before use 
Elution Buffer (500 mM) 
(GP purification) 
Binding Buffer (filtered)   15 ml 
2 M Imidazole (filtered)   5 ml 
Final Imidazole concentration: 500 mM 
Prepare immediately before use 
2 M Imidazole (GP purification) 
Imidazole (C3H4N2)     68.077 g 
dH2O         to 500 ml 
pH          7.4 
Filter (0.22 μm) 
6X Loading Buffer (SDS-PAGE) 
For non-reducing gel: 
4X Stacking*      7 ml 
Glycerol        3 ml 
SDS (NaC12H25SO4)     1 g 
Bromophenol blue     3.2 mg 
For reducing gel: 
Add 600 μl β-mercaptoethanol to the 
above or add 1 μl dithiothreitol (DTT) to 
each protein sample as needed. 
*4X Stacking: 
Tris Base (C4H11NO3)   6.05 g 
dH2O        to 40 ml 
pH         6.8 
Store at -20oC 
2 M NaCl (GP purification) 
NaCl         58.44 g 
dH2O         to 500 ml 
Filter (0.22 μm) 
1 M Na2HPO4 (GP purification) 
Na2HPO4        8.9 g 
dH2O         to 250 ml 
Filter (0.22 μm) 
1 M NaH2PO4 (GP purification) 
Na2HPO4        6.9 g 
dH2O         to 250 ml 




Nickel Buffer (GP purification) 
NiSO4.6H2O       6.57 g 
dH2O         250 ml 
Final NiSO4 concentration:  0.1 M 
Filter (0.22 μm) 
SDS-PAGE gel (western blot) 
This recipe makes two 0.75 mm gels 
Separating gel   8%  10% 12% 
dH2O      5.5 5  4.5 ml 
1.5 M Tris (pH 8.8)  2.5 2.5 2.5 ml 
Acrylamide (40%)  2  2.5 3 ml 
TEMED     10  10  10 μl 
SDS (10%)    100 100 100 μl 
APS (10%)    50  50  50 μl 
Layer absolute ethanol on top of gel until 
set for straight edge 
Stacking gel 
dH2O         3.25 ml 
0.5 M Tris (pH 6.8)     1.25 ml 
Acrylamide (40%)     465 μl 
TEMED        5 μl 
SDS (10%)       50 μl 
APS (10%)       25 μl 
10X SDS Running Buffer (western blot) 
Tris Base (C4H11NO3)    30.35 g 
Glycine (C2H5NO2)     288.26 g 
SDS (NaC12H25SO4)     10 g 
dH2O         to 1 L 
pH          8.3 
May need gentle heating to dissolve 
For 1X solution dilute 1/10 with dH2O 
Sodium Phosphate Buffer 
(GP purification) 
1 M Na2HPO4      38.7 ml 
1 M NaH2PO4      11.3 ml 
dH2O         to 500 ml 
Final sodium phosphate 
concentration:      0.1 M 
pH          7.4 
Filter (0.22 μm) 
50X TAE Buffer 
Tris Base (C4H11NO3)    242 g 
EDTA (C10H14N2Na2O8.2H2O)  14.6 g 
Glacial acetic acid (CH3COOH) 57 ml 
dH2O         to 1 L 
pH          8.2-8.3 
For 1X solution dilute 1/50 with dH2O 
10X Transfer Buffer (western blot) 
Tris Base (C4H11NO3)    30.35 g 
Glycine (C2H5NO2)     144.13 g 
dH2O         to 1 L 
pH          8.3 
May need gentle heating to dissolve 
For 1X solution dilute 1/10 with dH2O 
Washing Buffer (GP purification) 
Binding Buffer (filtered)   49 ml 
2 M Imidazole (filtered)   1 ml 
Final imidazole concentration: 40 mM 





A.4 Number of Sequences in B cell Development Dataset 
Table A-19: Number of heavy chain sequences in the full B cell Development Dataset. Only a 
single, modal, sequence of each clone is counted. 
Donor 
ID Gender Age Pre-B Immature Transitional Naïve Total 
122 F 24 1290 285 343 259 2177 
159 F 28 830 1880 502 349 3561 
138 M 41 2629 76 195 497 3397 
118 M 48 2149 478 294 647 3568 
146 F 50 3832 675 464 245 5216 
103 M 52 87 364 65 1606 2122 
141 F 65 722 1485 979 501 3687 
119 F 68 2966 1704 908 367 5945 
160 M 70 89 191 98 3109 3487 
111 F 71 620 74 19 1107 1820 
149 M 72 1120 1135 178 146 2579 
140 F 86 731 436 340 571 2078 
Total 17065 8783 4385 9404 39637 
 
Table A-20: Number of heavy chain sequences in the clean B cell Development Dataset. Only a 
single, modal, sequence of each clone is counted. 
Donor 
ID Gender Age Pre-B Immature Transitional Naïve Total 
122 F 24 934 220 274 202 1630 
159 F 28 632 1339 379 260 2610 
138 M 41 2042 54 154 378 2628 
118 M 48 1310 391 189 423 2313 
146 F 50 2876 506 351 172 3905 
103 M 52 69 280 56 1241 1646 
141 F 65 553 1081 577 359 2570 
119 F 68 1944 1305 678 245 4172 
160 M 70 62 149 81 2351 2643 
111 F 71 498 59 13 810 1380 
149 M 72 888 813 125 105 1931 
140 F 86 577 309 269 433 1588 





Table A-21: Number of light chain sequences in the full B cell Development Dataset. Only a 
single, modal, sequence of each clone is counted. 
Donor 
ID Gender Age 
Immature Transitional Naïve 
Total Kappa Lambda Kappa Lambda Kappa Lambda 
122 F 24 1380 308 349 52 470 87 2646 
159 F 28 1292 349 419 140 532 135 2867 
138 M 41 255 22 130 125 961 0 1493 
107 M 43 0 0 1476 686 163 152 2477 
120 M 44 0 0 841 568 378 212 1999 
118 M 49 464 348 249 88 281 58 1488 
146 F 50 948 516 485 109 131 37 2226 
103 F 52 371 164 15 3 554 307 1414 
128 F 52 567 400 360 234 0 0 1561 
126 M 53 259 83 664 242 1651 897 3796 
141 F 65 2021 1414 475 233 478 73 4694 
105 F 67 288 170 183 83 417 303 1444 
119 F 68 2175 1609 666 27 334 162 4973 
160 M 70 304 207 130 71 757 37 1506 
111 F 71 188 79 151 67 708 644 1837 
149 M 72 848 689 0 0 246 171 1954 
132 M 76 0 0 896 381 515 267 2059 
162 M 78 0 0 1139 1 1 249 1390 
140 F 86 553 368 279 174 764 382 2520 
Total 11913 6726 8907 3284 9341 4173 44344 
Table A-22: Number of light chain sequences in the clean B cell Development Dataset. Only a 
single, modal, sequence of each clone is counted. 
Donor 
ID Gender Age 
Immature Transitional Naïve 
Total Kappa Lambda Kappa Lambda Kappa Lambda 
122 F 24 958 213 194 31 312 47 1755 
159 F 28 819 198 266 82 397 103 1865 
138 M 41 130 18 101 103 678 0 1030 
107 M 43 0 0 1063 438 144 124 1769 
120 M 44 0 0 537 360 304 166 1367 
118 M 49 315 222 176 64 204 37 1018 
146 F 50 620 292 325 52 94 20 1403 
103 F 52 256 101 8 2 424 213 1004 
128 F 52 402 263 204 120 0 0 989 
126 M 53 123 49 332 121 1102 565 2292 
141 F 65 1342 869 358 137 339 42 3087 
105 F 67 186 89 142 59 333 247 1056 
119 F 68 1399 1002 512 15 267 101 3296 
160 M 70 175 101 102 52 622 28 1080 
111 F 71 99 51 116 38 558 414 1276 
149 M 72 552 374 0 0 177 115 1218 
132 M 76 0 0 519 219 404 180 1322 
162 M 78 0 0 770 1 1 189 961 
140 F 86 371 206 192 96 547 247 1659 





A.5 Number of Sequences in Ebola Caucasian Aid Worker Dataset 
Table A-23: Number of heavy chain sequences in full Caucasian Aid Worker Dataset. Only a 
single, modal, sequence of each clone is counted. 
Group 
Donor 
ID Gender Age IgA IgG IgM Total 
Ebola 
Survivors 
215 M 29 2910 3821 1745 8476 
216 M 34 2009 2257 1427 5693 




193 M 27 369 388 435 1192 
199 M 34 597 322 324 1243 




193 M 27 291 778 1106 2175 
199 M 34 310 273 118 701 
207 F 36 308 126 599 1033 
Total 7579 9431 7405 24415 
 
Table A-24: Number of heavy chain sequences in clean Caucasian Aid Worker Dataset. Only a 
single, modal, sequence of each clone is counted. 
Group 
Donor 
ID Gender Age IgA IgG IgM Total 
Ebola 
Survivors 
215 M 29 2309 3013 1368 6690 
216 M 34 1577 1796 1131 4504 




193 M 27 285 305 327 917 
199 M 34 480 251 254 985 




193 M 27 225 588 867 1680 
199 M 34 250 219 98 567 
207 F 36 216 94 471 781 





Table A-25: Number of light chain sequences in full Caucasian Aid Worker Dataset. Only a 
single, modal, sequence of each clone is counted. 
Group 
Donor 
ID Gender Age Kappa Lambda Total 
Ebola 
Survivors 
215 M 29 3992 1420 5412 
216 M 34 3606 1195 4801 




193 M 27 2133 347 2480 
199 M 34 1964 339 2303 




193 M 27 1543 756 2299 
199 M 34 1223 325 1548 
207 F 36 443 472 915 
Total 20367 5551 25918 
 
Table A-26: Number of light chain sequences in clean Caucasian Aid Worker Dataset. Only a 
single, modal, sequence of each clone is counted. 
Group 
Donor 
ID Gender Age Kappa Lambda Total 
Ebola 
Survivors 
215 M 29 2843 1182 4025 
216 M 34 2878 975 3853 




193 M 27 1607 293 1900 
199 M 34 1552 274 1826 




193 M 27 1154 585 1739 
199 M 34 920 263 1183 
207 F 36 339 374 713 





A.6 Number of Sequences in Ebola African Survivor Dataset 
Table A-27: Number of heavy chain sequences in full African Survivor Dataset. Only a single, 
modal, sequence of each clone is counted. 
Group Donor ID IgA IgG IgM Total 
Time Point 1 
2 1013 1393 958 3364 
50 520 729 261 1510 
14 654 635 215 1504 
82 436 698 416 1550 
15 685 855 412 1952 
Time Point 2 
2 826 924 131 1881 
50 842 645 117 1604 
14 730 669 187 1586 
82 338 535 413 1286 
15 758 774 465 1997 
Total 6802 7857 3575 18234 
 
Table A-28: Number of heavy chain sequences in clean African Survivor Dataset. Only a single, 
modal, sequence of each clone is counted. 
Group Donor ID IgA IgG IgM Total 
Time Point 1 
2 969 1335 913 3217 
50 501 702 249 1452 
14 631 616 205 1452 
82 419 671 393 1483 
15 657 822 394 1873 
Time Point 2 
2 799 891 125 1815 
50 807 609 112 1528 
14 709 640 174 1523 
82 331 514 390 1235 
15 735 744 448 1927 





A.7 Number of Sequences in Ribosome Display Library Dataset 
Table A-29: Number of scFv sequences in full Ribosome Display Library dataset. Only a single, 
modal, sequence of each clone is counted. 
Group Donor ID IgH IgK IgL Total 
PCR3 Input 
215 12716 2757 3407 18880 
217 7177 2989 2944 13110 
PCR4 Output 
215 474 275 72 821 
217 218 229 47 494 
Total 20585 6250 6470 33305 
 
Table A-30: Number of scFv sequences in clean Ribosome Display Library dataset. Only a single, 
modal, sequence of each clone is counted. 
Group Donor ID IgH IgK IgL Total 
PCR3 Input 
215 11689 2224 3078 16991 
217 6620 2570 2645 11835 
PCR4 Output 
215 428 209 53 690 
217 192 173 40 405 




















Figure A-4: HP-SEC traces of purified antibodies. Percentages next to antibody name indicate 
the proportion of the purified antibody that was in monomeric form. Peaks to the left of the 
large monomer peak indicate aggregated antibody. Peaks to the right of the large monomer 
peak indicate fragmented antibody.105  
                                                          




A.9 Optimal ELISA Antigen Coating Concentration Titration Curves 
A.9.1 Solid-Phase ELISA 
 
Figure A-5: Solid-phase ELISA antigen coating concentrations. To confirm that all control 
antibodies bound their corresponding antigen and to determine the optimal antigen coating 
concentrations, titration curves were conducted for each antigen (Table 2-34, page 111) using 
its corresponding control antibody (Table 2-35, page 111). The ELISA was blocked with 
3% (w/v) skimmed milk powder in PBS and both primary and secondary antibodies were 
diluted in 3% (w/v) skimmed milk powder in PBS. Antibodies were incubated for 1 h at room 
temperature. The optimal coating concentration was the concentration at which the curve 
plateaued or 10μg/ml, whichever was lower.Soluble ELISA using Biotinylated Insulin 
 
Figure A-6: Soluble ELISA biotinylated insulin coating concentration. To confirm that the anti-
insulin control antibody (Table 2-34, page 111) bound biotinylated insulin in the soluble ELISA 
format, and to determine the optimal biotinylated insulin coating concentration, a titration 
curve was performed. ELISA was blocked with 3% (w/v) skimmed milk powder in PBS and was 
incubated at room temperature for 1 h at 800rpm. Readings at 0.05μg/ml and 0.0125μg/ml 
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